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Abstract 
 
  The  assessment  of  the  benefits  of  pharmaceutical  products  through  health 
technology assessments (HTAs) has become a feature of health care decision-making in 
numerous  OECD  countries,  including  England  and  Germany.  Assessment  outcomes 
vary between countries but, to date, there is a lack of research on the factors that affect 
those  assessments.  This  thesis  addresses  this  shortcoming  by  examining  what 
determines the outcome of pharmaceutical benefit assessments in  two countries that 
employ formalised HTA procedures. It takes a novel theoretical approach by employing 
a framework of policy paradigms to explain an empirical phenomenon other than policy 
change. 
  The study presents a qualitative analysis that compares the reasoning processes 
that led to assessment outcomes in ten of the same cases of pharmaceuticals in England 
and  Germany.  It  finds  that  benefit  assessment  outcomes  are  determined  by  how  a 
similar set of themes around evidence gets interpreted and framed by a HTA body, e.g. 
the  National  Institute  for  Health  and  Care  Excellence  (NICE)  in  England  and  the 
Federal  Joint  Committee  (FJC)  in  Germany.  The  study  explains  the  differences  in 
addressing  a  similar  set  of  themes  around  evidence  by  reference  to  different  HTA 
paradigms that are applied, namely  a cost  effectiveness paradigm in England and a 
patient relevance paradigm in Germany. 
  The thesis makes a significant theoretical contribution because it demonstrates 
that policy paradigms can be used to explain empirical phenomena other than policy 
change. This requires an analysis of how paradigms are articulated in ‘normal decision-
making’, much akin to Kuhn’s analysis on the connection between ‘normal science’ and 
paradigms. The study calls for an expansion of the current use of policy paradigms to 
include how they are operationalised in practice as this leads to a better understanding 
of the crucial elements of a paradigm. 
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Chapter 1 
Introduction 
 
1.0. Introduction 
 
In October 2011 the National Insitute for Health and Care Excellence (NICE) in 
England  and  the  Institute  for  Quality  and  Efficiency  in  Health  Care  (IQWiG)  in 
Germany published their assessment of a medicine called Ticagrelor
1 for acute coronary 
syndromes. The assessment was based on an evaluation of the scientific evidence in the 
form of data from randomised controlled trials ( RCTs) and other studies submitted by 
the manufacturer of Ticagrelor. The  pharmaceutical manufacturer submitted the same 
evidence  in  England  and  Germany  (NICE,  2011;  IQWiG ,  2011).  Based  on  the 
assessment of the evidence, NICE recommended the use of Ticagrelor for all of the four 
types of acute coronary syndromes that are distinguished for clinical purposes (NICE, 
2011). NICE was satisfied that the expected health benefits for the eligible patient 
groups were sufficiently large to justify the costs incurred by the use of Ticagrelor. As a 
result, the costs for the use of Ticagrelor are covered by the National Health Service 
(NHS) in England. By contrast, IQWiG in Germany concluded there was a significant 
added benefit for only  one of the four types of acute coronary syndromes (IQWiG, 
2011). The benefit of Ticagrelor was assessed differently by NICE and IQWiG. How 
can this different assessment of the same pharmaceutical product be explained and why 
does it matter? 
This thesis addresses the research question of what determines the outcome of 
pharmaceutical  benefit  assessments  in  health  care  systems  that  employ  formalised 
health technology assessment (HTA) procedures. In doing so, it addresses the issue of 
how  differences  and  similarities  in  assessment  outcomes  can  be  explained.  In  the 
context  of  health  care  policy  this  is  an  important  issue  because  it  gives  rise  to  an 
empirical  puzzle  that  is  contrary  to  what  one  might  reasonably  expect  if  issue 
characteristics (Lowi, 1964) alone determined the outcome of public policy decisions. 
That is to say that one might expect that the benefits of a pharmaceutical product that 
has the same biochemical ingredients and characteristics worldwide would be assessed 
                                                        
1 In line with the HTA organisations’ use of the names of pharmaceutical products, the generic 
rather than the brand names of pharmaceutical products are used throughout this thesis.  
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similarly everywhere. However, comparisons of the outcomes of pharmaceutical benefit 
assessments between HTA organisations – organisations that review the evidence on the 
clinical and cost effectiveness of new medicines and other health technologies - have 
demonstrated that this is not the case (e.g. Kanavos, et al., 2010). While some benefit 
assessments  of  pharmaceuticals  are  similar,  others  are  divergent.  In  exploring  what 
determines  similarities and  differences  in  outcomes, this  thesis  seeks to offer novel 
empirical and theoretical insights into how evidential questions on new pharmaceutical 
products  are  framed  in  the  context  of  different  HTA  paradigms,  which  ultimately 
provide a more in-depth understanding of the  issues  that determine the outcome of 
pharmaceutical benefit assessments. 
For the policy process  and the actors that engage in it, the question of how 
differences  in  benefit  assessments  of  the  same  pharmaceutical  products  can  be 
explained  matters  because  different  outcomes  of  benefit  assessments  lead  to 
divergences  in  health care provision  in  countries  that employ HTA procedures.  For 
example, a negative assessment by NICE in England means that the NHS is not obliged 
to ensure access to the medicine or treatment in question. This implies that negative 
pharmaceutical benefit assessments can lead to a situation in which patients are denied 
access to a medicine or treatment. This in turn raises issues of political salience and 
ethical sensitivity, especially if access to the medicines in question is ensured in other 
countries or regions due to a different assessment of the benefit of the medicines.  
The political salience and ethical sensitivity of the issues arising in the context 
of HTAs are exemplified by NICE’s assessment of a new breast cancer drug called 
Kadcyla. In April 2014 NICE – the organisation that reviews evidence on the clinical 
and  cost  effectiveness  of  new  medicines  in  England
2 –  published  a  draft  guidance 
document on Kadcyla. NICE concluded that the “breast cancer drug costing tens of 
thousands  of  pounds  more  than  other  treatments  [is]  ‘unaffordable’  for  [the]  NHS” 
(NICE, 2014). According to NICE Chief Executive, Sir Andrew Dillon:  
 
[…]  the  reality  is  that  given  its  price  and  what  it  offers  to  patients,  it  will 
displace more health benefit which the NHS could achieve in other ways, than it 
will offer to patients with breast cancer (NICE, 2014).  
 
                                                        
2 NICE guidance usually applies to the NHS in England, but in selected circumstances it is also 
applied in Northern Ireland, Scotland and Wales (NICE, 2013).  
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Following NICE’s publication of the draft guidance, a consultant oncologist described it 
as a “huge blow” (BBC, 2014) as “Kadcyla represents a significant advance in […] 
breast cancer […]” (BBC, 2014), whilst the representative of a breast cancer patient 
charity  organisation  said  that  “[…]  we  are  concerned  by  the  increasing  number  of 
people we support telling us how anxious they are about being able to access treatments 
when they need them” (BBC, 2014). 
 The principle that patients should have access to the medical treatments they 
need, when they need it, regardless of their socio-economic and financial background, is 
arguably  one  of  the  central  pillars  that  modern  health  care  systems  are  built  on. 
However,  the  example  of  Kadcyla  demonstrates  that,  in  times  of  growing  financial 
pressures on public budgets, it is proving increasingly challenging to ensure the timely 
access to treatment, including access to medicines, based on the criterion of medical 
need  alone.  This  gives  rise  to  a  situation  in  which  politically  salient  and  ethically 
sensitive  decisions  on  the  allocation  of  health  care  resources  have  to  be  made. 
According  to  Freeman:  “To  guarantee  access  to  health  care  means  ensuring  the 
availability of medicines, and doing so means addressing familiar distributional issues 
of who gets what, when, how” (Freeman, 2009, p. 244).  
In order to address such distributional issues of health care access, in health 
policy a growing emphasis is placed on the assessment of the added value of medicines, 
both in medical and financial terms. Put differently, in an effort to find decision-making 
tools for making distributional choices, health policy-makers and decision-makers
3 have 
introduced requirements to evaluate the scientific evidence on a health care intervention 
or pharmaceutical product in order to decide whether access is justified in relation to the 
benefits and/or costs incurred. In a number of member states of the Organisation for 
Economic Co-operation and Development (OECD) this has led to the establishment of 
institutions  –  so-called  health  technology  assessment  (HTA)  institutions  –  that  are 
                                                        
3 For the purpose of this thesis, health policy-makers are political representatives of government 
and  opposition  parties  who  are  engaged  in  legislative  activities  that  provide  the  statutory 
framework  of  health  care.  Health  decision-makers  include  executive  bureaucrats  as  well  as 
actors at the operational level such as health care providers. Whilst assessments of medical 
interventions and pharmaceutical products emerge from statutory mandates in the majority of 
countries, the distinction between health policy-makers and health care decision-makers is made 
to highlight that such mandates can also arise from requirements of professional bodies such as 
physician associations or payers’ organisations such as sickness insurance funds. The distinction 
serves the purpose of differentiating between the actors who determine the general direction of 
health policy and the actors who are in charge of making decisions within a given health care 
system on a daily basis.  
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commissioned with carrying out evaluations of the scientific evidence of interventions 
and pharmaceutical products in health care.  
The  examples  of  Ticagrelor  and  Kadcyla  highlight  that  negative  HTA 
evaluations of new pharmaceutical products may result in a certain product not being 
covered under a national health care scheme, which effectively means that patients may 
be denied access to certain medicines or other treatments. Denying patients access to 
health  care  treatment  can  have  serious  political  consequences,  especially  when  it  is 
portrayed as a matter of injustice in the media and other public domains. For example, 
in 2008 patient campaigners protested against NICE’s decision not to recommend a 
number of kidney cancer medicines on the grounds that they were not cost effective by 
saying that kidney cancer patients “deserved the right to life” (Walker and Batty, 2008). 
The protest against NICE was framed around questions of ethics, equity and human 
rights, essentially arguing that NICE was denying kidney cancer patients the right to 
life.  This  underlines  the  political  salience  and  ethical  sensitivity  when  it  comes  to 
deciding “[…] who gets what, when, how” (Freeman, 2009, p. 244). It also underlines 
the importance of understanding how outcomes of pharmaceutical benefit assessments 
can  be  explained  in  an  effort  to  evaluate  whether  policy  goals  are  being  met  and 
whether public criticism is justified.  
Despite the political salience of the issue, empirical studies of HTA processes 
and outcomes remain incomplete. To date, studies on the subject predominantly focus 
on institutional structures and formal decision-making criteria. What is missing from 
these  studies  is  an  empirical  account  of  the  factors  that  determine  the  outcome  of 
pharmaceutical benefit assessments
4. For example, whilst criteria such as clinical and 
cost effectiveness are considered important to HTA decision-making processes, there is 
little understanding of how these criteria are prioritised, operationalised and balanced 
against other potential factors such as stakeholder views.  
Moreover,  an  account  of  how  questions  of  ‘evidence’  are  formulated  and 
interpreted in  different  national  HTA contexts  is  missing from the  extant literature. 
                                                        
4 In this study the term ‘health technology assessment’ (HTA) refers to HTAs that are conducted 
on pharmaceutical products. In this sense ‘HTAs’ and ‘pharmaceutical benefit assessments’ are 
used interchangeably as the latter represents a form of HTA. The definition of HTA provided in 
this  chapter  and  in  chapter  4  shows  that  HTAs  pertain  to  a  wide  array  of  health  care 
interventions including medical devices and pharmaceutical products. However, the focus of 
this thesis is on the HTAs of pharmaceutical products and therefore both terms are employed to 
describe  the  formal  evaluation  of  pharmaceutical  products  in  countries  that  employ  HTA 
procedures.  
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Given the centrality of ‘evidence’ to any HTA process, this is a surprising gap in the 
current  knowledge  on  what  determines  the  outcome  of  pharmaceutical  benefit 
assessments.  Additionally,  there  are,  to  the  best  of  my  knowledge,  no  comparative 
studies that trace how decisions on the same pharmaceutical products are arrived at in 
different countries. Given the good availability of data due to publicly available HTA 
decision  documents  and  given  the  ability  to  control  for  issue  characteristics  (Lowi, 
1964) such as different disease types, this is an area that this thesis seeks to address. 
The thesis addresses the outlined gaps by offering an account of the factors that 
determine pharmaceutical benefit assessment outcomes based on the qualitative analysis 
of the decision-making process of ten of the same pharmaceutical products
5 that were 
appraised in England  and Germany
6 in 2011 and 2012. Conducting a cross -national 
comparison on this issue offers a deeper understanding of the role that context plays to 
the outcome of what has been referred to as a case of “scientific-bureaucratic medicine” 
(Harrison, Moran and Wood, 2002).  
The  thesis  seeks  to  contribute  to  the  empirical  knowledge  of  health  policy 
generally, and HTA policy specifically, by providing  an analysis of the factors that 
determine  pharmaceutical  benefit  assessment  outcomes.  The  analysis  concludes  that 
how concepts, ideas and criteria of HTA decision-making are interpreted in different 
contexts determines the outcome of pharmaceutical benefit assessments. The research 
findings illustrate that pharmaceutical benefit assessments are not technocratic, value-
neutral  processes  that  invariably  result  in  similar  appraisals  of  available  evidence. 
Instead, they exemplify complex decision-making procedures in the realms of public 
policy that involve applying careful judgements to science on the basis of medical, 
scientific, economic, political and ethical considerations. What these considerations are, 
and how they are transformed into meaningful judgements around evidential questions, 
contributes to an understanding of what determines pharmaceutical benefit assessments 
in different countries.  
The thesis’ theoretical contribution lies in the fact that it offers a new model for 
understanding  HTA  processes  and  their  outcomes.  The  model  is  derived  from  an 
extension of theories on policy paradigms to the field of HTA. It demonstrates that 
                                                        
5 See chapter 2 for an overview of the cases of pharmaceutical benefit assessments that were 
analysed. 
6 See chapter 3 for the description of the case selection process that led to the choice of England 
and Germany as case studies.  
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policy paradigms, conceptualised as intellectual constructs that determine what is or is 
not  considered  important  in  a  HTA  process,  help  explain  both  convergence  and 
divergence  of  HTA  outcomes.  The  theoretical  approach  is  novel  in  that  it  applies 
theories that are commonly used to explain policy change to an empirical phenomenon 
other than policy change. In doing so, I demonstrate that the use of theories on policy 
paradigms can be expanded to explain a larger number of empirical questions than is 
currently the case. The adoption of policy paradigm frameworks resulted in the finding 
that  a)  the  goals,  values  and  ideas  that  shape  an  HTA  system  differ  in  different 
institutional  contexts  and  that  b)  even  ostensibly  neutral  concepts  such  as  clinical 
effectiveness have divergent meanings in different contexts. This in turn impacts on the 
final  outcome  of  pharmaceutical  benefit  assessments  and  can  help  explain  why 
decisions on the same pharmaceutical product may vary between HTA agencies.  
In the following sections I provide an account of the current challenges faced by 
health policy-makers and decision-makers. This provides the backdrop against which 
HTA  processes  to  inform  decision-making  in  health  care  have  to  be  understood. 
Following this account, the chapter offers an explanation of HTA processes and their 
discussion in the extant literature. The research question that guides this study – that is, 
what  determines  the  outcome  of  pharmaceutical  benefit  assessments  in  health  care 
systems  that  employ  formalised  HTA  procedures  –  emerges  from  this  discussion. 
Finally, this introductory chapter provides the structural outline of this thesis and its 
main research findings. 
 
1.1. Health Care: Challenges and Reforms 
 
According to the extant literature the biggest challenge facing the health care 
state  (Moran,  1995;  1999)  emanates  from  financial  pressures  connected  to  rising 
expenditures. Access to pharmaceutical products is not the only matter of expense that 
public or private payers of health care need to cover. Other expenses arise such as the 
costs for the provision of hospital services  as  well as  primary and  community care 
services. The provision of such services incurs large health care expenditures in OECD 
countries  (see  figure  1).  Moreover,  the  expenditures  are  increasing  at  a  pace  that 
exceeds that of inflation in a number of countries. According to the OECD (OECD, 
2014), the annual growth rate of expenditure on health care in real terms between the  
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years of 2000-2011 was 4.1%, with the United States of America (USA) averaging at 
4.8% and the United Kingdom at 4.5% (see figure 2).  
 
The reasons for the continued rise in health care expenditure are multiple and 
emerge  from  various  developments.  Hanisch  and  Kanavos  cite  “[…]  an  ageing 
population, increasing incidence of chronic disease, persistent inequalities, and rising 
citizen expectations […]” (Hanisch and Kanavos, 2008, p. 1) as factors that contribute 
to  the financial  strain  that  some health care systems  find themselves in. Blank and 
Burau add the development of “[…] new medical technologies […]” (Blank and Burau 
2006, p. 265) to the matrix of key drivers for the rise in health care costs. Similar 
assessments  can  be  found  in  Dixon  and  Poteliakhoff  (2012),  Freeman  and  Moran 
(2000), Ham and Honigsbaum (1998) and Ham (1997). The advancement of modern  
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medical  technology,  along  with  what  Abraham  refers  to  as  the  “expert  patient  or 
informed  patient  discourse”  (Abraham,  2009,  p.  935),  whereby  information  on  new 
medicines and therapies is readily available on the internet, leads to rising expectations 
of patients which further exacerbates the pressures on health systems to finance all that 
is medically possible. 
Moran  (1995;  1999)  explains  the  challenges  facing  health  care  systems  in 
capitalist economies as tensions arising from the phenomenon he calls the ‘health care 
state’. Moran (1995; 1999) argues that health care is more than an element of a state’s 
welfare activities in advanced industrial economies. In health care, the state assumes a 
central role, not just as the driver of welfare activities, but as an actor in the areas of 
industrial  activity  and  distributional  tasks.  Moran  (1995;  1999)  refers  to  these  state 
activities  as  “the  three  faces  of  the  health  care  state”.  In  addition  to  shaping  and 
guaranteeing  the  provision  of  health  care  to  its  citizens,  states  are  concerned  with 
supporting industrial activity, for example in pharmaceutical research and development, 
whilst also regulating the activities of, for example, health care professionals. It implies  
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that  states  face  a  number  of  competing  demands  and  challenges  that  need  to  be 
addressed without jeopardising the relative standing of any one of them. Taken together, 
these tensions within the health care state appear to be facilitators of rising health costs.  
The  continuing  trend  of  growing  health  care  expenditure  has  led  to  cost 
containment efforts in the majority of OECD countries. In an effort to contain costs 
policy-makers have sought to uncover untapped efficiency savings by evaluating the 
health benefits and cost effectiveness of clinical services. The idea behind this is that 
such evaluations, or assessments, will shed light on what works best and what does not, 
in turn allowing for an informed decision on which services and medications to fund. In 
this environment, HTAs have become a synonym for evaluations to determine what 
works in health care and whether the costs of ‘what works’ are justifiable in relation to 
health  benefits  that  can  reasonably  be  expected.  HTAs  are  evaluations  of  scientific 
evidence on a pharmaceutical product or other health care intervention with the aim to 
appraise it with regards to its therapeutic benefits and/or costs (e.g. Sloan, 1995; Nord, 
1999). Be it in the form of institutions such as NICE in England and Wales or academic 
advisory groups based at universities, a number of health care systems now incorporate 
HTAs as a feature in their decision-making (Sorenson, 2009). 
The introduction of HTA policies is part of a wider trend in health care, namely 
the trend towards rationing and prioritisation in times of growing financial pressures. 
The next section describes this trend in more detail in order to highlight a number of 
politically salient and ethically sensitive challenges that arise from it. 
 
1.1.1. Rationing and Priority Setting 
 
According  to  Ham  (1997)  the  move  towards  rationing  and  making  difficult 
priority setting choices is characteristic of a third phase of health care reforms in OECD 
countries. It follows the first and second phases, which marked an effort to achieve cost 
containment at a macro level (1970s until the early 1980s) and measures to increase 
efficiency at a micro level (1980s until the 1990s) respectively. The introduction of 
HTA procedures thus has to be viewed within the context of a general trend in health 
care reform that focuses on prioritising or rationing services based on their clinical and 
cost  effectiveness  to  address  the  continued  financial  pressures  faced  by  health  care 
systems. The need for setting priorities arises “because no country can afford to provide 
all  its  residents  with  every  possible  medical  or  public  health  intervention  […]”  
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(Littlejohns,  et al.,  2012, p.  286). Policy-makers are looking for ways  to determine 
priorities in a manner that will ensure the efficient and fair use of resources. To put it 
differently: “Priority setting in health aims to determine what, in the context of limited 
resources, is most important” (Clark and Weale, 2012, p. 293). 
How  rationing  and  priority  setting  relate  to  one  another  is  a  matter  of 
contestation. For example, Klein (2010) criticises the view that they are conceptually 
close because it leads to a situation in which the terms are used interchangeably in the 
literature. He argues for a clear distinction between the two concepts as: 
 
Priority setting describes decisions about the allocation of resources between the 
competing  claims  of  different  services,  different  patient  groups  or  different 
elements of care. Rationing, in turn, describes the effect of those decisions on 
individual patients, that is, the extent to which patients receive less than the best 
possible treatment as a result (Klein, 2010, p. 389).  
 
 
Klein  (2010)  also  distinguishes  between  explicit  and  implicit  forms  of  rationing. 
Explicit forms of rationing include mechanisms such as waiting lists or the denial of 
medicines and delaying of treatments while implicit forms are harder to discern (Klein, 
2010).  This  is  because  they  might  include  mechanisms  such  as  understaffing  in 
hospitals or holding off on specialist referrals in order to keep expenditure in check 
(Klein, 2010).  
In contrast to Klein, Coulter and Ham do not believe “[…] in drawing hard and 
fast distinctions between rationing and priority setting” (Coulter and Ham, 2000, pp. 1-
2) as rationing “[…] has come to be employed to describe the variety of ways in which 
choices  in  health  care  are  made  whether  they  affect  individuals,  communities  or 
countries” (Coulter and Ham, 2000, pp. 1-2). For the purpose of this research, Coulter’s 
and Ham’s approach is followed in that the distinction between priority  setting and 
rationing is not operationalised in a strict manner, but is understood to be fluid. This is 
because the development of HTA policies is part of a wider policy-making discourse on 
rationing  and  prioritisation  in  which  the  boundaries  between  the  two  are  not  easily 
demarcated. That is to say that the outcome of HTAs may, depending on the observer’s 
viewpoint, be understood as either a form of rationing in that it denies patients access to 
a certain medicine if the appraisal of the medicine is negative, or it may be perceived as 
a form of setting priorities by prioritising the use of medicines that are deemed to meet 
the criteria that a HTA system has set for positive recommendations.   
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According to Coulter and Ham, rationing is “contentious” (Coulter and Ham, 
2000, p.  11).  It  is contentious  because setting  priorities implies  that one issue, one 
treatment,  one  health  care  area  is  given  more  attention  than  another  which  in  turn 
suggests that not everybody’s expectations and needs can be met. Patients might be 
denied treatments  or medicines.  Littlejohns, et  al.  suggest: “In this  context,  priority 
setting should aim to produce allocation of healthcare resources that can be ethically 
justified, especially to those who lose out as a result of resource allocation decisions” 
(Littlejohns, et al., 2012, p. 286). As the controversies arising from priority setting have 
become clearer, the current literature notes a trend towards explicit prioritisation that 
focuses on “[…] making transparent the rational for these priorities and basing resource 
allocation decisions on agreed-upon priorities” (Kenny and Joffres, 2008, p. 147).  
One element of the trend towards explicit prioritisiation is the introduction of so-
called health technology assessments (HTAs) as an instrument to determine priorities 
and define the inclusion of services in health care benefit baskets. Some argue that HTA 
is considered a technique for determining priorities (Coulter and Ham, 2000, p. 11) 
while others label it a “[…] a new policy analytical tool for the health policy area” 
(Lehoux  and  Blume,  2000,  p.  1085).  As  such  HTAs  need  to  be  understood  in  the 
context of the wider debate on rationing and prioritisation in the current literature whilst 
giving rise to their own set of controversies that underline the view that a debate exists 
on “how it [priority setting] should be done” (Coulter and Ham, 2000, p. 11). 
In  the  next  section  I  provide  a  definition  of  HTA  and  outline  some  of  the 
controversies that the process of HTA gives rise to. In doing so, I explain the contextual 
backdrop  from  which  my  research  question  -  what  determines  the  outcome  of 
pharmaceutical  benefit  assessments  in  countries  that  employ  formalised  HTA 
procedures? – emerges. 
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1.2. Health Technology Assessment (HTA) 
 
  HTA procedures have become an important element of pharmaceutical reform 
efforts in OECD countries (e.g. Mossialos, Mrazek and Walley, 2004; Abraham, 2009; 
Sorenson, 2009; Maynard and Bloor, 2003). HTA is defined as: 
 
The systematic evaluation of the properties and effects of a health technology, 
addressing  the  direct  and  intended  effects  of  this  technology,  as  well  as  its 
indirect and unintended consequences, and aimed mainly at informing decision 
making regarding health technologies (HTA Glossary, 2014). 
 
Health  technologies  include  “diagnostic  and  treatment  methods,  medical  equipment, 
pharmaceuticals  […]”  (EUnetHTA,  2014).  HTAs  are  carried  out  on  the  basis  of 
scientific evidence such as randomised controlled trials (RCTs) that provide an insight 
into the “properties and effects of a health technology” (HTA Glossary, 2014). The 
underlying idea is that the evaluation of available evidence on a given technology or 
pharmaceutical product will help determine which priorities to set and what medicines, 
treatments and surgical procedures to provide. Kanavos, et al. summarise this idea in the 
following way:  
 
In an environment where resources are scarce, HTA agencies’ objective is to 
ensure  access  to  safe  and  effective  medicines,  while  managing  health  care 
expenditure  in  an  efficient  way  by  reimbursing  clinically  cost-effective 
treatments. In this discourse, pharmaceutical products are the main – but by no 
means the only – subjects of such appraisals (Kanavos, et al., 2010, p. 1).   
 
The latter part of Kanavos, et al.’s conceptualisation of HTA’s objectives alludes 
to fact that while HTA can be used to inform decisions in different areas, there is a trend 
towards basing pharmaceutical coverage decisions on HTAs. Sorenson makes a similar 
point by arguing:  
 
The use of HTA in pharmaceutical coverage decisions has grown substantially 
since the late 1990s and is likely to expand further, as national policy makers 
continue to face cost pressures and attempt to use evidence-based approaches to 
ensure  effectiveness,  efficiency  and  sustainability  of  their  health  systems 
(Sorenson, 2009, p. 4).  
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The trend towards the use of HTA to inform pharmaceutical coverage decisions 
forms the basis of the semantic use of HTA in this thesis. While I recognise that HTA 
can have a wider remit than pharmaceutical benefit assessments, in this thesis HTA 
refers to HTA procedures used to inform decision-making on pharmaceutical access or 
price setting. HTA is used interchangeably with pharmaceutical benefit assessments. 
That  is  to  say that  when the term ‘HTA’ is  used  I mean  HTAs on pharmaceutical 
products, thus connecting the use of the term to the empirical focus of my research. 
As highlighted by Kanavos, et al. (2010) and Sorenson (2009) pharmaceutical 
spending has been a prominent target of health care reforms generally and of rationing 
and  prioritisation  efforts  specifically.  There  are  three  reasons  for  this.  Firstly, 
pharmaceutical spending constitutes a large part of overall health care spending (see 
figure 3). The OECD average of spending on pharmaceuticals as a percentage of overall 
expenditure on health constituted 15.9% in 2012 (OECD, 2014). Secondly, the policy 
instruments  for  curtailing  pharmaceutical  spending  are  comparatively  varied  and 
provide  policy-makers  with  a  set  of  policy  choices.  For  example,  Freeman  (2009) 
highlights patient co-payments, reference pricing, profit controls for the pharmaceutical 
industry  and  generic  drug  prescription  as  possible  instruments  to  address  rising 
pharmaceutical expenditures.   
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Thirdly, the nature of the pharmaceutical market gives rise to a distinct set of 
complex and competing considerations with which policy-makers need to engage (e.g. 
Maynard  and  Bloor,  2003;  Mossialos,  Walley  and  Mrazek,  2004).  This  includes 
balancing issues such as the need to ensure safe and affordable access to effective and 
innovative  medicines  whilst  avoiding  waste.  It  also  includes  supporting  the 
pharmaceutical industry as a major provider of employment and an investor in research. 
The issues that this difficult balancing act gives rise to are reflective of the three faces 
of the health care state outlined by Moran (1995; 1999). 
Evaluating the health benefits and cost effectiveness of pharmaceutical products 
has also become popular because of the fast pace of technological innovation in the 
area. The intellectual premise of assessing pharmaceuticals is a) that a new medicine 
does not, as a matter of course, represent a technological innovation unless its health 
benefits in comparison to current treatments are substantial and b) that even if a new 
medicine is innovative in its effect, the extent of the effect will determine whether its 
cost  is  justified.  Such  is  the  intellectual  starting  point  of  pharmaceutical  benefit 
assessments,  but  as  the  following  sections  show,  their  use  as  a  priority  setting 
instrument is by no means uncontroversial. 
 
1.2.1. Controversies Arising from HTAs 
 
The extant literature depicts several areas of controversy around HTAs, which 
can be divided into political/economic, methodological and societal/ethical dimensions. 
They centre primarily on the conceptualisation of HTA as a scientifically objective and 
value-neutral policy tool and on the fact that complex judgements still to be made by 
decision-makers in the process. 
The political and economic dimensions of HTA arise from the high hopes that 
policy-makers have placed on HTA policies  as  remedies  to  some of the challenges 
facing health care states. Rationing and priority setting give rise to emotional debates, 
conflicts  and  protests  (e.g.  Kenny  and  Joffres,  2008).  Policy-makers  have  therefore 
searched for tools to make the decision-making processes on the allocation of health 
care resources more transparent and the final decisions less controversial, two goals 
hoped to be achieved by employing procedures such as HTA. Klein summarises this 
hope expressed by some of his colleagues in the following way: 
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[…] NICE represents an attempt to depoliticize decisions about who should get 
what […]. Science and evidence, not political whims or media panics, would 
shape NICE’s decisions and NHS practice: clinical and cost effectiveness would 
be the criteria when appraising technology and issuing guidance. Such at any 
rate was the theory when NICE was set up (Klein, 2010, pp. 389-393). 
 
 
  However, the ability of HTA processes to contribute to a ‘de-politicisation’ of 
the  complex  distributional  choices  in  health  care  is  increasingly  questioned.  For 
example, Landwehr argues, “[…] that the link commonly drawn between delegation to 
expert  bodies  and  de-politicization  of  an  issue  […]  does  not  seem  to  hold  […]” 
(Landwehr, 2009, pp. 599-600). In the context of health policy this view suggests that 
commissioning independent and scientific expert bodies such as NICE and IQWiG with 
the  task  of  recommending  which  pharmaceuticals  should  be  made  available  on  a 
national health care scheme does not solve the problem that recommendations might 
give rise to political opposition. As we shall see, the empirical results documented in 
this thesis support Landwehr’s assertion in the sense that they show that the effect of the 
‘de-politicisation’ of health care decisions appears to be questioned by policy-makers in 
England and Germany alike, leading to an increasing re-politicisation of the area. 
In addition to the above, several authors question the ability of HTA processes 
to  contribute  to  cost  containment  by  identifying  ineffective  or  wasteful  health  care 
interventions.  By  conducting  HTAs  health  decision-makers  can  distinguish  between 
cost effective and cost ineffective medical products, thus allowing for an exclusion of 
the  latter  in  the  health  care  benefit  baskets  of  a  given  country.  However,  so-called 
disinvestments as a result from HTAs are still limited and observers such as Mossialos, 
Walley and Mrazek fear that HTA “[…] may become one of the drivers of health care 
costs”  (Mossialos,  Walley  and  Mrazek,  2004,  p.  14)  because  more  products  are 
approved than denied.  
  Coulter and Ham (2000) point out that the debates surrounding HTA policies are 
not just marked by questions on whether it is an appropriate policy tool to address 
problems at hand, but also what format HTAs should take, how they should be carried 
out  and  conducted.  Rather  than  presenting  policy  and  decision-makers  with  an 
uncontested and rational tool for evaluating the effects of new pharmaceuticals, the 
methods used to that effect are varied and have given rise to disputes between experts. 
While HTA “[…] is a field of applied research that seeks to gather and synthesize the 
“best  available  evidence”  on  the  costs,  efficacy,  and  safety  of  health  technology”  
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(Lehoux and Blume, 2000, p. 1083), the means to achieve this objective are varied and 
subject to contestation. Cost effectiveness analyses, cost-benefit analyses, measurement 
of  outcomes  in  quality-adjusted  life  years  (QALYs)  and  the  efficiency  frontier  are 
examples of methods for the evaluation of pharmaceuticals
7. They differ in terms of the 
focus they set and the input they require, thus making it likely that they differ also in 
terms of the outcomes they produce.  Thus arises the methodological dimension of the 
controversies surrounding HTAs. 
  In addition to the political and methodological dimensions of HTA a third body 
of literature deals with the normative issues that priority setting and HT A give rise to 
(e.g. Norheim, 2002; Biller-Andorno, Lie and Meulen, 2002). Coulter and Ham  argue 
that one of the lessons learnt from international rationing experience is the  
 
[…] attention [drawn] to role of values in rationing. This is because the relative 
priority attached to different types of treatments or services […] depends in part 
on the value attached to different outcomes (such as improving the quality of life 
as opposed to increasing the length of life). […] The need to make these choices 
illustrates  the  ethical  dilemmas  involved  in  rationing  and  the  moral  basis  of 
decision making (Coulter and Ham, 2000, p. 10). 
 
 
Similarly, Kenny and Joffres (2008) assert that priority setting is essentially a normative 
and ethical process. Authors such as Biller-Andorno, Lie and Meulen have argued that 
coverage decisions based on HTA and evidence-based medicine threaten “[…] shared 
social  values  like  equity  and  solidarity”  (Biller-Andorno,  Lie  and  Meulen,  2002,  p. 
261). The criticism emerges from their skepticism of the methods used for economic 
evaluations in HTA such as the use QALYs which they describe as a “[…] decision 
making procedure divorced from real life choices” (Biller-Andorno, Lie and Meulen, 
2002, p. 269). Klein argues that the effect of rationing is that “[…] patients receive less 
than  the  best  possible  treatment”  (Klein,  2010,  p.  390),  which  makes  the  need  for 
careful judgement and justification a pressing concern for decision-makers. 
Holm (1998) and Landwehr (2009) assert that the above concerns arise from a 
second phase of rationing in which decision-makers have become increasingly aware 
that the introduction of HTA institutions does not preclude the necessity of making 
difficult value judgements. The body of literature on these concerns recognises that 
HTA  gives  rise  to  difficult  value  judgements,  which  in  turn  has  led  to  a  call  for 
                                                        
7 The differences between these methods are explained in chapter 5.  
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designing transparent and accountable decision-making processes in an effort to address 
them. Landwehr calls this development a case of “deciding how to decide” (Landwehr, 
2009)  while  Daniels  promotes  a  framework  of  “accountability  of  reasonableness” 
(Daniels,  2000), stipulating that it  is  easier to  agree on  fair processes  than it is  on 
content values that should guide decision-making.  
  The  brief  overview  of  the  political/economic,  methodological  and 
societal/ethical dimensions of HTAs highlights the political and ethical salience of HTA 
processes. Empirically, they are illustrated by the medicines Kadcyla and Ticagrelor. 
The breast cancer drug Kadcyla, for example, was not recommended by NICE on the 
grounds that it was too expensive even though consultants and patient groups agreed 
that  the  clinical  benefits  from  treatment  with  Kadcyla  are  substantial  (BBC,  2014). 
Given the controversies and theories surrounding the effect of HTAs, the question arises 
what factors actually determine the outcome of pharmaceutical benefit assessments. In 
other  words,  do  benefit  assessment  outcomes  reflect  political,  economic, 
methodological, ethical and/or purely medical considerations? And what impacts on the 
relative balance between these considerations in different countries? 
As the next section highlights, the extant literature on the factors that contribute 
to  the  outcome  of  pharmaceutical  benefit  assessments  is  limited  in  that  it  does  not 
include in-depth comparative empirical studies of cases of benefit assessments in order 
to determine the factors that matter most within different national contexts. This thesis 
addresses this shortcoming. In doing so, it hopes that the contributing factors that are 
discovered during the course of the analysis give insights into the extent to which the 
political, economic, methodological, ethical and medical dimensions of HTAs play a 
role in different national contexts and how they shape the final outcome of HTAs. In 
this sense, the preceding overview of the controversies surrounding HTAs also serves as 
a preliminary framework for interpreting the results of the empirical analysis presented 
in chapters 6-8. It can only serve as a preliminary framework because the analysis is the 
result of a deductive process in which themes emerged during the analysis rather than a 
priori. Nevertheless, the controversies surrounding HTA provide an initial set of themes 
that may appear in the empirical data. 
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1.3. Gaps in Knowledge on HTA 
 
Whilst  the  debates  regarding  the  political,  methodological  and  societal 
dimensions of HTA exhibit some detail, what is missing from the current literature is an 
empirical  analysis  of  these  dimensions  and  how  they  interact  with  each  other.  The 
opportunities for empirical research in this field are vast due the growing number of 
HTAs that are conducted and published on the websites of HTA bodies. The few studies 
on this question remain incomplete in the sense that they only explain variations in 
outcomes with reference to institutional differences and different statutory HTA criteria. 
The role of these factors notwithstanding, the extant literature on HTA lacks in-depth 
empirical examinations of whether these explanations offer an accurate account of what 
determines the outcome of pharmaceutical benefit assessments.  
Kanavos, et al. (2010) examine the differences and similarities in appraisals and 
recommendations made by HTA agencies in six different countries (Canada, Australia, 
England, Scotland, Sweden and France). The results of their study are significant in that 
they show that HTA outcomes differed in more than half of the cases (Kanavos, et al., 
2010,  p.  2).  The  study  also  looks  at  a  number  of  decision-making  criteria  that 
contributed  to  the  final  outcome  and  concludes  that  “[…]  there  are  considerable 
disparities in the information required, interpretation of evidence, rigour of the appraisal 
process and stated motivations for listing or not listing drugs” (Kanavos, et al., 2010, p. 
4). Similar conclusions can be found in Pomedli (2008) and Sorenson and Chalkidou 
(2012). Sorenson and Chalkidou (2012) include HTA objectives, processes, stakeholder 
involvement, assessment method and the application of evidence to decision-making as 
factors that impact on HTA outcomes and explain variations. However, while these 
studies make references to the political and ethical dimensions of HTA, their analysis 
remains focused on institutional features and methodological approaches rather than on 
analysing the interplay between the different factors in various cases. Moreover, they do 
not exhibit the same level of detail that is provided through the process-tracing approach 
contained in this thesis. 
The above studies are important to the research question at hand because they 
highlight the empirical puzzle that motivates this research, namely the observation that 
the outcome of HTAs varies even if they are concerned with the assessment of the same 
medicine with largely the same evidence base. As outlined, the studies also provide 
some  explanations  for  these  variations.  However,  the  explanations  fall  short  of  
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demonstrating how different factors interact to produce certain outcomes. For example, 
while the studies acknowledge that institutional factors play a role in determining HTA 
outcomes, they do not demonstrate how these institutional factors might interact with 
ideational factors such as ethical considerations and value judgements. Moreover, while 
reasons for variation offer interesting insights, reasons for similarities are by and large 
not covered in the aforementioned studies. However, as highlighted in the empirical 
chapters of this thesis, the reasons for similarities also offer useful insights as there are a 
number  of  cases  in  which  HTA  bodies  have  reached  the  same  conclusions  despite 
considering different issues during the decision-making process. This is counterintuitive 
to  what  one  might  expect  and  offers  an  additional  explanation  for  why  a  detailed 
empirical study on what determines the outcome of pharmaceutical benefit assessment 
is appropriate. 
The next section outlines how this thesis is structured in order to address the 
research question of what determines pharmaceutical benefit assessments in health care 
systems that employ formalised HTA procedures. 
 
1.4. Outline of the Study 
 
The  sections  above  placed  the  introduction  of HTAs  as  a  policy  tool  to  aid 
health  care  decision-making  in  the  context  of  a  general  reform  trend  that  includes 
measures to ration and prioritise services in OECD countries. Even though HTAs are 
conducted on a number of the same pharmaceutical products with the same evidence 
base in different countries, existing research in the field has shown that the outcome of 
HTAs frequently varies from country to country. This empirical puzzle, along with the 
fact that current studies on HTAs are limited and fall short of providing a satisfactory 
account of this puzzle, gives rise to the following research question:  
 
What determines the outcome of pharmaceutical benefit assessments in health 
care systems that employ formalised HTA procedures? 
 
The next chapter presents the theoretical framework that underpins this research. 
The theoretical framework emerges from the literature on the role of policy paradigms 
and ideas in public policy. The focus on policy paradigms offers an attractive approach 
for addressing this thesis’ research question because it allows for the consideration of a  
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multiplicity  of  factors  that  may  play  a  role  in  determining  the  outcome  of 
pharmaceutical  benefit  assessments.  It  also  offers  an  opportunity  to  account  for 
contextual,  that  is  country-specific,  factors  that  are  likely  to  play  a  role  since  the 
characteristics  of  the  pharmaceutical  products  that  are  analysed  as  case  studies  are 
controlled for and can therefore be ruled out as explanatory variables.  
Paradigms are conceptualised as intellectual frameworks that determine which 
factors and issues are considered important in the process of a pharmaceutical benefit 
assessment. Based on the extant knowledge on how policy paradigms and ideas matter 
in the policy process, the underlying assumption is that HTAs, like other policies, can 
be understood as a reflection of specific health care and HTA paradigms. My theoretical 
argument is that, when HTAs are understood as a reflection of specific paradigms, these 
paradigms can help explain similar and dissimilar outcomes of benefit assessments.  
In order to explain HTA outcomes with reference to paradigms, the paradigms 
have to be captured. Chapter 2 explains how I adapt Hall’s (1989; 1993) and Majone’s 
(1989)  work  in  order  to  capture  the  dominant  HTA  paradigms  in  England  and 
Germany
8. It also elaborates on the importance of examining how paradigms operate in 
‘normal’  practice.  The  concept  of  ‘normal’  practice  derives  from  Kuhn’s  (1962) 
arguments  on  ‘normal  science’  as  the  sphere  in  which  paradigms  operate.  The 
underlying idea is that one can only hope to  gain a better understanding of what a 
paradigm is and what its effects are if one looks at how it is established and articulated 
in the process of ‘normal science’ or, for the purpose of this thesis, the process of 
‘normal’ decision-making practice in HTA.  
The novel theoretical contribution lies in the fact that I apply theories of policy 
paradigms  to  an  empirical  puzzle  other  than  policy  change,  which  is  the  current 
preoccupation of authors in the field. Moreover, by extending Kuhn’s (1962) concept of 
normal science to HTA I also emphasise the importance of examining a paradigm’s 
features in ‘normal’ processes before looking at its role in policy change. In doing so, I 
demonstrate that the potential contribution of policy paradigms to explain empirical 
phenomena other than change in the policy process is underestimated, whereas their 
potential  to  explain  policy  change  is  overestimated.  That  is  to  say  that  the  extant 
literature  does  not  make  it  clear  how  paradigms  can  explain  policy  change  if  their 
                                                        
8 See chapter 3 for an explanation of the case selection process.   
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distinctive  features  and  how  they  are  established  in  normal  policy  processes  is  not 
understood. 
  The third chapter outlines the research design of the thesis. The thesis represents 
a comparative case study with an embedded design. The reasoning behind this choice of 
study design as well as the selection of England and Germany as case studies and the 
choice for the embedded case studies of pharmaceutical products are explained in this 
chapter. Moreover, the methods for data collection and analysis are presented. The data 
analysis  rests  on  are  the  publicly  available  documents  on  pharmaceutical  benefit 
assessments at NICE in England and the Federal Joint Committee (FJC) and IQWiG in 
Germany as well as on 23 interviews conducted with stakeholders who were involved in 
the  decision-making  processes  in  the  ten  cases  that  were  analysed.  The  data  was 
analysed using qualitative content analysis and process-tracing methods. 
Chapter 4 offers a descriptive overview of health care, pharmaceutical policy 
and pharmaceutical benefit assessments in the two countries that were used as case 
studies in this research, namely England and Germany. It is important to understand the 
institutional and historical differences and similarities between the health care systems 
in England and Germany as they help explain some of the research findings that follow.  
  Chapter 5 presents an initial analysis of the policy paradigms of pharmaceutical 
benefit  assessments  in  England  and  Germany  by  exploring  the  legislative  and 
methodological frameworks that HTA systems are built on. In doing so, the chapter 
seeks  to  capture  and  outline  the  dominant  HTA  paradigms  as  they  are  laid  out  in 
statutory  and  methodological  frameworks.  It  provides  an  introduction  into  what 
concepts,  ideas  and  values  guide  pharmaceutical  benefit  assessments  in  the  two 
countries. The discussion of the legislative and methodological basis of pharmaceutical 
benefit assessments helps with the interpretation of the results of the empirical chapters 
that follow. Essentially, at the end of the thesis, it allows for an assessment of whether 
the way benefit assessments are conceptualised in England and Germany impacts on 
how  decision-making  criteria  are  operationalised  or  whether  we  can  observe 
divergences  between  theory  and  practice.  Chapter  5  also  contains  a  more  detailed 
definition of the different methods that can be employed in carrying out pharmaceutical 
benefit assessments with reference to England and Germany. 
  The sixth chapter represents the first of three chapters that present and discuss 
the empirical findings. It outlines the six themes (see tables 3.5. and 6.1.) that arise from 
the  empirical  evidence,  i.e.  the  consultation  documents,  stakeholder  interviews  and  
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others. Its focus is on the conceptualisation of evidence in England and Germany as the 
most  important  issue  that  determines  the  outcome  of  pharmaceutical  benefit 
assessments. By analysing the decision-making processes in the cases of Cabazitaxel, 
Eribulin and Ipilimumab, all products for different types of cancer, the chapter offers a 
first insight into the finding that the way evidence is conceptualised and operationalised, 
and indeed what constitutes evidence in the first place, has a big effect on determining 
the outcome of pharmaceutical benefit assessments. It demonstrates that the issues that 
were considered in these cases reflect the values that are embedded in the paradigmatic 
constructs  of  pharmaceutical  benefit  assessments,  outlined  in  chapter  5,  but  that 
divergences in values between countries do not necessarily lead to differences in benefit 
assessment outcomes. This is an important finding because it suggests that a similar 
outcome  in  the  dependent  variable  (i.e.  the  outcome  of  the  pharmaceutical  benefit 
assessment) should not be equated with a similarity in judgements that were applied in a 
specific case. 
  In  chapter  7  I  discuss  the  operationalisation  of  the  policy  paradigms  of 
pharmaceutical  benefit  assessments  by  tracing  the  decision-making  processes  in  the 
cases of Fingolimod, Retigabine and Telaprevir. It is an extension of chapter 6 in that it 
also focuses on questions that are connected to the interpretation of evidence, which 
affect  how  policy  paradigms  of  benefit  assessments  are  operationalised.  Using  the 
examples of Fingolimod, Retigabine and Telaprevir I highlight that decision-makers 
make different judgement calls when it comes to questions such as the appropriateness 
of  patient  subpopulation  or  comparator  products  in  benefit  assessments.  These 
judgement calls  can lead to  different  outcomes  of benefit  assessments  for the same 
product in different countries. The chapter concludes that the most important variable in 
determining  the  outcome  of  pharmaceutical  benefit  assessments  is  the  ‘rules  of 
evidence’ (Majone, 1989) that guide decision-making processes. 
  Chapter  8  outlines  additional  themes  that  arise  from  the  empirical  evidence. 
These themes are discussed as auxiliary variables because they did not arise in every 
embedded case study. Their relevance needs to be explored in future research in order to 
understand their meaning in a wider set of cases. The auxiliary variables discussed in 
chapter  8  include  ‘public  pressure’  in  the  form  of  media  and  public  protests  to 
recommendations by NICE in England. For Germany, the auxiliary variables include 
bargaining  powers  of  different  stakeholders  and  the  conceptualisation  of  ‘patient 
relevance’. Whilst the external validity of the individual auxiliary variables cannot be  
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conclusively determined as they appeared to play a role in a limited number of cases 
only, the fact that they were different in England and Germany supports the finding that 
the policy paradigms under which pharmaceutical benefit assessments operate in the 
two countries differ from one another. 
  In the ninth and final chapter I draw together the research findings (summary in 
table 1.1.) and conclusions that arise from this study. There are eight research findings. 
The fact that five out of six themes that emerged from the data analysis were connected 
to questions around how scientific evidence should be interpreted gave rise to the first 
finding that ‘rules of evidence’ (Majone, 1989) play a substantial role in determining 
the outcome of pharmaceutical benefit assessments. Different rules of evidence help 
explain different outcomes. In the case of the epilepsy drug Retigabine, for example, 
different viewpoints by NICE and IQWiG on the appropriate comparator drug led to 
NICE  recommending  Retigabine  (NICE,  2011a)  whilst  IQWiG  did  not  conduct  an 
assessment on the basis that the ‘wrong’ comparator was used by the pharmaceutical 
manufacturer (IQWiG, 2012).  
  The second finding presented in chapter 9 is that different rules of evidence are a 
reflection  of  different  HTA  paradigms,  namely  a  paradigm  of  cost  effectiveness  in 
England  and  one  of  patient  relevance  in  Germany.  Within  these  paradigms  certain 
concepts and criteria are emphasised more than others. Cost effectiveness is emphasised 
in England whilst patient relevance is emphasised in Germany. This gives rise to what 
may be labeled core and periphery concepts that decision-makers refer to when making 
decisions (research finding number 4). The core concepts in the English and German 
HTA paradigms are the thresholds, namely cost effectiveness and patient relevance, that 
need to be met in order for a pharmaceutical product to receive a positive assessment 
(research  finding  number  5).  However,  despite  important  differences  between  the 
English and the German HTA paradigm a significant finding is that these contrasting 
HTA  paradigms  do  not  necessarily  lead  to  contrasting  outcomes  (research  finding 
number  3).  The  case  of  Telaprevir  that  is  discussed  in  chapter  7  demonstrates  that 
evidence can be interpreted very differently and yet the outcome may be similar. This 
suggests that a similarity in the outcome of a pharmaceutical benefit assessment, i.e. in 
the dependent variable, should not be equated with a similarity in factors that were 
considered by the decision-making body. The process-tracing exercise conducted in the 
empirical chapters shows that the same assessment conclusion can be arrived at by the 
consideration  of  different  issues.  Finally,  research  findings  6,  7  and  8  (table  1.1.)  
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provide a better understanding of how paradigms are established in practice and of what 
kind of independent variables play a role in their operationalisation.  
 
TABLE 1.1. – Summary of Research Findings 
 
1.  ‘Rules of evidence’ (Majone, 1989) matter 
2.  HTA paradigms take different forms 
3.  Contrasting HTA paradigms do not necessarily lead to contrasting outcomes 
4.  A core and a periphery of values exists 
5.  Thresholds are the expression of paradigms in normal decision-making 
6.  Paradigmatic coherence matters 
7.  Ideational and institutional variables matter 
8.  Paradigms can help explain empirical phenomena other than change 
 
Chapter 9 also elaborates on the empirical and a theoretical relevance of the 
research findings. They are of empirical relevance because they contribute to a more 
comprehensive  understanding  of  what  determines  the  outcome  of  pharmaceutical 
benefit assessments and make the important point that a comparison of the outcome of 
the dependent variable alone does not fully explain differences and similarities. The 
thesis’ findings indicate that the definition and operationalisation of evidence questions, 
which are central to any HTA process, plays the most important role in determining the 
outcome of pharmaceutical benefit assessments. In the case of pharmaceutical benefit 
assessments, institutional variables such as the format that a given HTA body takes 
seem to be secondary to the ‘rules of evidence’ as an independent variable that affects 
assessment  outcomes.  In  addition  to  the  empirical  contribution,  the  conclusion  also 
summarises  the  significant  theoretical  contribution  that  this  thesis  makes  by 
demonstrating that ideas in the form of policy paradigms matter, not just in times of 
policy  change,  but  also  in  explaining  the  outcome  of  complex  decision-making 
processes such as HTAs. Finally, I draw attention to some of the questions that this 
thesis was not able to address and in doing so I outline areas for future research.  
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1.5. Conclusion 
   
  The introductory chapter provided the contextual background against which this 
thesis has to be understood. By reviewing the literature on HTA, it highlighted why 
HTAs in the form of pharmaceutical benefit assessments are a politically salient policy 
tool that gives rise to political, methodological and ethical controversies. By exploring 
the question of what determines the outcome of pharmaceutical benefit assessments in 
countries  that  employ  formalised  HTA  procedures,  this  thesis  seeks  to  make  a 
contribution to the empirical knowledge on HTAs and on which factors play a role in 
determining their final outcome. 
The overview of the literature on the dimensions of HTA illustrated that there 
are knowledge  gaps  of  an empirical  nature that are waiting to  be addressed. These 
knowledge gaps relate to the lack of in-depth empirical studies that investigate how the 
different dimensions of HTA interact in certain cases which in turn demands an effort to 
connect  theory  and  practice.  Are  the  considerations  that  determine  the  final  HTA 
outcome in pharmaceutical coverage decisions political, methodological or ethical in 
nature? Or is the nature of considerations dependent on the kind of product that is being 
assessed  for  coverage,  i.e.  does  political  or  ethical  salience  take  precedence  over 
methodological and evidence-based considerations in some instances? These are some 
of the questions that the existing literature does not provide answers to. This thesis aims 
to fill this gap by examining the considerations that determine pharmaceutical benefit 
assessment outcomes in England and Germany. 
In addition to the outlined empirical contribution, this thesis seeks to make a 
significant theoretical contribution by using policy paradigms as constructs to explain 
an empirical puzzle other than policy change. In doing so, I demonstrate that policy 
paradigms play a role in shaping the outcome of complex decision-making processes 
such as HTAs not just in times of change, but in times of relative stability and continued 
policy implementation. In the following chapter I explain the theoretical premise that 
my research is built on in more detail. 
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Chapter 2 
Theoretical Framework 
 
2.0. Introduction 
   
This chapter outlines the theoretical approach that guides the empirical analysis 
in this thesis. The approach allows for an exploration of the factors that impact on the 
outcome of pharmaceutical benefit assessments. It is built around two main premises. 
Firstly,  it  emphasises  the  important  role  played  by  ‘evidence’  in  health  technology 
assessment (HTA) processes. This role will be operationalised with reference to what 
Majone  (1989)  labels  the  ‘rules  of  evidence’,  that  is  the  context-specific  rules  that 
determine, for example, which forms of evidence are prioritised over others. I make the 
theoretical argument that the ‘rules of evidence’, and other factors that emerge from the 
empirical  analysis,  are  shaped  by  policy  paradigms  of  pharmaceutical  benefit 
assessments.  This  argument  is  connected  to  the  second  premise  of  the  theoretical 
approach,  namely  that  policy  paradigms  have  an  effect  on  the  outcomes  of 
pharmaceutical benefit assessment by determining what is or is not considered relevant 
in the assessment process. Drawing on Kuhn’s (1962) work on the connection between 
‘normal  science’  and  paradigms,  I  emphasise  that  paradigms  can  be  captured  and 
understood  by  looking  at  how  they  are  articulated  in  their  routine  application,  e.g. 
during their application in pharmaceutical benefit assessment processes. Kuhn’s (1962) 
concept  of  ‘normal  science’,  Majone’s  (1989)  ‘rules  of  evidence’  and  an  adapted 
version of Hall’s (1993) concept of ‘policy paradigms’ represent the key theoretical 
principles that guide this research.  
The following paragraphs introduce the theoretical reasoning that underpins the 
emphasis  on the way in which rules  of  evidence are applied and the use of policy 
paradigms  to  understand  the  diverging  interpretive  approaches  to  HTA  evidence  in 
England and Germany. The concept of scientific evidence is the intellectual foundation 
upon which HTAs are built (e.g. Lehoux and Blume, 2000; Milewa and Barry, 2005). 
An assessment of a pharmaceutical product or medical intervention stands and falls by 
the  availability  and  quality  of  evidence  to  prove  effectiveness,  cost  effectiveness, 
additional benefit and other given outcomes one hopes to measure in the process. Given  
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that  ‘evidence’  characterises  the  core  of  HTAs
9,  regardless  of  the  institutional  or 
national setting, it is reasonable to hypothesise that questions of evidence are a major 
contributing factor to the outcomes of pharmaceutical benefit assessments. This thesis 
thus  begins  with  the  theoretical  assumption  that  ‘evidence’  is  a  key  variable  in 
determining  the  outcome  of  pharmaceutical  benefit  assessments  in  countries  that 
employ formalised health technology assessments.  
The above assumption is a solid theoretical starting point, but it does not explain 
why prima facie the same evidence on a pharmaceutical product does not, as a matter of 
course, lead to a similar assessment of the given product in different countries. Put 
differently, it does not explain why the same evidence leads to similar outcomes in 
some assessments and dissimilar ones in others. The availability and quality of evidence 
undoubtedly plays a role because it is the intellectual core of HTAs, but it cannot be the 
sole  determining  factor  in  explaining  the  outcomes  of  pharmaceutical  benefit 
assessments. The fact that assessment outcomes are dissimilar in some cases but similar 
in others despite the availability of the same evidence base, suggests that the ‘evidence 
variable’ alone does not adequately explain the empirical puzzle and, that there is an 
important piece missing in solving the puzzle. 
The  empirical  puzzle  indicates  there  must  be  factors  other  than  the  mere 
presence  or  absence  of  good-quality  evidence  that  explain  why  benefit  assessment 
outcomes vary between countries. The evidence base underlying the ten case studies of 
pharmaceutical  benefit  assessments  in  this  thesis  is  controlled  for,  i.e.  the  same 
randomised controlled trials (RCTs) and other clinical data are available for all ten cases 
due  to  the  global  nature  of  clinical  trials.  However,  the  empirical  analysis  of  the 
decision-making  processes  in  these  ten  cases  indicates  that  HTA  organisations  in 
England  and  Germany  attach  different  meaning  to  different  types  of  evidence  and 
prioritise clinical and other outcomes differently. This suggests that different rules are 
applied  to  the  same  evidence,  which  can  result  in  contrasting  interpretations  of  the 
evidence. It seems that it is the interpretation of the evidence, rather than any inherent 
characteristic of the evidence itself, that plays a key role in determining the outcome of 
pharmaceutical benefit assessments. According to Van Der Wilt and Reuzel: “[…] it is 
important to be aware of the fact that any HTA is likely to be constrained by normative 
                                                        
9 See definitions and discussions on HTA in chapters 1 and 5.  
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considerations, determining those facts to which we will turn our attention” (Van Der 
Wilt and Reuzel, 1998, p. 352).  
The previous remarks explain the emphasis on the interpretation of evidence as 
a  key  to  approaching  this  thesis’  research  question.  Evidence  questions  are  framed 
according to different criteria and values. This impacts on what counts as evidence in 
the first place and whether the evidence is deemed satisfactory. Biller-Andorno, Lie and 
Meulen  argue  that  “[…]  moral  values  often  play  a  hidden  role,  not  only  in  the 
production of ‘evidence’, but also in the way this evidence is used in policy making” 
(Biller-Andorno,  Lie  and  Meulen,  2002,  p.  261).  The  empirical  puzzle  therefore 
demands  a  theoretical  approach  by  which  one  can  discern  and  explain  the  rules  of 
evidence that impact on a comparable, i.e. identical, evidence base in the form of RCTs 
and  other  global  trial  data,  in  a  way  that  explains  both  converging  and  diverging 
assessment outcomes. 
The thesis employs the concept of policy paradigms to explain both converging 
and  diverging  pharmaceutical  benefit  assessment  outcomes  between  countries. 
Paradigms, henceforth conceptualised as intellectual frameworks that determine which 
issues are considered important and relevant in the assessment process, help explain 
why a number of features of an evidence base attain different meanings in different 
HTA systems and how this may lead to divergent HTA outcomes. Paradigms give rise 
to different rules of evidence and in doing so, paradigms function as guides for which 
pieces  or aspects  of  evidential information  will be considered  relevant  by decision-
makers. Paradigms may also influence stakeholders’ positions and views in assessment 
processes,  which  may  in  turn  impact  on  the  final  outcome  of  a  given  assessment. 
Understanding  what  determines  the  outcomes  of  pharmaceutical  benefit  assessment 
with reference to a policy paradigm framework is a two-step process in which, as a first 
step, both the paradigm and the rules of evidence have to be identified and, as a second 
step, the operationalisation thereof has to be examined. 
What follows in the proceeding sections is an overview of how policy paradigms 
have been conceptualised and employed as a theoretical construct in the literature on 
policy paradigms, ideas and the history of science. This includes an outline of the way 
in which policy paradigms are operationalised in this thesis as well as an outline of the 
main variables that emerge from the literature on policy paradigms. The chapter then 
continues  by  providing  a  brief  overview  of  some  of  the  ways  in  which  challenges 
around  questions  of  evidence  are  developed  and  explained  in  different  branches  of  
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literature  such  as  the  literature  on  evidence-based  policy  and  policy  analysis.  This 
serves  the  goal  of illustrating that evidence acquires  different  meanings in  different 
contexts, a phenomenon that Majone (1989) associates with different ‘rules of evidence’ 
in policy systems. Finally, a brief excursion is taken to look at some of the alternative 
theoretical models that were considered in the research process and to explain why these 
models were not pursued.  
 
2.1. Policy Paradigms 
 
The  roots  of  the  use  of  paradigms  to  explain  a  myriad  of  phenomena  are 
frequently  accredited  to  Kuhn  (1962),  who  introduced  ‘paradigms’  as  overarching 
frameworks  of  ideas  and  worldviews  to  explain  change  and  stability  in  scientific 
research within communities of scientists over the centuries. In exploring the history of 
science and scientific revolutions, Kuhn (1962) concluded that within a community of 
scientists paradigms influence which problems are defined as problems worth solving 
and, which methods and theoretical assumptions are deemed appropriate in trying to 
solve  them.  Kuhn  originally  defined  ‘paradigms’  as  “[…]  universally  recognized 
scientific  achievements  that  for  a  time  provide  model  problems  and  solutions  to  a 
community  of  practitioners”  (Kuhn,  1962,  p.  viii).  They  give  rise  to  “[…]  some 
accepted examples of actual scientific practice – examples which include law, theory, 
application and instrumentation […]” (Kuhn, 1962, p. 10). In other words, paradigms 
are more than overarching intellectual frameworks of ideas and worldviews, they also 
give rise to accepted rules, methods, theories and instruments to approach scientific 
puzzles. Scientific revolutions and change occur when the dominant rules, methods and 
theories are no longer adequate in explaining the problems that a scientific community 
is  trying  to  solve,  for  example  when  anomalies  in  one’s  theories  arise  from  new 
discoveries that need to be explained (Kuhn, 1962, pp. 52-53). 
The  concept  of  ‘paradigms’,  or  ‘policy  paradigms’,  is  the  subject  of  an 
expanding strand of literature in political science and public policy, which emphasises 
the importance of ideas, values and beliefs in explaining the policy process and policy 
change.  Theories  on  policy  paradigms  emerged  from  a  dissatisfaction  with  another 
theoretical  stream,  namely  that  of  new  institutionalism,  to  explain  institutional 
development and especially change (Béland and Cox, 2011a). This dissatisfaction gave 
rise  to  what  Béland  and  Cox  (2011a)  refer  to  as  “ideational  approaches”  –  which  
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include  policy  paradigms  -  to  the  policy  process.  There  is  now  a  growing  body  of 
literature that suggests that ideas play a role in shaping the policy process (e.g. Hall, 
1993; Campbell, 2002; Poteete, 2003; Menaheim, 2008; Béland and Cox, 2011). 
A  consistent  definition  of  ‘ideas’  is  lacking  in  the  ideational  literature. 
According  to  Poteete:  “Ideas,  broadly  understood,  encompass  everything  from 
normative and ontological beliefs to perceptions about the disposition of other actors to 
understandings of causal relationships” (Poteete, 2003, p. 531). Béland and Cox define 
ideas as “causal beliefs […], products of cognition” (Béland and Cox, 2011a, p. 3), 
which provide guides for action. While the lack of a consistent conceptualisation of 
‘ideas’ is acknowledged as a shortcoming, the issues that arise from it are secondary for 
the purpose of this thesis and are not expanded upon any further. For the purpose of this 
thesis, ideas are conceptualised as distinctive concepts related to one another in a logical 
framework of decision and analysis. These distinctive concepts can be normative or 
empirical assumptions about policy problems, goals and tools and they are embedded in 
HTA policy paradigms  at any given time.  As we shall see, an example of the role 
played by ideas is the distinctive and differing conceptualisation of evidence in HTA 
processes in England and Germany. While NICE recognises patient views as evidence 
in their own right, IQWiG does not consider views brought forward by stakeholders as 
evidence. This demonstrates a distinctive idea, a distinctive understanding, about the 
concept of evidence. For the theoretical argument of the thesis, an understanding of the 
concept of policy paradigms and the operationalisation thereof is more important than a 
precise definition of ‘ideas’. Indeed, limiting the theoretical approach to a precisely 
defined  outline  of  what  an  ‘idea’  is,  would  have  run  the  risk  of  missing  important 
ideational factors in the empirical analysis because a too narrowly specified definition 
of ‘ideas’ might have prevented it. 
Despite some differences in the definition and operationalisation of paradigms in 
the  public  policy  literature,  common  and  recurring  themes  can  be  identified.  These 
include an understanding of paradigms that denotes a common view of the world, be it 
the world of a scientific community or the world of a wider policy community (e.g. 
Kuhn, 1962; Hall, 1993; Poteete, 2003; Kay, 2007; Béland and Cox, 2013). They also 
include an assumption that values and beliefs are strongly embedded in paradigms and 
that, taken together, the worldview, values and beliefs give rise to a limited set of policy 
problems, options and tools in any given area (e.g. Hall, 1993; Béland and Cox, 2013). 
Paradigms are conceptualised as intellectual constructs that determine what is or is not  
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considered possible, viable, acceptable or desirable in a given field. As outlined in more 
detail in a later section of this chapter, Kuhn’s (1962) work on the history of science and 
the  role  of  paradigms  therein  had  an  influence  on  the  conceptualisation  of  policy 
paradigms  in  this  manner.  The  central  role  of  paradigms  as  a  limiting,  boundary-
defining, intellectual framework plays a major part in this thesis as it helps explain what 
is considered important in a given pharmaceutical benefit assessment process, i.e. what 
gets defined as ‘evidence’ in the first place, why notable differences in the rules of 
evidence in  HTAs exist and to  what  extent stakeholder positions  are permitted and 
considered during the process of assessment.  
Arguably the most influential research on the role of policy paradigms is by Hall 
(1989;  1993).  In  line  with  Kuhn’s  (1962)  analysis  of  paradigms,  Hall  employs  the 
concept to explain how policy change occurs when issues arise that can no longer be 
explained  or  solved  by  using  familiar  policy  options  and  tools.  Underlying  Hall’s 
thinking is a conceptualisation of the policy process as:  
 
[…] a process that usually involves three central variables: the overarching goals 
that guide policy in a particular field, the techniques of policy used to attain 
these goals, and the precise settings of these instruments (Hall, 1993, p. 278). 
 
Hall argues that the three central variables outlined above gain meaning and content in 
the context of policy paradigms: 
 
[…] policymakers customarily work within a framework of ideas and standards 
that specifies not only the goals of policy and the kind of instruments that can be 
used to attain them, but the very nature of the problems they are meant to be 
addressing [...] this interpretive framework is a policy paradigm (Hall, 1993, p. 
279). 
 
In  other  words,  a  policy  paradigm  acts  as  an  umbrella  of  ideas,  values  and  policy 
options under which policy actors engage and develop policies. Policy change occurs 
when there are alterations in policy paradigms, brought about by external or internal 
factors, that open up new policy options. 
   The function of policy paradigms as an umbrella of ideas, values, policy goals 
and options has been taken up by other authors  in the field (e.g. Menaheim, 1998; 
Bergeron and Kopp, 2002; Kay, 2007). For example, in an article on changes in public 
health insurance policies in Australia, Kay argues that:  
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Policy paradigms shape and structure how problems are framed; the imperatives 
for reform and the reform proposals offered; they are a relatively coherent set of 
assumptions about political, social and economic institutions and a policy road 
map of how to reform existing or how to introduce new programs. They contain 
a set of cognitive and normative maps or frames that orientates actors within a 
policy sector, defines the problems, the goals and the means of achieving these 
(Kay, 2007, p. 583). 
 
Similar views on policy paradigms can be found in case studies on a range of 
policy areas, the number of which is growing. Policy paradigms have been used as 
theories  to  explain  phenomena  in  the  areas  of  pension  policies  (e.g.  Melo,  2004; 
Orenstein,  2013),  water  policy  (Menaheim,  1998),  property  rights  policies  (Poteete, 
2003), drug abuse policies (Bergeron and Kopp, 2002), public health insurance policies 
(Kay, 2007) and economic policy (Hall, 1989). Most of these studies are case studies 
that are confined to a particular country, e.g. water policy in Israel (Menaheim, 1998) or 
property rights policies in Botswana (Poteete, 2003). Common to these case studies is a 
conceptualisation of policy paradigms as a framework of ideas that influence policy 
problems  and  solutions.  Frequently,  they  also  examine  the  role  of  institutions  as 
vehicles or obstacles to the implementation of ideas (e.g. Hall, 1989; Poteete, 2003). For 
example, Hall (1989) attributes the move towards Keynesian policies in post-war Great 
Britain  to  institutional  structures  that  lent  themselves  well  for  Keynesian  ideas.  He 
asserts  that:  “[…]  ideas  acquire  force  when  they  find  organisational  means  of 
expression” (Hall, 1989, p. 275).  
Hall’s (1989) preceding assertion is taken up in this thesis in the sense that HTA 
institutions such as the National Institute for Health and Care Excellence (NICE) and 
the  Institute  for  Quality  and  Efficiency  in  Health  Care  (IQWiG)  are  understood  to 
represent  the respective HTA paradigms  in  England  and Germany. The aim of this 
research is to identify the HTA paradigms in England and Germany and to compare and 
contrast how they impact on assessment outcomes. In light of this aim, I assume that 
national HTA paradigms become estabished in HTA bodies and I underline this point 
by examining how the main ideas of a given paradigm are applied in practice during the 
decision-making  processes  of  HTA.  I  examine  how  these  paradigms  are  being 
implemented post-policy change – the change from a situation in which there were no 
HTAs to a situation in which HTAs have become an established feature in health care 
decision-making  –  and  how  this  affects  the  final  outcomes  of  benefit  assessments. 
Institutional variables are considered in the analysis, but they are not at the forefront  
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because they give little insight into how rules of evidence are operationalised within 
different  HTA  policy  paradigms.  Put  differently,  identifying  that  an  idea  has  been 
institutionalised does not give insight into how this idea is operationalised in a ‘normal’ 
decision-making process. The reference to the concept of a ‘normal’ decision-making 
process is based on Kuhn’s (1962) concept of ‘normal science’, which is explained in 
more detail in the next section.  
Finally,  the  body  of  literature  on  policy  paradigms  makes  an  additional 
important theoretical contribution. It highlights that a number of different paradigms 
may exist in a policy area at any given time. For example, Bergeron and Kopp (2002) 
juxtapose  the  “harm  reduction  paradigm”  against  the  “psychoanalysis  paradigm”  to 
explain the perceived uniqueness of French drug abuse policies and the changes that 
have been introduced more recently. Similarly, Menaheim makes a distinction between 
two water policy paradigms in Israel between 1948-1997, namely a paradigm “[…] of 
expanding water resources and agricultural production […]” and “[…] a paradigm of 
priority of agricultural expansion over water conservation” (Menaheim, 1998, p. 283).  
The  assumption  that  a  number  of  different  paradigms  exist  in  a  policy  area 
suggests  that  any  research  that  is  built  on  the  centrality  of  policy  paradigms  as  a 
theoretical model requires an awareness of the currently existing policy paradigms and 
their main principles. Moreover, it requires an understanding of the currently prevailing 
paradigm in a policy field. For the purpose of this thesis, the prevailing HTA paradigm 
will be labeled the ‘dominant’ or the ‘emerging’ paradigm to denote its importance. In 
approaching the research question the task of identifying the emerging dominant HTA 
paradigm  is  comparatively  more  important  that  identifying  other,  perhaps  auxiliary, 
paradigms.  This  is  because  I  argue  that  the  outcomes  of  pharmaceutical  benefit 
assessments  are affected by divergent  HTA policy paradigms  in  different  countries; 
underlying this argument is the assumption that dominant HTA paradigms emerge in 
the  process  of  HTA  decision-making  and  that  these  impact  on  benefit  assessment 
outcomes.  Whilst  the  empirical  analysis  does  provide  some  insight  on  auxiliary 
paradigms, the focus of the thesis is on exploring a) how the dominant HTA policy 
paradigm  can  be  described,  b)  how  it  is  operationalised  during  the  ‘normal’ 
pharmaceutical benefit assessment process and c) how this operationalisation affects the 
final outcome of assessments.  
In summary, the literature on paradigms and policy paradigms gives rise to three 
key findings. Firstly, it ascribes an important role to ‘ideas’ in the policy process (e.g.  
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Béland and Cox, 2011; Kurzer, 2013). Ideas are embedded in paradigms that function as 
an umbrella construct under which certain policy options, or outcomes, are possible 
while  others  are  not.  Change  can  occur  under  a  given  umbrella,  but  the  impact  of 
change depends on the kind of policy challenges that it needs to respond to (Hall 1993; 
1989). The more significant the challenges, the more likely it is that an old paradigm 
gives way to a new paradigm (Hall, 1993). Secondly, institutions matter in the policy 
process. They matter because they are a reflection of certain policy paradigms that may 
or may not have changed over time (Radaelli, 1995). And thirdly, a number of policy 
paradigms can exist in a given policy area at any given time (e.g. Menaheim, 1998; 
Bergeron and Kopp, 2002) and it is for the researcher to identify these paradigms in 
order to distinguish between emerging dominant and auxiliary paradigms.  
 
2.2. Shortcomings in the Extant Literature 
 
The majority of researchers who employ ideational approaches generally, and 
policy paradigm approaches specifically, are concerned with explaining policy change. 
In doing so, and in line with Kuhn’s (1962) original thoughts on the subject, the focus is 
on paradigm shifts. Policy change is perceived as the dependent variable whilst policy 
paradigms,  and  the  changes  therein,  are  independent  variables.  Policy  change  is 
described as a shift in worldviews and perceptions that opens up previously impossible 
policy routes and possibly “[…] usher[s] in a new era […]” (Hall, 2013, p. 191). The 
preoccupation  lies  with  shedding  light  on  the  reasons  why  one  paradigm  became 
dominant over another and the circumstances that make transitions from one dominant 
paradigm to another possible (e.g. Bergeron and Kopp, 2002; Kay, 2007; Menaheim, 
2008).  Here,  Hall  (1993)  distinguishes  between  first  order  (affecting  the  instrument 
settings),  second  order  (affecting  the  instruments)  and  third  order  (affecting  the 
overarching goals) change in the policy process. Hall (1993) argues that the likelihood 
of true paradigmatic change, i.e. pursuing a policy path that was previously closed off, 
depends on which of the three policy process variables is targeted by a novel idea, how 
this idea sits with the current policy paradigm and the institutional characteristics of a 
system. 
The preoccupation with policy change represents a shortcoming in the current 
literature that employs policy paradigms as theoretical models to explain a variety of 
empirical phenomena. It is a shortcoming because it has led to an almost exclusive  
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focus on empirical phenomena of change in policy processes. In turn, this has led to a 
comparative  neglect  of  the  equally  interesting  question  of  how  emerging  dominant 
policy paradigms shape day-to-day outcomes in given policy areas such as HTA policy. 
In  other  words,  what  role  do  policy  paradigms  play  post-policy  change,  in  the 
implementation phase of the policy cycle? How are they operationalised and put to use?  
The  aforementioned  questions  are  comparatively  under-researched  in  the 
literature.  The  previous  discussion  of  case  studies  that  employ  policy  paradigms  as 
theoretical  contructs  has  shown  that  there  is  a  tendency  to  emphasise  the  role  of 
paradigms prior to policy implementation. In other words policy paradigms are used to 
explain the outcomes of the policy-making process. However, the theoretical premise of 
this thesis is that policy paradigms can also contribute to a better understanding of how 
policy is implemented, and to what effect, by looking at how paradigms operate when 
policy is put into practice. Theories on policy implementation have emphasised the need 
to examine how policy gets translated into practice, and perhaps transformed through 
the involvement of actors such as professionals and bureaucrats (e.g. Dunleavy, 1981; 
May and Winter, 2009; Honig, 2006), which in turn affects how policy is adapted at a 
later  date.  Policy  paradigms  can  offer  an  additional  angle  in  the  analysis  of 
implementation.  
However, it is not just against theories on policy implementation that the use of 
paradigms is worth exploring. It is also worth exploring because the traditional view of 
the policy process as consisting of several distinct phases of policy-making has been 
criticised.  Several  authors  have  argued  that  this  view  of  policy-making  is  over-
simplified and that, in reality, where policy-making ends and implementation begins 
(and vice versa) is more difficult to discern, with one affecting the other (e.g. Sabatier 
and Jenkins-Smith, eds., 1993). In line with this view, this thesis offers an additional 
theoretical perspective by examining the role of paradigms in policy implementation as 
an extension of the fluid process of the policy process. 
The  problem  that  arises  from  the  current  focus  in  the  literature  on  policy 
paradigms is that it implies that they are operationally static or insignificant during 
times in which policy changes, i.e. significant paradigm shifts, are not occurring. As a 
result  there  is  little  empirical  understanding  of  the  effect  and  characteristics  of 
paradigms  on  ‘normal’  decision-making  processes.  For  the  purpose  of  this  thesis 
decision-making processes are conceptualised as the argumentative processes that lead 
to decisions on the benefits of pharmaceutical products in the context of HTA. They are  
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the  processes  that  occur  when  HTA  policy  in  a  given  country  is  implemented  and 
refined. The  emphasis  on  normal processes is  derived  from  Kuhn’s  insights  on the 
importance  of  ‘normal  science’  for  capturing  and  understanding  paradigms  (Kuhn, 
1962, pp. 10-11). Kuhn introduces the term ‘normal science’ as a concept that is closely 
associated  with  the  dominant  paradigm  in  a  given  scientific  community.  Kuhn’s 
delineations on ‘normal science’ are frequently neglected in the public policy literature 
on paradigms, but the following paragraphs show that the conceptualisation of ‘normal 
science’  as  processes  in  which  paradigms  are  articulated  and  refined  is  useful  in 
capturing the essence of paradigms in public policy. 
In  a postscript  to  a later edition  to  his  original piece of work, Kuhn  (1969) 
distinguishes between a paradigm as consisting of beliefs and values shared by a certain 
community  and  a  paradigm  as  encompassing  more  practical  aspects  of  scientific 
research, for example appropriate methods and models in solving a problem (Kuhn, 
1969, p. 175). Over the years, Kuhn’s delineation of the term ‘paradigm’ has received 
much attention, some of it critical when it comes to the appropriateness of defining and 
using the term in the way he suggests. A discussion of these criticisms goes beyond the 
purpose of this section, let alone the aim of this thesis as a whole. However, Kuhn’s 
(1962)  contributions  with  regards  to  what  he  labels  ‘normal  science’  are  helpful  in 
underlining this thesis’ theoretical approach and contribution. 
According to Kuhn: 
 
[…]  ‘normal  science’  means  research  firmly  based  upon  one  or  more  past 
scientific  achievements,  achievements  that  some  particular  community 
acknowledges  for  a  time  as  supplying  the  foundation  for  its  further  practice 
(Kuhn, 1962, p. 10).  
 
When these achievements provide a sufficient number of scientific problems to solve 
and  when  they  are  more  convincing  than  their  competitors  in  offering  routes  to 
explanations of these problems, then they can be referred to as paradigms (Kuhn, 1962). 
In other words, in Kuhn’s view the terms ‘paradigm’ and ‘normal science’ lie closely 
together. Normal science can be thought of as paradigms in operation (Kuhn, 1962, p. 
11), that is an expression of the way paradigms are developed, established and put into 
practice.  
Kuhn also refers to ‘normal science’ as paradigm-based research (Kuhn, 1962, 
p.  25),  that  is  research  traditions  that  consist  of  laws,  theories,  applications  and  
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instrumentations (i.e. methods) that guide the work of scientific communities. Kuhn 
illustrates that these traditions of ‘normal science’ or paradigm-based research do not 
come  to  exist  overnight,  but  that  they  are  result  of  a  periods  of  development  and 
adjustment within branches of science by which paradigms of how to conduct research 
become ‘normalised’. Over time, the community of scientists comes to agree on what 
facts are relevant to their discipline, how these facts relate to dominant theories and how 
research should be conducted to further articulate those theories (Kuhn, 1962, pp. 32-
33).  In  the  process  of  articulating  research  paradigms,  rules,  for  example  on  the 
appropriateness of certain methods over others, emerge. Here, Kuhn asserts that the 
study of normal science and the rules contained therein provides insights into the given 
paradigm one is studying: “The study of normal-scientific traditions discloses many 
additional  rules,  and  these  provide  much  information  about  the  commitments  that 
scientists derive from their paradigms” (Kuhn, 1962, p. 40).  
Kuhn asserts that different rules between research paradigms can help explain 
why  similar  problems  and  solutions  are  viewed  differently  by  different  scientific 
communities. He illustrates his point with the following example: 
 
An investigator who hoped to learn something about what scientists took the 
atomic  theory  to  be  asked  a  distinguished  physicist  and  an  eminent  chemist 
whether a single atom of helium was or was not a molecule. Both answered 
without hesitation, but their answers were not the same. For the chemist the 
atom of helium was a molecule because it behaved like one with respect to the 
kinetic  theory  of  gases.  For  the  physicist,  […],  the  helium  atom  was  not  a 
molecule because it displayed no molecular spectrum.  Presumably both men 
were talking of the same particle, but they were viewing it through their own 
research training and practice (Kuhn, 1962, pp. 50-51).  
 
This example highlights the importance of normal science, paradigms and rules to the 
framing of problems and solutions. It is key to understanding this thesis’ theoretical 
approach. Paradigms can help explain why answers to similar questions, namely the 
question of what constitutes the benefits of a pharmaceutical product, are frequently 
different  in  different  countries.  Assessment  outcomes  vary  as  a  result  of  paradigm 
differences and, as Kuhn points out, such paradigm differences can be “consequential” 
(Kuhn, 1962, p. 51). In health policy they are consequential in the sense that the lead to 
differences in the access to new medicines that is covered by public health care systems. 
By emphasising the connection between normal science and paradigms, Kuhn 
(1962) makes the point that paradigms should not be thought of as static constructs, but  
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rather as constructs that get developed during the processes of normal science in which 
certain questions are considered worth pursuing by a given scientific community. He 
argues: “In a science, […], a paradigm is rarely an object for replication. Instead, like an 
accepted judicial decision in the common law, it is an object for further articulation and 
specification […]” (Kuhn, 1962, p. 23). He further argues that paradigms promise to 
contribute to the solution of problems and that normal science is the “actualization of 
that promise” (Kuhn, 1962, p. 24). It is this latter thought, the ‘actualization of the 
promise’  of  a  paradigm,  that  influenced  the  theoretical  focus  and  methodological 
approach of this thesis. Essentially, Kuhn argues that paradigms get articulated when 
put into operation and that during this process of operation they are further refined, i.e. 
their  promise  is  actualised  (or  not,  depending  on  the  strength  and  security  of  the 
paradigm). This suggests that one cannot hope to capture, let alone understand, the 
elements  of a paradigm without examining how it is  operationalised  and refined in 
‘normal’ practice. Hence the focus of this thesis is on analysing how policy paradigms 
of HTA are operationalised in England and in Germany and how this affects the final 
outcome of the assessments.  
The fact that Kuhn’s argument stems from an analysis of what he refers to as 
scientific revolutions  does  not  make it less applicable to  the study of  public policy 
generally and health policy specifically. This is because one of his main points, namely 
that paradigms are refined in the process of engaging in normal science, is transferable 
to  many  other  subject  matters.  One  can  learn  about  the  impact  of  paradigms  on 
empirical phenomena such as the outcome of HTAs not just by assuming that they are 
influential, but by examining how they are established in ‘normal’ practice and how this 
‘normal’ practice leads to manifestations or alterations in a given paradigm. Building on 
Kuhn’s  concept  of  normal  science  as  paradigm-based  research  I  argue  that  HTA 
decision-making  is  essentially  paradigm-based  and  that  the  identification  of  HTA 
paradigms can help explain variations and similarities in HTA outcomes. 
As  we  shall  see  in  chapters  6-8,  the  analysis  of  the  ten  case  studies  of 
pharmaceutical benefit assessments demonstrates that the influence of HTA paradigms 
is nuanced. Different paradigms do not, as a matter of course, lead to different HTA 
outcomes,  but  they  help  explain  the  different  conceptual  lenses  through  which,  for 
example, pieces of evidence are viewed. By looking at how the paradigms are applied in 
normal practice, one can learn about which elements undergo further definition, which 
ones are open to flexible interpretations and which ones represent minimum ‘thresholds’  
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that have to be met in order to fit with the paradigm. Put differently, HTA paradigms 
undergo further definition and specification beyond their formulation in statutory or 
methodological frameworks and this occurs during their routine application in specific 
decision-making or policy-making processes.  
In summary, the main shortcomings  of the  extant literature on paradigms  in 
public policy is the lack of studies on how paradigms are operationalised in periods 
other than policy change. Currently, policy paradigms are used as concepts to explain 
policy change without an in-depth elaboration on the characteristics of the paradigms 
and,  more  importantly,  how  they  have  become  articulated  and  specified  in  normal 
practice. The implications of this shortcoming should not be underestimated because the 
question arises how one can seek to understand the role of paradigms in policy change 
without fully understanding the way they are (were) put into practice in the first place. 
Understanding the operation of policy paradigms is undoubtedly  more arduous than 
describing their role in policy change. However, ultimately it might lead to a deeper 
understanding of paradigms and perhaps a more precise definition of what they are in 
the context of public policy-making. 
The  merits  of  the  above  approach  have  been  highlighted  in  the  previous 
paragraphs. However, a note of caution is necessary in that ‘normal’ decision-making in 
HTA  may  be  more  challenging  to  identify  than  the  ‘normal  science’  of  scientific 
communities that Kuhn (1962) refers to. This is in part because HTA processes include 
a  number  of  different  actors,  with  different  interests  and  from  different  disciplines. 
However, despite this complexity the empirical analysis contained in this thesis shows 
that  patterns,  rules  and  methods  do  exist  in  the  ‘normal’  HTA  decision-making 
processes and that these can be viewed as a reflection of different paradigms. Whether 
or not  these patterns, rules  and methods  coincide with  the belief systems  (Sabatier, 
1988)  of  one  community  of  stakeholders  rather  than  another  is  secondary  for  the 
purpose of this thesis’ research question. As a first step, this thesis seeks to understand 
what  determines  the  outcomes  of  pharmaceutical  benefit  assessments  in  different 
countries and how paradigms can be used to explain these outcomes. The second step, 
i.e.  a  closer  examination  of  whether  the  paradigms  align  with  those  of  certain 
stakeholder communities or whether they are indeed ‘shared paradigms’, is a step that 
goes beyond the scope of this research and would have to be undertaken as a separate 
research endeavour in the future.  
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In conclusion, this thesis does not seek to explain why policy change occurred. 
Instead, it seeks to explore how a policy paradigm, i.e. the dominant HTA paradigm in a 
given country, becomes established in a normal every-day decision-making process and 
how this affects the outcome of the process. In line with the extant literature in the field, 
the function of policy paradigms as an umbrella construct that encompasses a set of 
specific  policy  options  and  tools  is  at  the  heart  of  this  research,  but  rather  than 
examining  what  happens  to  policy  paradigms  in  periods  of  transition,  or  how  they 
explain these transitions, I examine how they matter in periods of perceived stability 
and how they impact on a politically salient case of decision-making in health care 
policy, i.e. that of pharmaceutical benefit assessments.  
In comparison to other policy paradigm approaches, the principles contained 
within policy paradigms still feature as the independent variables for the purpose of this 
study. However, in contrast to other case studies, the dependent variable is not policy 
change, but rather the outcome of decisions on the benefits of pharmaceutical products. 
My theoretical  contribution lies in the expansion of  the use of policy paradigms as 
theoretical  concepts  to  explain  empirical  puzzles  other  than  change.  The  theoretical 
insights  from  this  research  are  strengthened  by  the  comparative  cross-national  case 
study approach that is employed as this approach discloses different paradigms and how 
they  operate  under  ‘normal’  circumstances.  By  identifying  the  HTA  paradigms  in 
England  and  Germany  and  comparing  and  contrasting  how  they  are  articulated  in 
normal benefit assessment processes on the same pharmaceutical products, a deeper 
understanding of the function of paradigms as fluid constructs that influence outcomes 
is gained.  
The next section outlines how the above findings are adapted and developed in 
an effort to explain what determines the outcome of pharmaceutical benefit assessments 
in countries that employ formalised HTA procedures. 
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2.3. The Policy Paradigms of Pharmaceutical Benefit Assessments: A Conceptual 
Framework 
 
From the discussion of the literature on policy paradigms, one can conclude that 
different paradigms,  or  ways  of approaching  a  problem,  exist in  policy fields.  This 
suggests that different paradigms exist within national and international HTA decision-
making  and  it  might  help  explain  what  determines  the  outcome  of  pharmaceutical 
benefit assessments. In order to explore the validity of the assumption that different 
policy paradigms exist within the HTA policy arena, it is useful to recall how one of the 
professional networks dedicated to the promotion of HTA defines the concept. Here, the 
general idea of HTA is defined as: 
 
[…] a multidisciplinary process that summarises information about the medical, 
social, economic and ethical issues related to the use of a health technology in a 
systematic,  transparent,  unbiased,  robust  manner.  Its  aim  is  to  inform  the 
formulation of safe, effective, health policies that are patient focused and seek to 
achieve best value (EUnetHTA, 2014). 
 
The  above  definition  of  HTA  implies  that  decision-makers  have  a  range  of 
issues and tools to choose from when it comes to designing HTA policies. How the 
general ideas of HTA are articulated and developed in a given national context is crucial 
with regards to understanding HTA paradigms. Decisions have to be made with regards 
to what counts as medical, social, economic and ethical issues in a given country and 
whether  there  are  boundaries  to  these  issues.  Decisions  also  have  to  be  made  with 
regards to which methods are considered most appropriate to provide a transparent and 
unbiased assessment. Finally, an agreement has to be found on what constitutes a ‘focus 
on the patient’ and ‘best value’, especially because it is easy to conceive of a situation in 
which patient focus might not sit well with the idea of value for money and vice versa. 
For example, ‘patient focused’ policies may give rise to the view that medicines that 
extend a patient’s life by 3-4 months at the end of his/her life should be available and 
covered by the public health system, whereas a ‘best value’-approach would suggest 
that 3-4 months of additional lifetime gained does not justify the high costs of these 
medicines and that the money might be better spent elsewhere.  
The  above  scenario  exemplifies  a  common  dilemma  in  health  care  priority 
setting. That is the dilemma of making judgements on issues such as the ‘right’ care 
pathways and ideology on access to health care to apply when these might be in conflict  
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with  each  other  (e.g.  Lehoux  and  Blume,  2000;  Van  Der  Wilt  and  Reuzel,  1998). 
Resolving  this  dilemma  entails  making  difficult  choices  and  the  outcome  of  these 
choices is, for the purpose of this thesis, conceived of as a reflection of different policy 
paradigms.  Just  as  Kay  argues  that  “[…]  universal  public  health  insurance  has  a 
different meaning in a paradigm with patient choice at its core compared to one based 
on equality of access to service” (Kay, 2007, p. 583), I argue that HTA generally, and 
HTA evidence specifically, has a different meaning depending on the core features of a 
paradigm. In the context of the previous example, I would argue that the presented 
dilemma can be understood as a contest between a ‘patient focused’ paradigm and a 
‘best value for money’ paradigm.  
In the policy field of HTAs one is faced with a situation in which, from a single 
definition of HTA, potentially multiple sub-paradigms emerge. The relative priority that 
is given to issues contained in sub-paradigms depends on ideational and institutional 
factors that are specific to national  contexts. As Littlejohns, et al. point out: “Even 
explicit and seemingly “scientific” criteria such as clinical and cost effectiveness are 
embedded in views about, for example, the value of different health states” (Littlejohns, 
et al., 2012, p. 286). Given the complexities of HTAs, it is reasonable to assume that a 
variation in HTA paradigms between different countries exists, a variation that depends 
on the issues, criteria and methods – the rules of evidence - that are put at the centre of 
the assessments. These issues, criteria and methods are in turn shaped by the values and 
ideas  that  are embedded in  the health care context,  i.e. the overarching health care 
paradigm. Applying a policy paradigm framework to the HTA policy area thus entails 
the identification and analysis of paradigms at two levels that differ in terms of the 
range of fields for which they are relevant. 
At a first level one can identify paradigms that are limited to the specific policy 
area that is the subject of one’s study, e.g. drug abuse policy, inflation policy or, as in 
the case of this thesis, HTA policy. Within these policy areas one can describe currently 
dominant paradigms that give rise to problems, solutions and policy tools. These are 
what Hall labels “[…] narrower paradigms that often dominate specific fields of policy” 
(Hall, 2013, p. 191). The problems that are tackled and the tools that are used are a 
reflection of what Kuhn (1962) labels ‘normal science’ and they provide insights into 
how paradigms operate in normal routine practice. For example, in relation to evidence 
questions in HTA they help explain why HTA bodies may have divergent views on the 
same evidence on the same pharmaceutical products.   
  57 
The specific ‘narrow’ paradigms are usually not applicable to other policy areas 
such as elderly care policies or drug abuse policies for example. However, they  are 
shaped by broader paradigms of values and worldviews that are operational on a second 
analytical level. HTA, elderly care and drug abuse policies operate within wider health, 
social care, and public health paradigms that need to be considered if one seeks to 
understand the narrow paradigms of specific fields of policy (Hall, 2013). For example, 
Menaheim (1998) illustrates that water policy paradigms are closely connected with 
agricultural policy in Israel and explains it with reference to the overarching Zionist 
ideology – or paradigm - which ascribes a crucial role in Israel’s nation-building efforts 
to agricultural policy measures. When applied to health care, the above remarks suggest 
that the dominant HTA paradigm will also be a reflection of the overarching health care 
paradigm.  That  is  to  say  that  core  features  such  as  utilitarian  or  individualistic 
approaches to health care are likely to give rise to different HTA paradigms. 
For the purpose of this thesis, the narrow HTA paradigms emerge from statutory 
frameworks and methodological guidelines that HTA bodies are required to adhere to. 
However, as highlighted previously, their precise elements and articulation can only be 
understood  by  analysing  how  they  are  applied  in  practice  during  the  normal 
pharmaceutical decision-making processes, which explains why the empirical focus of 
this thesis is on the ten case studies of assessments. The broader health care paradigms 
emerge from the statutory and constitutional pillars of health care. However, while the 
broader health care policy paradigms will be identified, they are not the focus of this 
thesis. It is important to be aware of them and to identify them in order to understand to 
what extent the narrow HTA paradigms are a reflection of broader paradigms, but for 
the purpose of answering the research question, the focus is on analysing how different 
HTA  paradigms  are  operationalised.  The  aim  is  to  examine  how  different  rules  of 
evidence,  stakeholder  views  and  institutional  characteristics  that  emerge  from  HTA 
paradigms impact on the outcomes of pharmaceutical benefit assessments. 
In the next section I sketch how I adapt the independent variables that arise from 
the literature on policy paradigms before offering an overview of the crucial role of 
evidence  and  rules  of  evidence  (Majone,  1989)  in  the  way  policy  paradigms  are 
operationalised for the purpose of this thesis. 
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2.4. Variables 
 
The chapter on the methodological approach of this thesis (chapter 3) highlights 
that factors that contribute to the outcomes of pharmaceutical benefit assessments were 
deduced from the empirical data rather than specifying them a priori. This means that 
any variables that the previous discussion of the relevant literature gives rise to were not 
employed for hypothesis-testing purposes, but rather heuristically as a set of variables to 
refer back to in the completion phase of the empirical analysis. In the final stages of the 
empirical analysis, the themes and factors that emerged were examined in light of the 
variables that arise from the policy paradigm literature in order to understand whether 
new  and  previously  under-theorised  factors  arose.  The  following  section  is  kept 
comparatively brief so as to avoid preempting the results of the empirical analysis that 
are discussed in chapters 6, 7 and 8.  
The ideational and policy paradigm literature underlines the importance of ideas 
as variables in the policy process. However, due to the lack of a consistent definition of 
‘ideas’,  which  results  in  a  lack  of  a  consistent  operationalisation  of  the  concept, 
methodological  problems  emerge  when  capturing  ideas,  or  policy  paradigms,  as 
variables. Hall’s (1993) account of the policy process remains the most sophisticated 
account of the central variables that are at play in the context of a wider framework of 
ideas,  or  paradigms.  To  recall,  Hall  (1993)  conceptualises  the  policy  process  as  a 
process in which goals, techniques and instrument settings of a policy are shaped by an 
‘interpretive framework’ of ideas, the policy paradigm. If the three central variables – 
that is goals, techniques and instrument settings – are framed by a paradigm, then the 
logical inference is that they are also an expression of the dominant paradigm. Hall’s 
(1993)  central  variables  are  also  comparable  to  Kuhn’s  (1962)  analysis  of  normal 
science as a process in which paradigms get formulated and articulated. That is to say, 
that  looking  at  goals,  techniques  or  instrument  settings  (Hall,  1993)  or,  in  Kuhn’s 
(1962)  view,  looking  at  rules,  methods  and  instrumentation  in  normal  processes 
provides an avenue for identifying paradigms. In other words, identifying the goals, 
techniques and instrument settings will prove useful for the purpose of identifying the 
dominant HTA paradigms and their effect on benefit assessment outcomes. Based on 
this theoretical assumption, I adapt Hall’s and Kuhn’s insights in a manner that allows 
me to elicit the dominant HTA paradigms in England and Germany.  
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As outlined in section 2.3., policy paradigms  can be broad and narrow. The 
goals,  techniques  and  instruments  settings  will  serve  as  proxies  for  describing  the 
narrow policy paradigm, that is the dominant HTA paradigm. In other words, the HTA 
paradigm is operationalised by describing the main features of the paradigm in terms of 
its goals, techniques and instrument settings. Given that the guiding assumption of the 
theoretical  approach  is  that  the  HTA  paradigms  determine  the  outcomes  of  benefit 
assessments,  it  is  reasonable  to  assume  that  one  can  capture  these  paradigms  by 
reference to the variables that structure the policy process in which they operate. This 
assumption is consistent with Kuhn’s (1962) view that normal science is paradigms in 
operation and that looking at variables within normal processes will provide a better 
understanding of the elements of a given paradigm. 
The above remarks underline that two central tasks need to be fulfilled in order 
to understand the role of policy paradigms as variables in determining the outcome of 
pharmaceutical benefit assessments. Firstly, the broad health care and HTA paradigms 
in England and Germany have to be identified with the help of statutory frameworks 
and  methodological  guidelines.  As  outlined  previously,  the  goals,  techniques  and 
instrument  settings  of  HTA  policy  will  help  in  the  operationalisation  of  the  HTA 
paradigm. Since these variables are shaped by an overarching health care paradigm, 
their operationalisation will also help with the identification of the principles of the 
overarching paradigms. Secondly, the operationalisation of the narrow HTA paradigms 
needs  to  be  evaluated  in  the  case  study  analyses  in  order  to  determine  whether 
additional features can be identified that extend or alter the dominant HTA paradigm. 
The transferability of Hall’s (1993) framework to the empirical puzzle of this 
thesis might be questioned on the grounds that Hall’s work pertains to policy-making 
processes, policy change and policy learning rather than to decision-making processes 
as an extension of policy-making when policy is implemented. However, despite the 
‘scientific-bureaucratic’  (Harrison,  Moran  and  Wood,  2002)  nature  of  the  HTA 
decision-making  process,  Hall’s  (1993)  assertion  that  policy  goals,  techniques  and 
instrument  settings  are  central  to  understanding  policy  processes  is  applicable, 
especially  if  one  takes  into  consideration  Kuhn’s  (1962)  work  on  the  connection 
between  the  processes  of  normal  science  and  paradigms.  The  thesis’  theoretical 
contribution  is  in  demonstrating  the  applicability  of  Hall’s  and  Kuhn’s  work  and 
showing how policy paradigm frameworks are relevant to a wider number of empirical 
questions than their current use suggests.   
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In summary, the variables that are relevant to answering this thesis’ research 
question include policy paradigms as well as the goals, techniques and the instrument 
settings of policies. Since the operationalisation of policy paradigms is challenging, the 
goals, techniques and instrument settings – i.e. the variables of the ‘normal’ decision-
making process - of HTA policy in England and Germany are used as proxies for the 
dominant HTA paradigms. The underlying intellectual premise is that the way these 
variables are constructed in the statutory and methodological frameworks is a reflection 
of ideas and values that are contained within the overarching broader paradigm that 
shapes the narrower paradigms in a given policy area. When the process of identifying 
policy paradigms is supplemented by the dominant themes that emerge in the empirical 
analysis, the result is an in-depth understanding of what the HTA paradigms in England 
and Germany are, how they are established in normal practice and how this impacts on 
the  outcome  of  pharmaceutical  benefit  assesments.  The  variables  serve  the  primary 
function of assisting in the operationalisation of policy paradigms rather than guiding 
the empirical analysis, which is characterised by a more deductive process.  
The next section provides a brief introduction to the concept of evidence and 
rules  of  evidence  in  decision-making  processes  such  as  HTA  that  rely  heavily  on 
evidential  information.  The  section  further  underlines  how  the  policy  paradigms  of 
HTA are operationalised in this thesis, that is to say that Majone’s (1989) concept of 
‘rules of evidence’ is employed as a further means to identify the crucial characteristics 
of given HTA paradigms.  
 
2.5. Rules of Evidence 
 
  This chapter began by highlighting the important role that evidence plays in 
HTA  processes.  HTAs  are  built  on  the  intellectual  premise  that  scientific  evidence 
should and can inform decision-making in health care (Lehoux and Blume, 2000; Van 
Der Wilt and Reuzel, 1998). I argue that policy paradigms, as outlined above, influence 
the way key questions concerning the scientific evidence in a given benefit assessment 
are approached. That is not to say that evidence questions are the sole variable that is 
influenced by policy paradigms and that shapes the outcome of benefit assessments. 
However, the empirical analysis undertaken in this thesis did give rise to the centrality 
of  evidential  questions  in  assessment  processes  in  that  five  out  of  six  themes  that 
emerged from the data analysis are connected to questions around evidence (see table  
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3.5.).  This,  along  with  the  fact  that  this  thesis’  research  question  arises  from  an 
empirical puzzle in which the evidence base, i.e. the clinical studies on a pharmaceutical 
product, is controlled for, necessitates a brief excursion to the discussions on the role of 
‘evidence’  in  different  strands  of  literature  in  order  to  ascertain  how  controversies 
around  ‘evidence’  are  commonly  explained.  The  excursion  will  highlight  that  the 
process of interpretation can be thought of as a process in which different ‘rules of 
evidence’  (Majone,  1989)  are  applied  to  a  similar  evidence  base.  These  rules  of 
evidence,  which  are  similar  to  Kuhn’s  (1962,  p.  40)  ‘rules  of  the  game’,  can  be 
explained by reference to HTA policy paradigms, as outlined in the previous sections of 
this chapter.  
The extant literature emphasises the contextual nature of evidence, that is that 
the significance of evidence depends on what is relevant in a given policy or other 
context (e.g. Van Der Wilt and Reuzel 1998). This emphasis further strengthens the 
argument that policy paradigms  are useful in  explaining different  approaches to the 
same  evidence  questions  in  HTAs  as  paradigms  may  provide  the  researcher  with  a 
means to capture the ‘context’ within which pieces of evidence are interpreted. Theories 
on  the  use  and  conceptualisation  of  evidence  can  be  found  in  the  literature  on  the 
philosophy of science, evidence-based policy-making, policy analysis and knowledge 
utilisation, to name but a few (e.g. Weiss, 1979; Weiss, 1999). Moreover, the role of 
randomised controlled trials (RCTs) as the allegedly most reliable form of evidence in 
HTAs  and  evidence-based  medicine  has  recently  been  the  subject  of  research  in 
disciplines  such  as  health  policy,  health  ethics,  medicine  and  others  (e.g.  Rawlins, 
2012). This section does not discuss all of the approaches contained in these literatures 
in detail, but highlights a few of the main arguments that are raised and that are of 
relevance to this thesis.  
Uncertainty is an inevitable part in any research endeavour due to the fact that 
there are still a large number of scientific and social phenomena that current knowledge 
cannot yet explain. How policy institutions, research bodies and professionals deal with 
questions  of  uncertainty  specifically,  and  questions  of  interpretation  generally,  is  a 
crucial question when making decisions based on evidence. In discussing the limits of 
evidence-based policies, Pawson, Wong and Owen summarise the predicament around 
‘evidence’ in the following manner: “We seek to justify policy decisions on the basis of 
“known knowns”. The real problem is what to make of the “known unknowns” and the 
even more troubling “unknown unknowns” ” (Pawson, Wong and Owen, 2011, p. 519).  
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They go on to assert that it is almost inevitable that “[…] the knowledge base falls short 
of absolute, indubitable truth” (Pawson, Wong and Owen, 2011, p. 519).  
Pawson, Wong and Owen (2011) exemplify their assertions by conducting a 
systematic review of the evidence on the efficacy of a smoking-ban policy in vehicles 
carrying  children.  In  doing  so,  they  show  that  most  of  the  available  evidence  is 
correlational  rather  than  causal  and  that  a  number  of  confounding  factors  remain 
unaccounted  for.  Therefore  the  evidence  provides  no  definite  answer  to  the  above 
question.  They  conclude  that:  “Measurements  never  stand  alone;  they  always  need 
interpreting.  There  are  always  rival  explanations  of  any  experimental  result  […]” 
(Pawson, Wong and Owen, 2011, p. 542). 
Arguments comparable to those of Pawson, Wong and Owen (2011) are found 
in  the  literature  on  evidence-based  medicine,  HTAs  and  the  philosophy  of  science. 
Goldenberg illustrates that critics of the view that science and evidence are infallible 
argue that: “[…] observations are not “givens” or “data”, but are always the product of 
interpretation (in light of our background assumptions)” (Goldenberg, 2006, p. 2623). 
Similarly,  in  presenting  the  advantages  and  disadvantages  of  using  hierarchies  of 
evidence, i.e. ranking different forms of evidence according to their  alleged quality, 
Rawlins argues that: “[…] decision makers must exercise judgement; hierarchies are no 
substitute” (Rawlins, 2012, p. 1). The aforementioned viewpoints support the theoretical 
argument of this  thesis, i.e. because HTAs are based on evidence, and because the 
evidence  base  is  controlled  for  in  England  and  Germany,  outcomes  of  benefit 
assessment are likely to be explicable by looking at how evidence is interpreted in the 
context of diverging HTA paradigms. In order to answer this thesis research question it 
is  therefore  crucial  to  understand  how  evidence  is  interpreted  and  how  one  might 
explain why it is interpreted in a certain way. 
Cartwright and Hardie (2012) and Majone (1989) speak of ‘relevance’ in order 
to  explain  differences  in  the  interpretation  of  evidence.  A  given  evidence  base,  the 
methods applied to it and the resulting interpretation must be relevant to the policy 
question and context one is operating in. Cartwright and Hardie (2012) offer this advice 
to policy-makers by arguing that evidence-based policies will only prove successful if 
the evidence used is relevant to the given context. They caution policy-makers to rely 
too heavily on RCTs because: 
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An RCT gives you an important true fact, that this has worked somewhere, […]. 
But that won’t make for a secure conclusion if the evidence is weak in support 
of the right kinds of answers to the other questions you need to ask (Cartwright 
and Hardie, 2012, p. 9)
10.  
 
Cartwright and Hardie (2012) label this a ‘theory of relevance’ in which facts are good, 
but meaningless if the relevance to the given national and local context is not ensured. 
They assert that facts and evidence are made relevant to a given context through the 
process of reasoning and argumentation in which the relevance of certain pieces of 
evidence over others will become clear. 
Majone (1989) also highlights the crucial role of evidence as one feature in an 
argumentative  process  in  policy-making.  He  introduces  the  concept  of  ‘rules  of 
evidence’ (Majone, 1989, p. 11) – a concept used in this thesis to operationalise how 
different HTA bodies interpret evidence - to explain why certain pieces of evidence are 
deemed  more  relevant  than  others  in  the  process  of  argumentation.  According  to 
Majone: 
  
Selecting inappropriate data or models, placing them at a wrong point in the 
argument, or choosing a style of presentation that is not suitable for the intended 
audience,  can  destroy  the  effectiveness  of  information  used  as  evidence, 
regardless of its intrinsic cognitive value. […] evidence must be evaluated in 
accordance with a number of factors peculiar to a given situation, such as […] 
the prevailing rules of evidence […] (Majone, 1989, p. 11). 
 
  Majone  subsumes  the  answers  that  different  systems  offer  to  challenges 
surrounding evidence questions under the term ‘rules of evidence’: 
 
When the issues under discussion require complex patterns of reasoning and 
large  amounts  of  data  of  doubtful  reliability  and  relevance,  explicit  rules  of 
evidence become particularly important (Majone, 1989, p. 10).  
                                                        
10 A detailed account of the criticisms of RCTs is not provided in this thesis. This is because this 
thesis does not seek to contribute to this strand of literature, but seeks to elicit how similar 
pieces of evidence such as RCTs are interpreted differently in different context. Whether or not 
RCTs are the ‘right’ evidence for HTAs is irrelevant as the fact that NICE and the FJC/IQWiG 
regard RCTs as the highest quality evidence demands an analysis of how they deal with similar 
challenges contained in RCTs rather than questioning their intrinsic value. For the purpose of 
this chapter, suffice it to say that RCTs have been criticised for, amongst other aspects, being 
unrepresentative of the clinical reality in which a pharmaceutical product will be used as the 
strictly controlled experimental design of RCTs means that only patients with few to no co-
morbidities are included in the clinical trials. In this sense, the clinical trial patient group might 
not always reflect the group of patients likely to receive the medication in the ‘real-life’ clinical 
context.  
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Rules of evidence include the criteria that are being applied in evaluating the evidence, 
the questions that are asked in this process, what counts as evidence in the first place 
and what methods are used to analyse the data (Majone, 1989). When different rules of 
evidence are applied to the same data, the outcome might be a different assessment of 
what the evidence proves or does not prove. In this sense, different rules of evidence 
can help explain why the outcomes of benefit assessments on the same pharmaceutical 
products in England and Germany are dissimilar in some cases. When examining what 
determines the outcome of benefit assessments, this thesis therefore employs Majone’s 
(1989) concept of ‘rules of evidence’ to describe the criteria, thresholds and values that 
are applied to the evidence base in the assessment process. Since the rules of evidence 
can be found in what Kuhn (1962) would most likely label the ‘normal’ processes of 
decision-making, they are in turn a reflection of how a paradigm is formulated and 
established. 
Majone’s (1989) and Cartwright’s and Hardie’s (2012) elaborations on evidence 
as  a  concept  that  acquires  meaning  according  to  what  is  relevant  in  a  process  of 
argumentation are transferable to the research question at hand. HTA processes can be 
conceptualised as argumentative processes in which different interpretations are applied 
to a similar evidence base and ‘argued out’ according to what is deemed feasible and 
desirable within the given national context. Majone’s and Cartwright’s and Hardie’s 
arguments on the importance of relevance necessitates an examination of what facts and 
pieces of evidence are relevant in HTA processes in England and Germany. However, 
while  they  present  convincing  arguments  for  the  importance  of  ‘relevant’  evidence, 
their  assertions  fall  short  of  offering  a  conceptual  framework  that  can  explain  this 
relevance. In an effort to address this shortcoming, this thesis expands on Majone’s and 
Cartwright’s  and  Hardie’s  theories  of  relevance  by  using  policy  paradigms  as  a 
framework to  explain what  shapes  the relevance of  certain evidence questions  over 
others in the first place. 
  In conclusion, the brief overview of how the role of evidence has been discussed 
in different strands of literature gives rise to two theoretical arguments that are key to 
addressing this thesis’ research question. Firstly, evidence always requires interpretation 
and  judgement.  As  Goldenberg  argues:  “A  lesson  learned  from  the  philosophy  of 
science is that evidence is not self-apparent or “given” when gathered from even the 
most idealized and controlled observational setting” (Goldenberg, 2006, p. 2630). From 
this perspective, even RCTs, frequently labeled the ‘gold standard’ of evidence-based  
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approaches (e.g. Milewa and Barry, 2005; Rawlins, 2012), do not give rise to infallible 
results.  
  The  second  theoretical  argument  that  emerges  from  Cartwright  and  Hardie 
(2012) and Majone (1989) is that evidence acquires meaning by making it relevant to 
the given context. Even the ostensibly ‘best’ evidence is rendered meaningless if it does 
not answer questions that are relevant in the given policy context and if it does not meet 
the standards that are contained within the rules of evidence (Majone, 1989). For the 
purpose  of  this  thesis,  the  process  of  interpreting  the  evidence  can  thus  be 
conceptualised as a process in which evidence is made relevant in a given setting by 
applying rules to it. The rules of evidence emerge from different policy paradigms that 
are normalised in different countries. These policy paradigms tell decision-makers what 
evidence is relevant in a given national context. In this sense, this thesis links the notion 
of  evidence  with  that  of  a  paradigm.  In  doing  so,  it  brings  different  branches  of 
literature  together  in  order  to  examine  what  determines  pharmaceutical  benefit 
assessments.  
  The next section provides a brief overview of the alternative theoretical models 
that were considered during the research process of this thesis as well as an explanation 
of why these approaches were not pursued. 
 
2.6. Alternative Theoretical Approaches 
 
Several  alternative theoretical approaches were explored  in the search of the 
most  compelling  one  in  addressing  the  question  of  what  determines  pharmaceutical 
benefit assessments in health care systems that employ formalised HTA procedures. 
The  alternatives  that  were  considered  include  Sabatier’s  (1988)  advocacy  coalition 
framework, Haas’ (1992) work on epistemic communities and, albeit to a lesser extent, 
principal-agent theories. The following paragraphs provide a succinct explanation for 
why these alternatives were ultimately not pursued.  
Sabatier conceptualises public policies as belief systems:  
 
[…] public policies/programs incorporate theories about how to achieve their 
objectives and thus can be conceptualized in much of the same way as belief 
systems.  They  involve  value  priorities  […],  perceptions  of  world  states  […] 
(Sabatier, 1988, pp. 131-132).  
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A crucial element of Sabatier’s theory is the aggregation of actors in a policy subsystem 
into “[…] “advocacy coalitions”, each composed of people from various governmental 
and private organizations that […] (1) share a set of normative and causal beliefs and 
(2)  engage  in  a  nontrivial  degree  of  coordinated  activity  over  time”  (Sabatier  and 
Jenkins-Smith, 1999, p. 120). Sabatier’s (1988) focus on values and ‘perceptions of 
world  states’  illustrates  that  he  credits  ideational  variables  with  much  of  the  same 
importance as Hall (1989; 1993) does. However, in contrast to Hall, Sabatier (1988; 
1999) argues that constructs of ideas and values are specific to a group of policy actors 
who share the same beliefs over time and who strive to shape policy according to these 
beliefs.  An  application  of  Sabatier’s  theories  therefore  demands  an  identification  of 
existing advocacy coalition groups in a given policy area. Once the advocacy coalitions 
have been identified, Sabatier’s (1988) framework suggests that policy outcomes can be 
explained with reference to the role these coalitions, and their belief systems, play in the 
policy arena one is examining. 
Sabatier’s (1988) approach has an appeal to it because he attributes a central role 
to the values and worldviews held by advocacy coalitions who shape the policy process. 
However, the approach goes beyond what is initially required in answering this thesis’ 
research question. The aim of this thesis is – as a first step – to understand what factors 
determine  the  outcomes  of  pharmaceutical  benefit  assessment  processes.  This  task 
demands an identification of the factors as they arise from the empirical data. Once 
these factors have been identified, one could analyse whether they are a reflection of the 
dominance of one advocacy coalition’s belief system over another. However, this would 
be a different research endeavour from the one at hand. It would require a shift from the 
focus on the benefit assessment process to a focus on the stakeholders that are involved 
in  the  process  in  an  effort  to  elicit  their  belief  systems.  Moreover,  the  advocacy 
coalition framework is designed to examine policy change over a long period of time in 
an effort to explain change rather than to examine specific processes of decision-making 
in what could be labeled the implementation phase of the policy cycle.  
While the appeal of Sabatier’s framework in the context of HTA policy is not 
discarded,  this  thesis  presents  the  step  that  precedes  the  application  of  Sabatier’s 
theories to the empirical puzzle at hand. That is to say, the HTA policy paradigms need 
to be identified first before examining how they may have changed over time and before 
exploring whether they can be associated with the belief systems of certain advocacy 
coalition groups. In summary, while Sabatier’s theories are insightful, they go beyond  
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the scope of this research project and should be viewed as a model framework to be 
applied in future research. 
Similarly  to  Sabatier’s  work,  Haas’  arguments  on  the  role  of  epistemic 
communities, conceptualised as a group of knowledge-based experts (Haas, 1992, p. 3), 
offer valuable insights. Haas defines an epistemic community as “[…] a network of 
professionals with recognized expertise and competence in a particular domain and an 
authoritative  claim  to  policy-relevant  knowledge  within  that  […]  issue-area”  (Hass, 
1992, p. 3). Haas studies the role of epistemic communities in shaping international 
policy coordination. In a similar fashion, one could choose to study the role of epistemic 
communities in the HTA policy field, especially because the field is one in which the 
demand for professional expertise is high. However, once again this would go beyond 
the scope of the research question at hand. 
It is interesting that both Sabatier’s and Haas’ theories centre on the role of 
communities or groups of stakeholders as owners and advocators of specific values and 
belief systems. This is interesting because Kuhn’s (1962) original work on paradigms 
also identified them as a construct that was inherent to a specific group, namely that of 
scientists.  Due  to  the  fact  that  HTAs  are  based  on  expert  knowledge  and  technical 
expertise in an area of political salience, addressing different research questions through 
the theoretical models by Sabatier (1988) and Sabatier and Jenkins-Smith (1999) as well 
as Hass (1992) presents a worthwhile research endeavour in its own right. While the 
application of said theories is beyond the scope of this thesis, the results of the empirical 
analysis may provide a useful starting point for such future research as it provides an 
identification of the dominant HTA policy paradigms, which may or may not align with 
belief systems of certain advocacy coalitions or epistemic communities.  
Finally, the usefulness of principal-agent approaches in explaining this thesis 
empirical puzzle was explored. Principal-agent theories are theories of delegation in 
which a principal, e.g. a policy-maker, delegates certain responsibilities to an agent, e.g. 
a public organisation, because he/she is lacking the technical knowledge, expertise or 
time to make informed decisions in a complex policy area (e.g. Guston 1996; Parsons 
2005). It could be argued that NICE and the FJC as well as IQWiG are agents that have 
been tasked with making decisions on the benefit of pharmaceutical products to inform 
health care decision-making. From this perspective, pharmaceutical benefit assessment 
outcomes  might  be  viewed  as  the  agent’s  application  of  technical  criteria  in  the 
decision-making process.   
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However,  principal-agent  case  studies  are  predominantly  occupied  with 
examining  how  principals  can  ensure  that  their  goals  are  pursued  in  a  satisfactory 
manner by the agents (Crosson, 2013). That is to say that principals seek to minimise 
the uncertainty that arises from delegating tasks to other authorities (Crosson, 2013). In 
the context of HTA policy this approach once again offers interesting avenues for future 
research, but the research question at hand focuses on the specificities of how individual 
decisions  of  pharmaceutical  benefit  assessments  are  made  rather  than  examining 
whether they meet the goals envisioned by policy-makers. In other words, principal-
agent models would be more appropriate for examining the extent to which NICE and 
the FJC/IQWiG are carrying out their tasks according to the principles and goals that 
were stipulated by policy-makers rather than for examining what determines individual 
outcomes of pharmaceutical benefit assessments. 
 
2.7. Conclusion 
 
  This  chapter  outlined  the  theoretical  approach  that  guides  the  research.  It 
highlighted that paradigms are conceptualised as intellectual frameworks that determine 
which issues, questions and themes are considered important in the assessment process. 
The discussion of Kuhn’s (1962) work on the connection between normal science and 
paradigms also highlighted that these frameworks are not static, but that they require 
articulation, specification and interpretation. This implies that the identification of a 
paradigm necessitates the study of how it gets established and formulated in ‘normal’ 
decision-making processes. Whether the focus of these processes is normal science, i.e. 
the activities of a research community, or decision-making in health care is irrelevant, 
as the main point to adopt from Kuhn (1962) is that paradigms get established and 
articulated through normal every-day life processes. The main criticism of the extant 
literature on paradigms in public policy arises from this point. Policy paradigms are 
currently  employed  as  variables  to  explain  policy  change  without  a  thorough 
understanding of how they are applied in the relevant normal decision-making context. 
However, by looking at how they are articulated one can gain insights into how fluidly 
or rigidly different paradigmatic elements are applied, how this impacts on outcomes 
and how these might in turn impact on any future change. 
This chapter also emphasised that ‘evidence’ is a key concept that is a common 
feature  of  HTA  policies  in  different  countries.  The  work  that  emerges  from  the  
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literatures on evidence-based policy-making, policy analysis and philosophy of science 
suggests that the interpretation of this evidence will vary in different national contexts, 
depending on the  factors  that are  considered relevant  within that  context.  Majone’s 
(1989) concept of the ‘rules of evidence’ was introduced as a means to operationalise 
the divergent sets of criteria that are applied to the same evidence base in different HTA 
systems. In an effort to capture these rules of evidence and to explain how they impact 
on pharmaceutical benefit assessment outcomes, this thesis employs a framework of 
policy paradigms that suggests that rules of evidence are both an expression of, and 
shaped by, narrow HTA paradigms and broader health care paradigms that operate in 
given HTA contexts. In doing so, it creates a link between different branches of public 
policy  literature  and  explores  the  usefulness  of  extending  Kuhn’s  (1962)  work  on 
‘normal science’ to the field of HTA. 
The next chapter focuses on the research design that was employed in order to 
address  the  question  of  what  determines  the  outcome  of  pharmaceutical  benefit 
assessments in health care systems that employ formalised HTA procedures. 
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Chapter 3 
Research Design 
 
3.0. Research Aim 
 
  The review of the literature on health technology assessment (HTA) and the 
political  salience  of  the  field  gave  rise  to  the  following  research  question:  What 
determines the outcome of pharmaceutical benefit assessments in countries that employ 
formalised  HTA  procedures?  The  empirical  puzzle  that  guides  this  question  is  the 
variance in pharmaceutical benefit assessment outcomes across different countries that 
employ HTA procedures. This variance has been shown in several studies, for example 
in Kanavos, et al. (2010) and Sorenson (2009). However, studies on this subject fall 
short of providing an in-depth account of how processes and decision-making criteria 
impact on the final outcome in pharmaceutical benefit assessment. Moreover, previous 
studies are preoccupied with examining cases in which outcomes differ, thereby giving 
rise to the danger of selection biases that emerge when sampling cases on the dependent 
variable. The underlying assumption seems to be that these cases are more interesting 
than the cases in which outcomes are similar because similar outcomes suggest similar 
appraisals  of a  case.  The purpose of this  thesis  is  to  contribute to  a more in-depth 
understanding of how outcomes are arrived at, both in cases where the final outcome 
differed  and  in  cases  where  the  final  outcome  was  similar.  Incidentally,  the  use  of 
process-tracing methods to analyse the HTA decision-making processes illustrated that 
cases with a similar assessment outcome offer as much insight, if not more, into what 
determines pharmaceutical benefit assessments as cases with different outcomes. 
Against  the  background  of  this  thesis’  research  question  and  the  empirical 
puzzle, the aim of this research is to explore the issues, or the variables, that contribute 
to  the  outcome  of  pharmaceutical  benefit  assessments.  In  addition  to  the  aim  of 
understanding these variables, this research study also has an evaluative element in the 
sense that it seeks to evaluate the effect of HTA policy paradigms on pharmaceutical 
benefit assessments. In other words, the aim of understanding what variables contribute, 
and how, to the outcome of pharmaceutical benefit assessments is connected to the 
empirical contribution that this thesis strives to make and the evaluation of the effect of 
HTA  policy  paradigms  reflects  the  theoretical  contribution  the  thesis  aspires  to.  It  
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should be noted here that the evaluative character of the research aim does not imply 
engaging in policy evaluation in a temporal comparative fashion, i.e. comparing the 
policy  area  post-  and  pre-introduction  of  HTA  polices,  but  rather  in  a  spatial 
comparative  fashion,  that  is  evaluating  the  effects  of  different  HTA  paradigms  in 
different health policy contexts. 
The literature on HTA processes gives rise to a number of variables that can be 
explored as part of this research, but it also suggests that the way in which outcomes are 
arrived at is a result of complex processes. The various dimensions, e.g. the political, 
methodological and ethical dimensions, of HTA procedures are complex units that this 
study  needs  to  address.  This  study  starts  from  the  assumption  that  the  different 
dimensions of HTA are not easily delimited from each other and that each is likely to 
contribute,  to  some  extent,  to  the  final  outcome  of  the  pharmaceutical  benefit 
assessment. Guided by theories on ideas and policy paradigms that were outlined in the 
previous  chapter,  I  assume  that  the  outcome  of  pharmaceutical  benefit  assessment 
depends  on  the  dominant  HTA  policy-making  paradigm  in  a  given  country.  This 
assumption has implications for the research design in that the research methods chosen 
need to be able to explain the role of complex variables that might be institutional 
and/or  ideational  in  kind.  They  also  need  to  cater  for  the  possibility  that  a  set  of 
variables,  and  the  paradigmatic  interpretation  thereof,  lead  to  similar  and  different 
outcomes in different health care contexts. That is to say, that the mere presence or 
absence of specific variables in HTA decision-making might be less significant than 
how these variables are framed and interpreted within a given context. 
  
3.1. Methodology 
 
  In order to answer the research question a case-oriented comparative approach is 
employed. Several authors (e.g. della Porta, 2008; Yin, 2009; Ragin, 1994; George and 
Bennett, 2005) highlight the benefits of comparative and case study approaches when 
the research aim is to understand and explain complex processes in which one has to 
allow for the possibility that how variables matter carries equal or more weight than the 
question whether they are present or absent from a causal process. This explains the 
methodological choice of employing a qualitative case-oriented comparative approach 
because it allows for a contextual and interpretive analysis of the factors that determine 
the outcome of pharmaceutical benefit assessments.   
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Della Porta (2008) distinguishes between variable-oriented research that “[…] 
aims at establishing generalized relationships between variables, while case-oriented 
research seeks to understand complex units” (della Porta, 2008, p. 198). A case-oriented 
comparative approach thus presents a suitable methodology because it allows for the 
possibility that there may be different factors that contribute to the same or different 
outcomes in different health policy contexts. Della Porta refers to this possibility as 
plural  causation, i.e.  an effect  can have different  causes in  different contexts  (della 
Porta,  2008,  p.  205).  Considering  that  the  outcome  of  pharmaceutical  benefit 
assessments in different countries can be similar despite being based on different HTA 
policy paradigms, della Porta’s theory of plural causation is a valuable methodological 
starting point when exploring how benefit decisions are arrived at. 
The  idea  of  plural  causation  (della  Porta,  2008)  is  at  the  heart  of  what  the 
literature outlines as the benefits of comparative and case study approaches, despite 
authors using different terminology to describe this idea. For example, Ragin stipulates 
that comparative analysis: 
 
[…]  allows  for  the  possibility  that  there  may  be  several  combinations  of 
conditions  that  generate  the  same  general  outcome  […]  [It]  proceeds  by 
comparing  the  configuration  of  causes  and  not  by  comparing  presence  or 
absence of each condition with presence and absence of the outcome (Ragin, 
1994, p. 118).  
 
Ragin’s stipulation adds to that of della Porta by underlining that causal processes can 
have different effects but similar causes or the same effect but different causes as a 
result of “combinations of conditions” (Ragin, 1994). This unmasks a complexity that 
needs  to  be  considered  when  studying  heterogeneous  policy  processes  such  as 
pharmaceutical benefit assessments. As such comparative approaches seek to uncover 
causal patterns rather than causes (Ragin, 1994). George and Bennett (2005) make a 
similar  point  with  regards  to  the  advantages  of  case  study  approaches  when  they 
highlight: “[…] the methods’ ability to contribute to the development of theories that 
can accommodate various forms of complex causality” (George and Bennett, 2005, p. 
5).  
The idea of “complex causality” (George and Bennett, 2005), or plural causation 
(della  Porta,  2008),  is  key  to  understanding  how  I  approach  this  thesis’  research 
question.  Based on the extant literature, I work on the assumption that what determines  
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the outcome of pharmaceutical benefit assessments cannot be explained by reference to 
a set of easily measurable variables whose presence or absence lead to a particular 
outcome, but that the way ideational variables are conceptualised and operationalised 
contributes greatly to what determines the outcome. The idea of plural causation, or 
complex causality, lies at the centre of this assumption as it potentially explains why 
pharmaceutical benefit assessment outcomes can be different despite being based on the 
same pieces of evidence on, for example, clinical effectiveness. Clinical effectiveness 
could  be  used  as  an  independent  variable  and  measured  by  assigning  positive  or 
negative scores to it, depending on the results of clinical trials and the like. However, 
such an approach would only confirm that there are differences in outcomes, but one 
would have no way of explaining these outcomes, whereas the concept of complex 
causality allows one to examine how decisions are arrived at in order to explain the 
outcomes.  Additionally,  and  perhaps  more  interestingly,  employing  a  case-oriented 
comparative approach that allows for plural causation also  disclosed cases in which 
similar outcomes were arrived at by different reasoning such as in the case of Telaprevir 
(table 7.2.). Such cases  would have remained largely undetected when employing a 
methodology that does not incorporate the idea of complex causality. 
In addition to the above statements on the advantages of a qualitative case-study 
approach, this thesis greatly benefits from the comparative component it features. There 
is a long tradition of comparative studies in health policy and this thesis can be viewed 
in the context thereof (e.g. Marmor, Freeman and Okma, 2009; Moran, 1999; Immergut, 
1992; Giaimo 1995, 2001; Aaron and Schwartz, 1984). However, previous comparative 
studies  on  different  aspects  of  health  policies  have  focused  on  the  comparison  of 
institutional and structural variables to explain certain policy choices. In contrast, this 
study focuses on how ideational variables such as policy paradigms function in the 
context  of  different  health  care  systems.  One  could  have  chosen  to  approach  the 
question of the role of policy paradigms in determining HTA outcomes by examining 
one case study. However, by approaching the question with a comparative lens this 
study offers more room for inference and interpretation with regards to the similarities 
and differences that are at play when HTA paradigms are articulated. In other words, 
the results of the empirical analysis of pharmaceutical benefit assessment cases in one 
country acquire meaning when compared and contrasted to those of another country. 
  In  practice,  this  research  represents  a  small-N  multiple-case  study  with  an 
embedded design in that two cases (England and Germany) of HTA systems and their  
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paradigms are compared by way of examining smaller, embedded, units of analysis in 
the form of pharmaceutical products that have been assessed and appraised in both case 
study countries. Yin defines a case study as: 
 
[…] an empirical inquiry that [a.] investigates a contemporary phenomenon in 
depth  and  within  its  real-life  context,  especially  when  [b.]  the  boundaries 
between the phenomenon and context are not clearly evident (Yin, 2009, p. 18).  
 
This definition once again underlines the appropriateness of employing a comparative 
case study approach as HTA procedures are very much a contemporary phenomenon. 
As iterated in the section on the theoretical framework of this thesis what Yin refers to 
as  the  boundaries  between  phenomenon  and  context,  i.e.  the  boundaries  between 
pharmaceutical benefit assessment outcomes and institutional and ideational variables, 
are not clearly discernable in this research. A case study approach helps to shed light on 
the boundaries between variables, or on how variables interact to contribute a particular 
outcome.  
  Pharmaceutical products were chosen as the embedded units of analysis for this 
case study because they represent a unit in which important factors such as evidence 
base  and  disease  characteristics  can  be  controlled  for.  At  the  beginning  of  a  HTA 
process the pharmaceutical products, the disease indications for which they are licensed 
and the evidence that is available are the same in both Germany and England. As will be 
outlined in chapter 4 this is because the licensing procedures for new pharmaceutical 
products  are  largely  centralised  in  the  European  Union  (EU)  with  the  European 
Medicines  Agency  (EMA)  in  charge  of  granting  marketing  authorisations  for  new 
products.  While  the  products  are  the  same,  they  undergo  different  HTA  decision-
making processes at the Federal Joint Committee (FJC), the Institute for Quality and 
Efficiency  in  Health  Care  (IQWiG)  and  the  National  Institute  for  Health  and  Care 
Excellence (NICE), especially with regards to what evidence is deemed appropriate, 
why and what criteria need to be met in order to prove benefit. This thesis analyses the 
processes by which the same pharmaceutical products for the same disease categories 
are assessed in England and Germany, thus examining how the considerations in the 
final  decision  differ  from  each  other  and  whether  this  affects  the  outcome  of  the 
decisions. The details on the case selection are provided in the next section of this 
chapter.  
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During the process of choosing an appropriate method for answering this thesis’ 
research  question  I  also  considered  including  a  quantitative  analytical  approach. 
However, due to the fact that my research aim is to understand the complex processes 
that give rise to pharmaceutical benefit assessment outcomes and to evaluate the role of 
policy  paradigms  in  this  process,  I  decided  against  the  inclusion  of  a  quantitative 
analysis. This is mainly because, despite the fact that I could have included more cases, 
a quantitative analysis would not have given me insights with regards to how and why 
the decisions were arrived at and what issues featured in the decision-making process. 
Having said that, a quantitative analysis that examines ‘harder’ variables such as costs 
and extent of clinical effectiveness is one way in which this research might be expanded 
upon in the future. However, as della Porta (2008) points out, variable-oriented, more 
quantitative approaches, offer little to no room for plural causation. This is the main 
reason  why, for the purpose of this  study, they were not  considered an appropriate 
method  for  answering  the  research  question.  Finally,  Dixon’s  and  Poteliakhoff’s 
assessment of current comparative health policy analysis as a field that is no longer 
based on “[…] classifications of health systems and crude rankings, but on studies that 
try  and  understand  more  deeply  what  works,  where  and  why  […]”  (Dixon  and 
Poteliakhoff, 2012, p. 1) further supports the use of a qualitative comparative case study. 
 
3.2. Case Selection 
 
  In case study research the principal criterion to apply when selecting cases is 
that of relevance to the research aim (George and Bennett, 2005; della Porta, 2008). The 
research question of this thesis indicates that I am interested in cross-national insights 
on pharmaceutical benefit assessment processes in order to understand which factors 
determine the outcomes of these processes. The selection of cases needs to reflect this 
interest. 
The case selection with regards to the countries that were analysed was driven 
by a search for countries in which pharmaceutical benefit assessment is carried out on a 
national level. The emphasis on the national level ensured that the case selection was 
relevant to the research question’s focus on ‘countries that employ formalised HTA 
procedure’. The emphasis also meant pharmaceutical benefit assessment processes that 
inform regional priorities of health care decision-making were excluded from the case 
selection  processes  as  these  were  not  considered  relevant  to  the  research  question.  
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Additionally,  the  theoretical  framework  employed  in  this  thesis  necessitated  that 
pharmaceutical benefit assessments are closely tied to policy-making in a given country 
so as to be able to analyse the effects of different policy paradigms. The alternative 
would have been to examine pharmaceutical benefit assessments in research settings 
such as universities and research foundations, but these do not usually inform policy-
making and would not have provided insights on public policy paradigms. However, 
considering Kuhn’s (1962) arguments on  normal science and paradigms, a potential 
area for future research would be an analysis of whether the HTA policy paradigms in 
research settings differ from those in national settings and what effect this has on the 
way a product or health care intervention is assessed. 
For  reasons  of  comparability  I  restricted  the  search  for  appropriate  cases  to 
countries with public (tax-based) or statutory health insurance (SHI) health care systems 
in  member  states  of  the  Organisation  for  Economic  Co-operation  and  Development 
(OECD) because the extant literature suggests that HTA decision-making represents a 
popular policy for decision-makers in these countries (e.g. Sorenson, 2009). The goals 
and priorities of health care in non-OECD states are very different from those in OECD 
member states even if HTA instruments are employed. Examining this thesis’ research 
question in the context of non-OECD member states is an interesting opportunity for 
future  research.  However,  as  a  first  step  in  identifying  the  determinants  of  HTA 
outcomes and the role of paradigms therein, my focus was on countries with a tradition 
of providing public health care for their citizens. Effectively, this meant that the case 
search was restricted to industrialised countries with established health care systems and 
comparable income levels. These restrictions left me with a number of possible cases to 
choose from.  
In Europe the development of HTA as a policy-aiding instrument has developed 
steadily since the 1970s. The first HTA programmes and organisations were established 
in France and Spain, followed by Sweden and the Netherlands (Velasco-Garrido and 
Busse, 2005). Today HTA exists as an element of health care decision-making in most 
European  countries,  albeit  in  different  formats  and  with  different  decision-making 
remits (Sorenson and Calkidou, 2012; Landwehr and Böhm, 2013). Similarly, Australia 
and  Zealand  have  established  HTA  procedures  to  inform  pharmaceutical  coverage 
decisions.  I  examined  the  HTA  structures  in  relation  to  pharmaceutical  benefit 
assessments in Europe, Asia as well as Australia and New Zealand. This gave rise to a 
number  of  interesting  and  comparable  cases  that  would  have  been  relevant  to  this  
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study’s research aim. For example, cases of HTA decision-making in Scandinavia and 
the Netherlands would have represented interesting cases as these countries have a long 
tradition of including HTAs in their decision-making, which is known for its emphasis 
on values such as equity. 
In the end, a pragmatic decision was taken with regards to what was going to be 
feasible within the boundaries of this research project. The pragmatic decision was a 
result of two main considerations. Firstly, language barriers had to be considered. For 
example,  whilst  most  HTA  bodies  in  Scandinavian  countries  publish  decision 
documents on their respective websites, only some documents are published in English 
and these are usually limited to a summary of the results of the decisions. As such they 
would  have  not  given  me  sufficient  insight  into  the  considerations  that  led  to  the 
outcome of pharmaceutical benefit assessments.  
Secondly, the theoretical questions guiding this research led me to look for cases 
that exhibit a sufficient number of institutional and historical differences from which 
different HTA paradigms might emerge. The case selection employed can most closely 
described as a most-different system design approach. Employing a most-similar system 
design, i.e. comparing HTA outcomes amongst social insurance based health systems or 
amongst publicly financed health systems only, would have run the risk of not yielding 
in-depth insights into how paradigms function differently. However, based on one of the 
main results of this research, i.e. that different paradigms do not, as a matter of course, 
lead  to  different  HTA  outcomes,  future  research  should  be  conducted  employing  a 
most-similar system design in order to examine whether the inverse of the above finding 
can be observed, that is whether a similar paradigm leads to similar HTA outcomes in 
different countries. 
 In addition to the outlined pragmatic and theoretical considerations, I factored 
in the size of the population covered by the given health care system and the strength of 
the pharmaceutical sector in a given country. The strength of the pharmaceutical sector 
in a country measured in, for example, indicators such as the number of jobs in the 
sector  as  well  as  the  level  of  investment  in  research  and  development  activities 
(Freeman,  2009)  was  an  important  factor  to  consider.  This  is  because  one  can 
reasonably assume that a given government’s economic interest in the strength of the 
pharmaceutical  sector  and  the  lobbying  efforts  by  this  sector  are  comparable  in 
countries where the sector is similarly strong. A comparative analysis of HTA outcomes 
in  such  counties  sheds  light  on  whether  the  outcome  of  pharmaceutical  benefit  
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assessments is overly skewed in favour or against the pharmaceutical sector. In contrast, 
a comparison between countries in which the pharmaceutical sector is not similarly 
strong would have resulted in an inability to control for this variable as a contributing 
factor in HTA outcomes. This, along with the feasibility and theoretical considerations 
outlined above, led to a final choice between the National Institute for Health and Care 
Excellence (NICE) in England and Wales, the Federal Joint Committee (FJC) and the 
Institute for Quality and Efficiency in Health Care (IQWiG) in Germany and the Haute 
Autorité de Santé (HAS) in France.  
While the comparison of all four of the above mentioned HTA bodies would 
have been interesting, it would have been beyond what was feasible as part of the in-
depth analysis that I was keen to pursue in this thesis. I therefore selected NICE in 
England as well as the FJC and IQWiG and Germany as the cases for my study. Both 
England and Germany have introduced pharmaceutical benefit assessments as a formal 
element of health care decision-making, albeit with different policy directions, thereby 
exhibiting a number of important institutional differences. They have both established 
formalised  HTA  bodies  as  quasi-public  institutions  with  formal  decision-making 
mandates, thereby exhibiting institutional similarities. Moreover, England and Germany 
represent what can be considered ‘ideal-type’ examples of health care financing and 
structure,  the  former  representing  a  tax-based  system  and  the  latter  a  statutory 
insurance-based system (Abel-Smith, 1994). Being the birthplace for their respective 
health care system formats makes England and Germany the ideal cases for exploring 
what determines pharmaceutical benefit assessment outcomes as their systems are built 
on very different paradigms and  yet both have introduced HTA structures in recent 
years. By selecting England and Germany as case studies for this small-N case study I 
thus also hope to contribute to an understanding of how HTA paradigms differ in tax-
based and statutory insurance-based health care systems. 
Additionally,  England  and  Germany  are  amongst  the  top  ten  global 
pharmaceutical  markets  (IMS  Health,  2013  cited  in  ABPI,  2013).  The  relative 
equivalence between the role played by the pharmaceutical industry in, for example, the 
job market means that, despite their differences in health care financing and structuring, 
the two countries are comparable with regards to the importance of the pharmaceutical 
markets to their economies. Thus, any observed differences are likely to be attributable 
to  the  health  care  and  HTA  paradigms  operating  in  these  countries  rather  than  a 
variation in strength of the pharmaceutical industry.  
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The choice for England and Germany as cases for this study offers empirical and 
theoretical benefits. The empirical benefit lies in the fact that the effects of HTA policy 
paradigms on pharmaceutical benefit assessment outcomes are explored in ‘ideal-type’ 
health care settings. This in turn gives rise to the theoretical advantages in that it offers a 
good  starting  point  for  a  study  that  investigates  the  relative  role  played  by  policy 
paradigms in pharmaceutical assessment process. Since this is the first study of its kind, 
it makes sense to start the analysis using cases that are ‘ideal-type’ cases rather than 
ones that might be considered exceptional or similar from the beginning. At the same 
time, the fact that England and Germany are ‘ideal-type’ health care systems makes 
them  highly  relevant  in  addressing  this  thesis’  research  aim  as  the  results  provide 
avenues  for  further  examination  in  other  health  care  systems.  This  provides 
opportunities for further exploration, both by myself and by other researchers interested 
in HTAs and policy paradigms, in order to test whether the role of policy paradigms is 
similar in other cases of formalised HTA procedures. 
In addition to the empirical and theoretical merits of employing England and 
Germany as the cases for this study, it is worth noting that Anglo-German comparisons 
have a long research tradition in public policy, a research tradition which this thesis 
hopes  to  contribute  to.  There  are  numerous  studies  in  environmental  policy  that 
compare Germany’s and Britain’s responses to common problems such as the reduction 
of vehicle emissions, addressing the problem of acid rain and the regulation of various 
environmental  policy  areas  (e.g.  Boehmer-Christiansen  and  Skea,  1991;  Boehmer-
Christiansen  and  Weidner,  1995;  Weale,  O’Riordan  and  Kramme,  1991;  Sturm  and 
Wilks, 1997). Until it was closed in 2009 the Anglo-German Foundation commissioned 
and published numerous comparative studies on economic, environmental and social 
issues in the United Kingdom and Germany (Anglo-German Foundation, 2008), which 
can still be accessed online. Finally, in comparative health policy Giaimo has conducted 
several Anglo-German comparisons, exploring various aspects of health care reforms 
and relationships between health care stakeholders (e.g. Giaimo 1995; 2001; Giaimo 
and Manow, 1999) and Moran (1999) chose the United Kingdom and Germany as cases 
in his work on the health care state. 
 
 
 
  
  80 
3.3. Selection of Embedded Case Studies 
 
  The focus on pharmaceutical benefit assessments rather than on other areas such 
as diagnostic products that undergo HTAs arises from the benefits that this offers in 
terms of controlling for issues such as evidence base and disease characteristics. The 
embedded units of analysis that inform this study were selected according to temporal 
criteria. This means that the embedded case studies were not sampled on the dependent 
variable (namely the outcome of pharmaceutical benefit assessments), which in turn 
increases the internal validity of the study by ensuring that I am not sampling on the 
most interesting cases that may provide insights on the role of paradigms in determining 
HTA outcomes. Della Porta (2008) cites this as an important criterion that ensures that 
cases are not selected based on observations that confirm one’s theory. 
In  Germany,  the  legislation  that  introduced  the  requirement  for  the  benefit 
assessment  of  new  pharmaceutical  products  in  the  form  of  so-called  early  benefit 
assessments
11 came into practice in January 2011, thus the starting point for the search 
for pharmaceutical products was January 2011. In the interest of providing enough time 
for the analysis of the empirical cases, the endpoint for the search of the pharmaceutical 
products that were appraised by both NICE and the FJC/IQWiG was the end of August 
2012. A search of NICE’s, the FJC’s and IQWiG’s websites respectively showed that 
during  this  time  a  total  number  of  ten  of  the  same  pharmaceutical  products  were 
appraised by the organisations. The temporal delimitation gave rise to ten products that 
represent the units of analysis embedded in this comparative case study.  
Table 3.1. provides an overview of the products and the indications for which 
they  are  licensed.  Incidentally,  the  case  study  selection  for  the  embedded  units  of 
analysis based on temporal criteria gave rise to a sample of cases that is well balanced 
and does not over-represent particular disease areas. This is especially important in light 
of the fact that pharmaceutical benefit assessments are frequently undertaken for cancer 
medicines, which are usually very expensive, especially when treatments for end-of-life 
cancer stages are involved. However, the sample of cases analysed in this thesis is not 
skewed  towards  cancer  products.  The  sample  includes  four  new  pharmaceutical 
products  for  cancer  (Abiraterone,  Cabazitaxel,  Eribulin  and  Ipilimumab),  four  for 
chronic diseases (Boceprevir, Fingolimod, Retigabin and Telaprevir), one that is used as 
                                                        
11 The Act on the Reform of the Market for Medicinal Products 
(Arzneimittelmarktneuordnungsgesetz – AMNOG)  
  81 
a preventative measure (Apixaban) and one (Ticagrelor) that potentially affects a large 
number  of  patients  as  the  prevalence  of  coronary  diseases  continues  to  increase. 
Considering this balanced representation of different disease characteristics and areas, 
there was no need to  adjust for biases, which may have demanded the selection of 
further cases to ensure that the results of the analysis are not skewed.   
 
TABLE 3.1. – Overview of Pharmaceutical Products 
 
Product Name  Indication 
1.  Abiraterone  Prostate Cancer 
2.  Apixaban   Prevention of thromboembolic events (blood 
clots) after hip or knee replacements 
3.  Boceprevir   Chronic Hepatitis C, Genotype 1 
4.  Cabazitaxel  Prostate Cancer 
5.  Eribulin  Advanced Breast Cancer 
6.  Fingolimod  Multiple Sclerosis 
7.  Ipilimumab  Advanced Melanoma 
8.  Retigabin  Epilepsy 
9.  Telaprevir   Chronic Hepatitis C, Genotype 1 
10. Ticagrelor   Acute Coronary Syndromes 
 
3.4. Variables 
 
Since this study takes a case-oriented research approach, the themes, factors or 
variables  that  led  to  specific  outcomes  in  pharmaceutical  benefit  assessments  arose 
during the process of analysing the empirical data that formed the basis for this study. 
However,  that  is  not  to  say  that  there  were  no  variables  that  guided  the  analytical 
process. The dependent variable studied in this thesis is the outcome of pharmaceutical 
benefit  assessment.  As  shown  in  table  3.2.,  the  operationalisation  of  the  dependent 
variable is straightforward in the sense that there are a limited number of categories it 
can  take.  In  the  case  of  NICE  the  outcome  of  a  technology  appraisal  can  be 
‘recommended’, ‘optimised’, ‘not recommended’ and ‘only in research’ (NICE, 2014a). 
In  the  case  of  IQWiG  and  the  FJC  the  outcome  of  the  early  benefit  assessment  is 
comparatively more convoluted because a given pharmaceutical product is assigned one 
out of six possible benefit categories (BMJV, 2011). Nevertheless, the outcome cannot 
be anything but one of these six benefit categories, which is why the dependent variable 
remains easy to operationalise.   
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 The  question  of  the  independent,  or  explanatory,  variables  presents  more 
challenges than that of the dependent variable. While the theoretical framework and the 
literature on HTA gave rise to a range of possible variables, the aim of this research 
required an openness about the breadth and kind of possible variables that the collected 
data  could  give  rise  to,  especially  in  order  to  account  for  instances  in  which  a 
“combination of conditions” contributed to a specific outcome. Rather than treating the 
explanatory variables that the literature gives rise to as dichotomous units that either 
have or do not have an impact on benefit assessment outcomes, they were utilised as a 
way of interpreting the study’s findings. This ensured that additional factors, which may 
not  yet  be  accounted  for  in  the  literature,  could  be  considered  as  meaningful  in 
providing an explanation of what determines the outcome of pharmaceutical benefit 
assessments. The approach also allowed the analysis to be receptive to instances in 
which independent variables combined to produce certain outcomes.  
Table 3.2. provides an outline of the variables that are expected to play a role in 
explaining the dependent variable. The variables arise from the discussion on the role of 
policy paradigms in the previous chapter. The table also includes an overview of the 
factors that might be indicative for certain variables and the data sources in which these 
indicators  are  likely  to  appear.  The  overview  of  the  independent  variables  is  an 
indication of the types, i.e. ideational and institutional, of variables I expect the data 
might  give  rise  to.  The  table  thus  provides  guidance  when  interpreting  the  results 
without  discarding  the  possibility  that  the  empirical  material  might  give  rise  to 
additional,  previously  unaccounted  for,  explanations  for  the  puzzle  this  research 
addresses.   
  83 
TABLE 3.2. – Overview of Dependent and Independent Variables 
 
Variable  Operationalisation  Data sources 
Dependent variable:  Outcome of 
pharmaceutical benefit assessment 
arising out of formalised HTA 
procedures
12 
NICE 
4 possible outcomes:  
Recommended/not recommended/optimised/only in research 
FJC/IQWiG 
6 possible outcomes: 
Major, significant, marginal additional benefit (positive outcome) 
Additional benefit not quantifiable, no additional benefit, additional 
benefit less than that of the comparator (negative outcome) 
- NICE’s technology appraisals 
(available online) 
- FJC summary documentations on 
early benefit assessments 
(available online) 
Independent variable no. 1: Ideational 
factors in policy paradigms of HTA 
decision-making (Overarching 
framework) 
Indicators include: 
1) Reference to norms, values, principles, ethical ideas 
2) Social and ethical values that are considered in the decision-
making process 
- Methods and implementation 
guidelines & legislative 
documents 
Independent variable no. 2: 
Institutional factors in policy 
paradigms: Goals/purpose/techniques of 
HTA (Articulation of the paradigm) 
Indicators include: 
1)  Political  dimensions  of  HTA,  i.e.  is  the  purpose  of  HTAs  to 
inform  the  in-  or  exclusion  of  services  in  health  care  benefit 
baskets? 
2) Policy objectives of introducing HTA 
3) Public discourse around HTA 
4) Composition of decision-making body 
4) Degree and form of stakeholder involvement 
- Legislative documents 
- Stakeholder position papers 
- Media excerpts 
- Stakeholder interviews 
- NICE’s technology appraisal 
documents 
- FJC summaries on early benefit 
assessments 
Independent variable no. 3: 
Ideational & institutional factors of 
policy paradigms: Instrument settings of 
HTA (Articulation of the paradigm in 
the ‘normal’ decision-making process) 
Indicators include: 
1) ‘Rules of evidence’ (Majone 1989), i.e. what constitutes 
evidence? 
2) Hurdles/thresholds for a positive assessment etc. 
4) Algorithms & methods for assessment 
- Methodological guidelines 
- Minutes of decision-making 
body meetings for an overview of 
issues considered in the process 
- Stakeholder interviews 
                                                        
12 See chapter 4 for a more detailed description of the possible outcomes of HTAs in England and Germany.  
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3.4.1. Dependent Variable 
 
The fact that the dependent variable takes one of six possible forms in the case 
of  the  FJC  and  IQWiG
13 ,  all  of  which  are  not  straightforward  ‘yes’  or  ‘no’ 
categorisations, necessitates a word on the operationalisation of the dependent variable 
in comparison to the format that it takes in England. For the purposes of this thesis, the 
first three categories of additional benefit in Germany are assigned the score of ‘positive 
outcome’.  That  is  to  say  that  major,  significant  and  marginal  additional  benefit 
categorisations  by  the  FJC  are  interpreted  as  overall  positive  outcomes  in  a  given 
pharmaceutical benefit assessment procedure, despite their differences in terms of the 
extent of benefit. The lower three of the six benefit categories, i.e. additional benefit not 
quantifiable,  no  additional  benefit  and  additional  benefit  less  than  that  of  the 
comparator,  are  assigned  a  ‘negative  outcome’  score,  as  they  indicate  an  overall 
negative  appraisal  of  a  product’s  additional  benefit.  Operationalising  the  dependent 
variable in this way supports the comparison of the outcome of benefit assessments in 
Germany and England by evaluating whether the outcome can be interpreted as overall 
positive or negative.  
 
3.4.2. Independent Variables 
 
The selection of the independent variables gave rise to a set of challenges. These 
challenges are connected to the theory as well as the research aim of this study. The 
theory of this study requires an operationalisation of independent variables in a way that 
sheds  light  on  a)  what  the  overarching  HTA  decision-making  paradigm  in  a  given 
context is and b) how this paradigm operates in practice and c) whether the paradigm’s 
practical  application, i.e. its articulation during the normal decision-making process, 
deviates  from  its  theoretical  grounding.  Connected  to  this  is  the  study’s  ambitious 
research aim of disclosing if and how independent variables combine to form certain 
outcomes in different cases. With this in mind, independent variable one reflects the 
need  to  describe  the  policy  paradigm  as  laid  out  in  legislative  and  methodological 
documents,  while  independent  variables  two  and  three  are  connected  to  the 
operationalisation of the paradigm in practice. Methodologically this means that the 
                                                        
13 See chapter 4 for a detailed explanation of the benefit categories and their meaning.  
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examination  of  independent  variables  two  and  three  need  to  be  re-connected  to 
independent  variable  one  in  order  to  provide  insights  about  how  complex  causality 
works in the case of pharmaceutical benefit assessments.  
The independent variables presented in table 3.2. arise out of the variables that 
Hall (1993) presents in his policy paradigm framework, which is explained in chapter 2. 
In Hall’s view institutional variables such as policy goals combine with variables such 
as policy instruments whilst being guided by an overarching set of values that prescribes 
what is or is not possible under a certain paradigm. Since the aim of this research is to 
understand how these sets of variables combine in pharmaceutical assessment processes 
and  in  turn  to  evaluate  the  opportunities  Hall’s  approach  offers  in  terms  of 
understanding these processes, the analysis of independent variable number one – the 
policy paradigms of HTA decision-making – forms the basis for the interpretation of the 
research findings. 
The independent variable one is the policy paradigms of HTA decision-making 
in theory. It includes the values, norms and ethical basis that HTA decision-making 
processes are built on in a given country. Every case of a HTA system is based on 
normative  and  ethical  assumptions  that  can  be  found  in  documents  such  as  the 
legislation  that  introduced  the  system.  Independent  variable  number  one  is 
operationalised by way of analysing the documents that lay out the context, normative 
assumptions and purpose of HTA decision-making. However, the HTA policy paradigm 
is not just restricted to the documents pertaining to HTA mechanisms, but also to the 
wider health care context that embodies a set of values that need to be considered. Thus, 
the overarching framework of HTA decision-making is a combination of the value basis 
of  given  health  care  system  along  with  how  this  value  basis  is  reflected  in  the 
methodological guidelines that structure HTA processes. 
Independent variables number two and three, the goals and instrument settings 
of  HTA,  are  the  extension  of  number  one  in  that  their  consideration  allows  for  an 
assessment of how the HTA decision-making paradigm is operationalised in practice. 
Even  though,  for  ease  of  explanation,  I  outline  three  independent  variables,  it  is 
important  to  reiterate  that  the  focus  of  this  study  is  on  examining  the  connection 
between this variables and how they determine the outcome of the dependent variable 
rather than to assess whether one carries more weight than the other, notwithstanding 
the possibility that the research findings might indicate the relative importance of one 
variable over another.   
  86 
The operationalisation of independent variable two and three is more complex 
than the operationalisation of independent variable number one. This is because in the 
case of the HTA policy paradigms the focus is on unmasking which values and ethical 
norms are mentioned in legislative and methodological documents and how they are 
conceptualised. The goals, techniques and instrument settings of HTA are much more 
fluid concepts whose role can only be disclosed by examining how they featured in 
different cases of pharmaceutical benefit assessments. As outlined in table 3.2. their 
indicators  can  range  from  institutional  features  such  as  the  relative  influence  of 
stakeholders or the public discourse around a certain case to the technical feature of 
which  methods  are  used  to  assess  evidence  in  a  given  case.  The  list  of  indicators 
presented in  the column on the operationalisation of independent  variables two and 
three is not exhaustive because the collected data might give rise to additional factors 
that may be considered an indicator of either of those variables.  
As the next section will show, in practice the above remarks mean that the HTA 
policy  paradigm  is  analysed  by  means  of  textual  analysis  of  statutory  and 
methodological documents which is followed by tracing the decision-making processes 
in the ten embedded case studies. The latter exercise is loosely guided by a search for 
indicators of independent variables two and three. The results of the process-tracing 
exercise  are  then  compared  with  the  results  of  the  textual  analysis  of  the  HTA 
paradigms in order to a) meet the thesis’s theoretical ambition of examining the effects 
of policy paradigms in the area of pharmaceutical benefit assessments and b) understand 
the combinations of conditions that lead to certain outcomes.  
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3.5. Data Sources, Collection and Analysis 
 
The following list presents the data sources that are analysed to  answer this 
thesis’ research question: 
  Consultation  and  decision  documents  on  pharmaceutical  benefit 
assessments by NICE, the FJC and IQWiG 
  Statutory documents on HTA and pharmaceutical benefit assessments 
  Methods and implementation guidelines for NICE, the FJC and IQWiG 
  Stakeholder interviews 
  A limited number of media excerpts 
  A limited number of stakeholder position papers 
 
All of the above sources of evidence are available online with the exceptions of the 
stakeholder interviews, which were carried out between October 2012 and June 2013.  
The publicly available consultation documents from NICE include the scoping 
document, the pharmaceutical manufacturer’s dossier, the Evidence Review Group’s 
(ERG) assessment of the evidence, comments from stakeholders at different stages of 
the  consultation  process,  any  relevant  draft  guidance,  reviews  as  well  as  the  final 
guidance on a given product. The available data from NICE can thus be described as 
detailed and inclusive of a range of views and issues that played a role during a given 
consultation process. Moreover, NICE’s final guidance on a product includes an outline 
of the Appraisal Committee’s (AC) reasoning on different issues in a given case. 
The publicly available documents from the FJC and IQWiG are detailed, but 
comparatively lacking in the detailed reasoning that featured in the decision-making 
process. The documents include the manufacturer’s dossiers, IQWiG’s review of the 
dossier as well as the written and oral statements that were given by stakeholders during 
the hearing process. The latter is very detailed in that the minutes of the oral hearing 
proceedings are included in the documents. This proved helpful in terms of tracing the 
argumentative processes in individual cases. However, the grounds for decision-making 
presented by the FJC and IQWiG are more limited in the publicly available documents. 
Whether this is due to a lack of transparency or an indication that the organisations 
adhere to the HTA paradigm in Germany in a strict fashion that makes reason-giving 
superfluous is explored in the empirical chapters (chapters 6-8).  
In summary, the consultation documents that are available on the HTA bodies’ 
respective  websites  are,  despite  their  differences,  vast  and  detailed  and  provided  a 
useful data base for the empirical analysis. A strength of the FJC documents is that the  
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minutes of the oral hearings are included, a benefit that is missing in NICE’s documents 
as  these  only  summarise  the  consultation  proceedings.  However,  this  apparent 
shortcoming is balanced out by outlining the decision-making reasoning in individual 
cases,  an  aspect  which  is  comparatively  weaker  in  FJC  documents.  Thus,  the 
consultation documents on pharmaceutical benefit assessments by NICE, the FJC and 
IQWiG  provide  a  solid  basis  for  exploring  what  determines  the  outcome  of  these 
assessments.  
The main work of the empirical analysis of this thesis rests on the outcome of 
the dependent variable and an examination of the role of the outlined independent, or 
indeed previously unaccounted for, variables as seen in these consultation documents. 
The documents, which span 500-600 pages per case in both England and Germany, are 
the foundation for exploring the processes, both procedural and substantive, that lead to 
a certain outcome. However, in order to mitigate against the outlined weaknesses of the 
evidence, the data was triangulated by carrying out interviews with stakeholders and 
analysing  a  limited  number  of  media  excerpts  and  stakeholder  position  papers,  the 
details of which are described in the next sections. 
In  addition  to  the  consultation  documents  statutory  documents  on  HTA  and 
pharmaceutical benefit assessments as well as methods and implementation guidelines 
for  NICE,  the  FJC  and  IQWiG  are  an  important  data  source  in  this  thesis.  Their 
importance arises in relation to the research aim of exploring the effects of different 
HTA  paradigms  on  the  outcomes  of  pharmaceutical  benefit  assessments.  For  the 
purpose  of  this  thesis,  the  legislative  documents,  methods  and  implementation 
guidelines are interpreted as a reflection of the HTA paradigm in a given health care 
system. The purpose, values, processes, stakeholder involvement and methodological 
direction presented in these documents are viewed as the embodiment of a given policy 
paradigm.  Therefore,  while  the  consultation  documents  are  central  to  answer  the 
question of how policy paradigms operate in normal practice and how this impacts on 
assessment outcomes, the legislative, methods and implementation documents play a 
key role in disclosing the normative basis of the paradigms. A holistic analysis of the 
consultation as well as legislative and methods documents is thus presumed to shed 
light on the theory and practice of HTA policy paradigms in England and Germany. 
Included in the above list of data sources are a limited number of media excerpts 
and stakeholder position papers. The term ‘a limited number’ is used to indicate that 
media excerpts and position papers were not used in a systematic fashion for every  
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pharmaceutical  product  that  was  analysed,  but  only  in  those  cases  in  which  the 
consultation documents and stakeholder interviews indicated that the public discourse 
around an individual case might have contributed to the outcome of the pharmaceutical 
benefit assessment in question.  
 
3.5.1. Interview Process 
 
  The evidence collected from the consultation, statutory and methods documents 
was  triangulated  by  carrying  out  23  semi-structured  interviews  with  stakeholders 
involved  in  the  respective  assessment  and  appraisal  processes.  The  sample  of 
interviewees arose out of the investigation of which stakeholders were involved in the 
individual pharmaceutical benefit assessment processes. That is to say that a purposive 
sampling process was used in order to identify those employees and representatives of 
decision-making  bodies,  professional  physician  associations,  patient  groups  and 
pharmaceutical manufacturers that were involved. The method of randomly sampling 
interviewees was dispensed with as it was not deemed appropriate for the research aim 
of this study. As Tansey states, in process-tracing exercises: 
 
the aim is not to draw a representative sample of a larger population of political 
actors  that  can  be  used  as  a  basis  to  make  generalizations  about  the  full 
population,  but  to  draw  a  sample  that  includes  the  most  important  political 
players  who  have  participated  in  the  political  events  being  studied  (Tansey, 
2007, p. 765). 
 
 
The interviewee sampling process started by drawing up a list of stakeholders 
for every case of pharmaceutical benefit assessment and dividing these stakeholders into 
the categories of ‘decision-making representative’, ‘professional physician association’, 
‘patient group’ and ‘pharmaceutical manufacturer’. This list was easily drawn up on the 
basis  of the respective  consultation  documents  as  these contain the details  of every 
stakeholder  group  that  was  involved  in  a  HTA  process.  Based  on  this  list,  the 
stakeholders were contacted via e-mail or phone between September 2012 and January 
2013 in order to inquire whether they were available for an interview. Approximately 
60 interview requests were sent and 23 individuals responded positively. This translates 
to a successful response rate of more than a third. After completion of the 23 interviews 
the  possibility  of  conducting  further  interviews  was  considered.  However,  data  
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saturation was reached already in the sense that no new themes had emerged during the 
last five interviews that were conducted. The interview process was thus completed 
after 23 interviews. 
Table 3.3. gives an overview of the category and the number of stakeholder 
groups  that  were  interviewed  in  England  and  Germany.  In  order  to  safeguard  the 
anonymity of the stakeholders, the table presents the category of stakeholders rather 
than the name of the stakeholder group that was interviewed. 
 
TABLE 3.3. – List and Number of Stakeholders Interviewed 
 
 
Category of stakeholder  
 
England  Germany 
Decision-making body  One former 
executive director 
of NICE 
  One FJC 
representative 
  One IQWiG 
representative 
Professional physician 
association 
Three 
representatives  
Three representatives  
Patient groups and charities  Five 
representatives  
None 
Pharmaceutical manufacturers & 
pharmaceutical industry 
representatives 
Two 
representatives 
Seven representatives 
Total number of interviews  n=11  n=12 
 
 
Even though the total number of interviews, when compared to the number of 
potential stakeholder groups involved in each assessment process, indicates that not 
every stakeholder group was interviewed - mainly due to the response rate of a third -, 
table 3.4. shows that at least one interview was conducted for every pharmaceutical 
product. In addition, interviews with representatives from the decision-making bodies 
and  the  pharmaceutical  industry  were  not  case-specific  as  these  stakeholders  are 
involved in every benefit assessment process. As such the interviews are not skewed 
towards certain pharmaceutical products.  
While table 3.3. shows a balanced distribution between the number of interviews 
conducted in England and in Germany, it also shows that the interviews in England are 
slightly skewed towards patient groups, whereas the interviews in Germany are skewed 
towards representatives of pharmaceutical manufacturers.  
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TABLE 3.4. – Number of Interviews According to Product and Country 
 
Pharmaceutical product  Number of interviews in 
England 
Number of interviews in 
Germany 
Abiraterone  n=1 (patient charity 
organisation) 
n=1 (pharmaceutical 
manufacturer) 
Apixaban  n=2 (patient charity 
organisation and 
professional physician 
association) 
 
Boceprevir  n=2 (patient charity 
organisation and 
professional physician 
association) 
 
Cabazitaxel  n=1 (patient charity 
organisation) 
n=1 (pharmaceutical 
manufacturer) 
Eribulin  n=2 (patient charity 
organisations) 
n=1 (professional 
physicians association) 
Fingolimod  n=1 (pharmaceutical 
manufacturer) 
n=1 (pharmaceutical 
manufacturer) 
Ipilimumab     n=1 (professional 
physician association) 
Retigabine  n=1 (professional 
physician association) 
n=2 (pharmaceutical 
manufacturer and 
professional physician 
association) 
Telaprevir  n=2 (patient charity 
organisation, 
pharmaceutical 
manufacturer and 
professional physician 
organisation) 
n=1 (pharmaceutical 
manufacturer) 
Ticagrelor    n=1 (pharmaceutical 
manufacturer) 
 
In  Germany  the  lack  of  responses  from  patient  organisations  was  striking.  I 
experienced not  only  a  lack of responses from  patient  groups,  but  an overall small 
number of patient groups. Moreover, the patient groups were hard to identify. Most 
patient groups in Germany are self-help groups with few organisational and financial 
resources. These groups are committed to helping affected patients, but seem to play 
little to no role in pharmaceutical benefit assessment processes. This might partly be 
explained by the fact that patients are represented by a pooled patients’ representation in 
the  FJC.  This  representation  is  involved  in  the  appraisal  process  of  the  FJC,  albeit 
without the right to vote. Upon sending the official patient representation at the FJC an  
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interview request I was informed of an official policy that prohibits the representation to 
take part in PhD research. This explains why, despite my best efforts, unfortunately I 
was  unsuccessful  in  securing  an  interview  with  a  patient  group  in  Germany. 
Interestingly, the lack of organised patient representation and the effect of this on HTA 
processes also emerged as a theme during the analysis of the empirical data. 
  The  response  rate  from  pharmaceutical  manufacturers  was  more  cautious  in 
England than in Germany. I received a number of responses that explained that the 
respective pharmaceutical manufacturer was not available for an interview for reasons 
of  confidentiality.  In  contrast,  the  response  rates  by  representatives  from  the 
pharmaceutical manufacturers and industry in Germany were overwhelmingly positive. 
The  kind  of  responses  I  received  seemed  to  indicate  that  there  is  a  real  interest  in 
research being undertaken on HTA processes, especially because the requirement for 
early benefit assessments is relatively new to the German system.  
  Despite the under-representation of interviews with patient groups and the over-
representation of interviews with pharmaceutical manufacturers in Germany, and the 
vice-versa situation in England, the data collected contributes greatly to the empirical 
basis of this study. The aforementioned over- and under-representation means that the 
interview data runs the danger of being skewed in one direction or another. However, 
interview  data  is  always  more  subjective  than  other  forms  of  data  as  it  contains 
viewpoints from individuals that might be bias towards certain positions. This means 
that interview data has to be handled with caution in any research. For the purposes of 
this study, when interview data is used the source of the data, i.e. whether it stems from 
a decision-maker or a pharmaceutical manufacturer, is mentioned in order to account for 
any  potential  biases  that  the  data  might  give  rise  to.  However,  despite  the 
aforementioned challenges and the need to account for potential biases, the interview 
process was a fruitful exercise in that it supported the importance of certain themes that 
were already visible in the consultation documents and gave rise to additional ones, 
especially with regards to what I discuss as auxiliary variables such as public pressure 
in  chapter  8.  Thus,  using  interview  data  to  triangulate  other  data  sources  proved 
beneficial when it came to the research findings. 
  The aim of the interviews was to ascertain the stakeholders’ perceptions on what 
determines the outcome of pharmaceutical benefit assessments, both generally and in 
the specific cases that they were involved in. This purpose is reflected in the format of 
the  interview  questions  and  the  interview  protocol.  Although  the  interviews  were  
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carried out in a semi-structured way, a set of questions loosely guided the interview 
process
14. These questions included, but were not limited to, the following: 
 
  How would you describe the main principles that guide decision-making 
at [NICE, the FJC, IQWiG]? 
  What determined [NICE’s, the FJC’s, IQWiG’s] ultimate decision in the 
case of [insert name of pharmaceutical product]? 
  Do you feel your involvement in the process made a difference? 
 
The interview protocol that is attached as an appendix shows that respondents 
were initially asked to describe their role and involvement in the assessment process as 
well as whether they felt that their involvement made a difference. These  questions 
served the purpose of creating a relaxed atmosphere and establishing a good rapport 
between respondent and interviewer. The interview protocol differed slightly in England 
and Germany, which reflects specific themes that emerged during the analysis process 
of the consultation documents. That is to say, that the interviews were carried out after 
the analysis of the consultation documents was almost completed and this allowed for 
an exploration of some of the themes that emerged. This explains, for example, why the 
interview protocol  includes  a specific question on the role of ‘patient  relevance’ in 
Germany. In this sense, the interview process permitted a further examination of the 
themes that characertise the English and the German HTA paradigms respectively. 
Interviews were carried out in English in England and in German in Germany. 
Any quotations used from the stakeholder interviews in Germany were translated by 
myself.  Depending  on  the  interviewee’s  answers  to  different  questions,  follow-up 
questions  were  asked,  thus  allowing  for  the  flexibility  that  marks  semi-structured 
interview processes. Despite this flexibility all of the questions that are contained in the 
interview protocol were asked in every interview. The average length of interviews was 
between 45-60 minutes. With the consent of the interviewees, the interviews were voice 
recorded in order to transcribe them anonymously at a later date. The transcription of 
the 23 interviews was carried out by myself between April and September 2013.  
 
 
 
 
                                                        
14 See appendix B for interview protocol.  
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3.5.2. Data Analysis 
 
The data was analysed by employing methods of process-tracing and qualitative 
content  analysis.  According  to  George  and  Bennett:  “Process-tracing  offers  the 
possibility  of  identifying  different  causal  paths  that  lead  to  a  similar  outcome  in 
different cases” (George and Bennett, 2005, p. 215) and to uncover previously neglected 
variables.  They  also  highlight  the  advantages  of  using  process-tracing  methods  to 
uncover  causal  patterns.  They  point  out  that  the  goal  of  process-tracing  is  not  the 
generalisability of findings to all possible cases, but rather the uncovering of complex 
patterns in which variables might combine in order to shape a certain outcome. This 
suggests that process-tracing methods can be employed for the purpose of acquiring a 
deeper understanding of different sets of causal mechanisms. As the aim of this research 
is to understand not just which variables play a role in determining the outcome of 
pharmaceutical benefit assessments, but how they matter in individual cases, process-
tracing methods are appropriate tools for analysing this thesis’ data. 
By employing process-tracing exercises, this research demonstrates that there is 
more than one possible path that may lead to  similar or dissimilar outcomes in the 
dependent variable. Which path is pursued and which outcome it leads to, is largely 
determined by opportunities and constraints that decision-makers are faced with within 
HTA policy paradigms. The process-tracing exercise, as presented in chapters 6, 7 and 8 
illustrates that drawing conclusions based on the outcome of the dependent variable 
alone  is  not  conducive  to  understanding  what  determines  pharmaceutical  benefit 
assessment  outcomes  in  a  meaningful  way.  This  is  substantiated  by  the  empirical 
finding  that  benefit  assessments  can  result  in  similar  decision  outcomes,  even  if 
different decision-making criteria are employed in the process, as seen in several cases 
such as the cases of Cabazitaxel (table 6.3.), Eribulin (table 6.4.) and Telaprevir (7.2.) 
In terms of the practicalities of using process-tracing methods, it should be noted 
that I traced the content of the decision-making processes in the embedded cases of 
pharmaceutical benefit assessments rather than the procedural steps that resulted in the 
final  outcome  of  the  benefit  assessments.  The  formalised  nature  of  pharmaceutical 
benefit assessments processes in England and Germany, which is outlined in chapter 4, 
allowed me to assume that every case of benefit assessment went through the same 
respective  procedural  steps  that  are  prescribed  by  the  institutional  settings  in  both 
countries. Therefore, I do not trace the structural processes anew in every case, but  
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rather focus on the content of the decision-making processes in these cases. This study 
thus represents a study of the decision-making processes and criteria rather than a study 
of institutional procedures. The reasoning behind decisions is considered the result of a 
process, namely the process of applying different decision-making values and criteria to 
the same cases,  the outcome of which forms  the focal  point of the thesis. Process-
tracing  methods  were  used  to  trace  the  processes  of  reasoning  and  argumentation 
through  which  final  decisions  were  arrived  at.  These  processes  of  reasoning  and 
argumentation are  akin  to  what  Kuhn (1962) believes  happens  when paradigms  are 
articulated in the processes of normal science. The use of process-tracing methods is 
thus also an accurate reflection of the theoretical framework that guides this thesis. 
In addition to using process-tracing methods, the consultation documents and 
interview transcripts as well as statutory guidelines and position papers were analysed 
by employing qualitative methods of content analysis. The documents were analysed 
with  a view to  uncover themes  and views  that  play  a role in  determining the final 
outcome of pharmaceutical benefit assessments. These themes were identified during an 
analytical exercise in which the data was read repeatedly and marked according to the 
themes that emerged. The themes were then compared between each other in order to 
assess  whether  congruencies,  discrepancies  or  additional  subjects  arose  in  different 
documents. Apart from one theme, which is discussed in chapter 8, the findings that 
resulted  were  largely  congruent  between  different  data  sets,  which  strengthens  the 
internal validity of the research findings. 
The data analysis gave rise to six themes that repeatedly emerged during the 
argumentative  processes  of  pharmaceutical  benefit  assessment  in  England  and 
Germany.  Table  3.5.  provides  an  introductory  overview  of  these  themes.  They  are 
introduced in further detail in chapter 6 and then discussed in chapters 6, 7 and 8. For 
now, suffice it to emphasise that apart from theme six, the themes that played a role in 
the  argumentative  processes  of  HTAs  were  similar  in  both  countries.  However,  the 
questions that were asked within these broadly similar themes differed in England and 
Germany. This presents the starting point for the analysis of how paradigms can explain 
the differential emphasis on broadly similar scientific, procedural and political themes. 
Due to the breadth of the collected empirical material, excerpts from the consultation 
documents, the interview transcripts as well as other data sources are used illustratively 
in the discussion of the results of the data analysis throughout the empirical chapters. 
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3.6. Concluding Remarks 
   
  This  chapter  provided  an  overview  of  the  research  design  employed  in 
addressing the research question. The outlined research methods arise from the research 
aim of this study, that is to gain a deeper understanding of how variables combine to 
determine the final outcome of pharmaceutical  benefit assessments in  countries that 
employ HTA processes. The research design is also a logical extension of the thesis’ 
theoretical  premise,  which  suggests  that  ideas  and  values  in  the  form  of  policy 
paradigms  play  a  role  in  determining  the  outcome  of  pharmaceutical  benefit 
assessments. The ideas and values that are outlined as policy paradigms in chapter 5 can 
be  captured  not  just  by  analysing  which  variables  matter,  but  by  tracing  how  they 
matter, why they matter, and how they are framed and understood in different HTA 
systems.  This  will  provide  insight  into  how  a  paradigm  is  established  and 
operationalised in ‘normal’ decision-making processes. 
  The next chapter offers a descriptive overview of the institutional arrangements 
of health care, pharmaceutical policy and pharmaceutical benefit assessment in England 
and Germany. It sets the contextual scene for the analytical chapters that follow.   
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TABLE 3.5. – Themes that Emerged from the Data Analysis (Ranked in order of Prevalence) 
Themes  Properties/questions of the theme in England  Properties/questions of the theme in Germany 
1.  Permissibility, quality and 
validity of evidence 
  What is accepted as evidence?  
  Evidence  applicable  to  UK  clinical 
practice? 
  What  does  the  evidence  say  about  the 
product?  
  Does it meet the decision-making criteria? 
  What is accepted as evidence? 
  Does  the available evidence reflect  marketing 
authorisation and clinical guidelines? 
  What does the evidence say about the product? 
  Are  the  presented  clinical  endpoints  patient 
relevant? 
2.  Choice of comparator 
product 
  Is  the  choice  of  comparator  reflective  of 
UK clinical practice? 
  Is  the  choice  of  comparator  reflective  of  the 
current standard alternative? 
3.  Patient population 
subgroup divisions 
  Do  the  subgroup  divisions  adequately 
reflect the patient groups likely to receive 
the treatment in routine clinical practice? 
  Do the subgroup division adequately reflect the 
patient  population(s) for which the product  is 
licensed? 
4.  Operationalisation of 
criteria for HTA decision-
making and role of 
algorithms 
  Algorithm  is  applied:  Cost  effectiveness 
threshold  in  terms  of  incremental  cost 
effectiveness  ratio  (ICER)  per  quality-
adjusted life year (QALY) 
  Is an algorithm for the categorisation of added 
benefit  applied  by  IQWiG  in  assessment 
process? 
  Algorithm applied by the FJC not transparent 
(stakeholder opinion). 
5.  Suitability of paradigms 
for cases such as chronic 
diseases 
  How  to  make  decisions  in  cases  where 
natural  progression  of  the  disease  is 
uncertain and patients live with the illness 
for a long time? 
  Questions  around  the  applicability  of  patient 
relevant endpoints such as mortality in disease 
indications  where  natural  progression  of  the 
disease is uncertain and patients live with the 
illness for a long time (stakeholder opinion) 
6.  The question of political 
power and influence: 
Public pressure and 
distribution of bargaining 
power of stakeholders 
  What is the effect of public pressure in the 
form  of media  and patient  campaigns  on 
the final result of HTAs? 
  Does the differential distribution of bargaining 
power of stakeholders affect the final result of 
HTAs?  
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Chapter 4 
 
Health Care, Pharmaceutical Policy and Pharmaceutical Benefit 
Assessment in England and Germany 
 
4.0. Introduction 
   
This chapter provides an overview of the structure and financing of the health 
care  systems  in  Germany  and  England.  It  introduces  the  reader  to  the  features  of 
pharmaceutical regulation and pharmaceutical benefit assessment in the two countries, 
including the role played by the institutions that are the focus of this study, namely the 
National Institute for Health and Care Excellence (NICE) in England, the Federal Joint 
Committee (FJC) and the Institute for Quality and Efficiency in Health Care (IQWiG) 
in Germany. The chapter presents an introduction to the institutional specificities that 
need to be considered when engaging in a comparative analysis of what determines the 
outcome of pharmaceutical benefit assessments based on health technology assessment 
(HTA) procedures.  
The institutional specificities include procedural and substantive similarities and 
differences  in  the  way  HTA  processes  are  conducted  in  Germany  and  England.  A 
descriptive overview of these, including the form that the dependent variable, i.e. the 
outcome  of  pharmaceutical  benefit  assessments,  can  take  in  the  two  countries  is 
followed by a comparative summary in section 4.9. in order highlight the first important 
distinction between the German and the English HTA policy paradigm. That is, while 
the German HTA paradigm operates on the idea that there are thresholds for the ‘right’ 
price of a pharmaceutical product, the English HTA paradigm operates on the idea that 
there  are thresholds  for the inclusion or exclusion  of a pharmaceutical  product,  i.e. 
thresholds above which a product will no longer be considered good value for money. 
The concept of thresholds is thus employed for different purposes in England and in 
Germany, which inevitably leads to differences in how the concept is operationalised in 
normal  practice.  Whether  or  not  this  difference  can  explain  the  differences  or 
similarities in HTA outcomes is explored in the later parts of this thesis. What follows is 
an overview of the health care systems, pharmaceutical policy and the HTA processes 
in England and Germany in order to get a sense for the institutional context in which the 
emerging dominant HTA paradigms are established.  
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  England and Germany represent two different types of health care systems that 
are  characterised  as  ideal  types  in  the  health  policy  literature.  The  literature 
distinguishes between types of financing, service provision and mode of governance in 
health care. Abel-Smith (1994) outlines that health care financing can take the form of 
public or private health expenditure or compulsory health insurance. These types of 
health care organisation are exemplified by the German and the English health care 
systems.  Table  4.1.  provides  an  overview  of  the  main  features  of  the  health  care 
systems. In light of this thesis’ research question only the institutional and structural 
elements that are considered relevant to the question are presented in more detail in the 
following sections.  
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TABLE 4.1. – Health Care in England and Germany 
 
Characteristics  England  Germany 
Financing  Publicly financed based on taxation  Publicly financed based on statutory health 
insurance (SHI) 
Health care expenditure as % of GDP in 2012 
(OECD, 2014) (figures for more recent years 
not available) 
9.3% (figure for United Kingdom)  11.3% 
Population covered by public health care  63.2 million legal residents (Department of 
Health, 2013) 
90% of population covered by SHI, the rest is 
covered under private insurance (BMG, 2013) 
Health care service structure  Division between primary and secondary 
care. General practitioners (GPs) hold role 
as gatekeepers in the systems. 
Division between ambulatory and hospital 
care. Ambulatory care includes patient access 
to specialist consultants. No strong 
gatekeeping role for GPs.  
Service charges for patients  Free at the point of access. Cost-sharing for 
prescription charges with exemptions for 
certain population groups. 
Free at the point of access. Cost-sharing for 
prescription charges and for some preventive 
services. 
Decision-making structure/Mode of governance  Purchaser/provider split. Local clinical 
commissioning groups (CCGs) decide 
which services are commissioned and 
service level agreements are drawn up with 
providers. 
Emphasis on self-governance. Self-governing 
sickness insurance funds negotiate terms, 
conditions and prices for health care services 
with providers. 
National/federal bodies with a decision-making 
mandate on health care service provision 
NICE’s technology appraisal guidance has 
to be implemented by local CCGs. 
FJC makes federal decisions on the minimum 
of services to be covered by sickness 
insurance funds. 
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4.1. Health Care in England 
 
4.1.1. Financing 
 
  The health care system in England represents a publicly financed system based 
on  taxation.  It  is  frequently  referred  to  as  the  ‘Beveridge’  model  of  health  care 
financing, named after a British economist, William Beveridge, who in 1942 produced 
the so-called Beveridge Report “[…] which advocated free and universal health services 
[…]”  (Aaron  and  Schwartz,  1984,  p.  13).  What  was  then  envisaged  in  theory  was 
implemented  in  practice  in  1948  with  the  creation  of  the  National  Health  System 
(NHS). Since then the NHS is financed predominantly through taxes and has a fixed 
annual budget to cover the services it provides. While there are other sources of income 
such as prescription charges paid by patients, in comparative terms the NHS in England 
represents a relatively ‘pure’ case of a tax-based health care system. 
An annual fixed health care budget that consists of taxpayers’ money comes 
with its own unique challenges with regards to planning services and being accountable 
in the eyes of the taxpayer. The Department of Health (DH) summarises this in the 
following way: “The challenge faced by the NHS is how to spend that budget in a way 
that results in the best possible outcomes for individual patients and delivers value for 
money for the public” (Department of Health, 2013, p. 6).  
 
4.1.2. Principles, Structure and Health Care Provision 
 
  The most important and long-standing principle of the NHS is that its services 
are free at the point of access. Additional principles of the NHS are laid out in the so-
called  NHS  Constitution  (Department  of  Health,  2013a).  The  Constitution  lays  out 
seven principles that include the provision of a comprehensive service to all, access to 
health care services irrespective of ability to pay, the centrality of the patient, value for 
money and accountability to the public (Department of Health, 2013a).  
With its financing based on taxation, the role played by the state is traditionally 
bigger in systems such as the NHS than in statutory health insurance (SHI) systems. 
While the government delegates responsibility for the provision and planning of health 
care services to autonomous actors in SHI systems, publicly financed systems mean that 
the responsibility, and hence accountability, of service provision lies more directly with  
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state organisations. Thus, while actors such as GPs are autonomous in England in that 
they  run  their  own  practices  and  purchase  services  for  their  patients  from  service 
providers, the NHS system exhibits a higher degree of centralisation in decision-making 
than  that  which  we  observe  in  health  care  systems  with  a  different  financing 
mechanism. 
Most decisions on which services to fund and provide are made on a local and 
regional level. The reasoning behind this is that the local demographics of a region 
determine  the  health  care  needs  of  the  area  (Department  of  Health,  2013).  Making 
decisions on a local level allows for prioritising services that are perceived to be needed 
the most and from which the local population benefits the most (Department of Health, 
2013). Since April 2013 the regional organisations in charge of making decisions about 
which services to provide are the Clinical Commissioning Groups (CCGs) (Department 
of  Health,  2013).  These  groups  took  over  from  the  so-called  Primary  Care  Trusts 
(PCTs). At a national level the NHS Commissioning Board, also known as the NHS 
England, make commissioning decisions that relate to rare diseases, offender health care 
and health care for the armed services as these may entail special requirements that need 
to be addressed (Department of Health, 2013, p. 7). 
The  allocation  of  health  resources  in  England  has  not  been  without  its 
challenges. For example, concerns about the effects of health resource allocation and 
priority setting have included concerns about the so-called “postcode lottery” (Ham, 
2009, p. 128) of service provision in which access to treatment for a patient might 
depend on the area where he/she lives, thus giving rise to concerns over a regionally 
determined inequality of access. In 1999 these concerns led to the establishment of the 
National Institute for Health and Clinical Excellence (Ham, 2009), now the National 
Institute  for  Health  and  Care  Excellence  (NICE).  By  evaluating  treatments  and 
pharmaceuticals  and  issuing  guidelines  and  recommendations  in  these  areas,  NICE 
seeks “[…] to reduce variation in the availability and quality of NHS treatments and 
care” (NICE, 2013). An overview of the structure and mandate of NICE is provided in a 
later section of this chapter. For now I briefly turn to the role of cost containment in the 
NHS. 
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4.1.3. Cost Containment 
 
  In comparison to Germany, England has a long tradition of cost containment in 
the form of rationing or prioritisation due to its dependence on annual fixed health care 
budgets (Robert, 2003). Ham highlights that until the 1970s rationing occurred rather 
implicitly in the form of long waiting lists or denial of access to specialist services 
(Ham, 2009, p. 127). From the 1970s policy-makers began to acknowledge a need for 
putting priority setting on the health policy agenda, albeit with a reluctance to take 
responsibility for making decisions on which services to fund (Ham, 2009). Ham asserts 
that: “The reluctance of governments to take a lead in setting priorities derives from the 
political  costs  involved  in  taking  unpopular  decisions”  (Ham,  2009,  p.  127).  This 
explains  why,  for  the  most  part,  rationing  and  health  priority  setting  in  England  is 
considered  an  issue  to  be  resolved  at  the  local  level  through  commissioning 
responsibilities which in turn gives rise to the previously described phenomenon of the 
‘postcode lottery’ where access to services depends on where one lives (Ham, 2009). 
 
4.1.4. Summary   
 
  In contrast to Germany’s health care system, decision-makers and providers in 
England  are  constrained  by  annual  fixed  budgets  that  leave  little  room  for  variable 
spending increases. Unexpected or new developments such as a particularly severe flu 
season or positive recommendations by NICE which CCGs are under an obligation to 
fund put strains on local budgets which are not necessarily taken into account when 
budget allocation occurs. This means that local health care decision-makers in England 
are frequently faced with the question of which services can justifiably be displaced by 
the coverage of new services. In the past, this has given rise to regional differences in 
health care service provision, which policy-makers have sought to address through the 
introduction of NICE (Ham, 2009).  
  For  the  purposes  of  this  thesis  the  analysis  of  the  pharmaceutical  benefit 
assessment process in England has to be undertaken against the contextual backdrop of 
a)  an  institutionally  setting  in  which  decisions  on  health  care  provision  are 
predominantly taken at the local level by way of health care commissioning; the legal 
obligations  of  local  health  care  commissioners  include  the  obligation  to  prioritise 
services  such  as  described  by  the  government  and  to  fund  treatments  and  
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pharmaceuticals that are recommended by NICE  and b) a financing mechanism that 
means that local health care commissioners are constrained by annual budgets that are 
fixed by central government. While commissioners are payers for health care services in 
that they purchase them from providers, they are not payers in the sense that they decide 
how much money is available to them. This decision is made centrally in annual budget 
negotiations.  This  element  of  health  care  decision-making  presents  an  important 
distinction to the German case in which payers hold a more active negotiating role when 
it comes to the level of reimbursement for services.  
 
4.2. Health Care in Germany 
 
4.2.1. Financing 
 
The health care system in Germany represents a system that is publicly financed 
through compulsory social insurance. It is a statutory health insurance (SHI) system that 
dates back to 1883 when the Chancellor of the German Empire, Otto von Bismarck, 
introduced laws that mandated compulsory health insurance for industrial workers and 
workers of other trades (Simon, 2010). For this reason the German health care system is 
frequently referred to as the ‘Bismarck’ model of health care financing (Simon, 2010).  
There  is  a  statutory  obligation  for  all  residents  in  Germany  to  have  health 
insurance which, depending on one’s salary, is provided by quasi-public, not-for-profit 
insurance bodies called statutory sickness funds or by private insurance bodies (Simon, 
2010). The insurance contribution rates are divided between employers who currently 
pay a rate of 7.3% and employees who pay a rate of 8.2% of the gross salary towards 
statutory health insurance (BMG, 2013a). This means that in addition to monthly taxes, 
15.5% of a given monthly gross salary will be deducted to pay for statutory health 
insurance (BMG, 2013a). There are special provisions for children, unemployed family 
members  and  unemployed  members  of  society.  Children  and  unemployed  family 
members are insured free of charge with the employed members of the family and the 
insurance fees for citizens on social benefits are covered by the state (BMG, 2013b). 
Since  2009  the  SHI  contributions  are  pooled  in  the  so-called 
‘Gesundheitsfonds’,  a  health  fund  in  which  SHI  contributions  are  collated,  tax-
supplemented and then redistributed to sickness funds in a risk-adjusted manner (BMG, 
2013c). The creation of this health fund included the introduction of the previously  
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mentioned  uniform  SHI  rate  of  15.5%  in  order  to  ensure  planning  stability  for 
employers  and  employees.  The  introduction  of  a  tax-based  element  in  form  of  tax 
supplements as part of the health fund to mitigate some of the expenditure increases in 
health care represents a novel policy in health care financing in Germany in that it is no 
longer covered solely by employers and employees but supplemented directly by the 
state.  This  is  an  example  of  what  Saltman  (2012)  means  when  he  asserts  that  the 
traditional boundaries between health care systems, such as the distinction between tax-
based  and  social  insurance-based  systems,  are  beginning  to  fade,  thereby  opening 
possibilities for a wider array of cross-national research.  
 
4.2.2. Principles, Structure and Health Care Provision 
 
  The  health  care  structure  in  Germany  rests  on  several  important  principles. 
According to Simon (2010) they include the constitutional duty of the state to provide 
social services, the principle of subsidiarity, the principle of solidarity and the principle 
of self-administration. For the purpose of this thesis, only the principles of solidarity 
and self-administration are explained briefly in the following sections as they represent 
institutional and normative features that are key to understanding the discussion of the 
HTA paradigms which is presented in the next chapter. 
The principle of solidarity is anchored in §1 and § 3 of the Social Code Book V 
(SGB V) (BMJV, 2013), the statutory framework that guides health care in Germany. 
This principle forms the normative pillar of the German health care system in that it 
outlines  that  health  care  financing  is  a  communal  responsibility.  Members  of  the 
community show solidarity by paying for statutory health insurance and accepting that 
the fees they pay will be used when other members of the society require health care 
(Simon, 2010). The principle of solidarity is based on an understanding of reciprocity, 
which renders it acceptable because members of the SHI community know that they too 
have a right to access health care when they need it. As such the system represents a 
solidary agreement between the healthy and the ill members of society.  
The  principle  of  self-administration,  or  self-governance,  is  an  institutional 
feature commonly found in SHI systems and it is connected to the structure of decision-
making  and  health  care  provision.  SHI  systems  are  characterised  by  de-centralised 
decision-making procedures in that the state lays out the legislative mandate for health 
care,  but  delegates  the  responsibility  of  implementation  to  independent  health  care  
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bodies and actors (e.g. Giaimo, 1995). In Germany this delegation is manifested in the 
principle of self-governance. This means that self-governed sickness funds, professional 
physician  representations,  hospital  organisations  and  professional  dentist  bodies 
negotiate the terms and conditions of service provision, remuneration scales and pricing 
amongst  each  other  (Simon,  2010).  It  is  for  this  reason  that  the  German  system  is 
frequently referred to as a corporatist system which “[…] hands over certain legally 
defined  rights  of  the  state  to  self-governing  institutions”  (Pfaff,  2009,  p.  104).  In 
practice this means that health care decision-making in Germany is diverse and complex 
in that it takes place at different levels of federal and regional tiers. If an agreement 
cannot  be  reached  between  negotiating  parties,  then  the  matter  is  referred  to 
independent  bodies  of  arbitration  which  aim  to  solve  the  dispute  and  prevent 
participating parties from taking legal action.  
At the federal level, decisions on which services to include or exclude from the 
health care benefit basket are made by the main decision-making body, the Federal Joint 
Committee  (FJC).  The  next  section  briefly  outlines  the  set-up  of  the  FJC  and  its 
mandate with regards to health care decision-making. Its role in pharmaceutical benefit 
assessment is discussed in more detail in section 4.8.. 
 
4.2.3. The Federal Joint Committee (FJC) 
 
  The FJC is the main decision-making body in health care in Germany and as 
such  it  constitutes  the  most  important  body  of  the  self-governing  structure  (Simon, 
2010,  p.  102).  The  FJC  consists  of  five  representatives  of  the  payer  (the  statutory 
sickness  funds)  and  provider  associations  (physicians,  dentists  and  hospitals) 
respectively,  three  impartial  members  as  well  as  five  patient  representatives  (FJC, 
2013). The latter may take part in deliberations and propose resolutions, but they do not 
have voting rights. FJC decisions and guidelines cover services such as pharmaceutical 
coverage, needs planning, disease management programmes (DMPs) for chronically ill 
patients,  therapeutic  and  diagnostic  devices.  The  FJC’s  decisions  are  binding  for 
statutory sickness funds, health care providers and SH-insured members alike (Simon, 
2010, p. 102). 
  The division between ambulatory and hospital care in Germany is visible in the 
decision-making remit and regulations of the FJC. In the ambulatory care setting a new 
diagnostic or therapeutic method will only be reimbursed if the service has received a  
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positive decision from the FJC (§ 135 Abs. 1 SGB V). By contrast, in the hospital care 
setting a new diagnostic or therapeutic method will be reimbursed unless it has received 
a negative decision by the FJC (§137c SGB V). Thus, in terms of service coverage, the 
default position of what is provided is different in ambulatory and in hospital care. In 
hospital care the default position is to ‘do’ unless a service is specifically excluded, 
whereas in ambulatory care the default position is ‘do not do’ unless it is specifically 
included.  Special  rules  pertain  to  the  coverage  of  new  pharmaceuticals,  which  are 
explained in section 4.8..  
 
4.2.4. Cost Containment 
 
In SHI systems the health care budget does not compete for funds with other 
tax-financed policy areas such as education or defence. However, this does not mean 
that SHI systems are immune to the impact from economic downturns. The fact that the 
SHI  contribution  rates  are  dependent  on  salaries  indicates  that  the  development  of 
health care expenditure is closely linked to the economic climate. That is to say that 
contributions decrease when unemployment increases or salaries stagnate. This suggests 
that health care policy-makers in Germany are facing similar challenges as those in 
other countries.  
To address the pressures on the German health care system that stem from rising 
expenditures  policy-makers  have  introduced  several  reform  measures.  Busse  (1999) 
discusses the reform, rationing and priority setting measures in different health care 
sectors  in  Germany.  Measures  have  included  the  introduction  of  diagnostic-related 
groups (DRGs) for the payment of hospital services, various supply- and demand-side 
measures  in  the  pharmaceutical  policy  area  and  “[…]  maintaining  stability  in  the 
average SHI contribution rate […]” (Busse, Schreyoegg and Henke, 2005, p. 329). In 
2010, policy-makers introduced a law to help curtail the prices of new pharmaceuticals 
in  Germany,  the  Act  on  the  Reform  of  the  Market  for  Medicinal  Products 
(Arzneimittelmarktneuordnungsgesetz – AMNOG) (Bundesgesetzblatt, 2010), which is 
described in more detail in section 4.4..  
Despite  these  reform  measures  the  question  of  whether  prioritisation  and 
rationing is happening in the German health care context is a contested issue. Calls for 
an  open  debate  on  prioritisation  have  predominantly  been  voiced  by  professional 
physician  bodies  such  as  ethics  commission  of  the  German  Medical  Association  
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(Zentrale Ethikkommission bei der Bundesärztekammer, 2007). These calls have not 
received much response from policy-makers who remain reluctant to engage in debates 
about rationing and prioritisation (Ärzteblatt, 2011). This reluctance was confirmed by a 
qualitative  study  by  Klingler,  et  al.  in  which  “respondents  attested  a  traditional 
reservation towards associating health benefits with financial values” (Klingler, et al., 
2013, p. 275). 
The lack of a public discourse around issues of priority setting in health care is 
an  important  institutional  feature  to  bear  in  mind  when  deconstructing  the  HTA 
paradigm  in  Germany.  However,  despite  the  lack  of  a  public  discourse  on  such 
questions, there are suggestions that rationing is, at least implicitly, already happening 
in everyday clinical settings in Germany, especially in the hospital sector (e.g. Strech, et 
al.,  2009;  Marckmann,  2009).  While  the  extent  of  this  implicit  rationing  is  still 
unknown  (Marckmann,  2010),  it  is  predominantly  attributed  to  reforms  such  as  the 
introduction of DRGs as a method for the payment of hospital services (Altenstetter and 
Busse, 2005). Yet, despite this there are also reports of a surplus of funds in the health 
fund (F.A.Z., 2013). In August 2013 this surplus amounted to 29 billion Euros (F.AZ., 
2013),  a  figure  that  might  contribute  to  the  perceived  lack  of  need  to  engage  in 
discussion about prioritisations in health care.  
 
4.2.5. Summary 
 
The  German  health  care  system  is  characterised  by  a  corporatist  mode  of 
governance  in  which  autonomous,  self-governing  actors  negotiate  the  terms  and 
conditions of health care provision amongst themselves with the state mandating the 
minimum requirements and criteria of this provision (Altenstetter and Busse, 2005). In 
relation to its financing, it is dependent on the stability of SHI contribution rates, a 
stability that can only be achieved in favourable economic climates.  
Based  on  the  above  remarks,  an  analysis  of  the  early  benefit  assessment  of 
pharmaceuticals has to take into consideration a) an institutionally complex bargaining 
system that includes a diverse set of actors, both from the payer and from the provider 
sides, who negotiate health care service provision and b) a financing mechanism that 
allows for a certain degree of flexible health care decision-making and that is, for the 
moment,  running a surplus,  but  that does  not  shield from  negative external  shocks. 
Moreover, policy-makers and decision-makers alike appear to be reluctant to engage in  
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debates  on  priority  setting  and  rationing.  Addressing  the  question  whether  this  is  a 
genuine reluctance or a perceived one, or whether it merely reflects a lack of need to 
prioritise in a system that frequently runs surpluses, is beyond the scope of this thesis. 
However, the reluctance, be it real or perceived, might contribute to the interpretation of 
the results of the empirical analysis presented in chapters 6, 7 and 8. 
 
4.3. Health Care in England and Germany: Concluding Remarks 
 
  The above overview of the English and German health care system provided an 
introduction  to  the  institutional  characteristics  that  are  important  to  consider  when 
examining the HTA policy paradigms in both countries. At its core, this thesis presents 
a juxtaposition of the German health care system which is characterised by decision-
making structures  that are based on bargaining  vis  à vis the English  system  that is 
characterised  by  localised  decision-making  processes  that  are  guided  by  legal 
obligations and annual fixed budgets subscribed by central government. I compare and 
contrast a system that is currently running a surplus of health care funds with one that 
has experienced the constraints of fixed budgets since its inception in 1948 and has thus 
had to face the difficult choices of rationing and prioritisation from an early point in its 
life cycle. 
While the institutional differences are stark, the next section illustrates that they 
are by no means insurmountable or indeed a barrier to institutional comparison. This is 
because  one  area,  namely  pharmaceutical  policy,  has  played  a  large  role  in  reform 
efforts  in  both  Germany  and  England.  Reform  measures  in  this  field  have  been 
comparable, especially when it comes to the creation of so-called HTA bodies. In the 
next section I give a brief overview of pharmaceutical regulation, policy and pricing in 
both countries before outlining the workings of the main decision-making bodies in the 
field, NICE in England and the FJC and IQWiG in Germany. 
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4.4. Pharmaceutical Spending, Policy and Regulation 
 
Pharmaceutical  regulation  and  policy  includes  instruments  used  by  national 
governments to ensure the safety of available medicines, the responsible and efficient 
use  and  prescription  thereof  and  measures  to  contain  the  costs  of  pharmaceutical 
spending  (Seiter,  2010).  It  also  relates  to  regulatory  measures  affecting  the 
pharmaceutical industry, an industry which is a significant economic player in both 
Germany  and  the  United  Kingdom  (UK)  in  terms  of  exports  and  job  provision 
(Mossialos and Oliver, 2005).  
As briefly outlined in chapter 1, pharmaceutical spending has been a prominent 
target  of  health  care  reforms  in  OECD  countries.  England  and  Germany  are  no 
exception  to  this  trend.  Pharmaceutical  spending  constitutes  a  large  part  of  overall 
health care expenditure in the two countries. In 2011
15 the UK
16 spent approximately 
£13 billion on its medicines bill, that is 9.8% of the total NHS expenditure  (Hawe and 
Cockcroft, 2013, pp. 137-138). In 2013 the sickness insurance funds in Germany spent 
€30  billlion  on  medicines,  that  is  14.4%  of  their  total  expenditure  (Statista,  2014). 
While  these  proportions  of  total  health  care  spending  on  pharmaceuticals  may  not 
immediately appear significant at between 10-15%, their significance becomes salient 
when  considering  that  pharmaceutical  spending  is  “[…]  the  third  biggest  spending 
component  after  inpatient  and  outpatient  care”  (OECD,  2012).  This  explains  why 
pharmaceutical spending has been subject to reform measures such as the introduction 
of patient co-payments, reference pricing, profit controls and generic drug precriptions 
(Freeman, 2009) and, more recently, health technology assessments. 
The expenditure on medicines in England and Germany is not the only aspect 
that  policy-makers  in  both  countries  are  concerned  with  in  pharmaceutical  policy. 
England  and  Germany  are  amonst  the  top  ten  global  pharmaceutical  markets  (IMS 
Health  cited  in  ABPI,  2013).  In  the  area  of  research  and  development  (R&D),  for 
example, the pharmaceutical sector in the UK constitutes the business sector with the 
highest R&D expenditure. “The expenditure accounts for 28% of the total expenditure 
on R&D performed in UK businesses in 2011” (ONS, 2012, p. 4); this figure compares 
with,  for  example,  the  aerospace  industry’s  R&D  expenditure  of  just  8%,  which  is 
considered  the  largest  aerospace  business  in  Europe  (ONS,  2012).  Using  a  slightly 
                                                        
15 Figures for years later than 2011 not yet available 
16 Figures only available for UK and not for England alone  
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different  example for Germany, Germany’s pharmaceutical sector employs the most 
employees compared with other pharmaceutical sectors in Europe, making it the biggest 
pharmaceutical market in Europe in terms of people employed (IW and vfa, 2013).  
The significant strength of the pharmaceutical sector in England and Germany 
adds  to  the  complexity  of  pharmaceutical  policy  and  regulation.  It  underlines  the 
political and economic salience of the introduction of HTA policies because the need 
for containing pharmaceutical spending has to be balanced against the need to provide 
an attractive environment for investments in jobs and R&D efforts. The complexities of 
meeting competing demands in the area of pharmaceutical policy-making, which have 
been highlighted by the illustrative figures above, form the background against which 
the following sections and chapters have to be understood. 
 
4.4.1. Pharmaceutical Licensing 
 
Before  a  pharmaceutical  product  can  be  marketed  in  a  given  country,  the 
pharmaceutical manufacturer has to acquire a license, a so-called market authorisation. 
In  the  European  Union  (EU)  this  licensing  procedure  has  been  harmonised.  Most 
pharmaceutical products that are new to the European market go through what is called 
the centralised procedure (CP) which allows pharmaceutical manufacturers to apply for 
a market authorisation with the European Medicines Agency (EMA) (EMA, 2013). If 
the EMA is satisfied that the product meets the necessary standards of quality, safety 
and efficacy, the European Commission (EC) grants the license (EMA, 2013). This 
means that the pharmaceutical product in question will be licensed in all EU member 
states  at  the  same  time.  The  advantage  of  this  procedure  is  that  pharmaceutical 
manufacturers only have to go through a licensing process once and that they can use 
one  evidence  base,  usually  in  the  form  of  randomised  controlled  trials  (RCTs),  to 
acquire  their  license.  Alternatively,  manufacturers  can  choose  to  follow  the 
decentralised procedure (DCP), thus applying for a license via national authorisation 
systems that are in place in every EU member state. If successful in securing a license 
the manufacturer may then apply for the license to be recognised in more than one 
member state under the so-called Mutual Recognition Procedure (EMA, 2013).   
  Pharmaceutical  licensing  in  Germany  was  introduced  in  1968  with  the 
Medicines Act 1968, as a result of scandals surrounding the use of unsafe medicines. 
The  agency  responsible  for  the  licensing  and  registration  of  pharmaceuticals  and  
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medical devices is the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), 
the  Federal  Institute  for  Drugs  and  Medical  Devices.  The  institute  carries  out  its 
responsibilities  under  the  Arzneimittelgesetz  (AMG),  the  German  Medicines  Act. 
Pharmaceutical manufacturers can apply for a license directly to the BfArM under the 
decentralised procedure that is available to manufacturers in EU member states. As an 
authorisation  agency,  the  BfArM  “[…]  reviews  the  proof  of  efficacy,  safety  and 
adequate pharmaceutical quality of the finished medicinal products” (BfArM, 2013) and 
“the  pharmaceutical  companies  must  provide  proof  of  the  pharmaceutical  quality, 
efficacy,  and  safety  of  the  product.  If  they  fail  to  do  so  the  BfArM  refuses 
authorisation”  (BfArM,  2013).  The  institute  monitors  existing  and  new  drugs  for 
potential side effects even after they have entered the market, as such its role does not 
stop when the license is granted.   
The British equivalent of the BfArM is the Medicines and Healthcare Products 
Regulatory Agency (MHRA). The application and authorisation procedure functions in 
much of the same way as that of the BfArM with efficacy, quality and safety being the 
main criteria that  have  to  be met.  In order to  assess the safety and efficacy of the 
product in question the pharmaceutical company supplies the MHRA with all necessary 
data  resulting  from  clinical  trials,  toxicological  tests  and  the  like  (MHRA,  2013).  
Monitoring of the products does not stop after licensing and the MHRA can withdraw 
licenses at any time (MHRA, 2013).    
 
4.4.2. Pricing and Reimbursement 
 
Once a medicine has been licensed decisions have to be made about its price. 
Even though the price setting mechanisms in England and Germany differ, they have in 
common that restrictions exist on the extent to which pharmaceutical manufacturers are 
allowed to set prices freely.  
In  England  the  prices  for  licensed,  branded,  patented  pharmaceuticals  are 
regulated  via  the  Pharmaceutical  Price  Regulation  Scheme  (PPRS),  a  voluntary 
agreement  between  the  Department  of  Health  and  the  pharmaceutical  industry 
represented  by  the  Association  of  the  British  Pharmaceutical  Industry  (ABPI) 
(Department of Health, 2009). Mossialos, Walley and Mrazek refer to this form of price 
regulation  as  an  “indirect  price  control  through  profit  or  rate-of-return  regulation” 
(Mossialos, Walley and Mrazek, 2004, p. 11). This kind of regulation aims to regulate  
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manufacturers’  profits.  The  negotiating  parties  negotiate  profit  margins  on  the 
manufacturers’  return  on  capital  (ROC)  employed  (Walley,  Mrazek  and  Mossialos, 
2005, p. 393). If a manufacturer exceeds this margin, it has to pay a rebate to the NHS 
or if it underperforms  it is  allowed to  raise prices  (Walley, Mrazek and Mossialos, 
2005). Walley, Mrazek and Mossialos (2005) argue that this sort of regulation creates a 
stable  business  environment  that  allows  for  innovation  and  investment  in  R&D. 
However, the PPRS has also been criticised for being intransparent in its negotiations 
and weak in its incentives for cutting prices (Walley, Mrazek and Mossialos, 2005).  
In  Germany  the  prices  for  unpatented,  i.e.  generic,  pharmaceuticals  are 
controlled  via  a  so-called  reference  pricing  scheme  that:  “[…]  aims  to  contain 
pharmaceutical expenditure by defining a fixed amount to be paid by the government 
(or  other  third-party  payer)”  (Mossialos  and  Oliver,  2005).  This  means  that  for 
medicines  containing  the  same  substance,  similar  substances  or  medicines  with 
comparable efficacy “[…] an upper limit for the costs reimbursable by the sickness 
funds”  (Busse,  Schreyoegg  and  Henke,  2005,  p.  345)  is  imposed.  The  FJC  is 
responsible  for  the  classification  of  the  substance  of  these  medicines,  i.e.  grouping 
together medicines with a similar substance, while the sickness funds set the actual 
prices.  
The price of pharmaceuticals that are new to the German market is dependent on 
the manufacturer providing evidence that the product in question provides an ‘additional 
benefit’ in comparison to the medicines currently used in the indication for which the 
product is licensed. This requirement came into force in January 2011 under the Act on 
the Reform of the Market for Medicinal Products (AMNOG) (Bundesgesetzblatt, 2010). 
Before January 2011 pharmaceutical companies in Germany were allowed to set the 
prices  for  new  products  freely.  Not  only  has  this  freedom  been  abolished  with  the 
introduction  of  the  AMNOG,  the  extent  of  ‘additional  benefit’  that  a  new  product 
provides  now forms  the basis for price negotiations  between the manufacturers and 
sickness funds. While manufacturers can still set the prices for their products, sickness 
funds no longer have to pay these prices but can negotiate lower prices depending on 
the extent of the ‘additional benefit’ of a new pharmaceutical. If the FJC finds that the 
new product does not offer an additional benefit, then the product is assigned to a group 
under  the  reference  pricing  scheme  and  will  only  be  reimbursed  in  line  with  the 
reference prices set therein. 
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4.5. ‘The Fourth Hurdle’: Health Technology Assessment (HTA) 
 
  In most EU countries acquiring a license for a pharmaceutical product no longer 
means that it will automatically be covered or reimbursed by a given national health 
care  system.  EU  member  states  such  as  Germany  and  England  have  introduced 
additional control mechanisms in the form of HTA
17 systems in order to decide whether 
a new medicine is worth its coverage under the national health system (Sorenson, 2009). 
This  means  that  a  market  license  is  no  longer  a  guarantee  for  pharmaceutical 
manufacturers to market their products successfully in member states.  
Upon acquiring a market license, the pharmaceutical manufacturers embark 
upon the effort to get their pro ducts through different HTA systems across Europe, a 
process that commentators have labeled the “fourth hurdle” (e.g. Eichler, et al., 2010; 
Mrazek and Mossialos, 2004) after proving safety, efficacy and quality at the European 
level. The representations of multi-national pharmaceutical companies in different EU 
member states work to meet the national requirements for having their products made 
available in the given health care systems. In order to achieve this they have the same 
evidence base at their disposal, namely the evidence base that was used for acquiring 
the  marketing  authorisation.  However,  this  evidence  base  needs  to  be  re-worked  in 
order to meet different  national  requirements.  This  entails  meeting the  standards of 
HTA agencies in different countries. 
HTA  takes  different  forms  in  different  national  contexts.  Sorenson  (2009) 
describes  a  general  trend  towards  the  establishment  of  HTA  agencies  to  inform 
decision-making, although this is not a prerequisite for the use of HTA as a decision-
making tool. In terms of institutional features, Sorenson (2009) distinguishes between 
advisory  and  regulatory  bodies.  Advisory  bodies  carry  out  the  assessment  of  the 
evidence  for  the  use  of  a  pharmaceutical  product  whilst  having  little  or  no  direct 
decision-making powers on whether the product gets included in the health care benefit 
basket  (Sorenson,  2009).  In  contrast,  regulatory  bodies  have  direct  decision-making 
powers  and  are  involved  in  the  appraisal  phase  of  a  product.  In  addition  to  their 
institutional formats, HTAs can also differ in how they are carried out, especially with 
regards to the methods employed to show cost effectiveness, cost-benefit relationships 
                                                        
17 See chapter 1 for a definition of HTA.  
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or added benefit. These differences will be elaborated on in chapter 5 as they form an 
important part of HTA policy paradigms in England and Germany. 
In the next section I outline the HTA processes and institutions in England and 
Germany in order to illustrate the procedural and substantive differences between the 
two systems. 
 
4.6. The HTA Process in England and Germany 
 
  This section provides an overview of the structure, decision-making mandate 
and  procedures  of  the  organisations  that  are  involved  in  the  production  of 
pharmaceutical benefit assessments in England and Germany. These are the Federal 
Joint  Committee  (FJC)  and  the  Institute  for  Quality  and  Efficiency  in  Health  Care 
(IQWiG) in Germany and the National Institute for Health and Care Excellence (NICE) 
in England. While all three institutions have a legal mandate that extends beyond the 
field of pharmaceutical benefit assessments, for the purpose of answering this thesis’ 
research question I concentrate on explaining how the HTA process for pharmaceuticals 
works in these institutions. The section focuses on outlining institutional features such 
as the composition, decision-making remit and procedural workings of the FJC, IQWiG 
and  NICE  respectively.  While  the  legal  mandate  and  the  possible  outcomes  of 
pharmaceutical benefit assessments form part of this outline, the detailed criteria that 
determine these outcomes are discussed in the next chapter as they represent the ideas 
that constitute the HTA policy paradigms  in  Germany and England. Thus,  the next 
section  represents  an  analytical  overview  of  the  institutional  workings  of  the  FJC, 
IQWiG  and  NICE  rather  than  a  discussion  of  how  the  HTA  policy  paradigms  are 
applied within these institutions.  
  Table  4.2.  presents  a  comparative  overview  of  nine  of  the  most  important 
institutional  features  of  the  NICE,  the  FJC  and  IQWiG.  The  choice  for  these 
institutional features is based on an assessment of what institutional factors might play a 
role  in  determining  the  outcome  of  pharmaceutical  benefit  assessments.  The  most 
distinctive difference between the FJC/IQWiG and NICE lies in their composition and 
in  their  decision-making  mandate.  While  the  people  who  make  the  final 
recommendations  on  a  pharmaceutical  product  at  NICE  are  professionals  from  the 
health care arena (NICE, 2009), but not commissioners of services, the individuals who 
make these decisions in German are members of the previously described bargaining  
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structures in the German health care system  (FJC, 2013). While payers (i.e. CCGs, 
formerly PCTs) and providers (i.e. professional physician representations) are invited to 
comment and give evidence on appraisals at NICE, in Germany representations of these 
entities are the ones who make the decisions. This lack of separation between the bodies 
that make the decisions and the ones that have to pay for it has led to criticism by other 
stakeholders in the process, especially by pharmaceutical manufacturers, who question 
the  objectivity  of  the  decision-makers  in  these  processes  (Interviewee  No.  6,  2013; 
Interviewee No. 8, 2013). However, because the FJC decision informs the price setting 
negotiations in Germany rather than the recommendation for the use or non-use of a 
pharmaceutical  product  in  routine clinical  practice, the effect  of the involvement  of 
payers  and  providers  in  decisions  on  pharmaceutical  benefit  assessments  might  be 
mitigated by the legal remit of their decisions.   
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TABLE 4.2. - Institutional Features of NICE, the FJC and IQWiG: Comparative Overview 
 
  NICE  FJC 
 
IQWiG 
Composition  Appraisal Committee members are 
appointed for a three-year term and include 
members from the NHS, patient and carer 
organisations, academia and representatives 
of the pharmaceutical industry 
Representatives of the self-governing health 
care system: 5 representatives of the payers 
(the sickness funds), 5 representatives of the 
providers (physicians, dentists, hospitals) and 3 
impartial members 
Salaried employees 
Decision-making mandate  Recommendations are binding for NHS 
organisations (=regulatory body) 
Final decision-making power on 
pharmaceutical benefit assessments 
(=regulatory body) 
Recommendations to FJC, non-
binding (=advisory body) 
Purpose of assessment & 
appraisal 
To recommend the use or non-use of a 
medicine in routine NHS practice based on 
clinical and cost effectiveness criteria 
To inform price negotiations between sickness 
funds and pharmaceutical manufacturers 
To assess the pharmaceutical 
manufacturer’s dossier on the 
‘additional benefit’ of a product 
and make recommendations to the 
FJC 
Who commissions an 
appraisal? 
Commissioned by the Secretary of State for 
Health, based on topic recommendations by 
the National Institute for Health Research 
Horizon Scanning Centre 
All pharmaceutical products with a new active 
substance  must  be  appraised  (§135a  Social 
Code Book V) 
Commissioned by the FJC 
What gets appraised?  Topics referred to by Secretary of State for 
Health based on criteria such as likely 
significant benefit to patients, new 
technology is likely to be at different price 
All pharmaceutical products with a new active 
substance 
All pharmaceutical products with a 
new active substance 
Scoping process  Yes  No  No 
Patient involvement  Yes. Patient organisations invited to submit 
comments beginning at the scoping stage. 
Yes. No voting rights.  Yes.  Patients  invited  to  fill  out 
questionnaire. 
Appeals procedure  Yes  No, only via the social courts.  No, only via the social courts. 
Publication  of  appraisal 
documents 
Yes, but not of minutes of decision-making 
deliberations. 
Yes,  but  not  of  minutes  of  decision-making 
deliberations. 
Yes,  but  not  of  minutes  of 
decision-making deliberations.  
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4.7. The HTA Process in England 
 
  NICE was established in 1999 as “[…] a special authority to reduce variation in 
the availability and quality of NHS treatments and care” (NICE, 2013). This variation in 
the availability of treatments was a result of the so-called postcode lottery, whereby 
access to treatment and pharmaceutical depended on where one lived due to the regional 
health care commissioning authorities, the Primary Care Trusts (PCTs), taking different 
decisions on how to spend their budgets (Ham, 2009). The establishment of NICE was 
an  outcome  of  political  efforts  to  reduce  the  inequitable  access  to  health  care  that 
resulted from local variations. Since its inception NICE has undergone several changes 
in relation to its operational remit. In 2005 its remit was expanded to include guidance 
on public health and more recently, in 2013, its remit was expanded to the development 
of guidance for social care practitioners (NICE, 2013). 
  NICE  operates  three  centres  that  produce  evidence-based  guidelines  for  the 
NHS.  These  centres  are  the  Centre  for  Clinical  Practice  (responsible  for  producing 
clinical  guidelines  for  health  care  practitioners),  the  Centre  for  Public  Health 
(responsible for producing guidelines for public health authorities and practitioners) and 
the Centre for Health Technology Evaluation (responsible for recommending the use or 
non-use  of  pharmaceuticals,  medical  devices,  surgical  procedures  in  routine  NHS 
practice).  NICE’s  guidance  comes  in  different  forms,  depending  on  the  centre  it  is 
produced in and the topic it pertains to. For the purpose of this thesis, the guidance that 
comes in the form of so-called technology appraisals (TAs) and that is produced by the 
Centre for Health Technology Evaluation is the most important guidance.  
Based on evidence of clinical and cost effectiveness as well as evidence brought 
forward by patient and clinical expert groups, TAs recommend the use or non-use of a 
given pharmaceutical, a diagnostic and surgical procedure or medical devices (NICE, 
2014a).  TA  recommendations  are  legally  binding  for  the  NHS,  meaning  that  local 
health care commissioners are obliged to fund the treatments that are recommended 
under the NICE technology appraisal procedure (NICE, 2014a). This legal obligation to 
fund  the  services  recommended  by  NICE  is  different  from  the  guidelines  that  the 
Centres for Clinical Practice and Public Health produce because these guidelines are not 
binding.  Regardless  of  this  difference  in  the  binding  character  of  the  produced 
guidelines, NICE issues implementation tools for all of its guidance in order to ensure a 
wide uptake of its guidance.  
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  Topics for appraisal are referred to NICE by the Department of Health (DH) 
based on a number of criteria such as the likely impact of a new technology on NHS 
resources and whether there is a likely inappropriate variation in the clinical practice 
related  to  the  new  or  existing  technology  (NICE,  2008,  p.  7)
18. Before a topic for 
appraisal is referred to NICE by the DH, the relevant consultees and commentators for 
the topic are identified and invited to participate in the so-called scoping process (NICE, 
2008). Consultees include all groups that might have an interest in or face a direct 
impact of the new  technology under appraisal ( NICE,  2008). These groups include 
patient  and  carer  representations,  hea lth  professional  bodies,  manufacturers,  the 
Department of Health,  the Welsh Assembly Government and local health boards. 
Consultees can submit evidence, comment on appraisal documents and appeal the final 
recommendations made by NICE (NICE, 2008). They can also nominate patient experts 
or clinical specialists for the consultation process at NICE (NICE, 2008). In contrast to 
consultees, commentators can only comment on and participate in the appraisal process, 
but they cannot appeal the final decisions made by NICE. Commentators might include 
research groups, manufacturers of comparator technologies or organisations such as the 
MHRA.  
  The  so-called  scoping  process  identifies  the  disease  area,  patients,  current 
treatments and clinical practice, likely impact  and open questions in relation to the 
technology for which a n appraisal is proposed (NICE, 2008 ). In this process NICE 
works closely together with consultees and commentators to get a sense of current 
clinical practice in a given area. This includes the convention of a scoping workshop in 
which consultees, commentators and NICE representatives discuss the relevant issues 
and questions for a  given appraisal (NICE, 2008 ). If the scope suggests that the 
technology meets the criteria for being appraised, i.e. t he impact of a new treatment is 
likely to be big, and the relevant decision problem and comparator products have been 
identified, then the DH can refer the topic to NICE for appraisal. 
  There are two possible routes for technologies to be appraised at NICE , the 
single technology appraisal (STA) and the multiple technology appraisal (MTA) (NICE, 
2012). In a STA a single technology for a single indication is appraised, while a MTA 
appraises more than one technology for more than one indication. Due to the fac t that 
                                                        
18 For the purpose of this thesis the 2008 version of NICE’s Guide to the methods of technology 
appraisal is used. This is because the case studies contained in this thesis were appraised on the 
basis of this version.  
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appraisals are frequently conducted for products that are new to the market, meaning 
that  pharmaceutical  manufacturers,  clinicians  and  patients  might  have  an  interest  in 
getting  the  product  appraised  quickly  so  that  their  speedy  uptake  is  ensured,  the 
majority of products seem to be appraised under STA procedures. This includes the 
products that form the basis of the empirical investigation in this thesis, which is why 
this section explains the STA process in order to illustrate how pharmaceutical benefit 
assessment works in England
19. 
  Once a topic, e.g. a pharmaceutical product, is referred to NICE for an appraisal, 
the manufacturer of the product submits evidence in relation to the clinical and cost 
effectiveness of the product in question. At the same time, consultees submit their initial 
statements and evidence to NICE. In contrast to IQWiG, NICE does not itself evaluate 
the manufacturer’s evidence. Rather it commissions one of several academic research 
groups, the so-called Evidence Review Group (ERG), to carry out the assessment of the 
evidence (NICE, 2012). This reflects a common distinction between the assessment and 
the appraisal stages of HTA processes, assessment being the evaluation of scientific 
evidence  and  appraisal  being  the  application  of  decision-making  criteria  to  this 
evidence. The ERG carries out the assessment and NICE carries out the appraisal. The 
ERG assessment and the submissions by consultees and commentators are then collated 
and referred to a so-called Appraisal Committee (AC) at NICE. Rather than being made 
up  of  NICE  employees,  this  committee  consists  of  representatives  from  the  NHS, 
academia, patient and carer groups and the pharmaceutical industry (NICE, 2009). The 
committee forms an independent advisory committee to NICE and its individuals sit on 
the  committee  for  three-year  terms.  The  AC  is  responsible  for  producing  the 
recommendations, the appraisal of a product, based on the evidence it receives. During 
its  consultations it also hears evidence from clinical  experts and patients  who were 
nominated by consultees.  
  If the AC recommendations are negative or restrictive they are published in the 
form of an Appraisal Consultation Document (ACD). Consultees and commentators are 
then given an opportunity to comment on these recommendations and to submit new 
evidence. In some cases this additional consultation phase leads to a reversal of the draft 
recommendations (NICE, 2008). Once the stakeholders have been consulted again, the 
                                                        
19 While  the  STA  and  MTA  procedures  differ  in  scope  and  timeline  of  the  appraisal,  it  is 
important to note that the methods of appraisal which are touched upon in this section and 
elaborated on in more detail in the next chapter are the same.   
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AC makes its final recommendations and publishes them in the form of the so-called 
Final  Appraisal  Determination  (FAD),  which  consultees  can  appeal.  If  there  are  no 
appeals, the FAD forms NICE’s guidance on the particular technology at hand. If the 
AC’s recommendations are positive after the initial consideration of the evidence, then 
the ACD phase of the appraisal is skipped and a FAD is produced instead.  
 
4.7.1.  The  Dependent  Variable:  The  Outcome  of  Pharmaceutical  Benefit 
Assessments in England 
 
  There  are  four  possible  outcomes  of  technology  appraisals  made  by  NICE: 
recommended, optimised, only in research and not recommended (NICE, 2014a). If the 
evidence of clinical effectiveness is convincing and the cost effectiveness ratios are 
favourable, then an AC usually recommends the product in question for use in the NHS. 
This is the case when the incremental cost of using a product is no higher than between 
£20,000-£30,000  per  quality-adjusted  life  year  gain  (QALYs).  QALYs  are  a 
measurement of health benefits in relation to life years gained by using a particular 
medicine or treatment (NICE, 2014b). Together with the concept of the incremental cost 
effectiveness ratio (ICER) it forms an important part of the HTA paradigm in England 
and both concepts are discussed in more detail in the next chapter. The ICER refers to 
the  increase  in  cost  that  a  decision-maker  might  articulate,  “[…]  above  which  a 
programme would not be acceptable” (Drummond, et al., 2005, p. 43). If an AC decides 
to  recommend  a  product  even  though  the  ICER  is  higher  than  £30,000  per  QALY 
gained, it has to make a special case and justify why it still considers the use of the 
product in question a cost effective use of NHS resources. Similarly, if an AC does not 
recommend a treatment even thought the ICER is below £20,000 per QALY gained, it 
has to justify why it believes that this is the right course of action. 
The  ‘optimised’  category  that  a  pharmaceutical  benefit  assessment  can  take 
refers to instances in which a technology is recommended, but for a smaller sub-set of 
patients than laid out in the license of a product. This might be the case if there is 
evidence that a certain group of patients benefits more than others from the use of the 
medicine in question. The ‘only in research’ category is applied when the clinical and 
cost effectiveness evidence is not sufficient yet and the AC therefore recommends the 
use of the product in research settings, i.e. in clinical trials. Finally, the use of a product 
is not recommended if there is a lack of sufficient or convincing clinical evidence or its  
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use would not be considered cost effective, i.e. if the increase in health care cost is not 
justified in relation to the benefits it provides.  
 
4.8. The HTA Process in Germany  
 
  Since  the  introduction  of  the  AMNOG  in  2011  a  so-called  early  benefit 
assessment has to be carried out for every pharmaceutical with a new active substance 
or ingredient. The early benefit assessment is based on a dossier that the pharmaceutical 
manufacturer has to provide upon introducing a new product to the German market 
(FJC, 2013a). This dossier includes the manufacturer’s assessment of the ‘additional 
benefit’  of  the  product  in  question  and  is  based  on  a  presentation  of  the  scientific 
evidence such as RCTs. There is a statutory obligation for the early benefit assessment 
to present evidence in comparison to the ‘appropriate comparator’ that is currently used 
for treatment in the indication for which the new product is licensed (FJC, 2013a). The 
FJC makes the decision on which alternative medication represents the most appropriate 
comparator for a given product. 
  The  FJC  can  commission  IQWiG  with  the  production  of  an  early  benefit 
assessment (FJC, 2013a). Without being commissioned, IQWiG cannot carry out an 
assessment of the benefits of a pharmaceutical product. IQWiG was created in 2004 as 
an independent scientific body that produces evidence-based reports on a number of 
topics including pharmaceutical products, surgical procedures, diagnostic procedures, 
screening  programmes,  treatment  guidelines  and  disease  management  programmes 
(DMPs) (IQWiG, 2013). Its evidence-based reports can take the format of so-called 
reports,  rapid  reports,  dossier  assessments,  health  information  and  working  papers, 
depending on what IQWiG is commissioned to carry out by the FJC (IQWiG, 2013). 
For the purpose of this thesis, this section focuses on the dossier assessments as they are 
the outcome of the early benefit assessment process. 
The early benefit assessment under §35a Social Code Book V (SGB V) takes the 
form of dossier assessments. Upon receiving the dossier that was submitted to the FJC 
by the pharmaceutical manufacturer, IQWiG has three months to review and assess the 
dossier  and  the  evidence  contained  in  it  (IQWiG,  2013).  Using  internal  expertise, 
IQWiG assesses the data contained in the dossiers and can, if necessary, carry out its 
own research on a given product (IQWiG, 2011a). In order to attain a broader view on a 
given product’s additional benefit, IQWiG involves external clinical experts and patient  
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groups by inviting them to reply to a questionnaire about the product. At this stage of 
the early benefit assessment the questionnaire is the only means by which patients and 
clinical experts are involved. Once the dossier assessment is referred to the FJC for a 
final decision, an oral and written hearing procedure is carried out by the FJC (FJC, 
2013a).  
The maximum period for the production of the dossier assessment by IQWiG is 
three months. After three months the dossier assessment, i.e. the review of the evidence, 
is referred back to the FJC, which is responsible for making the final decision on a 
product’s  additional  benefit  (IQWiG,  2011a).  This  decision  is  prepared  in  a  sub-
committee on pharmaceutical products of the FJC before it is referred to the full FJC to 
appraise the product (FJC, 2013a). The division of labour between IQWiG and the FJC 
represents the important procedural distinction between the assessment and the appraisal 
of  a  medicine’s  benefits.  The  assessment  reviews  the  robustness  and  quality  of  the 
scientific evidence whilst the appraisal process includes the application of criteria and 
value judgements to this evidence in order to reach a conclusion on the benefit of a 
given product (NICE, 2014b). 
 
4.8.1.  The  Dependent  Variable:  The  Outcome  of  Pharmaceutical  Benefit 
Assessments in Germany 
 
Germany’s  approach  to  appraising  a  pharmaceutical  product  involves  the 
categorisation of the product’s additional benefit. There are six categories of ‘additional 
benefit’,  which  represent  the  dependent  variable  of  this  study.  The  benefit  of  a 
pharmaceutical is defined as “[…] the patient-relevant therapeutic effect, in particular in 
respect of the improvement in the state of health, the reduction of the duration of the 
disease, […] an improvement in  the quality of life” (Bundesgesetzblatt,  2010). The 
issue of ‘patient relevance’ is at the core of the German HTA policy paradigm and is 
discussed in more detail in the next chapters. According to Section 5, § 7 of the FJC’s 
Rules of Procedure (G-BA, 2013, pp. 8-9): 
 
[…] the extent of the additional benefit and the therapeutic importance of the 
additional benefit compared to the appropriate comparator must be quantified as 
follows, taking into account the severity of the disease:  
 
1.  There is a major additional benefit if a sustained and large improvement in 
the therapy-relevant benefit […] is achieved, which has not previously been  
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achieved  […],  in  particular  a  recovery  from  the  disease,  a  considerable 
increase  in  life,  long-term  freedom  from  severe  symptoms  or  extensive 
avoidance of severe side-effects […].  
2.  There is a significant additional benefit if a considerable improvement in 
the therapy-relevant benefit […] is achieved, which has not previously been 
achieved  […],  in  particular  a  lessening  of  severe  symptoms,  a  moderate 
extension in life, an easing of the disease, which is noticeable to patients 
[…]. 
3.  There is a marginal additional benefit if a moderate improvement and not 
merely a slight improvement in the therapy-relevant benefit […] is achieved 
[…], in particular a reduction in non-severe symptoms of the disease or a 
relevant avoidance of side-effects. 
4.  There is an additional benefit, which is not quantifiable however, because 
the scientific data base does not permit this. 
5.  There is no additional benefit. 
6.  The benefit […] is less than the benefit of the appropriate comparator
20. 
 
 
The  six  categories represent the so -called  extent  of  ‘additional  benefit’.  In 
addition to the extent of the additional benefit, the appraisal of a product also depends 
on the ‘probability’ of additional benefit (G-BA, 2013). This ‘probability’ is connected 
the quality of the evidence. This means that the extent of additional benefit, i.e. the 
category assignment a product receives, may be lowered or raised depending on the 
quality  of  the  presented  evidence.  The  dependent  variable,  i.e.  the  outcome  of 
pharmaceutical  benefit  assessments  in  Germany,  is  thus  a  categorical  expression  of 
‘additional  benefit’  that  is  dependent  on  the  extent  of  the  significance  of  statistical 
results on the one hand and the quality of the presented evidence on the other. How this 
categorisation is operationalised in practice forms a discussion that is presented in the 
empirical chapters of this thesis. For now, suffice it to say, that the six categories of 
additional  benefit  serve  the  purpose  of  informing  price  negotiations  between  the 
sickness funds and pharmaceutical manufacturers. In theory, the higher the category that 
an  early  benefit  assessment  results  in,  the  higher  the  price  that  the  pharmaceutical 
manufacturers can demand from the sickness funds. Vice versa, if a product receives a 
low category of additional benefit, the sickness funds will not be as willing to pay a 
high price for the product. In the German context the concept of thresholds is employed 
to describe thresholds between different categories of additional benefit, which impact 
on  the  price  negotiations  between  the  sickness  funds  and  the  pharmaceutical 
manufacturers. 
                                                        
20 Highlights added by the author of this thesis.  
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4.9. Institutional Features of NICE, the FJC and IQWiG: Comparative Summary 
 
  The  preceding  sections  provided  an  overview  of  the  pharmaceutical  benefit 
assessment  processes  in  England  and  Germany.  The  institutions  that  carry  out  the 
benefit assessment both produce evidence-based guidance. As such their mandates are 
to inform health care decision-making based on the available scientific evidence in a 
given field.  However, the way they carry out this mandate differs procedurally and 
substantively. It differs procedurally in the commissioning of the evidence review to 
outside  groups  and  in  the  procedural  steps  that  characterise  the  HTA  process. 
Substantively,  the  HTA  processes  differ  in  the  way  the  benefit  assessment  is 
operationalised,  especially  with  regards  to  the  way  the  concept  of  thresholds  is 
employed.  
  Procedurally, the main difference between the HTA processes lies in the fact 
that two bodies (FJC and IQWiG) are involved in the assessment and appraisal process 
in Germany while there is only one in England (NICE). However, the significance of 
this  should  not  be  overestimated  as  it  is  connected  to  the  distinction  between  the 
assessment and the appraisal stages of a HTA process rather than to a substantially 
different idea on how to carry out HTAs. That is to say, Germany chose to create an 
independent organisation, IQWiG, to carry out the evidence assessment while policy-
makers  in  England  did  not  do  so.  Yet,  in  England  the  assessment  part  of  an  HTA 
process  gets  ‘outsourced’,  i.e.  NICE  commissions  an  ERG  with  this  task.  This  is 
comparable to the FJC commissioning IQWiG to carry out the dossier assessment in 
Germany. Thus, the role played by IQWiG in Germany is akin to the role played by the 
ERG in England. In both cases, the tasks of assessment and appraisal are separate and 
the  final  decision-making  occurs  outside  of  the  bodies  charged  with  the  evidence 
assessment.  
  Another procedural difference lies in the number of steps that make up the HTA 
process. At NICE, the number of steps is large and includes the scoping process, the 
evidence review, consultations in both of these phases, the ACD, further consultations, 
the FAD and finally the appeals procedure. What is important about this observation is 
that consultees and commentators are involved not just at one stage of the appraisal 
process, but at each stage. They have an opportunity to comment in the scoping phase, 
they submit evidence during the consultation phases, they can comment and submit new  
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evidence at the ACD phase and they can appeal the final decision. This means that the 
opportunities for involvement at NICE are vast.  
The  number  of  steps  in  the  German  HTA  process  is  more  limited  by 
comparison. There is no formalised scoping process, but only an opportunity for the 
pharmaceutical manufacturer to apply for an advisory meeting with the FJC ahead of an 
early benefit assessment. There are no opportunities for stakeholders to comment on 
FJC draft proposals. The FJC hearing is based on the dossier assessment produced by 
IQWiG, which provides a categorisation of the benefit, but does not give an indication 
of whether the FJC is likely to follow this categorisation in its appraisal. As such there 
is a procedural difference in the number of steps that stakeholders are involved in and in 
the fact that hearings are carried out on the evidence review rather than on the initial 
appraisal decision pertaining to a product. 
  Substantively, the HTA processes in Germany and England differ in the purpose 
for which they are conducted and in the way ‘benefit’ is operationalised. In Germany 
the early benefit assessment is carried out in order to inform price negotiations between 
the  sickness  funds  and  the  pharmaceutical  manufacturers.  Whilst  the  FJC  has  a 
decision-making remit that extends to the inclusion or exclusion of a service in the 
health care benefit basket, the default position for new pharmaceuticals is that they will 
be  reimbursed,  the  question  is  just  at  which  price.  This  is  a  substantively  different 
paradigmatic  situation  from  that  in  England  where  the  default  position  for  new 
pharmaceuticals is that they will only be covered if they are clinically and cost effective.  
The  substantively  different  purposes  that  HTAs  serve  might  explain  the 
differences  in  how  ‘benefit’  is  being  operationalised  in  Germany  and  England.  In 
Germany pharmaceutical benefits are categorised into one of six categories in order to 
support negotiating parties in compromising on an acceptable price. Thresholds are used 
when it comes to distinguishing between these categories, although chapter  7 and 8 
show  that  these  thresholds  are  neither  fully  transparent  nor  accepted  amongst 
stakeholders. In England pharmaceutical benefits are viewed in relation to their costs. 
This suggests that Germany’s HTA paradigm operates on the presumption that the value 
or benefit of a pharmaceutical, even if it is low, can be reflected in the price the payers 
pay, while the English HTA paradigms operates on the idea that a threshold exists at 
which the value or benefit ceases to be sufficiently beneficial in relation to its costs and 
thus its uptake is no longer justified. To put it differently, the German HTA paradigm is 
characterised  by  the  idea  that  there  are  thresholds  for  the  ‘right’  price  of  a  
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pharmaceutical, while the English HTA paradigm is characterised by the idea that there 
are thresholds for the inclusion or exclusion of a pharmaceutical product from use in the 
NHS. 
 
4.10. Conclusion 
   
  This chapter introduced the reader to the institutional features that characterise 
the  HTA  paradigms  in  Germany  and  England.  It  did  so  by  summarising  the  most 
important  procedural  and  substantive  differences  between  the  HTA  processes  in 
Germany and England. On a procedural level these include the different bodies to whom 
the assessment task of an HTA is ‘outsourced’ and the number of formalised procedural 
steps that need to be followed in order to protect HTA outcomes from appeals. On a 
substantive level the differences include a different understanding on what the purpose 
of HTAs is and how they are operationalised.  
Whilst both the FJC and NICE employ thresholds to aid decision-making, the 
purpose  of  these  thresholds  and  how  they  are  operationalised  is  very  distinct.  In 
Germany  thresholds  are  used  to  assign  benefit  categories  and  inform  price  setting 
negotiations whilst in England they are used to inform the inclusion or exclusion of a 
pharmaceutical product for use in NHS practice. Whether or not this distinction matters 
in  determining  the  final  outcome  of  HTA  processes  is  explored  in  the  analytical 
chapters of this thesis. However, before exploring this question, I further elaborate on 
the  policy  paradigms  of  pharmaceutical  benefit  assessments  with  regards  to  their 
ideational basis in the next chapter. 
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Chapter 5 
 
The Policy Paradigms of Pharmaceutical Benefit Assessments in 
England and Germany 
 
5.0. Introduction 
 
This  chapter  offers  an  analytical  overview  of  the  pharmaceutical  benefit 
assessment policy paradigms in Germany and in England. The policy paradigms are 
discussed by reference to a) the legislative framework that provides the construct for the 
health care systems and b) the methods guidelines of the National Institute for Health 
and Care Excellence (NICE), the Federal Joint Committee (FJC) and the Institute for 
Quality and Efficiency in Health Care (IQWiG). As such this chapter, along with the 
previous  chapter,  identifies  the  broad  HTA  paradigms  in  England  and  Germany. 
However, the identification of the paradigms in the relevant statutory materials does not 
offer insights into how the paradigms operate, i.e. what their role is in ‘normal’ HTA 
decision-making. As Cartwright and Hardie (2012) and Majone (1989) highlight, in 
policy-making  evidence  requires  careful  judgement  and  interpretation.  While  the 
identification of the paradigms in this chapter provides an initial impression of how 
evidence questions might be approached in England and Germany, this is supplemented 
by the empirical analysis that follows in the next chapters in order to understand how 
the paradigms are operationalised in practice. 
For  ease  of  understanding  this  chapter  is  divided  into  parts  that  reflect  how 
policy paradigms are operationalised for the purpose of this study. In comparison to the 
previous chapter the principles discussed in these sections are more ideational in kind. 
In sections 1-4 of this chapter I lay out the values on which the health care systems in 
England and in Germany are built. I then discuss the political and institutional purpose 
of benefit assessment which is different in Germany and in England. In sections 6-8 I 
discuss the principles and values that guide HTA decision-making as they are specified 
in  the  methods  guidelines  before  outlining  the  criteria  of  HTA  decision-making.  In 
section 9 I analyse the case of Apixaban, a pharmaceutical product for the prevention of 
thromboembolic  events  after  hip-  or  knee  replacements,  as  a  case  that  represents  a 
comparatively straightforward application of the HTA paradigm in both Germany and 
England.  Finally,  I  offer  some  concluding  remarks  that  provide  guidance  for  the 
interpretation of the empirical findings in the next chapters.   
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Table 5.1.
21 provides an overview of the values and principles conta ined in the 
statutory framework and methodological guidelines, which shape the work of NICE, the 
FJC and IQWiG. Together, these values and principles constitute the broad HTA 
paradigms in England and Germany. The identification of the HTA paradigms resulte d 
in a number of findings. Firstly, the health care paradigms give rise to tensions that need 
be  resolved  when  HTA  paradigms  are  established  in  their  routine,  i.e.  normal, 
application.  For  example,  both  the  English  and  the  German  paradigms  contain 
principles that relate to the breadth of health services that should be provided whilst 
ensuring an efficient, or cost effective, use of resources without making it clear how 
decision-makers should balance these principles. This balancing act occurs during 
normal  decision-making  in  which  different  rules  and  criteria  are  applied.  The 
differences between the German and the English HTA paradigm are especially notable 
when it comes to the use of thresholds even though the underlying idea of HTAs 
appears to be similar, that is costs or prices of pharmaceuticals need to be justifiable in 
relation to their clinical benefits. In England this idea is operationalised by using 
incremental cost effectiveness ratios (ICERs), whereas in Germany it is operationalised 
by reference to ‘patient relevance’ and benefit categories.  
                                                        
21 The  table  distinguishes  between  principles  and  criteria  of  HTA  decision-making.  The 
principles  of  decision-making  (number  three)  are  the  values  that  are  embedded  in  HTA 
decision-making, i.e. that arise from the wider paradigm, while the criteria represent the way in 
which these principles are supposed to be translated into practice. The criteria for decision-
making (number four) are the means by the values are safeguarded, they are the rules of the 
game under which the paradigm operates in normal decision-making. For example, in the case 
of  NICE  equality  and  non-discrimination  represent  the  values  that  guide  NICE’s  decision-
making whilst the application of social value judgements and end-of-life-criteria are the means 
by which they are translated into practice.  
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TABLE 5.1. - The HTA Paradigms in England and Germany 
 
Features  of  the  HTA 
paradigm 
NICE  (Main  HTA  decision-
making body) 
FJC  (Main  health  care  decision-
making body) 
IQWiG (Body that carries out HTAs) 
1) Principles & values 
within the wider health 
care  context  (=  broad 
policy paradigm) 
NHS Constitution (Department 
of Health, 2013a):  
- Comprehensive service, 
ensuring equality & non-
discrimination 
- Clinical need 
- Service to ensure excellence & 
professionalism 
- Value for taxpayers’ money 
- High quality care 
 
German Constitution (BMJV, 1949):  
- Social/welfare state principle (§20 & 
28) 
Social Code Book V (BMJV, 2013):  
- Solidarity (§ 1) and individual 
responsibility 
- Provision of health care service based 
on ‘generally accepted state of 
medical knowledge’ (§ 2) 
- Efficiency (§ 12) 
- In cases of severe, rare and/or life-
threatening illnesses: Right to health 
care intervention even when ‘generally 
accepted state of medical knowledge’, 
i.e. evidence, is not available or not 
conclusive (‘Nikolaus’ court ruling) 
(Das Bundesverfassungsgericht, 2005) 
German Constitution (BMJV, 1949): 
- Social/welfare state principle (§ 20 & 
28) 
Social Code Book V (BMJV, 2013):  
- Solidarity (§ 1) and individual 
responsibility 
- Provision of health care service based on 
‘generally accepted state of medical 
knowledge’ (§ 2) 
- Efficiency (§ 12) 
- In cases of severe, rare and/or life-
threatening illnesses: Right to health 
care intervention even when ‘generally 
accepted state of medical knowledge’, i.e. 
evidence, is not available or not 
conclusive (‘Nikolaus’ court ruling) (Das 
Bundesverfassungsgericht, 2005) 
2) Purpose of HTA 
process as set out in 
methodological 
guidelines (=narrow 
policy paradigm) 
- To appraise health benefits 
and costs of medical 
interventions (NICE, 2008) 
- To make transparent and legally 
sound decisions that reflect the 
‘generally accepted state of medical 
knowledge’ (BMJV, 2013) 
- To support FJC in making its decision 
about the coverage of pharmaceuticals 
under SHI schemes by assessing the 
therapeutic benefit of a new medicine 
(IQWiG, 2013)  
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3) Principles & values 
that guide HTA 
decision-making (= 
narrow policy 
paradigm) 
- Consistency  
- Equality 
- Non-discrimination 
(NICE, 2008) 
- Transparency and legal soundness 
- Decisions should reflect ‘generally 
accepted state of medical knowledge’ 
- Consider issues of quality and health 
care provision 
- Consider interests of stakeholders 
- Efficiency (BMJV, 2011) 
- Independence 
- Patient-oriented 
- Transparency 
- Evidence-based medicine 
(IQWiG, 2011a) 
4) Criteria and 
methods  of HTA 
decision-making 
(Instrument settings of 
the paradigm) 
- Clinical & cost effectiveness 
- End-of-lifetime 
considerations 
- Social value judgements 
- Innovation 
- Assessment across disease 
areas (NICE, 2008) 
- Therapeutic benefit (=patient 
relevant therapeutic effect) 
- Medical necessity 
- Efficiency 
- Assessment within disease areas 
(G-BA, 2013) 
- Evidence-based medicine 
- Therapeutic benefit (= patient 
relevant therapeutic effect) 
- Assessment within disease areas 
(IQWiG, 2011a)  
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5.1. Principles and Values within the wider Health Care Context 
 
  According to the World Health Organization (WHO) the purpose of a health 
care system is to promote, maintain or restore health (WHO, 2014). This purpose lies at 
the  core  of  health  care  systems  around  the  world.  However,  the  means  by  which 
countries seek to fulfill the purpose are varied. The definition of health, the financing of 
health care and the expectations of populations and policy-makers are but a few of the 
factors  that  depend  on  national  values  and  principles.  In  order  to  understand 
pharmaceutical benefit assessment outcomes it is therefore necessary to understand the 
wider values and principles that guide health care in a given country. 
 
5.2. England: Principles and Values in Health Care 
 
  The values and principles  that form  the core of the National  Health Service 
(NHS)  in  England  can  be  found  in  the  so-called  NHS  Constitution  (Department  of 
Health, 2013a). This document distinguishes between the principles and values of what 
the NHS does. There are seven principles for the services that the NHS provides: 
 
1.  NHS services are comprehensive and available to all; 
2.  Access to NHS services is based on clinical need and not ability to pay; 
3.  Excellence and professionalism is aspired to when providing services; 
4.  Patients are at the heart of NHS services; 
5.  The NHS works across service boundaries and with other services in the interest 
of its patients; 
6.  The NHS seeks to provide the best value for taxpayers’ money and the most 
effective and fair use of finite resources; 
7.  The  NHS  is  accountable  to  the  public  and  patients  (Department  of  Health  
2013a). 
 
Embedded in the above principles is a myriad of social values. Principles one 
and two reflect the values of equality and non-discrimination. The NHS Constitution 
specifies principle one by stating that NHS services are: 
 
“[…]  available  to  all  irrespective  of  gender,  race,  disability,  age,  gender 
orientation,  religion,  belief  […].  It  [the  service]  has  a  wider  social  duty  to 
promote  equality  through  the  services  it  provides”  (Department  of  Health, 
2013a, p. 3).  
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In principle one comprehensiveness is highlighted as a principle in its own right, 
but the rest of the principle focuses on making NHS services available to all. Given the 
NHS’  long  history  of  making  difficult  prioritisation  decisions  within the  context  of 
limited  health  care  budgets  (Robert,  2003),  the  question  arises  whether 
comprehensiveness is defined in terms of a comprehensive access to services rather than 
access to comprehensive, i.e. all-encompassing, services. 
From a comparative point of view this is an important question because it is an 
example of how the principle of comprehensiveness might be laid out differently in 
different  HTA  policy  paradigms.  Comprehensive  access  is  different  from 
comprehensive  services.  The  latter  suggests  that  health  care  services  are  likely  to 
include most of what is medically and technologically possible, but it does not mandate 
who  will  have  access  to  these  services.  Comprehensive  access  on  the  other  hand 
guarantees that all members of society have access to the health care services provided, 
but it does not mandate that these services have to be comprehensive. Whilst a detailed 
discussion  of  this  issue  is  beyond  the  scope  of  this  thesis,  the  distinction  between 
comprehensive access and comprehensive services may help explain why rationing and 
prioritisation measures are deemed acceptable in the English context despite the fact 
that comprehensiveness is manifested in principle one of the NHS Constitution. It might 
also help explain why the centrality of cost effectiveness thresholds in the English HTA 
paradigm, which is further discussed in a later section of this chapter, is not perceived to 
be at odds with the wider health care paradigm. 
In addition to the social values of equality and non-discrimination contained in 
principles one and two, principles five-seven indicate a high regard for the values of 
professionalism, transparency and accountability in the English context. Based on the 
distinction  between  procedural  and  substantive  values  made  by  Kenny  and  Joffres 
(2008),  the  latter  two  can  be  labelled  procedural  values  in  that  they  connote  a 
responsibility  by  the  NHS  towards  the  public,  the  patients  and  the  taxpayers.  This 
responsibility needs to be fulfilled by ensuring transparent, professional and accountable 
decision-making procedures, as stated implicitly in principle five-seven. As outlined in 
the previous chapter, the technology appraisal process at NICE reflects these principles 
of the English health care paradigm by anchoring transparency and accountability as 
important features in the decision-making process. Consultees are engaged at every step 
of  the  appraisal  process,  all  relevant  documents  are  published  and  there  is  a  clear 
appeals process in place, which ensures accountability.  
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It is interesting that the NHS Constitution includes a principle (principle six) that 
explicitly spells out the fact that the NHS is faced with finite resources. Principle six 
connects the reference to finite resources with the values of fairness and the need to 
make decisions that represent best value for taxpayers’ money (Department of Health, 
2013a). Despite the principle being comparatively short in length, it gives insight into 
the  challenges  faced  by  the  NHS  and  the  tensions  that  the  principles  of  the  NHS 
Constitutions give rise to. That is to say that principle six might not always sit easily 
with the other principles that the NHS strives to promote and maintain. However, by 
including principle six, policy-makers and NHS practitioners have made it explicit that 
the NHS resources are finite and that tough decisions, which balance the interests of 
patients  and  the  wider  public  have  to  be  made.  As  highlighted  in  section  5.3.,  a 
comparative acknowledgement of the finite nature of resources is lacking in Germany. 
The  fact  that  the  challenge  of  finite  resources  is  explicitly  mentioned  in  a 
guiding  document  provides  a  paradigmatic  framework  that  decision-makers  can  fall 
back on. In this sense explicitness itself, i.e. being explicit about challenges, can be 
interpreted as a value that is contained in the English health care system.  By being 
explicit about the fact that the NHS is facing finite resources, the principles of the NHS 
Constitution  can  be  interpreted  as  a  paradigmatic  framework  that  seeks  to  mitigate 
against high expectations that patients might have and offer decision-makers a value 
construct to guide their decisions.  
The  NHS  Constitution  (Department  of  Health,  2013a)  goes  on  to  specify  a 
number of additional values that are important in the NHS context. These values include 
compassion,  respect,  dignity,  improvement  of  life,  quality  of  care  and  non-
discrimination  as  values  that  should  be  at  the  heart  of  everything  the  NHS  does. 
However,  for  the  purpose  of  this  thesis  the  focus  lies  on  the  principles  and  values 
discussed in the previous paragraphs as they reflect procedural and substantive values 
that play an important role in NICE’s technology appraisals. That is not to say that 
values such as compassion, respect and dignity do not play an important role. However, 
these  values  are  more  important  in  the  context  of  the  every-day  clinical  services 
provided by the NHS and the relationship between NHS staff and patients.  
In  summary,  the  broad  paradigm  of  the  health  care  system  in  England  is 
characterised by a number of social values that are not limited to the health care context. 
Equality and non-discrimination are values that go beyond the health care context, but 
they may be especially important to promote in health care as individuals are more  
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vulnerable in this setting. Equality, non-discrimination and comprehensive access to 
health care services feature prominently in the NHS’ guiding framework (Department of 
Health, 2013a). These, along with the requirement for fairness and value for money in 
making  funding  decisions,  can  be  viewed  as  the  substantive  ideas  that  provide  a 
construct  for  the  English  health  care  system.  On  the  procedural  side,  the  NHS 
Constitution  stipulates  professionalism,  transparency  and  accountability 
(Department of Health, 2013a). Again, these are values that are not limited to the health 
care context, but guide other areas of public policy too.  
The principles and values embedded in the NHS Constitution are a reflection of 
the institutional structure of the English health care system in that ideas such as value 
for money, transparency and accountability are important in systems where health care 
services are paid for by a collective societal entity, in this case the taxpayer community. 
Most  importantly,  the  acknowledgement  that  health  care  resources  are  finite  is  an 
important part of the health care paradigm that is reflected in the ‘rules of the game’ in 
the HTA process. Such an acknowledgement does not feature in the German health care 
paradigm. 
 
5.3. Germany: Principles and Values in Health Care 
 
  The principles and values that the German health care system is built on can be 
found in the Constitution of the Federal Republic of Germany (BMJV, 1949) as well as 
the legislative framework that mandates health care, the Social Code Book V (BMJV, 
2013).  
  Germany’s  Constitution  (BMJV,  1949)  is  important  for  understanding  the 
underpinnings  of  the  health  care  system  in  that  it  contains  the  social/welfare  state 
principle (Art. 20 & 28), which stipulates that the German state is a welfare state. The 
welfare  state  principle  forms  the  basis  of  welfare  and  health  care  provisions.  The 
operationalisation of principles and values in respective areas can be, and has been, 
challenged  in  front  of  the  courts  in  Germany.  There  have  been  important  Federal 
Constitutional Court rulings such as the so-called Nikolaus-decision
22 in 2005 in which 
the state’s obligations have been interpreted generously in favour of patients who are 
seeking access to health care services (Das Bundesverfassungsgericht, 2005). As we 
                                                        
22 Named after the day of Saint Nicholas which is traditionally celebrated in Germany on 6 
December and which was the date of the court ruling in question.  
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shall see, in the Nikloaus-decision the Federal Constitutional Court decided that patients 
with rare or life-threatening conditions are entitled to specific treatments even if the 
clinical benefits of that treatment are not conclusive. The constitutional welfare state 
principle has wide-ranging implications for the way in which Germany’s health care 
system functions. On the institutional level this includes a large role that the courts play 
in  defining  the  state’s  obligations,  and  the  limits  thereof,  under  the  welfare  state 
principle.  
Moving from the constitutional principle of the welfare state to the principles 
found  in  the  statutory  framework,  the  values  of  solidarity,  efficiency,  individual 
responsibility and medical/scientific knowledge are laid out as guiding principles within 
the health care context (BMJV, 2013). In Article 1 of the Social Code Book V the 
statutory sickness insurance is defined as a solidaristic community that is charged with 
the task of maintaining, restoring and improving the health of the insured members. 
Article 3 of the Social Code Book V extends the principle of solidarity to the way in 
which the health care system is financed, i.e. through shared contributions by employees 
and employers and through risk-pooling between and across insurance funds.  
Individual responsibility is anchored in Article 1 of the Social Code Book V 
(BMJV,  2013).  According  to  this  article  individuals  have  a  responsibility  to  live 
healthily and take preventive measures in order to avoid ill health whilst sickness funds 
have  a  responsibility  to  promote  healthy  living  through  the  services  they  provide 
(BMJV,  2013).  Buyx  (2008)  highlights  that  personal  responsibility  is  frequently 
mentioned as a possible criterion for denying patients access to a specific health care 
service  in  the  academic  and  political  debates  about  rationing  and  prioritisation,  for 
example when a disease is thought to be brought about by a particular lifestyle choice 
such  as  smoking  or  excessive  food  consumption.  However,  due  to  ethical  concerns 
associated with the difficulty of demonstrating causality between lifestyle choice and a 
disease,  health  care  and  policy  decision-makers  shy  away  from  pursuing  personal 
responsibility as a criterion for prioritisation decisions (Buyx, 2008).  
It  is  noteworthy  that  Germany’s  statutory  framework  contains  individual 
responsibility, not just as a footnote or a by-line, but as a principle in a prominent 
position. However, personal responsibility is not used as a criterion to decide which 
patients have access to services or what services are included in the health care benefit 
basket. Personal responsibility appears to be better explained in terms of the importance 
of  the  principle  of  solidarity  in  which  members  of  the  solidaristic  community  
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understand  that  their  right  to  services  comes  with  a  commitment  to  individual 
responsibility.  The  fact  that  personal  responsibility  is  neither  referred  to  in  the 
legislative framework setting out HTA decision-making criteria nor considered in any 
of  the  empirical  cases  analysed  as  part  of  this  thesis  supports  the  understanding  of 
personal responsibility as being connected to the principle of solidarity rather than a 
stand-alone value. 
The Social Code Book V (BMJV, 2013) sets out efficiency and the ‘generally 
accepted state of medical knowledge’ as principles to guide health service provision and 
decision-making  in  Germany.  According  to  Article  12  services  have  to  sufficient, 
appropriate and efficient (BMJV, 2013). However, the article does not specify what is 
considered efficient, which suggests that the operationalisation of the term is at the 
discretion  of  the  self-governing  health  care  bodies  in  Germany.  Moreover,  the 
‘generally accepted state of medical knowledge’ is not specified. As section 8 of this 
chapter shows, in the context of pharmaceutical benefit assessments this principle is 
operationalised by using methods associated with the field of evidence-based medicine.  
Finally, for cases of severe, rare and life-threatening diseases, Article 2 of the 
Social Code Book V (BMJV, 2013) contains a right for patients to access a treatment 
even if it is not part of what is usually funded by the sickness funds or if the efficacy 
evidence for the treatment is not conclusive. This article is a result of the previously 
mentioned Nikolaus-decision of 6 December 2005 in which the Federal Constitutional 
Court  overruled  previous  social  court  rulings  with  regards  to  a  patient  with  a  rare 
disease  called  Duchenne  muscular  dystrophy  (Das  Bundesverfassungsgericht,  2005). 
There is currently no generally accepted and evidence-based treatment for this disease. 
The patient made an application for his sickness fund to cover the cost for a so-called 
bioresonance therapy which he had already been receiving but which his parents had 
previously paid for (Das Bundesverfassungsgericht, 2005). The sickness fund refused 
this  application  on  the  grounds  that  there  was  no  causal  evidence  to  suggest  that 
bioresonance therapy would improve the patient’s health status. After the social courts 
upheld the sickness fund’s decision, the Federal Constitutional Court overturned the 
social courts’ ruling and ruled that the sickness fund’s decision was a breach of the 
patients’ basic rights under Article 2 (right to free development of personality and right 
to life and physical integrity) of the German Constitution (BMJV, 1949). The Federal 
Constitutional Court also connected this breach of rights to the state’s obligation under 
the welfare state principle.   
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Article 2, paragraph 2 of the Social Code Book V (BMJV, 2013) reflects the 
ruling in the Nikolaus case by granting patients the right to treatment even if there is no 
evidence of efficacy of a treatment. Even though the article pertains to life-threatening 
and  rare  diseases  for  which  no  alternative  treatments  are  available,  the  Nikolaus-
decision has significant implications for the ability of health care decision-makers to 
restrict access to treatments on the grounds of efficacy and efficiency. Arguably, the 
implementation of rationing and prioritisation policies has been made more difficult as a 
result of the Nikolaus-decision, which is now firmly anchored in the German health care 
paradigm. 
In  summary,  the  values  that  frame  health  care  in  Germany  include  a 
constitutionally  embedded  welfare  state  principle  (BMJV,  1949),  the  principles  of 
solidarity and personal responsibility (BMJV, 2013), the values of efficiency and 
medical knowledge (BMJV, 2013) in the form of evidence-based medicine as well as a 
right to health care treatment that overrides evidence-based medicine in severe cases. 
The ideational base of the Social Code Book V is connected to a number of values 
frequently associated with the welfare and health care areas rather than with area of 
public life at large. Altenstetter and Busse assert that the normative ideas underlying 
statutory health insurance policy-making in Germany “[…] may include competitive 
elements but are mediated by the influence of the three Ss – solidarity, self-governance, 
and subsidiarity (i.e., leaving decisions to the smallest capable unit)” (Altenstetter and 
Busse, 2005, p. 138).  
 
5.4. Comparative Views 
 
  The preceding sections identify the main features of the English and the German 
health care paradigm. The identification thereof is important because it gives rise to the 
HTA  paradigms  that  are  identified  in  the  next  sections.  What  is  striking  from  a 
comparative point of view is that in the German health care context one finds little to no 
reference to wider social values such as equality and non-discrimination. In contrast, 
these social values play a big role in the NHS Constitution and NHS decision-making 
generally. A possible explanation for this might be the German Constitution, which 
guarantees  rights  in  all  areas  of  public  life.  The  Constitution  includes  the  right  to 
equality,  non-discrimination  and  freedom  of  expression  (BMJV,  1949).  By  
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constitutionally  guaranteeing  rights  such  as  equality  and  non-discrimination,  these 
values do no have to be reiterated in every piece of legislative guidance.  
  Another possible explanation for the absence of any reference to wider social 
values in the German paradigm is connected to the lack of acknowledgement that health 
care  resources  are  finite.  Acknowledging  that  resources  are  finite  implies  an 
acknowledgement  that  not  everything  can  be  done  for  everyone  and  that  difficult 
choices will have to be made. In an effort to make these choices fair, legitimate and 
acceptable, principles such as equality and non-discrimination become more important. 
This  might  explain  why  the  NHS  Constitution  emphasises  the  importance  of  non-
discrimination  and  equality.  To  put  it  differently,  if  it  is  not  acknowledged  that 
resources are finite, then it is less important that they are distributed equally because 
there are enough resources for everyone to benefit.  
  There are flaws to the above attempts at explaining the absence of wider social 
values  from  the  German  health  care  paradigms,  the  most  obvious  one  being  the 
implication that the need for equality and non-discrimination is greater when resources 
are finite. This implication is flawed because even in a hypothetical system of infinite 
health care resources  decisions  would have to  be made about  how to  distribute the 
resources in order to ensure that everyone, and not just certain members of society, 
benefit from them. A further elaboration on these points is beyond the scope of this 
thesis. The main point for the discussion that follows is that the English health care 
paradigm specifically acknowledges the finite character of health care resources while 
the German one does not. At the same time wider social values that are not just limited 
to the health care arena can be identified in the English paradigm, but not in the German 
one. Whether or not these features are associated with one another – i.e. whether an 
acknowledgement of finite resources necessitates the adherence to wider social values – 
is a question that could be addressed in future research. 
The overview of values embedded in the health care paradigms also shows that 
procedural  values  such  as  transparency  and accountability are not mentioned in  the 
German context. The principles referred to in the German context are more substantive 
in  kind,  whereas  in  England  they  are  both  procedural  and  substantive.  The  lack  of 
procedural values in the German context may be explicable with reference to the self-
governing health care system which implies that procedural issues need to be dealt with 
at self-governing level rather than at state level.   
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It is an interesting empirical observation that the lack of procedural values at 
paradigm level is congruent with a frequently voiced criticism by stakeholders about the 
lack of transparency in health care decision-making in Germany (e.g. Interviewee No. 6, 
2013; Interviewee No. 8, 2013; Interviewee No. 9, 2013). This observation is discussed 
in more detail in chapters 6, 7 and 8. For now, suffice it to say that there appears to be a 
difference in the importance attributed to procedural values in the German and English 
paradigms.  It  suggests  that  in  comparing  the  German  and  English  systems  of 
pharmaceutical benefit assessments one faces two cases that place a different emphasis 
on substantive and procedural  values. Whether  or not  this  difference is reflected in 
pharmaceutical benefit assessment processes and whether it impacts on the outcome of 
assessments will have to be addressed when comparing the empirical results with the 
discussion of paradigms presented in this chapter. 
  A common characteristic of the English and the German HTA paradigms is that 
they give rise to tensions that have to be resolved at the decision-making level, i.e. 
during HTA decision-making. At their core, HTA processes are about the identification 
of clinically effective vs. non-effective treatments and/or about the identification of cost 
effective vs. cost ineffective treatments. In the English health care paradigm, the finite 
nature  of  resources  is  acknowledged  whilst,  at  the  same  time,  the  principle  of 
comprehensive  services  is  firmly  anchored  in  the  NHS  Constitution.  Similarly,  the 
German health care paradigm includes the principle of efficiency, whilst the Nikolaus-
ruling resulted in a statutory paragraph that potentially challenges attempts to adhere to 
the principle of efficiency.  
Neither the English nor the German paradigms provide decision-makers with 
guidance on how to resolve the tensions that arise, i.e. how to provide comprehensive 
services when resources are finite or how to provide efficient services when severely ill 
patients have a right to treatment for which there is no evidence that it is effective, let 
alone efficient.  These tensions  need to  be  resolved at  the ‘normal’ decision-making 
level. They support the theoretical argument made in chapter 2 that it is not enough to 
identify the broad features of a paradigm when trying to understand their effect on 
empirical  phenomena.  Paradigms  acquire  meaning  and  articulation  when  they  are 
operationalised in practice and the empirical chapters that follow provide initial insights 
into how the above tensions, among others, are resolved in practice. While paradigms 
set boundaries for what is considered possible in a policy area, the outlined tensions 
suggest that there is room for how these boundaries are established in practice.  
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Before  turning  to  the  purposes  and  goals  as  institutional  features  of  HTA 
paradigms, I briefly raise the question of whether the above tensions result in a situation 
in which certain values are given more weight than others. This question emerges from 
the Nikolaus-case (Das Bundesverfassungsgericht, 2005) in Germany, which appears to 
suggest  that  the  right  to  treatment  trumps  the  principle  of  evidence-based  medicine 
anchored in the Social Code Book V and the guidelines of the Federal Joint Committee 
(FJC). If this is the case, then the decision problem becomes one of how decision-
makers adhere to guiding values such as efficiency without risking patients invoking 
their rights under Article 2, paragraph 2 of the Social Code Book V (BMJV, 2013). In 
the context of pharmaceutical benefit assessments, the empirical analysis undertaken in 
this thesis suggests that a core and a periphery of values exist. The core is the cost 
effectiveness thresholds in England and patient relevance in Germany, both of which 
appear  to  be  weighted  more  than  other  principles  contained  in  the  decision-making 
paradigms. The empirical evidence thus suggests that certain concepts trump others, a 
finding that adds another tier of complexity to the analysis of policy paradigms.  
 
5.5. Purpose and Goals of HTA Processes 
 
  The goals HTA processes are designed to achieve are important features of HTA 
policy  paradigms  as  they  inform  the  way  the  processes  are  structured  and  provide 
explanations for the methods that are employed in these processes. The purposes that 
HTA processes serve in different contexts can thus be viewed as an integral part of the 
policy paradigms that guide them.  
The previous chapter outlined that HTA processes in England inform decisions 
on  the  inclusion  or  exclusion  of  pharmaceutical  products  in  routine  NHS  practice 
whereas  in  Germany  they  serve  as  the  basis  for  price  negotiations  between  the 
pharmaceutical  manufacturers  and  the  sickness  funds.  This  institutional  difference 
represents different ideas about what purposes HTA processes can and should serve. 
This  in  turn  explains  the  difference  in  how  the  purpose  of  HTA  processes  is 
conceptualised in the methodological frameworks for the FJC, IQWiG and NICE. In the 
next  section  I  turn  to  this  conceptualisation  in  order  to  show  how  different 
understandings about a policy idea, that of HTA, are reflected in the way the goals of 
HTA processes are framed in institutional guidelines. 
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5.5.1. England and Germany: Purpose of HTA Processes 
 
  The guiding document pertaining to pharmaceutical benefit decisions at NICE is 
the ‘Guide to the methods of technology appraisal’ (NICE, 2008). For the purpose of 
this thesis, the 2008 version of this guide is used as this version informed the appraisals 
that are analysed as part of this research. According to this guide, the purpose of NICE 
appraisals is “[…] to appraise the health benefits and the costs” (NICE, 2008, p. 7) of 
technologies, e.g. of pharmaceutical products. As will be shown in the next sections, 
NICE  operationalises  health  benefits  as  clinical  effectiveness  and  costs  as  cost 
effectiveness  in  relation to  the opportunity  costs of services  that are possibly being 
displaced by a positive recommendation from NICE (NICE, 2008). This is important to 
note because it shows that health benefits and costs are viewed in relation to one another 
within the HTA paradigm rather than viewing the two as separate stand-alone ideas.  
  The FJC identifies its purpose as making transparent and legally sound decisions 
that reflect the generally accepted state of medical knowledge (G-BA, 2013a). With 
regards to pharmaceutical benefit assessments it does so by carrying out early benefit 
appraisals  of  a  new  medicine  in  order  to  inform  pharmaceutical  price  setting  in 
Germany. The inclusion of the ‘generally accepted state of medical knowledge’ as a 
criterion to be considered when carrying out its tasks is one that reoccurs in a number of 
the guiding documents of HTA processes and it reflects the principles in the Social 
Code Book V. The reference to ‘making legally sound decisions’ can be attributed to 
the big role that the courts in Germany play with regards to the legality of health care 
decision-making.  That  is  to  say  that  the  German  system  is  characterised  by  a 
comparative  lack  of  institutional  appeals  structures  (Landwehr,  2009)  and  the  most 
common way to appeal FJC decisions or an individual funding decision by a sickness 
fund  is  to  take  legal  action  in  court.  Thus,  in  making  its  decisions,  the  FJC  is 
particularly aware of making decisions that are legally sound. As one representative 
phrased  it  in  an  interview:  “[…]  in  Germany  […]  in  contrast  to  other  countries, 
everything can be taken to court and this sword of Damocles of judicial appeals hangs 
over all of our decisions” (Interviewee No. 16, 2013, pp. 5-6).  
The  fact  that  the  procedural  value  of  transparency  is  mentioned  by  the  FJC 
suggests  that  this  is  a  means  by  which  the  Committee  seeks  to  ensure  the 
aforementioned legal  soundness  of their decisions.  How this  value is  perceived and 
operationalised is the subject of a later part of this thesis. Suffice it to say at this point  
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that the reference to transparency in a section pertaining to the purpose of the FJC’s 
work is noteworthy in that it indicates that procedural values play a role in the FJC’s 
work despite their comparative under-representation in the value framework discussed 
in the previous section. Finally, IQWiG defines its purpose as supporting the FJC in its 
decision-making  by  assessing  the  therapeutic  benefit  of  a  new  medicine  (IQWiG, 
2011a).  This  reflects  IQWiG’s  institutional  role  as  the  assessment  rather  than  the 
appraisal body in Germany. 
  While  the  purpose  of  HTA  processes  in  Germany  includes  a  reference  to 
transparency, a procedural value, a similar reference is lacking in the methodological 
guidelines of NICE. However, the lack thereof in the English context should not be 
overstated as it seems to be a result of semantic and structural lay-out decisions rather 
than of decisions that are paradigmatically significant. As the previous section on the 
wider values in health care in England highlighted, procedural values play a large role 
in health care decision-making in general. The next sections show that this is reflected 
in the principles and criteria of HTA decision-making.  
In summary, the purpose and task of both NICE and the FJC is the appraisal of 
pharmaceutical products. However, the difference between the organisations pertains to 
what aspects in relation to the scientific evidence on a product are being appraised and 
to what end. In England, health benefits and costs are appraised with the purpose of 
recommending  the  use  or  non-use  of  a  pharmaceutical  product  in  routine  clinical 
practice.  By  contrast,  in  Germany  the  question  of  costs  is  left  aside.  Only  the 
‘therapeutic benefits’ of a new medicine are appraised with the purpose of informing 
pharmaceutical price setting in Germany. The aspects that are considered and the ends 
of an appraisal can be illustrated schematically in the following way: 
   
England: 
 
Assessment & appraisal of health benefit + assessment & appraisal of costs  
Recommendation of the use or non-use in routine clinical practice 
 
Germany:  
 
Assessment & appraisal of therapeutic benefits  Pharmaceutical price setting 
to reflect the added benefit of a product 
 
 
The significance of the similarity of appraising benefits as the purpose of HTA bodies 
in England and Germany is decreased by the dissimilarity in what factors take priority  
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in appraisals and to what end. This exemplifies how a seemingly scientifically objective 
concept such as benefit appraisal gets reinterpreted to fit national policy paradigms. 
This reinterpretation occurs when operationalising institutional goals during the process 
of normal decision-making. 
 
5.6. Principles, Criteria and Methods of HTA Decision-Making 
 
  The  principles,  criteria  and  methods  of  HTA  decision-making  are  important 
elements of the policy paradigms in that they offer an insight into how the paradigms 
are operationalised. The principles of HTA decision-making are the values that reflect 
the policy paradigms at large whereas the criteria, and more importantly the methods of 
conducting HTAs, are the way these values get translated into practice. Before setting 
out these principles, criteria and methods, it is important to be aware of the distinction 
between different scientific methods for conducting HTAs, which all require slightly 
different evidential inputs and methods of analysis and are important to understanding 
the difference between the HTA paradigms in Germany and England. In a sense, the 
methods for conducting HTAs form the pool of potential instruments which decision-
makers can choose from. 
  The most important inputs in HTA processes usually centre on evidence around 
clinical effectiveness, cost effectiveness, clinical benefits, side effects and other such 
measures. However, there are different methods to analyse the data that is presented in 
the  context  of  such  evidence.  The  most  prominent  methods  for  analysing  the  data 
include cost effectiveness (CEA) and cost-benefit (CBA) analyses. Sloan defines these 
as: “[…] formal methods for comparing the benefits and costs of a medical intervention 
in order to determine whether it is worth doing […]” (Sloan, 1995, p. 3). Eichler, et al. 
(2010, p. 280) point out that there is no generally agreed definition of CEA, but it 
usually refers to the value for money.  
In cost effectiveness analyses, which are used by NICE in England, the costs and 
benefits of a medicine or an intervention are compared with the current standard therapy 
for a given disease indication. Cost effectiveness analyses express clinical outcomes and 
benefits in non-monetary units such as quality-adjusted life years (QALYs) and costs in 
monetary units such as incremental costs, two concepts which will be explained in turn. 
NICE defines QALYs as:  
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A measure of the state of health of a person or group in which the benefits, in 
terms of length of life, are adjusted to reflect the quality of life. One QALY is 
equal to 1 year of life in perfect health. QALYs are calculated by estimating the 
years  of  life  remaining  for  a  patient  following  a  particular  treatment  or 
intervention and weighting each year with a quality of life score (on a zero to 1 
scale).  It  is  often  measured  in  terms  of  the  person's  ability  to  perform  the 
activities  of  daily  life,  freedom  from  pain  and  mental  disturbance  (NICE, 
2014b). 
 
In other words, QALYs are used to evaluate a pharmaceutical according to the increase 
in quality of life it provides and how much a patient’s life might be prolonged as a result 
of treatment with the pharmaceutical. However, QALYs only express “the measure of 
the state of health of a person”. In order for them to be useful in an HTA process that 
empahsises cost effectiveness, they have to be used alongside methods that express the 
marginal costs, additional costs or cost savings per QALY. 
In England, the incremental cost effectiveness ratio (ICER) has been used to 
express the incremental costs associated with a treatment or intervention per QALY. In 
other words, expressing cost effectiveness as an ICER per QALY provides an indication 
of how much additional money will have to be spent on the new treatment in order to 
gain one extra QALY, i.e. one extra year in perfect health. However, once again the 
expression of an ICER per QALY is just one step in combining the two concepts in 
order  to  inform  decision-making  on  cost  effectiveness.  In  order  to  make  sense  of 
incremental cost per QALY measures, decision-makers need to know what would be 
considered  a  justified  cost  increase  compared  with  an  unjustified  cost  increase.  Put 
differently, there needs to be system in place that allows decision-makers to understand 
how much cost increase is justified by how much clinical benefit. As we shall see, NICE 
employs cost effectiveness thresholds above which a new pharmaceutical product will 
usually not be considered a cost effective use of NHS resources.  
The advantage of using ICERs and QALYs as measures of cost effectivness is 
that they provide the decision-making agency with a comparative measure to evaluate 
cost  effectiveness.  QALYs  can  be  used  to  measure  the  effect  of  a  medicine  on  a 
person’s  health  regardless  of  the  illness  for  which  that  medicine  is  indicated.  This 
means that clinical benefits and costs of a range of medicines can be measured across 
different disease areas and that, based on ICER per QALY measures, decision-makers 
are able to recommend the most cost effective medicine for coverage under a national 
health  system.  This  might  be  considered  important  in  a  cash-limited  health  system  
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where opportunity costs – i.e. the microeconomic principle that every unit of money one 
spends  in  one  area  is  not  available  to  be  spent  in  another  –  are  an  important 
consideration when providing health care. Connecting the ICER/QALY method with 
opportunity costs suggests that spending money on a treatment that is considered cost 
ineffective is not justified considering that benefits from alternative, and perhaps more 
cost  effective  treatments,  will  be  foregone.  While  the  use  of  QALYs  is  not 
uncontroversial  and  its  critics  argue  that  it  does  not  allow  for  the  consideration  of 
important  value  judgements  (Nord,  1999,  p.  3-4)
23 ,  it  represents  an  important 
methodological instrument that HTA decision-makers have employed. 
Moving away from cost effectiveness analyses and on to an example of cost -
benefit analysis, the so-called efficiency frontier is a relatively new method used for 
measuring and expressing the cost-benefit ratio of a given intervention.  Thus far it is 
only used by IQWiG  in Germany and while it is widely used in other economic 
evaluation contexts it is new in the context of measuring the cost-benefit ratio of health 
care interventions (Caro, et al. 2010, p.  1123). Drummond and Rutton describe the 
method in the following way: 
 
To compare costs and benefits in a particular therapeutic area […] a diagram 
with costs on the X-axis and ‘value’ on the Y-axis [is constructed] and then […] 
the existing therapies in this therapeutic area [are plotted] as points on the graph 
(Drummond and Rutten, 2008, p. 7),  
 
 
with the most dominant existing interventions forming the “efficiency frontier” in the 
graph  as  expressed  in  their  cost-benefit  ratios.  For  products  under  assessment  this 
results in a diagram such as the following: 
 
                                                        
23 A detailed overview of the criticisms of QALYs and the associated ICER thresholds is beyond 
the scope of this thesis.  
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          Figure 4: The Efficiency Frontier 
 
(Source: IQWiG, 2008, p. 14) 
 
Plotting  different  interventions  on  the  graph  aids  decision-maker  to  judge  which 
interventions  provide the best  benefits  in  comparison  to  the associated costs. While 
authors such as Caro, et al. (2010) argue that this method is useful, others such as 
Drummond and Rutten (Drummond and Rutten, 2008, p. 9) criticise it for the danger 
that it plots therapies on the graph whose cost effectiveness is not proven. This danger 
arises because the efficiency frontier demands that all medicines or interventions for a 
particular illness are included in the graph, even if effectiveness studies are not available 
for some of them due to their age (Drummond and Rutten, 2008, p. 9).  
  The brief overview of the methods for evaluating the benefits and costs of a 
given pharmaceutical product suggests that there is no such thing as one method for 
assessing and appraising a product’s benefits. HTAs are complex processes in which a 
myriad of methods can be used. The choice of methods and the reasoning behind this 
need to considered when examining what determines the outcome of pharmaceutical 
benefit assessments as they provide insights into the dominant HTA paradigm in a given 
country. More importantly though the empirical chapters in this thesis highlight that the 
way these methods or, to use Kuhn’s (1962) words the ‘rules of the game’, operate in 
normal decision-making provides a deeper understanding of the effect that they have on 
the outcomes and on how a paradigm operates in practice.  
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5.7. England: Principles, Criteria and Methods of HTA Decision-Making 
 
  The  principles  that  guide  HTA  decision-making  at  NICE  are  consistency, 
equality and non-discrimination (NICE, 2008). Of these principles consistency is one 
that is not mentioned as a guiding principle in any of the previously discussed tiers of 
the policy paradigm. Consistency can be viewed as an extension of and a reinforcing 
element  of  equality  and  non-discrimination.  By  ensuring  that  the  decision-making 
process at NICE is comparable and that the same criteria are applied on a case-by-case 
basis a consistent approach promotes equality and non-discrimination. In order to apply 
the principle of consistency in practice, NICE has developed a ‘reference case’ for its 
assessments (NICE, 2008, p. 4). This reference case provides a framework of necessary 
criteria and methodological steps that technology appraisals at NICE must follow. It 
specifies aspects of HTAs including, but not limited to, what the relevant comparator 
should  be  (i.e.  therapies  routinely  used  in  the  NHS),  how  health  effects  are  to  be 
measured and expressed (i.e. in quality-adjusted life years (QALYs)) and what type of 
economic evaluations should be used  (i.e. cost effectiveness analysis) (NICE, 2008, p. 
30).  
The  principle  of  consistency  is  therefore  put  into  practice  by  means  of  a 
reference case that stakeholders, including pharmaceutical manufacturers and decision-
makers at NICE, can use as a roadmap when navigating through the pharmaceutical 
benefit assessment process. NICE explains the reasoning for using a reference case as a 
tool in the decision-making process in the following way:  
 
The Institute has to make decisions across different technologies and disease 
areas. It is, therefore, crucial that the analyses of clinical and cost effectiveness 
undertaken to inform the appraisal adopt a consistent approach. To allow this, 
the Institute has defined a ‘reference case’ that specifies the methods considered 
[…]  to  be  the  most  appropriate  for  the  Appraisal  Committee’s  purpose  and 
consistent  with  an  NHS  objective  of  maximising  health  gain  from  limited 
resources (NICE, 2008, p. 31). 
 
 
This reasoning is congruent with the wider paradigm under which the NHS operates in 
that  it  makes  reference  to  the  limits  of  health  care  resources.  It  therefore  becomes 
necessary to make decisions across disease areas because the English paradigm accepts 
that  resources  are  limited.  Therefore,  if  one  is  to  uphold  two  other  important 
paradigmatic  features  of  the  health  care  system  in  England,  i.e.  equality  and  non- 
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discrimination, the best way to do so is by ensuring a consistent approach in decision-
making, thereby reflecting a procedural value akin to a fair process. Following on from 
this, the methods laid out in NICE’s reference case reflect the paradigmatic need to 
make decisions across disease areas whilst ensuring a fair process by stipulating that the 
reference case needs to be adhered to.  
The  principle  of  consistency,  and  by  extension  of  quality  and  non-
discrimination, is operationalised by employing NICE’s reference case. The reference 
case is built on a conceptualisation of criteria for HTA decision-making such clinical 
and cost effectiveness (across disease areas). According to NICE, 
 
[…] technologies can be considered clinically effective if, in normal clinical 
practice, they confer an overall health benefit, taking into account any harmful 
effects when compared with other relevant treatment alternatives. Technologies 
can  be  considered  cost  effective  if  their  health  benefits  are  greater  than  the 
opportunity  costs  measured  in  terms  of  the  health  benefits  associated  with 
programmes that may be displaced to fund the new technology. In other words, 
the  general  consequences  for  the  wider  group  of  patients  in  the  NHS  are 
considered alongside the effects for those patients who may directly benefit from 
the technology of interest (NICE, 2008, p. 9). 
 
 
In addition to providing the definitions of clinical and cost effectiveness in the context 
of  NICE’s  decision-making  process,  the  above  excerpt  from  NICE’s  guide  to 
technology appraisals illustrates that the needs of the many, i.e. the “wider group of 
patients in the NHS” (NICE, 2008, p. 9) are balanced with the needs of the few, i.e. “the 
patients who may directly benefit from the technology of interest” (NICE, 2008, p. 9). It 
also suggests that clinical effectiveness is a necessary but not a sufficient condition for a 
positive appraisal by NICE.  
The methods and criteria of NICE’s decision-making process are designed to 
accommodate the paradigmatic idea that a balance has to be struck between different 
patients’ needs. Health benefits are expressed in terms of QALYs. This method allows 
for a comparison between different pharmaceutical products, for different disease areas, 
in order to assess their comparative effectiveness in relation to their costs. In addition, 
the incremental cost of an intervention is calculated and compared with the additional 
clinical benefit as expressed in QALYs. This gives rise to the ICER, which compares 
the mean costs with the mean clinical outcomes of a treatment (NICE, 2014b).   
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As long as thresholds are defined, employing ICERs allows decision-makers to 
decide which interventions are cost effective and which ones are not. The underlying 
assumption of the use of ICERs is that there are thresholds above which the additional 
costs  incurred  are  no  longer  justified  by  the  extent  of  expected  additional  clinical 
benefits. However, the way in which these thresholds are set (NICE’s current threshold 
is at £30,000 per QALY) is contested. Further elaboration on this is beyond the scope of 
this thesis. In the context of this thesis, it is important to highlight that ICERs and 
QALYs  are  more  than  scientific  tools  for  conducting  HTAs.  They  are  the  logical 
methodological choice that emerges from a paradigm that a) accepts that health care 
resources are limited and b) requires balancing the needs of the many with the needs of 
the few. Williams summarises this choice in the following words: 
 
The methodological underpinnings for TAs [technology appraisals] derive from 
non-welfarist health economics, and are driven by the objective of maximizing 
population health subject to budget constraint. This leads to the use of a decision 
criterion formulated in terms of the extra costs that would have to be incurred in 
order to bring about a unit improvement in health. […] But ranking technologies 
according to their cost-per-QALY score still does not get us to our destination, 
because  we  still  lack  a  cut-off  point  beyond  which  we  say  “this  far  but  no 
further” […] (Williams, 2004, pp. 6-7). 
 
In addition to clinical and cost effectiveness as criteria for decision-making, the 
Appraisal Committees (ACs) at NICE are to take into consideration the clinical need of 
patients, “the potential for long-term benefits to the NHS of innovation” (NICE, 2008, 
p. 52) as well as NICE’s guideline on social value judgments (NICE, 2008a). More 
recently, NICE has also developed a supplementary advice on appraising end-of-life 
treatments that permits ACs to recommend a pharmaceutical product even if its ICER 
is above the usually accepted threshold of £30,000 per QALY if the product is licensed 
for the end-of-life treatment of a terminal disease (NICE, 2009a). This was developed as 
a result of a number of appraisal processes, especially on expensive end-of-life cancer 
treatments, in which ACs were not able to recommend the use of the treatments on 
clinical and cost effectiveness alone, but needed additional decision-making criteria for 
the special situations pertaining to the end-of-life stages of diseases such as cancer. 
Thus, while clinical and cost effectiveness are the most important pillars of the HTA 
decision-making processes at NICE, the HTA paradigm has developed in such a way  
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that permits for a consideration of other factors and values in special circumstances such 
as end-of-life settings or innovative developments.  
In summary, the principles and criteria of HTA decision-making as they are laid 
out  in  NICE’s  guide  to  technology  appraisals  are  a  reflection  and  extension  of  the 
values found in the wider health care context. Equality and non-discrimination are 
expressed  in  the  principle  of  consistency  and  operationalised  by  means  of  NICE’s 
reference  case. This ensures a fair process and provides stakeholders and decision-
makers  with  a  decision-making  algorithm  in  that  they  know  what  steps  need  to  be 
followed and what criteria need to be met. In the case of cost effectiveness the algorithm 
is  clear in  that products  with  ICERs  above £30,000 per QALY need to meet  other 
criteria  such  as  the  end-of-life  criteria  or  innovation  considerations  in  order  to  be 
recommended for use (NICE,  2008).  In this  way, while the English  HTA decision-
making  paradigm  provides  a  consistent  algorithm,  it  also  allows  exceptions  if  the 
algorithm does not do justice to the benefits of the treatment in question.  
What is striking about the English HTA paradigm, especially in comparison to 
the German paradigm explored in the next section, is the unequivocal acceptance of the 
limits of health care resources. The decision-making structures are designed in a way 
that  permits  fair  decision-making  whilst  knowing  that  the  NHS  cannot  provide 
everything that might be desirable or even necessary. This unequivocal acceptance leads 
to a HTA paradigm that seeks to strike a balance between the needs of the many with 
the needs of the few, whilst providing ways around it in special circumstances.  
 
5.8. Germany: Principles, Criteria and Methods of HTA Decision-Making 
 
  Like the English HTA decision-making paradigm, the principles that guide HTA 
decisions in Germany are a reflection of the wider health care context. The FJC’s Rules 
of  Procedure  include  the  principles  of  transparency  and  legal  soundness,  the 
generally  accepted  state  of  medical  knowledge, the need for considering justified 
interests  of  stakeholders  and  efficiency  (G-BA,  2013).  The  principle  of  legal 
soundness has been elaborated on in a previous section of this chapter and reflects the 
fact that appeals opportunities other than taking legal action are limited in the German 
HTA  context.  The  ‘generally  accepted  state  of  medical  knowledge’  reflects  the 
inclusion of this value in Article 1 of the Social Code Book V as does the principle of 
efficiency in Article 12 of the Social Code Book V (BMJV, 2013). Thus, except for the  
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specification of considering issues of quality and health care provision when making 
decisions, the only newly introduced principle in the FJC’s Rules of Procedures is the 
need to consider the interests of stakeholders; how this principle is operationalised is 
addressed in the empirical chapters that follow. IQWiG as the evidence review body, or 
assessment body, in the German context highlights its  independence as a scientific 
body,  transparency  and  the  principle  of  evidence-based  medicine  as  its  guiding 
principles when making decisions (IQWiG, 2011a). 
  However, the most meaningful insights into HTA decision-making in Germany 
cannot be found in the above principles, but in the way the most important decision-
making  criterion,  namely  that  of  ‘therapeutic  benefit’,  is  conceptualised  and 
operationalised.  Therapeutic  benefit  is  understood  as  the  additional  benefit  of  the 
appraised medicine in comparison to currently available alternatives. The Ordinance for 
Assessing the Benefits of Pharmaceuticals specifies that:  
 
the  benefit  of  a  pharmaceutical  is  the  patient-relevant  therapeutic  effect,  in 
particular in respect of the improvement in the state of health, the reduction of 
the duration of the disease, longer survival, the reduction of side-effects or an 
improvement in quality of life (Bundesgesetzblatt, 2010).  
 
This  conceptualisation  of  therapeutic  benefit  as  an  expression  of  patient  relevance 
suggests that the clinical effectiveness of a pharmaceutical product, i.e. its ability to 
achieve what it sets out to do in a normal clinical setting, is not sufficient for it to 
receive a positive appraisal in the form of the assignment to a high additional benefit 
category.  Rather,  clinical  effectiveness  in  Germany  is  conceptualised  and 
operationalised as a concept of categorical quality which does not automatically amount 
to an additional benefit. IQWiG specifies that the concept of patient relevance includes 
how a patient feels, how he/she can go about his/her daily activities, whether a patient 
survives as well as questions of mortality, morbidity and health-related quality of life 
(IQWiG, 2011a).  In the German context all clinical trial endpoints have to be patient 
relevant in order to be included as valid endpoints when making appraisal decisions. 
The concept of patient relevance can be considered the most important criterion in HTA 
decision-making. 
Despite patient relevance being the most important criterion of HTA decision-
making, it is not clear which principle or value of the wider health care system or the 
HTA process it reflects or arises from. This is different from the English paradigm in  
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which the connections between the different paradigmatic value tiers are more easily 
discernible.  Moreover,  the  empirical  analyses  in  the  next  chapters  show  that,  for 
example in the case of Boceprevir (G-BA, 2012) and Telaprevir (G-BA, 2012a), the 
operationalisation of patient relevance does not  always sit easily  with  the  generally 
accepted state of medical knowledge. In the case of Boceprevir and Telaprevir, both 
indicated  for  chronic  hepatitis  C  of  genotype  1,  this  meant  that  the  main  clinical 
endpoint in the form of sustained virological response (SVR) was initially not accepted 
by IQWiG as being patient relevant even though medical experts agreed that it was the 
most important indicator of successful treatment in hepatitis C (G-BA, 2012; G-BA, 
2012a). The case illustrates that it is not clear how patient relevance should be defined 
on  a  case-by-case  basis  and  which  methods  should  be  used  to  demonstrate  patient 
relevance  if  the  methods  employed  in  demonstrating  clinical  effectiveness  are  not 
deemed satisfactory by IQWiG or the FJC. Germany’s HTA decision-making paradigm 
includes a conceptualisation of clinical effectiveness as the patient relevant therapeutic 
effect, but in comparison to England it does not provide a decision-making construct 
such as NICE’s reference case to offer guidance on the operationalisation of patient 
relevance. 
  Despite the lack of a reference case and despite its emphasis on evidence-based 
medicine, the importance of patient relevance is congruent with a paradigm that, as a 
result  of  the  Nikolaus-case  court  ruling  (Das  Bundesverfassungsgericht,  2005),  also 
needs  to  cater  for  the  right  to  treatment  even  when  effectiveness  evidence  is  not 
available or sufficient. The concept of patient relevance, i.e. what really matters to the 
patient,  may  be  seen  as  an  attempt  to  accommodate  this  unique  HTA paradigmatic 
feature. It may also explain why, apart from the principle of efficiency, matters of costs 
or  cost  effectiveness  do  not  feature  as  decision-making  criteria  in  German 
pharmaceutical benefit assessments. What matters solely is the additional benefit of a 
new medicine in comparison to what is currently available, not whether this medicine is 
cheaper or more expensive in relation to the benefits it offers. Additionally, a cost-
benefit assessment, in which IQWiG would conduct an economic evaluation using the 
‘efficiency frontier’ method described earlier, is not conducted automatically but has to 
be commissioned separately from an early benefit assessment. In contrast to England, 
where there is an acknowledgement of the limits of health care resources, in Germany 
the opposite appears to be the case in that there is a reluctance to engage with questions 
of costs and cost effectiveness in pharmaceutical benefit assessment  processes. This  
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claim is substantiated by the empirical case studies presented in the next chapters in that 
cost  effectiveness  arguments  raised  by  the  pharmaceutical  industry  and  other 
stakeholders are discarded as irrelevant by the FJC.  
  In addition to the importance of patient relevance and the comparative lack of a 
consideration of  cost  issues,  the benefit  assessment within disease areas  rather than 
across disease areas is an important feature of the German HTA paradigm. In a way this 
is a result of the decision to conduct benefit analyses rather than cost-benefit analyses in 
the German context which in turn is a result of a specific paradigmatic idea of what 
purpose HTAs should serve. In other words, in the German context HTAs are supposed 
to provide insight into the additional benefits of one medicine in comparison to another 
in the same disease area rather than insight into which medicine can be considered cost 
effective across disease areas. As IQWiG points out this decision is based on a value 
judgment about whether it is right or fair to compare medicines for different diseases 
and potentially different disease severity with one another (IQWiG, 2011a). Within the 
German decision-making paradigm it is not deemed acceptable to assess the value of 
benefits across disease areas and both the FJC and IQWiG are explicit about this. 
  To summarise, there are three features that stand out from the principles and 
criteria  of  HTA  decision-making  in  Germany,  namely  the  conceptualisation  of 
therapeutic  benefit  as  patient  relevant  effect,  the  comparative  lack  of  the 
consideration of cost issues and the benefit analyses within disease areas rather than 
across different diseases. While the comparative disregard of cost issues is a reflection 
of the institutional purpose of the German HTA paradigm, i.e. its purpose is to inform 
price  setting,  the  conceptualisation  of  therapeutic  benefit  and  the  decision  to  assess 
benefit within disease areas reflect a specific value view of what is or is not acceptable 
when making decisions in health care.  
It is worth noting that the principle of innovation is not included as a criterion in 
the  methodological  guidelines.  This  may  be  because  the  highest  benefit  category  is 
thought of as a recognition of the innovative character of a new medicine. However, 
considering that the early benefit assessment process was introduced to mitigate against 
an  increasing  number  of  so-called  pharmaceutical  innovations  that  were,  on  closer 
inspection, not innovative in comparison to already existing medicines, it is interesting 
that innovation does not constitute a separate criterion. The empirical analysis in the 
proceeding chapters sheds light on whether innovation is considered in normal HTA 
decision-making processes in Germany.  
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What  is  striking  about  the  German  HTA  paradigm  is  the  idea  that  clinical 
effectiveness alone is not a sufficient indicator to prove that a new medicine provides an 
additional benefit. What is exceptional about the German paradigm is the criterion used 
to  assess  comparative  effectiveness,  namely  that  of  patient  relevance.  While  the 
common approach to evaluating a pharmaceutical product’s comparative effectiveness 
is to analyse its statistically significant parameters and to put these in relation to costs, 
Germany’s approach introduces an additional hurdle that clinical effectiveness needs to 
meet in that it has to be patient relevant. However, in doing so the methodological 
guidelines  provide  little  insight  into  how  patient  relevance  should  be  defined  and 
whether there is a decision-making algorithm that indicates the thresholds or minimum 
criteria  for  the  assignment  of  a  new  medicine  to  one  of  the  six  possible  benefit 
categories
24. The latter might change in the future as IQWiG is currently developing 
new methodological guidelines. However, for the cases that are analysed  in this thesis 
the lack of clear guidance on the operationalisation of patient relevance and the benefit 
categories was one of the points raised in each assessment process.  
Finally, when examining the theoretical and the empirical aspects of the German 
HTA paradigm a dissonance arises that is difficult to disentangle. When analysing the 
methodological guidelines and legislative framework one faces a paradigm that is 
characterised by cautious and seemingly conscious attempts to avoid some of the ethical 
conundrums of health care decision-making. That is to say that the HTA paradigm is set 
out in such a way that even the assignment of a medicine to a negative benefit category 
will not automatically lead to its exclusion  in the health care benefit basket. Similarly, 
the decision to appraise benefits within rather than across disease areas means that one 
group of patients will never gain benefits at the expense of others. In times of health 
care rationing and prioritisation these are striking paradigmatic features. However, when 
it comes to the operationalisation of the paradigm, and especially the outcomes of 
benefit assessment processes in different cases, the FJC’s appraisal of the benefits of a 
new product is frequently more restrictive than NICE’s. Thus arises a dissonance within 
the paradigm in that it contains ideas that are more favourable to individual patients’ 
needs than NICE’s, but it is lacking on guidance on how to operationalise these ideas so 
that theory and practice meet. 
 
                                                        
24 See previous chapter for an overview of the benefit categories.  
  156 
5.9. The Case of Apixaban: How are HTA Paradigms Operationalised? 
 
  In this section I introduce the case of Apixaban (G-BA, 2012b; NICE, 2012a) as 
an example of how HTA paradigms are operationalised in England and Germany. While 
the cases discussed in the next chapters are cases in which challenging questions around 
the evidence arose, the case of Apixaban illustrates a comparatively straightforward 
example of the reasoning that led to the final outcome during the normal HTA decision-
making process. That is to say that the previously presented decision-making criteria, 
especially in relation to the methods used, were applied without much controversy by 
NICE, IQWiG and the FJC respectively. Yet, despite a lack of controversy within the 
decision-making  institutions  and  despite  the  consideration  of  the  same  pieces  of 
evidence,  the  institutions  came  to  slightly  different  decisions  on  the  benefit  of 
Apixaban. As a result, Apixaban is a useful case to illustrate how differences in the 
rules of evidence can lead to slightly different outcomes even in the seemingly most 
straightforward cases of pharmaceutical benefit assessments. 
Table 5.2. provides an overview of the product, the dependent variable as well as 
the main issues that were considered by NICE, the FJC and IQWiG in the decision-
making process on Apixaban.  
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TABLE 5.2. – Case Study: Apixaban 
(Indicated for: Prevention of thromboembolic events (i.e. blood clots) after total hip or knee replacements) 
 
  NICE (NICE, 2012a)  FJC (G-BA, 2012b) 
Dependent variable: Outcome 
of benefit assessment 
Recommended  Different benefit appraisal for the two patient 
populations: 
-  For knee-replacement population: No additional 
benefit 
-  For hip replacement population: Marginal 
additional benefit 
Reasoning/discussions/topics 
raised/public context 
-  More clinically effective and cheaper than at least 
one comparator (Enoxaparin) 
-  Two (ADVANCE 2 & 3) out of four good quality 
RCTs comparing Apixaban with Enoxaparin 
relevant to UK clinical practice. Primary efficacy 
endpoints was a composite of all incidences of 
venous thromboembolisms (VTE), i.e. pulmonary 
embolisms, symptomatic and asymptomatic deep 
vein thrombosis (DVT) 
-  Issues with trial outcome components: Clinical 
specialists highlighted that there were limited 
data to show relationship between one of the 
major components of the composite primary 
outcome, i.e. the relationship between 
asymptomatic DVT and clinically relevant VTE. 
Appraisal Committee agreed that it was a widely 
used outcome measure and was relevant for 
consideration. 
-  Advantage of oral application 
-  Separate  consideration  for  the  two  patient 
populations  for  which  Apixaban  is  licensed 
because surgery methods and the associated risks 
are different for knee and hip replacements. 
-  Two relevant RCTs (ADVANCE 2 & 3) 
-  Issues  with  trial  outcome  components: 
Asymptomatic  deep  vein  thrombosis  (DVT)  is 
not  patient  relevant  because  in  routine  clinical 
practice  it  does  not  get  treated.  Therefore, 
endpoints  that  include  DVT  cannot  be 
considered.  Correlation  between  asymptomatic 
DVT  and  other  clinically  relevant  venous 
thromboembolisms  (VTEs)  not  demonstrated  in 
the scientific data.  
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Differences/similarities   Positive recommendation 
 
-  Accepted 2 RCTs 
-  Questioned correlation between asymptomatic 
DVT and clinically relevant VTEs, but accepted 
clinical outcomes presented by manufacturer as 
widely used outcome measures 
-  Positive recommendations even though ICERs 
were not clear but all likely under the threshold 
-  Advantages of oral treatment mentioned 
 
 Positive & negative recommendation for one of the 
two patient populations 
-  Accepted 2 RCTs 
-  Questioned correlation between asymptomatic 
DVT and VTEs, especially in relation to its 
patient relevance. Did not consider asymptomatic 
DVTs as a patient relevant endpoint. 
-  Cost effectiveness not considered 
 
-  Advantages of oral treatment not mentioned  
-  Oral hearing: Extensive discussions around the 
patient relevance of endpoints  
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5.10. Discussion 
   
Table  5.2.  shows  that  the  outcome  of  the  benefit  assessment  process  on 
Apixaban  was  positive  in  Germany  and  England.  However,  the  FJC  qualified  its 
positive appraisal in the sense that it only found an additional benefit for one of the two 
patient populations for which Apixaban is indicated, namely that of the hip replacement 
population (G-BA, 2012b). The FJC and IQWiG came to this conclusion because the 
surgery methods and associated risk for venous thromboembolisms (VTE) and deep 
vein thrombosis (DVT) are different for the two patient populations, hence they looked 
at the two populations separately and found that the statistical results of the clinical 
trials were different for the two population (G-BA, 2012b). 
It is interesting that in the case of Apixaban both NICE and the FJC accepted the 
same evidence in the form of two RCTs as being reflective of routine clinical practice 
(G-BA, 2012b; NICE, 2012a). As will be seen in later chapters, this agreement on the 
evidence base for a benefit assessment is not always the case. The records also show 
that  the  question  of  whether  one  the  main  components  of  the  composite  primary 
outcome, i.e. whether asymptomatic DVT is relevant to the occurence of VTE, was 
considered by both NICE and the FJC (G-BA, 2012b; NICE, 2012a). After hearing 
different  opinions  from  medical  experts  on  this  issue,  NICE  decided  to  accept  the 
component as part of the composite primary outcome of the clinical trial. 
The FJC heard similar contrasting opinions by medical experts, but in contrast to 
NICE it decided that, based on the criterion of patient relevance, asymptomatic DVT 
would not be considered in this appraisal (G-BA, 2012b). The FJC argued that it was 
not a patient relevant endpoint because in routine clinical practice patients would not get 
treated for an asymptomatic DVT (G-BA, 2012b, p. 6). The reasoning behind this was 
that it is only in the context of a clinical trial that one would diagnose an asymptomatic 
DVT and treat it, which means that it is not relevant to the wider patient population. 
Furthermore, IQWiG and NICE were not convinced that there is sufficient scientific 
data to suggest a correlation between asymptomatic DVT and clinically relevant VTEs. 
The case of Apixaban thus shows how HTA bodies can come to different conclusions 
on the same problem when the respective decision-making paradigm is applied. 
Theoretically the different appraisal of the patient populations in Germany could 
mean that sickness funds could negotiate a lower price for the knee replacement patient 
population because no additional benefit was found for this population. Whether this  
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would be feasible and whether it is actually done in practice is a difficult question to 
answer  as  the  price  negotiations  between  the  sickness  funds  and  pharmaceutical 
manufacturers are confidential, meaning that the public and researchers do not have 
access to the records of these meetings. However, empirical evidence gained as part of 
the interview process suggests that the price is aggregated for all patient populations 
rather than agreeing on a different price for different populations (Interviewee No. 23, 
2013, p. 7). A further implication of the FJC’s decision in the case of Apixaban could 
be that the product does not find its way into routine clinical practice because of the 
lack of additional benefit. However, while opening interesting empirical questions, this 
question is beyond the scope of this thesis. 
The case of Apixaban is a good example of how HTA paradigms are applied 
because the clinical evidence on it was comparatively straightforward, apart from the 
above  mentioned  issue  of  the  correlation  between  asymptomatic  DVT  and  VTEs. 
Moreover, outside pressures such as media involvement or patient group action were 
virtually non-existent in this case because it was uncontroversial. The costs of the use of 
Apixaban were also comparatively low. Apixaban is a case in which factors such as 
clinical  evidence, external  pressures  and cost  considerations  are  controlled for. Yet, 
despite controlling for these variables we observe a slightly different outcome on the 
dependent variable in this case. The reason for this cannot be found in clinical and cost 
effectiveness issues per se but rather in the interpretation thereof, i.e. in how the HTA 
paradigms  are  operationalised.  The  application  of  a  patient  relevant  paradigm  in 
Germany  led  to  a  slightly  more  restrictive  overall  appraisal  of  Apixaban  while  the 
application  of  the  cost  effectiveness  paradigm  in  England  led  to  a  positive 
recommendation as Apixaban was more clinically effective and cheaper than at least 
one  of  comparators  (NICE,  2012a).  In  other  words,  while  the  assessment  of  the 
weaknesses of the evidence was similar in England and in Germany, the appraisal of 
these weaknesses was different due to differing decision-making criteria. In the end, this 
led to a slightly more generous overall appraisal by NICE than by the FJC. 
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5.11. Conclusion 
 
  Before turning to a more in-depth analysis of how the English and German HTA 
paradigms are operationalised in practice, I offer a number of concluding remarks about 
what  the  previous  discussion  suggests  about  what  we  might  expect  about  HTA 
paradigms in operation. This is particularly relevant to the policy implications of HTA 
decision-making  in  that  how  paradigms  are  operationalised  plays  a  role  in  whether 
health care funding decisions are deemed to be generous or restrictive. 
  The  differences  between  the  English  and  the  German  HTA  paradigms  are 
multiple. NICE operates on a paradigm that emphasises consistency, equality and non-
discrimination. It operationalises these values by employing a ‘reference case’ that 
includes clinical and cost effectiveness, innovation, social value judgments and end-of-
life considerations as decision-making criteria (NICE, 2008). It subscribes to the idea 
that costs matter and that a balance needs to be struck between the needs of patients 
with  different  conditions.  To  this  end,  NICE’s  paradigm  contains  decision-making 
algorithms  and  thresholds,  most  importantly  in  the  form  of  ICERs,  that  provide 
guidance for stakeholders and decision-makers alike. ICERs allow for the comparison 
across disease categories in order to identify the most cost effective treatments across 
different  disease  indications  and  interventions.  Moreover,  the  English  paradigm 
specifically acknowledges that health care resources are finite and that this calls for 
transparent, fair and accountable decision-making.  
By contrast, the FJC and IQWiG operate on a paradigm that puts the concept of 
patient relevance at the heart of decision-making. This reflects a wider health care 
framework that emphasises solidarity and the right to health care treatment even when 
evidence is not conclusive or not available. Questions of costs and the balance between 
different patients’ needs are not considered, at least there is no sign of it in the statutory 
framework or methodological guidelines. In contrast to NICE, the FJC only compares 
clinical benefit categories within disease categories. The underlying rationale for this 
appears to be the belief that it would not be fair or solidaristic to compare interventions 
for patient populations with very different diseases.   
Most  importantly,  NICE  and  the  FJC/IQWiG  operate  on  different 
understandings  of  clinical  effectiveness.  In  NICE’s  case  clinical  effectiveness  gains 
meaning in relation to costs through employing the concept of the ICER. For IQWiG 
and the FJC it gains meaning in relation to the idea of patient relevance. In light of this,  
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the concept of thresholds is put to different uses. At NICE, thresholds, or ICERs, are 
used to indicate the maximum incremental cost of a medicine that NICE considers an 
appropriate use of NHS resources in relation to expected clinical benefits. At the FJC 
and IQWiG the use of thresholds is less formalised in that the operationalisation of the 
six benefit categories is not always clear. However, the operationalisation of benefit by 
means of categories suggests that there are thresholds for the maximum price that is 
justified by the expected additional clinical benefit.  
Despite the important distinction between how, and to what end, thresholds are 
operationalised in England and Germany the underlying rationale for conducting HTAs 
appears to be similar. It suggests that there is a limit to the price that a society is willing 
to pay for pharmaceutical products and that this limit is dependent on the additional 
clinical benefits that a product provides. Thresholds play an important role in this regard 
as they are a methodological expression of the aforementioned limit. This has important 
implications  for  the  framework  of  policy  paradigms.  In  the  case  of  pharmaceutical 
benefit assessments policy-makers established that there should be limits to what the 
health care system pays for a new product and that these limits should be related to the 
clinical benefits. However, neither in England nor in Germany did policy-makers define 
the nature of these limits, how they should be operationalised and where they should be 
set.  The  articulation  of  these  specifics  occurs  when  the  paradigm  is  established  in 
normal decision-making, i.e. when decision-makers conduct HTAs. Normal decision-
making  thus  serves  the  purpose  of  articulating  the  specifics  of  the  paradigm  and 
resolving tensions that it gives rise to, such as the ones discussed in section 5.4. The 
question of what this means in practice is presented in the next chapters. For now, 
suffice it to conclude that the underlying idea of the HTA paradigm in England and 
Germany  is  that  costs,  or  prices,  need  to  be  justified  by  clinical  benefits,  but  this 
underlying  idea  is  translated  into  practice  by  different  rules  and  methods,  thereby 
affecting outcomes.  
  In comparison to the FJC, which focuses on the criterion of patient relevance, 
NICE’s decision-making paradigm allows the consideration of a variety of issues and 
criteria.  The  question  arises  whether  this  leads  to  more  generous  outcomes  of 
pharmaceutical benefit assessments. Arguably, the possibility of considering multiple 
issues  when  making  decisions  would  lead  to  more  generous  decisions  as  decision-
makers  have  a  wider  array  of  argumentative  rationales  to  employ  when  making 
decisions.  However,  as  the  next  chapters  show,  this  logic  does  not  hold  true  when  
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looking at  the empirics of individual cases. This  is  mainly because of the apparent 
existence of a value core in which cost effectiveness trumps other considerations. While 
the FJC does, overall, take more negative decisions on the additional benefit of a new 
pharmaceutical product, the net result of this has little impact as it only impacts on price 
negotiations and not on the availability of the product.  
  There  are  two  further  preliminary  conclusions  I  draw  from  the  previous 
discussion. The first one is that both theory and empirics suggest that there is a core of 
values within HTA paradigms, meaning that some concepts are weighted more than 
others. For the English paradigm this appears to be the principle of cost effectiveness 
while for the German paradigm it is the principle of patient relevance. The idea of a 
value core, whilst having empirical implications, is especially relevant with regards to 
the theoretical contribution this thesis makes in that it confirms that paradigms impact 
on what is considered possible in a policy area. The identification of the relevant values, 
and their relative importance, might help in better understanding this impact.  
The second additional conclusion relates to the question of whether ideational or 
institutional variables matter when it comes to the outcome of pharmaceutical benefit 
assessment  processes.  The  above  analysis  and  the  example  of  Apixaban  show  that 
ideational  factors  such  as  conceptualisations  of  clinical  effectiveness  and  patient 
relevance play a large role when determining the outcome of pharmaceutical benefit 
assessments.  However,  the  extent  to  which  this  role  matters  when  it  comes  to  the 
availability  of  new  medicines  depends  on  the  institutional  purpose  of  HTAs.  This 
explains why a pharmaceutical product is usually still available in Germany even if the 
FJC’s decision on it was negative because HTAs are used to inform price setting. The 
institutional  construct  in England is  different  in  that a negative recommendation by 
NICE usually means that a product is not made available for routine use in the NHS. 
Interestingly though, a clinical commissioning group (CCG) could still decide to fund 
the  respective  product  even  if  its  use  is  not  recommended.  However,  the  financial 
constraints within the NHS are such that this is unlikely to happen. This shows that 
there might be situations in which a decision is institutionally possible, but politically or 
financially not feasible due to external constraints. 
In addition to a close interconnection between ideational and institutional factors 
that  determine  the  outcome  of  pharmaceutical  benefit  assessments,  the  policy 
implications  emerging  from  ideational  factors  appear  to  be  kept  in  check  by  an 
institutional construct that overrides the ideational one. This holds true for both England  
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and  Germany.  However,  this  should  not  lead  to  the  conclusion  that  institutional 
variables  are  more  significant  than  ideational  ones  in  determining  the  outcome  of 
pharmaceutical benefit assessments. As seen in this chapter, institutional constructs are 
a reflection of ideational frameworks in the form of the values that underlie the wider 
health  care  systems.  The  interplay  between  ideational  and  institutional  variables  is 
varied and complex. At times they mutually reinforce  each other, they can provide 
checks and balances to the other and they can act as overriding principles in some cases. 
This complexity is explored in the following chapters to shed further light on what 
determines the outcome of pharmaceutical benefit assessments in health care systems 
that employ formalised HTA procedures.  
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Chapter 6 
 
Policy Paradigms in Operation I: 
The Conceptualisation of Evidence 
 
6.0. Introduction 
 
This chapter marks the first of three chapters that present the empirical analysis 
of what determines the outcome of pharmaceutical benefit assessments in countries that 
employ formalised health technology assessment (HTA) processes. As such it is the 
beginning of the analysis of how HTA paradigms operate in practice, that is how they 
are  applied,  articulated  and  established  in  ‘normal’  decision-making  processes.  The 
chapter commences by summarising the themes that emerged from the data. Six themes 
emerged in total (table 6.1.) and they are presented in order of prevalence. The summary 
of the themes is followed by an in-depth analysis of case studies of pharmaceutical 
benefit assessments in order to demonstrate how the findings arise from the empirical 
data. At the end of every case study analysis an overview of the main research findings 
is  provided.  Overall,  the  empirical  evidence  suggests  that  the  outcome  of 
pharmaceutical benefit assessments is largely determined by the conceptualisation and 
interpretation  of  scientific  evidence,  which  in  turn  is  shaped  by  the  HTA  policy 
paradigm in a given health care context, thus confirming the assumption that ideational 
approaches  can  contribute  to  explaining  the  outcomes  of  pharmaceutical  benefit 
assessments. 
Following the summary of the themes that emerged during the data analysis 
process, the first part of the empirical analysis is presented in this chapter. The main 
focus is theme one (table 6.1.) as it was raised in all of the cases. It is the question of 
what constitutes appropriate evidence and how its weaknesses and strengths should be 
assessed.  The  chapter  demonstrates  that  the  way  strengths  and  weaknesses  in  the 
evidence are addressed by HTA bodies, and indeed what constitutes evidence in the first 
place, is connected to different ‘rules of evidence’ (Majone, 1989). These rules give an 
idea of what is considered relevant in a given context, thus supporting Cartwright’s and 
Hardie’s (2012) assertion that pieces of evidence can only support decision-making if 
they are relevant to the problems that decision-makers and policy-makers face.   
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Empirically, the analysis of the cases of Cabazitaxel, Eribulin and Ipilimumab 
form the centre of this chapter. They represent cases in which NICE (2012b; 2012c; 
2014c),  the  FJC  (G-BA,  2012c;  2012d;  2012e)  and  IQWiG  (2012;  2012a;  2012b) 
accepted the same evidence in the form of randomised controlled trials (RCTs). This led 
to a similar outcome in the dependent variable despite applying different HTA decision-
making criteria to the evidence. The chapter traces the substantive arguments of the 
decision-making processes in the above cases in order to compare and contrast how the 
final outcome of the benefit assessments was arrived at.  
As outlined in chapter 3, the data was analysed by employing process-tracing 
methods. The process-tracing exercise focused on tracing the reasoning processes in the 
ten embedded case studies, that is on identifying the issues, values and ideas that were 
employed by decision-makers to formulate the outcome of the benefit assessments. This 
explains the relative neglect of structural elements of the decision-making processes in 
the empirical analysis that follows. That is to say that, institutionally and structurally, 
the  step-by-step  HTA  processes  (see  chapter  4)  were  consistent  amongst  the  cases. 
Unless otherwise stated in the analysis, the reader can assume that the decision-makers 
followed the institutionally laid out procedural stages for conducting pharmaceutical 
benefit  assessments.  This  consistency  permitted  focusing  on  the  decision-making 
reasoning in order to address the research question. 
In summary, this chapter introduces the themes that emerged during the analysis. 
It then discusses the first theme (see table 6.1.) by illustrating what constitutes evidence 
in  Germany  and  England  by  reference  to  the  cases  of  Cabazitaxel,  Eribulin  and 
Ipilimumab. The discussion highlights that the ultimate decision by NICE and the FJC 
was based on the same scientific evidence. However, different decision-making criteria, 
or rules of evidence (Majone, 1989), were applied to the evidence, which in turn meant 
that different reasons for similar decisions were given. In terms of using paradigms to 
explain outcomes of pharmaceutical benefit assessments this is a significant finding in 
that it suggests that different paradigms do not, as a matter of course, lead to different 
outcomes.  
The chapter also includes the discussion of theme five (see table 6.1.), namely 
the suitability of paradigms for ‘special’ cases such as chronic diseases. This theme is 
discussed here because the questions that were raised fit with the wider questions of 
what constitutes evidence and how it should be assessed in relation to specific diseases. 
Even  though  theme  five  was  not  as  prevalent  as  the  other  themes  because  it  only  
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pertained to the cases of chronic diseases, it gives informative insights on the potential 
limits of the English and German HTA paradigms as identified by stakeholders.  Its 
discussion therefore highlights the extent to which HTA paradigms are applied flexibly 
during normal decision-making where ‘special’ cases are concerned.  
 
6.1. Empirical Results 
 
The  empirical  research  that  forms  the  basis  for  this  study  exemplifies  the 
challenges  and  controversies  that  arise  from  employing  evidence-based  measures  to 
inform decision-making in the health care context. Having examined  how decisions 
were  reached  in  ten  cases  of  new  pharmaceutical  products  that  were  assessed  and 
appraised by NICE, the FJC and IQWiG, one of the conclusions I draw is that the way 
concepts of evidence and data are understood and interpreted contributes greatly to how 
decisions on benefit assessments of products are made. The term ‘interpretation’ refers 
to the kind of criteria that is applied in the decision-making process. Discussions about 
the  appropriateness  of  data  and  the  available  evidence  feature  prominently  in  the 
publicly available assessment and appraisal documents on the ten cases. The scientific 
base  and  interpretation  thereof  was  also  a  common  theme  that  was  raised  in  the 
interviews that I conducted with stakeholders in both Germany and England. It is the 
most prevalent theme that emerges from the data and its properties and questions are 
outlined under theme one in table 6.1. 
Table 6.1.
25 provides an overview of the six themes raised in the pharmaceutical 
benefit assessment documents and stakeholder interviews. The way these themes were 
presented in the respective documents and the interviews allows inferences about what 
determines the outcome of pharmaceutical benefit assessments.  The table shows that 
most themes that were raised in the relevant documents related to questions  around 
evidence and technical problems such as whether the evidence included the right choice 
of comparator. As we shall see in this chapter, theme one relates to the permissibility, 
quality and validity of evidence. The first question that NI CE, IQWiG and the FJC 
                                                        
25 The columns on England and Germany in table 6.1. illustrate the focus and direction in which 
the themes were addressed by the respective institutions. Questions that were primarily raised 
by stakeholders such as physicians’ professional bodies are highlighted as such in the relevant 
columns. Where such highlights are lacking, it indicates that these questions were considered by 
most stakeholders, including decision-makers, rather than being limited to certain stakeholders.  
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engage  with  during  a  HTA  process  is  the  question  of  which  evidence  to  consider. 
Questions around the quality and validity of the presented evidence and whether or not 
the evidence meets the respective decision-making criteria form a substantial part of the 
benefit  assessment  processes.  The  empirical  data  suggests  that  this  holds  true  for 
England and Germany. However, the way questions are addressed and resolved differs 
in the two countries, which leads to the consideration of different evidence and helps 
explain differing assessment outcomes in some cases. In the case of Retigabine (table 
6.6.), for example, NICE appraised all of the evidence submitted by the pharmaceutical 
manufacturer whilst IQWiG and the FJC accepted none of the evidence on the basis that 
none of the presented studies compared Retigabine with the appropriate comparator. 
 Themes two, three and four – the choice of comparator product, the patient 
population subgroup divisions and the operationalisation of criteria for HTA decision-
making and the role of algorithms - could have been discussed as sub-themes of theme 
number one as they are all related to evidential questions. These evidential questions 
focused  on  whether  appropriate  comparators  (theme  two)  and  subgroup  populations 
(theme three) were identified in the evidence and how study results on these should be 
interpreted  (theme  four).  They  constituted  distinct  and  in-depth  discussions  in  the 
appraisal documents and their importance was also highlighted by stakeholders who 
were interviewed. This warrants for a discussion of themes two-four in their own right, 
which is presented in chapter 7.  
Theme  five  (the  suitability  of  paradigms  for  ‘special’  cases  such  as  chronic 
diseases) and theme six (political power and pressures) did not feature in every case, but 
only in the cases of Retigabine and Fingolimod (table 7.1.), and Abiraterone (table 8.1.) 
and Fingolimod respectively. However, they raised a sufficient number of noteworthy 
points about paradigms that merit their discussion as separate themes in this chapter and 
chapter 8. Whilst themes one-four are similar in that they centre on evidential questions, 
the emergence of themes five and six seems to suggest that there are cases in which the 
dominant, or the emerging dominant, HTA paradigm might be challenged, or might not 
provide satisfactory answers in the light of the nature of some cases. For example, in the 
case of Retigabine and Fingolimod the suitability of the dominant paradigm was called 
into  question  because  of  the  chronic  nature  of  epilepsy  and  multiple  sclerosis 
respectively, which, according to some stakeholders, means that the benefits of these 
drugs should not be assessed by the same standards as non-chronic conditions.   
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Despite the differences in the institutional design of evidence-based measures to 
inform  pharmaceutical  coverage  decisions  in  England  and  Germany,  controversies 
around the above themes exist in both countries. Moreover, they appear to be played out 
anew in every new case, sometimes more, sometimes less controversially. England’s 
and Germany’s HTA systems thus exhibit an interesting similarity in that controversies 
around what constitutes good science and good evidence are occurring. According to 
Majone this is because:  
 
When the issues under discussion require complex patterns of reasoning and 
large  amounts  of  data  of  doubtful  reliability  and  relevance,  explicit  rules  of 
evidence become particularly important (Majone, 1989, p. 10).  
 
 
The so-called ‘rules of evidence’ (Majone, 1989) include distinctions between different 
forms of evidence such as in “[…] the judicial law of evidence with its sophisticated 
distinctions among proofs of facts, testimony, hearsay, presumptions […]” (Majone, 
1989, p. 10). As shown in the following sections, the content of the controversies in the 
institutionalised  HTA  arenas  in  England  and  Germany  differ  from  each  other  in 
substance, but they have in common that they  are controversies  about  the ‘rules of 
evidence’  that  Majone  (1989)  ascribes  a  great  importance  to  in  the  policy  analysis 
process.   
The  empirical  examples  highlight  the  similarities  and  differences  of  the 
controversies about science and evidence in England and Germany. The fact that such 
controversies exist, albeit in different formats, suggests that the conceptualisation and 
operationalisation of evidence is an important factor that determines the decision on the 
price  (in  Germany)  and  on  the  availability  (in  England)  of  a  new  pharmaceutical 
product. The controversies are not unique to HTA systems that are relatively new, nor 
do they seem to be fully resolved in countries that introduced HTA systems over a 
decade ago, despite their constant re-developments. This suggests that HTA paradigms 
are not static, but are confirmed and articulated anew in every decision-making case. 
Evidence, even the ‘same’ evidence in the form of RCTs, is not interpreted in the same 
way in different contexts. How it is interpreted depends on the institutional context in 
which it is interpreted as well as on the values and principles that are embedded therein.   
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TABLE 6.1. - Themes Emerging from the Data (Ranked in order of Prevalence) 
 
Themes 
 
Properties/questions of the theme in England  Properties/questions of the theme in Germany 
1.  Permissibility, quality and 
validity of evidence 
  What is accepted as evidence?  
  Evidence applicable to UK clinical practice? 
  What  does  the  evidence  say  about  the 
product?  
  Does it meet the decision-making criteria? 
  What is accepted as evidence? 
  Does  the  available  evidence  reflect  marketing 
authorisation and clinical guidelines? 
  What does the evidence say about the product? 
  Are  the  presented  clinical  endpoints  patient 
relevant? 
2.  Choice of comparator product    Is the choice of comparator reflective of UK 
clinical practice? 
  Is the choice of comparator reflective of the current 
standard alternative? 
3.  Patient population subgroup 
divisions 
  Do the subgroup divisions adequately reflect 
the  patient  groups  likely  to  receive  the 
treatment in routine clinical practice? 
  Do  the  subgroup  division  adequately  reflect  the 
patient  population(s)  for  which  the  product  is 
licensed? 
4.  Operationalisation of criteria 
for HTA decision-making and 
role of algorithms 
  Algorithm  is  applied:  Cost  effectiveness 
threshold  in  terms  of  incremental  cost 
effectiveness  ratio  (ICER)  per  quality-
adjusted life year (QALY) 
  What is the algorithm for categorisation of added 
benefit applied by IQWiG in assessment process? 
  Algorithm  applied  by  the  FJC  not  transparent 
(stakeholder opinion). 
5.  Suitability of paradigms for 
‘special’ cases such as 
chronic diseases 
  How  to  make  decisions  in  cases  where 
natural progression of the disease is uncertain 
and patients live with the illness for a long 
time? 
  Questions  around  the  applicability  of  patient 
relevant  endpoints  such  as  mortality  in  disease 
indications where natural progression of the disease 
is uncertain and patients live with the illness for a 
long time (stakeholder opinion) 
6.  The question of political 
power and influence: Public 
pressure and the distribution 
of bargaining power of 
stakeholders 
  What is the effect of public pressure in the 
form of media and patient campaigns on the 
final result of HTAs? 
  Does  the  differential  distribution  of  bargaining 
power of stakeholders impact on the final result of 
HTAs? (stakeholder opinion)  
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The presence of similar controversies about the rules of evidence in Germany 
and England highlights the pivotal role evidence plays in determining pharmaceutical 
coverage decisions. The substantive differences in the controversies highlight that this 
pivotal role should not be equated with the assumption that the same evidence means 
the same thing to everybody concerned. The ten case studies embedded in this thesis 
exemplify how the same evidence can be interpreted differently in different contexts, 
thus giving rise to varying degrees of comparable outcomes in the ultimate decisions. 
 
6.2. Theme One: Permissibility, Quality and Validity of Evidence 
 
  One  of  the  reasons  why  the  case  of  HTAs  of  pharmaceuticals  lends  itself 
particularly well to a comparison of what determines their outcome is that its evidence 
base is, broadly speaking, comparable. The evidence base in HTA processes is usually 
the  same  as  that  used  in  the  process  of  acquiring  a  license  under  the  centralised 
procedure  of  the  European  Medicines  Agency  (EMA)
26. This includes randomised 
controlled trials (RCTs). In contrast to other policy areas such as the environment where 
regional environmental impact studies ahead of a policy proposal hold a very localised 
character, the evidence base of new pharmaceutical products is largely the same when it 
enters  national  HTA  structures.  Thus,  when  exa mining  how  decisions  on  benefit  
assessments are reached one can control for the variance in evidence and assume that 
observed differences or similarities are the outcome of other factors . As will be seen, 
what counts as evidence in the first place and how it is interpreted depends on the  
dominant national HTA paradigm.  
One of the first and most important steps in assessing and appraising a ne w 
pharmaceutical product is the critical assessment of the available evidence in order to 
decide whether it offers answers to the relevant paradigmatic decision questions. This 
process involves making decisions about which patient populations the medicine  is 
indicated for, which patient population it is likely to be used in, what the current 
treatment alternatives are and what issues need to be resolved during the appraisal 
process. The ability of an HTA body to answer the questions it has set itself depends on 
the evidence  that  is  presented by  the pharmaceutical  manufacturer .  The  Evidence 
Review Group (ERG) at NICE, and IQWiG as a body that is commissioned to carry out 
                                                        
26 See chapter 4 for an outline of how the licensing process works.  
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assessments by the FJC, look at different features of the evidence in order to decide a) 
whether the evidence available provides answers to the questions one is interested in, 
i.e.  by  being  of  good  quality  and  comparing  the  product  with  the  ‘right’  treatment 
alternative,  b)  if  yes,  what  the  results  presented  in  the  evidence  suggest  about  the 
product and c) how to proceed if the evidence is not powered to provide answers to the 
relevant questions.  
One of the first tasks of an assessment group is thus to decide which evidence is 
permissible in the first place. This is necessary because there are different types of 
evidence  ranging  from  clinical  trials  to  observational  studies  or  patient  surveys. 
Scientifically speaking, the type of evidence has an impact on the certainty with which 
one can assume that the observed outcome under the new treatment is a direct result of 
the treatment rather than of exogenous factors. In clinical settings RCTs are assumed to 
be the most valid path for demonstrating the causality of a desired treatment outcome. 
In designing RCTs one tries to control for as many patient characteristics as possible in 
order to, ideally, compare two identical patient groups, with one receiving the medical 
intervention  one  is  interested  in  and  the  other  receiving  a  placebo  or  a  comparator 
product (NICE, 2014b). Other forms of evidence such as patient surveys, observational 
studies or indirect comparisons give rise to more challenges in that they are open to 
bias, subjectivity and methodological weaknesses. The paradigmatic decision on which 
evidence  is  acceptable  to  a  HTA  body  is  vital  in  understanding  differences  and 
similarities in the outcome of pharmaceutical benefit assessments. 
Before exploring the empirical examples of how NICE and the FJC appraise the 
same evidence, a brief overview of what the methodological guidelines say about the 
permissibility of evidence is helpful to provide a backdrop against which to understand 
the analysis. The main points of this overview are presented in table 6.2. In terms of 
permissibility of evidence, the FJC and NICE have in common that they subscribe to a 
‘hierarchy of evidence’ that is frequently found within HTA structures. According to 
NICE: “Study types [are] organised in order of priority, based on the reliability (or lack 
of potential bias) of the conclusions that can be drawn from each type” (NICE, 2014b).  
For the appraisal of pharmaceuticals this means that both the FJC and NICE 
have expressed their preference for direct head-to-head clinical trials which take the 
form of RCTs (NICE, 2008, p. 15; G-BA, 2013). However, the rigour by which the FJC 
and NICE subscribe to the supremacy of RCTs differs. The NICE Guide to Methods of 
Technology Appraisal states that:   
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Non-RCT, both experimental and observational, evidence will be required, not 
just for those situations in which RCTs are unavailable, but also to supplement 
information from RCTs when they are available. The problems of confounding, 
lack of blinding, incomplete follow-up […] will usually be much worse on non-
randomised studies than in RCTs. But in some circumstances, evidence from 
those studies will be needed in addition to RCT data […]. In the absence of valid 
RCT  evidence,  evidence  from  studies  least  open  to  bias  will  be  considered 
preferentially with reference to the inherent limitations of the specific design 
(NICE, 2008, p. 16). 
 
This  excerpt  of  the  NICE  Guide  to  Methods  of  Technology  Appraisal  signals  the 
preferential  use  of  RCTs  as  an  evidence  base  whilst  not  excluding  the  potential 
contribution from non-RCT evidence despite the “limitations” (NICE, 2008, p. 16) that 
such data might bring with it.  
In Germany, the FJC divides evidence into seven different levels in its Rules of 
Procedure, namely: 
 
1.  I a systematic reviews of studies of evidence level I b 
2.  I b randomised controlled studies 
3.  II a systematic reviews of evidence level II b 
4.  II b prospective comparative cohort studies 
5.  III retrospective comparative studies 
6.  IV Case series and non-comparative studies 
7.  V  Associative  observations,  […],  descriptive  representations,  single  case 
reports,  expert  opinions  not  underlined  by  studies,  […],  reports  of  experts 
committees (G-BA, 2013, p. 94)
27. 
 
The FJC further specifies:  “[…] if it is impossible to carry out studies at the highest 
level of evidence, then the best available evidence level must be accepted […]” (G-BA, 
2013, p. 94). Adding to this, IQWiG explains that the basis of a benefit assessment is 
the proof of causality – i.e. the benefit experienced by the patient when taking a new 
medicine  is  caused  by  him/her  taking  this  medicine  and  not  by  other  confounding 
factors – which is why, most of the time, RCTs will be considered the only studies that 
are powered to show this causality (IQWiG, 2008, p. 12). The rigorous division into 
seven evidence levels with the specification that the lower ranking level of evidence 
will be considered in the absence of the highest ranking evidence indicates that the 
hierarchy of evidence in Germany is operationalised much more as a categorical matrix 
in which the evidence levels are viewed as separate from each other and impermeable 
                                                        
27 Translation provided by the author of this study.  
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between the levels.  In contrast, NICE’s operationalisation of the evidence hierarchy 
indicates that evidence levels are more permeable and viewed as contributing to each 
other, notwithstanding the general preference for RCTs. Thus, while the emphasis in 
terms of what constitutes evidence, or at least good-quality evidence, lies on RCTs in 
both Germany and England, the above remarks offer a first insight into the rigour by 
which the preference for RCTs is applied and to what extent other forms of evidence are 
permissible. 
Even when HTA systems stipulate a preference for RCTs one has to look closely 
to understand the extent to which this preference is followed and what other evidence 
might  be  permitted.  In  Germany  the  adherence  to  RCTs  as  the  ‘gold  standard’  of 
pharmaceutical  benefit  assessment  seems  to  be  very  strict,  with  IQWiG’s  General 
Methods specifying that the highest level of certainty in a study (i.e. proof of one of the 
six categories of additional benefit) can only be reached if two RCTs of comparable 
good quality show similar results on clinical data (IQWiG, 2011a). In contrast, a similar 
requirement in terms of the number of RCTs needed to  attain comparable certainty 
cannot be found in NICE’s Guide to Methods of Technology Appraisal. NICE instead 
labels views by patients and experts as ‘evidence’ (NICE, 2008, pp. 17-19) which in 
turn suggests a wider permissible remit in what constitutes evidence.  
 
6.2.1. Permissibility of other Types of Evidence 
 
The preceding analysis gives rise to the question of what happens in cases in 
which the available evidence is of poor quality or not considered suitable under a given 
paradigm. In other words, the question arises whether and what types of other evidence 
are permissible under a given paradigm when the available evidence  does not  yield 
answers to the questions posed within the respective decision-making paradigms. The 
principle of the ‘hierarchy of evidence’ that is present in the methods guidelines for all 
three institutions examined here would suggest that evidence of the next highest ranking 
is sought when evidence of the highest ranking is insufficient or unavailable. However, 
in  practice  the  hierarchy  of  evidence  is  adhered  to  differently  by  different  HTA 
institutions, which suggests that contrasting rules of evidence are at play.  
Beyond the operationalisation of certain types of evidence such as RCTs, the 
permissibility  of  other,  lower-ranking,  types  of  evidence  plays  an  important  role  in 
determining pharmaceutical coverage decisions.  This comes back to the question of  
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what is regarded as appropriate and good-quality evidence. As outlined above, RCTs 
are  preferred  by  IQWiG,  the  FJC  and  NICE  alike.  Beyond  this,  NICE’s  Guide  to 
Methods of Technology Appraisal (NICE, 2008) and its assessment documents suggest 
it is more open to recognising additional and alternative sources of evidence such as 
patient and clinical expert opinions. NICE (2008) goes considerable lengths to explain 
why  patient  and  clinical  expert  views  can  and  should  be  considered  as  evidence. 
According to NICE,  
 
patient  evidence  can  include  views,  assessments,  evaluations  of  individual 
patients,  individual  carers,  groups  (such  as  groups  of  patients,  carers  or 
voluntary organisations that represent patients). […] Patient evidence refers to 
any  information  originating  from  patients  and/or  carers  that  may  inform  the 
appraisal of a technology […]. […] Patients are a [...] unique source of expert 
information about the personal impact of a disease and its treatment which can 
[…] enable the realistic interpretation of clinical and economic data […]. Patient 
evidence  can  identify  limitations  in  the  published  research  literature;  in 
particular, the failure to capture the true concerns of individual patients related 
to  HRQL over and above measurements  using  standardised instruments […]  
(NICE, 2008, p. 22).  
 
The fact that NICE labels the views and statements by patients and other experts as 
evidence offers an indication of the permissibility of these views to inform the decision-
making of the  Appraisal  Committee. Thus, while RCTs are preferred,  patients’ and 
clinicians’  views  are  heard  and  considered  on  a  case-by-case  basis  within  NICE’s 
decision-making paradigm.  
A similar regard for patient and clinical  expert views as  evidence  cannot be 
found  in  IQWiG’s  assessment  documents  and  methodology  papers  or  the  FJC’s 
guidelines.  The  General  Methods  of  IQWiG  highlight  that  the  basis  for  a  benefit 
assessment is the proof of causality (IQWiG, 2011a, p. 8), i.e. the scientific proof that 
an improvement or change of a patients’ well-being is caused by the medicine that is 
undergoing  assessment.  Since  RCTs  are  the  most  reliable  source  of  demonstrating 
causality they are considered the highest form of evidence in IQWiG’s decision-making 
paradigm (IQWiG, 2011a). Patients are invited to submit their views in the form of 
answers to a questionnaire (IQWiG, 2011a), but the assessment documents analysed as 
part of this thesis do not give insight into how this views are being considered. As we 
shall see in the next chapter, in Germany a benefit appraisal hinges on the so-called 
patient relevant endpoints that need to be included in a clinical trial and that need to 
show significant effects in order for a new pharmaceutical to be categorised as offering  
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a significant added benefit. The Ordinance for Assessing the Benefit of Pharmaceuticals 
(Verordnung über die Nutzenbewertung von Arzneimitteln nach § 35a Absatz 1 SGB V 
für Erstattungsvereinbarungen nach § 130b SGB V, AM-NutzenV) specifies that: 
 
the  benefit  of  a  pharmaceutical  is  the  patient-relevant  therapeutic  effect,  in 
particular in respect of the improvement in the state of health, the reduction of 
the duration of the disease, longer survival, the reduction of side-effects or an 
improvement in quality of life (BMJV, 2011).  
 
The requirement for patient relevance is firmly anchored in how IQWiG and the 
FJC  operationalise  clinical  effectiveness  results,  namely  by  assessing  only  those 
endpoints that are deemed patient relevant. Even thought the phrase ‘patient relevance’ 
gives rise to connotations of patient preference, it should not be equated with the latter. 
Indeed, it is one of the more puzzling elements of the German pharmaceutical benefit 
decision-making paradigm that what is considered relevant by the patients is not always 
considered as patient relevant under the decision-making framework. An interviewee 
describes patient relevance in the following way: 
 
[…] we would be interested in what the patients notice, what do the patients 
feel? This means […] that everything that is connected to morbidity is patient 
relevant, everything that is connected to side effects […] is patient relevant […]. 
[…] there are surely things that the patients feels but where we would say […] 
this is not a medical problem […] there was the discussion about the insulin 
analogues and the question whether […] they are easier to take […] here I would 
say […] the patients feel this but it is nothing that is allowed to lead to costs in 
the SGB V […] (Interviewee No. 23, 2013, p. 5). 
 
  The benefit assessment in Germany is so closely tied to the requirement for 
showing patient relevance that it seems to override other potential considerations as 
well as the possibility of permitting other levels and sources of evidence when RCTs 
cannot provide answers to the questions sought. The default position of IQWiG and, 
albeit to a lesser extent, of the FJC seems to be the idea that if a RCT cannot provide 
statistically significant patient relevant endpoint results, then other forms of evidence 
such as indirect comparisons, patient and expert views can definitely not produce the 
missing information or proof of added benefit, hence the benefit will not be proven or it 
will be considered ‘non-quantifiable’.  It  seems  to  result in  a situation in which the 
patient relevance of a clinical effectiveness study is a prerequisite for other forms of 
evidence  to  be  considered.  Thus,  when  reading  the  assessment  documentation  of  
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IQWiG and the FJC we find ourselves immersed in detailed discussions about whether 
endpoints are patient relevant or not.  
Prominent  examples  of  a  discussion  of  patient  relevance  are  the  cases  of 
Telaprevir  (IQWiG,  2012c)  and  Boceprevir  (IQWiG,  2011b)  in  which  IQWiG  was 
reluctant to accept the patient relevance of the main clinical endpoint, namely sustained 
virological response (SVR) because, as IQWiG argued, it is a laboratory endpoint that 
does not give rise to meaningful conclusions about the effect on individual patients. 
This position was met with fierce criticism by clinical experts who pointed out that SVR 
is a worldwide accepted endpoint in hepatitis C and that it was internationally accepted 
that a SVR equated to healing the patient from his/her infection (G-BA, 2012a). 
The principle of patient relevance is worthy of a discussion in its own right in a 
later chapter of this thesis. For the purposes of this chapter it is important to recognise 
that  patient  relevance  in  Germany  is  closely  connected  to  the  decision-makers’ 
operationalisation of clinical effectiveness, which offers striking differences to other 
HTA decision-making paradigms. This is a further indication for the hypothesis that 
what is considered as evidence and what types of evidence are permitted in the first 
place is closely interwoven with how elements of HTA frameworks such as clinical and 
cost effectiveness are conceptualised and operationalised in a given health care context. 
The values, principles and priorities of a given health care system and the society that 
benefits  from  its  services  are  embedded  in  the  HTA  systems  that  policymakers 
construct, thereby giving rise to the different rules of evidence outlined in this chapter.  
In  the  following  section  I  introduce  the  cases  of  Cabazitaxel,  Eribulin  and 
Ipilimumab as cases in which, on balance, the same evidence in the form of RCTs was 
accepted by NICE, the FJC and IQWiG. Despite slightly different foci in the appraisal 
discussions the institutions came to broadly similar conclusions about the evidence that 
was presented. 
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TABLE 6.2. – Permissibility of Evidence and the Hierarchy of Evidence 
 
What constitutes 
evidence? 
NICE  FJC/IQWiG 
1. Hierarchy of 
evidence 
Preference for randomised 
controlled trials (RCTs) 
Preference for randomised 
controlled trials (RCTs) 
2. In the absence of 
good-quality RCT 
data/permissibility of 
other forms of 
evidence 
  “[…] evidence from 
studies least open to 
bias will be 
considered […]” 
(NICE, 2008, p. 16) 
  Non-RCT evidence 
allowed 
  Other forms of 
evidence permitted, 
i.e. patient and expert 
views also labeled 
evidence (NICE, 
2008, pp. 17-19) 
  “[…] best available 
evidence level must 
be accepted […]” 
(G-BA, 2013, p. 94) 
  In theory other forms 
of evidence 
permitted, in practice 
this is difficult to 
implement due to 
criteria of proof of 
causality and patient 
relevance 
3. Hurdles/thresholds  Clinical effectiveness 
essential but positive 
recommendation depends on 
cost effectiveness as 
expressed in incremental 
cost effectiveness ratios 
(ICERs) 
Positive benefit assessment 
hinges on results of patient 
relevant endpoints 
 
6.3. Theme One: The Cases of Cabazitaxel, Eribulin and Ipilimumab 
 
  The cases in which NICE, the FJC and IQWiG came to different assessment 
decisions constitute a large part of this thesis as they provide insights into how the 
different  paradigms  are  operationalised.  However,  the  cases  in  which  the  HTA 
organisations  came  to  broadly  similar  conclusions
28 about a product offer equally 
rewarding opportunities to learn about how paradigms are applied in practice. This 
became clear during the process of tracing how and why the final decisions on the same 
pharmaceutical products were made in England and Germany. The process gave rise to 
the observation that a similar assessment of the weaknesses and strengths of a particular 
evidence base can result in similar decisions on the benefit of a product even if different 
                                                        
28 For comparative purposes ‘broadly similar conclusions’ are conceptualised as either positive 
or negative recommendations. This means that the benefit categories ‘major, significant and 
marginal’ additional benefit within the German HTA paradigm are operationalised as positive 
recommendations, whereas the lower three benefit categories are operationalised as negative 
recommendations. More details on this can be found  in chapter 3.  
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decision-making  criteria,  or  rules  of  evidence,  are  applied.  This  was  the  case  for 
Cabazitaxel, Eribulin and Ipilimumab. The reason for this seems to lie with the extent of 
the certainties or uncertainties that a particular piece of evidence gives rise to. That is to 
say that the quality of evidence and the resulting outcomes (both negative and positive) 
might be so convincing or uncontroversial that applying different paradigmatic criteria 
to  the  evidence  will  not  make  a  difference  in  determining  the  final  outcome.  This 
suggests that the good quality or poor quality of a form of evidence can be so extensive 
that the paradigms that are applied to it do not play a big role. 
Before explaining the above in more detail, an overview of the outcome of the 
dependent variables in the mentioned cases, the salient issues that were raised as well as 
the main differences and similarities in the appraisal between NICE and the FJC/IQWiG 
is presented in tables 6.3.-6.5. 
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TABLE 6.3. – Case Study: Cabazitaxel (NICE, 2012b; G-BA, 2012c; IQWiG, 2012) 
(Indicated for: Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen) 
 
  NICE  FJC 
Dependent 
variable: 
Outcome of 
benefit 
assessment 
Not recommended (Negative outcome)  Different benefit appraisals for two different patient populations 
(Negative outcome overall): 
-  Best-supportive care population: Indication for marginal 
additional benefit 
-  Docetaxel-re-therapy population: No additional benefit 
substantiated 
Reasoning/discus
sions/topics 
raised/public 
context 
-  Uncertainty about robustness of ICER 
-  ICER too high at £87,500/QALY 
-  Effective, life-extending treatment but too much 
additional weight would have to be put on QALYs to 
make it an appropriate use of NHS resources 
-  1 RCT (TROPIC) 
-  Major concerns around adverse effects 
-  Following consultation on the appraisal consultation 
document (ACD) the manufacturer provided additional 
evidence to justify utility values for stable and progressive 
disease 
-  Transferability of study results to clinical practice was 
questioned (patients have more co-morbidities and are older 
in reality) 
-  Data missing for docetaxel-retherapy population 
-  Additional benefit (in endpoint of overall survival) yes, but 
have to be weighed against severe side effects  
-  No health-related quality of life (HRQoL) data available = 
problematic (IQWiG, 2012, p. 48) 
-  Discussion about division of patient population 
-  Operationalisation of categorisation thresholds unclear (G-
BA, 2012c, p. 121) 
Similarities in 
assessment & 
appraisal 
-  Accepted the same RCT (TROPIC) 
-  Overall survival improvement statistically significant 
-  Major concern was adverse effects (NICE, 2012b, p. 35) 
 
-  Considerable uncertainty about utility values used in cost 
effectiveness model because HRQoL not available 
-  Accepted the same RCT (TROPIC) 
-  Overall survival improvement statistically significant 
-  Major  concern  was  adverse  effects,  these  were  weighed 
against endpoint of overall survival which in turn led to a 
lower benefit category 
-  Considerable weakness that HRQoL data was not available 
Differences in 
assessment & 
appraisal 
-  Accepted progression free survival as secondary endpoint 
-  Questions of equality between prostate cancer and breast 
cancer patients were raised by patient groups 
-  Manufacturer appealed the decision: Appeal was rejected 
 
-  Did not accept progression free survival as a patient relevant 
endpoint 
-  Questions of the categorisation of added benefit were raised. 
Cabazitaxel  initially  received  the  same  categorisation  of 
added  benefit  as  Abiraterone  despite  having  more  adverse 
effects.  
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TABLE 6.4. – Case Study: Eribulin (NICE, 2012c; G-BA, 2012d; IQWiG, 2012a) 
(Indicated for: The treatment of locally advanced or metastatic breast cancer) 
 
  NICE  FJC 
Dependent variable: 
Outcome of benefit 
assessment 
Not recommended (Negative outcome)  Different benefit appraisals for two different 
patients populations (Negative outcome overall):  
-  For patients who cannot be re-treated with 
regimens containing taxane or anthracycline 
(different types of chemotherapies): Hint of 
a marginal additional benefit 
-  For patients who can be re-treated with the 
other chemotherapies: Additional benefit 
less than that of the appropriate comparator 
because of more significant harmful adverse 
effects 
Reasoning/discussions/to
pics raised/public context 
-  ICER of £68,600/QALY likely to be underestimated because of 
concerns over toxicity profile 
-  Less well tolerated than comparators 
-  No HRQoL collected = important omission 
-  Manufacturer’s model underestimated costs and disutilities of 
adverse effects 
-  End-of-life criteria not met, overall survival gain less than 3 months 
-  Manufacturer handed in a patient access scheme (PAS) at the 
beginning of the process 
-  Small number of patients contained in the subgroup analyses of the 
clinical trial = clinical data in support of Eribulin unconvincing  
-  Higher risk of severe adverse effects than 
with the comparator 
-  Overall survival gain: yes, but no HRQoL 
data, hence lower benefit category 
-  Uncertainty due to the fact that only one 
clinical study is available and this included 
a small number of patients 
Similarities in assessment 
& appraisal 
-  Accepted the same RCT (EMRBACE) 
-  Concerns over toxicity profile were high 
-  No HRQoL data = important omission 
-  Accepted the same RCT (EMBRACE) 
-  Concerns over toxicity profile were high 
-  No HRQoL data = important omission 
Differences in assessment 
& appraisal 
-  Patients acknowledged there were concerns over side effects and the 
lack of HRQoL 
-  Manufacturer appealed the decision: Appeal was rejected 
-  Doctors very skeptical about the benefit of 
Eribulin  
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TABLE 6.5. – Case Study: Ipilimumab (NICE, 2014c; G-BA, 2012e; IQWiG, 2012b) 
Indicated for: Previously treated advanced (unresectable or metastatic) melanoma 
 
  NICE  FJC 
Dependent  variable:  Outcome 
of benefit assessment 
Recommended (Positive outcome)  Significant additional benefit (Positive outcome) 
Reasoning/discussions/topics 
raised/public context 
-  ICER £28,600-£47,900/QALY 
-  Initially not recommended 
-  End-of-life  criteria  met:  It’s  a  life-extending 
end-of-life treatment 
-  Manufacturer  submitted  a  patient  access 
scheme (PAS) 
-  Treatment  associated  with  long-term  survival 
for a small number of patients, but no patient 
characteristic or biomarkers can be identified 
to identify these patients prospectively 
-  Appraisal  Committee:  Innovative  therapy 
because  of  few  advances  in  the  area  of 
melanoma  in  recent  decades;  currently  the 
treatment option for these patients is enrolment 
in  clinical  trials.  Significant  innovation  for  a 
disease with a high unmet clinical need 
-  Clinicians:  this  is  a  step-change,  first  new 
treatment  in  30  years  that  may  offer  clinical 
benefit and possible long-term survival gain 
-  Stakeholders opinions in hearings: This is an innovative 
therapy  which should  be recognised.  Innovative  in the 
sense  that  its  mode  of  action  is  new  in  that  it  is  an 
immunotherapy  that  does  not  directly  impact  on  the 
tumour but on the immune system’s ability to fight it. 
Special  situation  in  that  there  is  a  lack  of  available 
alternatives for the patients. 
 
Similarities  in  assessment  & 
appraisal 
-  Overall survival benefit significant, provides at 
least  an  additional  3  months  compared  with 
current NHS treatment 
-  Overall survival benefit is a significant improvement to 
currently  available  treatment  alternative  of  ‘best-
supportive care’ 
Differences  in  assessment  & 
appraisal 
-  Focused  on  innovation  as  a  justification  for 
recommending  a  treatment  whose  ICER  is 
higher than that usually considered acceptable 
within NICE’s paradigm 
-  Innovation not specifically mentioned 
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6.3.1. Discussion 
   
Tables  6.3.-6.5.  show  that  only  Ipilimumab  for  previously  treated  advanced 
(unresectable,  i.e.  not  operable,  or  metastatic)  melanoma  received  a  positive 
recommendation by both NICE and the FJC. In the cases of Cabazitaxel and Eribulin 
the appraisals were negative despite FJC’s decision to assign a marginal benefit to one 
of two patient subgroups in both cases. Since the ‘marginal benefit’ category is the 
lowest of the positive benefit categories in Germany and the appraisal for the second 
patient population was very low in both cases (i.e. in Eribulin’s case the benefit for the 
second  patient  population  was  less  than  the  appropriate  comparator),  we  observe  a 
situation  in  which  both  NICE  and  the  FJC  came  to,  broadly  speaking,  similar 
conclusions  about  the  available  evidence  despite  applying  different  criteria  to  the 
evidence. 
  Cabazitaxel and Eribulin represent new chemotherapies for metastatic prostate 
cancer and breast cancer respectively. In both cases NICE (2012b; 2012c) and the FJC 
(2012c; 2012d) accepted the same RCT as the available evidence. The assessment of the 
weaknesses of the evidence presented in the RCTs was similar in both cases and for 
both institutions. In both cases there was significant concern around the adverse effects. 
This, along with the lack of health-related quality of life (HRQoL) data, made a positive 
appraisal  of  the  two  substances  challenging.  Even  though  both  NICE  and  IQWiG 
accepted  that  the  overall  survival  improved  when  patients  received  treatment  with 
Cabazitaxel and Eribulin respectively, the extent of overall survival was not deemed 
significant enough to justify a positive appraisal because the uncertainties as well as the 
incidences of adverse effects outweighed the overall survival benefit.  
NICE and the FJC justified their decisions on Cabazitaxel and Eribulin in the 
context of their HTA paradigms. For NICE this meant that although an overall survival 
benefit was acknowledged, the threshold for a positive recommendation within the cost 
effectiveness paradigm was not met. In the case of Eribulin the Appraisal Committee at 
NICE stated that the ICER for Eribulin: 
 
[…] was regarded as a significant underestimate because the concerns about the 
toxicity profile of eribulin, the uncertainties about health-related quality of life, 
[…] the use of generic prices to estimate the price of comparators […] would 
result in a further increase in the ICER per QALY gained […] (NICE, 2012c, p. 
43).   
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That  is  to  say  that,  in  addition  to  concerning  toxicity  profiles,  at  ICERs  of 
£68,500/QALY for Eribulin and £87,500/QALY for Cabazitaxel, the increase in overall 
survival was not enough to justify the recommendation of the two substances. 
In the context of the German paradigm of patient relevance, the endpoints of 
overall survival and adverse effects were accepted as being patient relevant. However, 
because IQWiG and the FJC operationalise the paradigm by aggregating the results of 
all endpoints including those of the adverse effects, IQWiG (2012; 2012a) and the FJC 
(2012c;  2012d)  came  to  the  conclusion  that  the  benefit  in  overall  survival  was 
outweighed by the risk of severe adverse affects. In summary, Eribulin and Cabazitaxel 
represent cases in which NICE and the FJC came to similar conclusions about what the 
evidence  says  about  the  products,  but  justified  the  resulting  negative  decisions  by 
employing the standards of their decision-making frameworks.  
Ipilimumab  is  a  cancer  treatment,  currently  indicated  for  previously  treated 
advanced and non-operable melanoma, that works by activating the immune system to 
fight cancer cells. In this sense it is different from Cabazitaxel and Eribulin, both of 
which are chemotherapies that do not work in such a manner. Ipilimumab received a 
positive appraisal by both NICE and the FJC, mainly due to the fact that the clinical trial 
showed a statistically significant overall survival benefit for patients on Ipilimumab and 
the adverse reactions were considered manageable and tolerable. In comparison to the 
evidence  presented  in  the  cases  of  Cabazitaxel  and  Eribulin,  there  were  less 
uncertainties and both HTA bodies were satisfied that the adverse reactions did not 
outweigh the gain in overall survival. The Appraisal Committee at NICE also concluded 
“[…] that there was an unmet need for effective therapies in this patients population” 
(NICE, 2014c, p. 27).  
What is interesting about Ipilimumab as a case study is that when Ipilimumab 
was introduced to the market patients with previously treated advanced melanoma had 
little to no treatment alternatives. Both in England and in Germany patients were treated 
according to so-called best-supportive-care regimens, i.e. treatments used in palliative 
settings in order to alleviate pain. Alternatively, patients had the option of enrolling in 
clinical trials in the hope of gaining a few months of life expectancy. In the meantime 
another treatment called Vemurafenib for the group of patients for which Ipilimumab is 
indicated  entered  the  market.  However,  at  the  time  at  which  this  analysis  was 
undertaken,  there  was  a  distinct  lack  of  alternative  treatments.  This  lack  of  viable 
treatment alternatives, along with the severity and low life expectancy of the disease,  
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arguably  contributed  to  a  situation  in  which  the  decision-makers  in  Germany  and 
England were able to recommend Ipilimumab, despite it, for example in England, being 
over the usually accepted cost effectiveness threshold. Again, this is a different situation 
from the one observed in the cases of Cabazitaxel and Eribulin in that there are viable 
treatment  alternatives  for  patients,  whereas  the  patients  eligable  for  treatment  with 
Ipilimumab have no alternative except palliative care.  
Ipilimumab also presents an interesting case in that it is the case that received 
the highest benefit category (benefit category 2 = significant added benefit) in Germany 
of all ten cases. According to the benefit assessment documentations this was because 
this categorisation followed the aggregation of both positive and negative results (G-
BA, 2012e). In contrast to NICE it is unclear whether other factors such as innovation 
played  a  role  in  the  final  appraisal  decision  of  the  FJC.  In  its  final  appraisal 
determination the Appraisal Committee at NICE: 
 
[…]  acknowledged  that  few  advances  had  been  made  in  the  treatment  of 
advanced melanoma in recent years and that ipilimumab could be considered a 
significant  innovation  for  a  disease  with  a  high  unmet  clinical  need  (NICE, 
2014c, p. 33). 
 
 
Even  though  the  pharmaceutical  manufacturer  of  Ipilimumab  mentioned 
innovation as one of the positive aspects of the product, it is unclear whether the FJC 
recognised this as a relevant consideration. According to the manufacturer:  
 
Ipilimumab is a product that does not, like others, affect the tumour directly but 
it is an immunotherapy that activates the immune systems. […] In our view this 
is an innovation (G-BA, 2012e, p. 104).  
 
Considering  that  the  methodological  guidelines  and  interviews  with  stakeholders  in 
Germany suggest that the aspects that IQWiG and FJC will usually consider are those 
that are considered patient relevant, i.e. mortality and co-morbidity, it is unlikely that 
the  innovative  character  of  Ipilimumab  featured  prominently  in  the  FJC’s  decision-
making.  However,  IQWiG  and  the  FJC  were  satisfied  that  the  endpoints  that  were 
presented in the clinical trials were patient relevant and that the results were, when 
aggregated, favourable towards a positive recommendation.  
Despite the different reasoning that went into the final decisions, Ipilimumab 
represents a case in which the evidence was, overall, assessed in a similarly positive  
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fashion by NICE and the FJC. It demonstrates that the cost effectiveness paradigm in 
England  offers  flexibility  when  a  given  ICER  is  higher  than  might  usually  be 
considered cost effective. In situations like these decision-makers can refer to additional 
aspects  such  as  innovation  that  may  ultimately  justify  the  recommendation  of  the 
product. However, the German paradigm does not provide for a similar ‘contingency 
plan’. 
  In summary, the case of Ipilimumab is a special case in that the clinical need for 
a new treatment was dire and the presented clinical evidence was convincing. In all of 
the above three cases the decisions came down to a similar assessment of the available 
evidence. This means that, in these instances, the fact that differing criteria of decision-
making  were  applied,  i.e.  innovation  at  NICE  in  the  case  of  Ipilimumab  and  an 
aggregated  version  of  clinical  endpoints  by  IQWiG  and  the  FJC  in  the  case  of 
Cabazitaxel and Eribulin, did not result in significant differences in the final appraisals. 
The empirical evidence suggests that the outcome in the dependent variable of these 
cases  was  comparable  because  ultimately  the  decision-makers  in  England  and  in 
Germany  felt  that  the  available  evidence  in  the  form  of  RCTs  addressed  the  main 
criteria  and  concepts  as  outlined  in  the  HTA  paradigms  in  an  appropriate  way. 
However, the case of Ipilimumab is also an instance in which additional values, i.e. 
innovation,  had  to  be  invoked  so  that  the  operationalisation  of  cost  effectiveness 
matched the significance of the clinical benefits. 
The above observations are significant in two ways. Firstly, they suggest that 
there is a value core within HTA policy paradigms, that is to say certain values and 
concepts have to be adhered to. This claim arises from the empirical evidence because 
in Germany the reasoning in the assessment processes for the above cases was centred 
on the question of patient relevance, whereas in England the reasoning focused on the 
question of cost effectiveness.  
The fact that in Ipilimumab’s case NICE based its decision on additional values 
such as innovation does not contradict the overriding importance of cost effectiveness 
within  the  English  paradigm.  This  is  because  the  core  of  NICE’s  decision-making 
reasoning was still cost effectiveness, its default position. That is the focal point from 
which decisions are taken. In the absence of cost effectiveness thresholds being met 
NICE has developed a number of additional values that sit just outside the core value of 
cost effectiveness; they may be brought into the core in order to provide additional 
grounds of reasoning in certain cases. Thus, and secondly, rather than contradicting the  
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inference that cost effectiveness is the most important value in NICE’s HTA paradigm, 
the  additional,  or  periphery,  values  that  were  invoked  by  NICE  in  the  case  of 
Ipilimumab suggest a within-paradigm flexibility of reasoning in cases which are not 
considered cost effectiveness.  
As shown in the next chapters a comparable within-paradigm flexibility that is 
expressed by outlining values that might be invoked if the criteria of the overriding 
concept are not met is lacking in Germany. If the criterion of patient relevance is not 
met, Germany’s HTA paradigm contains few to no additional values at the outliers of 
the core of patient relevance that might be invoked.  While the policy paradigms of 
pharmaceutical benefit assessments in Germany and England show similarities in that 
core and a periphery of values exists, they show differences in the form they take and 
how  decision-making  situations  are  managed  when  the  available  evidence  does  not 
address the most important decision-making criteria in a satisfactory way. 
 
6.3.2. Research Findings 
 
  Cabazitaxel,  Eribulin  and  Ipilimumab  illustrate  that  in  cases  in  which  the 
decision-makers  rely  on  the  same  forms  of  evidence  and  assess  the  strengths  and 
weaknesses of this evidence in a largely similar way, the result in the outcome of the 
dependent variable might be similar even if different rules of evidence are applied to the 
data.  The  above  analysis  suggest  that  this  will  be  the  case  if  a)  the  same  form  of 
evidence is accepted by two HTA bodies and b) the weaknesses of the evidence do not 
undermine  the  most  important  criteria  in  the  value  core  of  the  respective  HTA 
paradigm.  
For  the  cases  of  Cabazitaxel,  Eribulin  and  Ipilimumab,  the  aforementioned 
conditions were satisfied. NICE, the FJC and IQWiG accepted the same RCTs as the 
basis  for  decision-making.  Despite  a  different  focus  during  the  decision-making 
process, i.e. NICE focusing on innovation and the FJC focusing on the aggregation of 
patient relevant endpoints in the case of Ipilimumab, the HTA bodies came to largely 
the same conclusions about the products. The empirical evidence suggests that this was 
possible because the RCT data addressed the most important decision-making criteria 
for NICE and the FJC in a convincing way. For Cabazitaxel and Eribulin, NICE found 
that  the  incremental  costs  for  the  intervention  were  too  high  in  comparison  to  the 
marginal  benefits  the  products  offer,  even  when  alternative  economic  models  were  
  188 
employed.  Thus,  NICE  was  able  to  justify  its  decision  on  the  grounds  of  cost 
effectiveness, or in these cases, the lack thereof.  
In  the  case  of  Ipilimumab  the  usual  cost  effectiveness  threshold  for 
recommending interventions was exceeded. However, upon the application of additional 
criteria such as end-of-life considerations and the question of innovation, NICE was 
able to recommend Ipilimumab. Whilst NICE’s decision-making process in these cases 
centred on the questions of cost effectiveness, the FJC’s primary concern was whether 
the clinical endpoints of the trial were patient relevant. Being satisfied that they were 
met, the RCT evidence was deemed appropriate to address the most important questions 
under Germany’s HTA paradigm.  
The way in which NICE addressed the issue of cost effectiveness in the above 
cases demonstrates how the values that are embedded in the wider health care paradigm 
and the HTA policy paradigm are reflected in  the practical application of decision-
making criteria. NICE’s main focus in the presented cases was the question of cost 
effectiveness, which has its roots in what is described as ‘value for money’ in the NHS 
Constitution (Department of Health, 2013a). NICE’s consideration of innovation in the 
case of Ipilimumab demonstrates that it applies this concept in practice by using it in its 
reasoning process in cases in which cost effectiveness criteria might not be satisfied. 
Equally, the fact that the FJC and IQWiG did not accept the question of innovation as a 
valid consideration in the case of Ipilimumab also reflects how the wider health care 
and  HTA  paradigms  are  put  into  practice.  As  outlined  in  the  previous  chapter, 
innovation is not specifically mentioned as a value within the German HTA paradigm. 
This helps explain why, in the case of Ipilimumab, the FJC and IQWiG did not consider 
it in its decision-making process.  
In conclusion, the cases of Cabazitaxel, Eribulin and Ipilimumab give rise to the 
following findings:  
1.  The application of different policy paradigms can lead to similar outcomes if 
the  most  important  values/criteria  of  the  respective  paradigm  are 
safeguarded,  thus  suggesting  that  contrasting  policy  paradigms  do  not 
necessarily lead to contrasting outcomes. 
2.  HTA  policy  paradigms  take  different  forms  in  different  countries  as 
demonstrated by the fact that contrasting issues were considered by NICE, 
the FJC and IQWiG when making decisions on Cabaxitaxel, Eribulin and 
Ipilimumab.  
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3.  The issues that were considered by the decision-making bodies in the cases 
of Cabazitaxel, Eribulin and Ipilimumab reflect the values that are embedded 
in  the  paradigmatic  constructs  of  pharmaceutical  benefit  assessments  in 
Germany and England, which were outlined in the previous chapter. 
4.  Finally, the above cases illustrate the central importance of the principle of 
cost effectiveness within the English HTA paradigm and the principle of 
patient relevance within the German HTA paradigm. The majority of the 
decision-making  process  in  the  two  countries  focused  on  these  two 
principles  respectively.  This  suggests  that  the  operationalisation  of  cost 
effectiveness  and  patient  relevance  plays  a  central  role  in  shaping  the 
outcome of pharmaceutical benefit assessments. As will be shown in the 
next  chapters,  the  two  concepts  can  be  described  as  the  most  important 
values within the respective HTA paradigms. In paradigmatic terms, they 
dictate what is considered possible, feasible and desirable within the process 
of  normal  decision-making.  However,  despite  the  presence  of  these 
important values, the case of Ipilimumab also demonstrates that England’s 
paradigm is characterised by a within-paradigm core and periphery of values 
that allows additional values to be invoked if cost effectiveness thresholds 
are not met.  
 
Overall, the above cases demonstrate that there are lessons to be learnt from 
cases  in  which  the  outcomes  of  pharmaceutical  benefit  assessments  are  similar  in 
different countries. This is because the in-depth analysis of the decision-making process 
provides insights into how the decisions were made and which issues were considered. 
The difference in the issues that were considered can be interpreted as a reflection of 
different policy paradigms and rules of evidence that are at play. Thus, an important 
theoretical lesson is that cases in which the outcome of the dependent variable is similar 
provide as powerful insights when addressing a given research question as cases in 
which the outcome of the dependent variable is dissimilar. 
In the next  section  I turn to  a discussion of the suitability of paradigms  for 
‘special’  cases  (theme  five)  as  an  additional  variable  that  arises  from  the  empirical 
evidence.  
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6.4. Theme Five: Suitability of Paradigms for ‘Special’ Cases 
 
  I summarise a theme that was raised in the cases of Retigabine and Fingolimod 
(see  chapter  7)  as  questions  about  the  ‘suitability’  of  the  HTA  decision-making 
paradigms for ‘special’ cases such as treatments for chronic diseases. The term ‘special’ 
is  used  here  for  want  of  a  better  expression.  What  is  meant  is  that  the  cases  of 
Retigabine and Fingolimod gave rise to a set of challenges that are unique to diseases 
that  a)  are  chronic  in  kind,  i.e.  they  can  span  a  long  timeline  and  b)  still  pose 
unanswered questions in terms of their natural progression and causes. The discussion 
that follows shows that the questions and arguments that were raised in these cases 
reflect questions of what evidence is permissible (theme one) for the ‘special’ set of 
issues and uncertainties that chronic diseases give rise to.  
The question of the suitability of the HTA policy paradigms for ‘special’ cases is 
relevant  to  the  research  question  because  the  way  in  which  HTA  bodies  approach 
challenges in cases such as chronic diseases might have implications for the likelihood 
of positive assessments in these circumstances. As the following paragraphs show, the 
question of the suitability of the HTA decision-making paradigms for these cases also 
links back to how a HTA body deals with uncertainties in evidence and what kind of 
evidence is permissible in the first place. It also reflects a more general concern within 
the academic community about the appropriateness of relying heavily on RCT data to 
inform health care decision-making (Klein, 2003). This is largely due to the limitations 
of RCTs to answer questions that go beyond those of clinical effectiveness and safety, 
for example value judgements that they are not powered to answer.  
  In  the  following  paragraphs  the  case  of  Retigabine  is  used  to  illustrate  that 
NICE’s  cost  effectiveness  paradigm  seems  well  equipped  to  cope  with  the  special 
challenges that arise in  assessing medicines for chronic, long-term, conditions. This 
seems to be a result of a paradigm that includes a number of ‘contingency’ arguments 
and values that decision-makers can rely on if a decision cannot be justified on the 
grounds  of  cost  effectiveness  alone.  However,  the  generalisability  of  the  claim  that 
NICE’s cost effectiveness paradigms is better equipped to deal with such situations 
should be viewed with caution as it is only based on the two cases in which this theme 
emerged as part of this thesis. 
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6.5. Theme Five: The Case of Retigabine 
 
The  case  of  Retigabine  (table  6.6.)  serves  as  an  example  in  which  the  hard 
clinical endpoints that are measured in a RCT, for example mortality and morbidity, 
might not be appropriate to answer questions about the additional therapeutic value that 
a new medicine offers. NICE specifically recognises the limitations that RCTs might 
exhibit in that “[…] RCT data are often limited to selected populations and may include 
comparator treatments and short time spans that do not reflect routine or best NHS 
practice” (NICE, 2008, p. 15). The empirical research presented in this thesis suggests 
an additional and equally pressing limitation of the use RCTs, namely the limitations of 
RCTs to address issues of clinical effectiveness specific to chronic diseases where the 
scientific knowledge about the natural progression of the diseases is still limited and 
hence  RCTs  might  not  give  sufficient  insight  about  the  treatment  effect  of  a  new 
medicine. 
As outlined in table 6.6. Retigabine is indicated for epilepsy, a chronic disease 
under which patients suffer from seizures that is caused by “[…] a sudden burst of 
intense electrical  activity” (Epilepsy Action, 2012) in the brain. The three available 
RCTs for assessing Retigabine’s clinical effectiveness focused on the outcomes “[…] 
responder rate (proportion of patients experiencing >- 50% reduction in 28-day total 
partial  onset  seizure  frequency  from  baseline  […];  proportion  of  patients  achieving 
seizure  reduction  categories  […],  quality  of  life  scores”  (NICE,  2011a,  p.  10)  and 
adverse effects. Retigabine “[…] demonstrated statistically significant benefits in terms 
of responder rate, reduction in seizure frequency and patients achieving freedom of 
seizures” (NICE, 2011a, p. 9). Despite recognising several limitations to the available 
cost effectiveness data on Retigabine NICE recommended it as a treatment option while 
IQWiG  and  the  FJC  did  not  see  proof  of  the  added  benefit  of  Retigabine,  mainly 
because the wrong comparator product had been chosen which rendered the available 
RCTs unemployable for the proof of additional benefit (IQWiG, 2012d; G-BA, 2012f). 
The reasons for NICE’s and IQWiG’s/FJC’s decision are traced in more detail in the 
next  chapter.  In  this  section  the  focus  lies  with  taking  a  closer  look  at  the  clinical 
endpoints that were measured in the RCTs and what clinical experts in Germany and 
England had to say in relation to the appropriateness thereof.  
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TABLE 6.6. – Case Study: Retigabine (NICE, 2011a; G-BA 2012f; IQWiG, 2012d) 
Indicated for: The adjunctive treatment of partial onset seizures in epilepsy 
 
  NICE  FJC 
Dependent variable: Outcome 
of benefit assessment 
‘Conditional’ recommendation  only when treatment with 
9 other options has failed 
Additional benefit not substantiated 
Reasoning/discussions/topics 
raised/public context 
-  ICERs highly uncertain, but recognised a novel mode 
of action 
-  Provision of new treatment option where others have 
failed 
-  Compared Retigabine with a number of other 
alternatives: sometimes it was associated with fewer 
QALYs and more costs, sometimes with more 
QALYs and fewer costs 
-  Problem around deciding what the 
appropriate comparator was. There are a 
number of alternatives with no clear 
rankings, hence the most efficient 
(cheapest) one (Lamotrigin) was chosen 
in compliance with the Rules of 
Ordinance on early benefit assessment 
-  Could not accept any of the presented 
evidence as none of the trials compared 
Retigabine with Lamotrigin 
-  In the hearings: discussions about 
difficulty of designing clinical studies 
for chronic conditions such as epilepsy 
Similarities in assessment & 
appraisal 
-  Difficult to decide where Retigabine fits in the 
treatment pathway 
-  Difficult to decide where Retigabine fits 
in the treatment pathway 
Differences in assessment & 
appraisal  
-  NICE acknowledged the problem of not knowing 
exactly where Retigabine would fit in the treatment 
pathway but saw itself in a position to make a 
decision on Retigabine because it represented an 
additional treatment option in situations where other 
treatments have failed. 
-  The FJC and IQWiG did not see 
themselves in a position to make a 
decision about the additional benefit of 
Retigabine because there were no 
studies comparing Retigabine with the 
appropriate comparator 
-  Pharmaceutical manufacturer took the 
product off the German market  
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The question that arises with regards to the preference for RCTs in the HTA 
decision-making frameworks is whether these are appropriate to answer the complicated 
issues of cause and effect in all disease areas regardless of their issue characteristics 
(Lowi, 1964). Chronic diseases like epilepsy differ from other disease areas in that they 
pose different challenges due to the longer time that patients live with the disease. Most 
chronic diseases will develop gradually over time with variations in their severity at 
different stages of the disease, which may or may not increase the chances for co-
morbidity or death. Patients with diseases such as epilepsy or multiple sclerosis will 
present  themselves  with  very  individual  and  different  stages  of  their  diseases, 
suggesting that a ‘one size fits all’ treatment might be more difficult to prescribe in 
comparison  with  other  diseases  that  are  acute  rather  than  chronic  in  nature. 
Consequentially, there are challenges that arise with regards to what novel treatments 
need  to  achieve  and  how  to  design  RCTs  that  appropriately  measure  the  treatment 
effects.  This  is  compounded  by  the  fact  that  the  knowledge  about  the  natural 
progression of some chronic diseases, including epilepsy, is still limited. One clinical 
expert who was involved in the appraisal process of Retigabine at NICE phrased this in 
the following way: 
 
[…] we don’t really know what the drugs do, we don’t really know why people 
have epilepsy and you could argue that treating epilepsy the way we do is the 
same as someone who would be treating aneamia blindly […] you try this, try 
that, eventually you will get 80%-90% better […] (Interviewee No. 20, 2013, p. 
1). 
 
  Arguably, the more uncertainties around the natural progression and occurrence 
of a chronic disease, the more difficult it will be to design satisfactory clinical trials 
(Interviewee  No.  20,  2013;  Interviewee  No.  15,  2013)  because  of  the  number  of 
variables that remain unknown. Nevertheless, the accepted endpoints that are measured 
in  RCTs  on  epilepsy  medication  are  responder  rates  in  terms  of  seizure  reduction 
(Interviewee No. 20, 2013; Interviewee No, 15, 2013). The most prominent outcome is 
a 50%-seizure reduction rate. However, clinical experts in Germany and in England 
who were interviewed as  part of this  thesis outlined concerns they have with  these 
endpoints:  
 
[…]  the  usual  outcome  which  is  used  for  regulatory  authorities  is  the  50% 
seizure reduction but the 50% seizure reduction doesn’t really […] have a lot of  
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clinical weight […] it would be like jumping from the 5
th floor instead of the 
10
th  […] they [the outcomes] have no clinical meaning, they are ok to convince 
the  FDA  and  the  EMA  […]  but  […]  it  won’t  help  me  sell  the  drug  to  my 
patients, what I’m looking for is seizure freedom (Interviewee No. 20, 2013, pp. 
1-2). 
 
In a similar vein the clinical expert involved in the appraisal process of Retigabine in 
Germany noted that:  
 
[…]  in  epilepsy  we  are  talking  about  […]  a  substance  that  achieved  a  50% 
reduction of seizures, but this is completely irrelevant for the patient. The big 
qualitative leap would be zero seizures or one seizure, not 5 or 10 seizures. 
Seizure  freedom  is  the  big  big  endpoint  […]  we  no  longer  need  the  tenth 
substance that is as good as carbamazepine, we need the eleventh substance that 
is better than carbamazepine (Interviewee No. 15, 2013, pp. 3-4)
29. 
 
  The above challenges are reflected in NICE’s appraisal document on Retigabine 
in the form of reference to uncertainties and limitations in the data. NICE technology 
appraisal guidance 232 states that:  
 
[…] The Committee accepted that there may be limitations to the clinical trails 
data  […]  the  Committee  understood  that  […]  patient  experts  valued  seizure 
freedom more than a reduction in the number of seizures. […] the Committee 
agreed  that  the  ICERs  presented  were  all  highly  uncertain  because  of  the 
limitations in the availability of data […] (NICE, 2011a, pp. 22-24). 
 
In contrast to NICE, IQWiG and the FJC did not even get as far as recognising the 
limitations of the clinical data because they dismissed the case outright on the basis that 
the manufacturer had not compared Retigabine to the appropriate comparator therapy 
which the FJC had set, namely add-on lamotrigine. The conclusion reached by IQWiG 
was the following:  
 
[…]  in  its  dossier  the  pharmaceutical  company  compared  retigabine  with 
lacosamide  and  thus  deviated  from  the  G-BA’s  specifications.  Moreover  it 
provided  no  adequate  justification  for  this  deviation.  […]  By  choosing  a 
different comparator therapy […] the pharmaceutical company did not address 
the question […]. Accordingly, the studies submitted […] were not relevant for 
the benefit  assessment  – neither for a direct  nor for an indirect  comparison. 
Therefore no proof of an added benefit of retigabine in comparison with the 
appropriate comparator can be inferred […] (IQWiG, 2012e, p. 1). 
                                                        
29 Translation provided by the author of this project.  
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Despite uncertainties and limitations NICE still recommended Retigabine on the 
basis of the evidence it heard from clinical and patient experts and after balancing those 
with the uncertainties arising from the trials. With reference to the innovation of this 
technology NICE stated that: “Retigabine has a novel mode of action and therefore 
could be an important additional treatment option were it to provide response in those 
people  considered  resistant  to  current  therapies”  (NICE,  2011a,  p.  27).  This  is  an 
example of NICE’s more flexible approach in terms of the evidence base it permits 
within its decision-making framework. Whereas IQWiG and the FJC dismissed even the 
available RCTs on the basis that they did not compare Retigabine to the appropriate 
comparator – in other words they felt that the wrong data had been collected in the first 
place which rendered the information and the evidence that was crafted from this data 
useless  - NICE acknowledged the weaknesses of the clinical and cost effectiveness data 
and weighed these up against other evidence and considerations it heard during the 
appraisal process. How the German HTA institutions addressed the case of Retigabine 
seems  to  confirm  Majone’s  viewpoint  that:  “Selecting  inappropriate  data  or  models 
[…], can destroy the effectiveness of information used as evidence, regardless of its 
intrinsic  cognitive  value”  (Majone,  1989,  pp.  10-11).  In  the  case  of  Retigabine  the 
pharmaceutical manufacturer addressed the ‘wrong’ questions in its dossier as IQWiG 
and  the  FJC  were  interested  in  the  effectiveness  of  Retigabine  against  a  different 
comparator.  
 
6.5.1. Research Findings 
 
The  case  of  Retigabine  serves  to  illustrate  two  important  points  about  the 
presentation of information as evidence in the form of RCTs. Firstly, RCTs’ ability to 
answer  questions  appropriately  might  not  always  be  given,  which  in  turn  poses 
challenges for the decision-making agencies about what information to choose from the 
available stock of data (Majone, 1989). Secondly, the comparative view on how NICE 
and the FJC/IQWiG dealt with Retigabine suggests that even evidence of the highest 
ranking within the hierarchy of evidence might not be considered sufficient evidence if 
the RCT in question is at odds with other important aspects of the decision-making 
framework as was the case in Germany. This illustrates that the “ ‘scientific evidence’ ” 
(Klein, 2003) represented by RCTs might be accepted, declined or re-interpreted in  
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different HTA settings depending on the wider decision-making paradigms. This affects 
the ultimate outcome of a pharmaceutical benefit assessment.  
Whilst Retigabine was recommended in England, its ‘no proof of added benefit’ 
categorisation in Germany led to the pharmaceutical manufacturer taking its product off 
the German market. As a consequence clinicians and patients have to apply to their 
respective  sickness  funds  to  have  Retigabine  imported  from  another  country  if  the 
clinician and the patient feel that this is the right treatment pathway or if the patient is 
on Retigabine already due to his/her partaking in the clinical trials (Interviewee No. 15, 
2013). 
In summary, the discussion underlines the following research findings:  
1.  Rules of evidence matter. The analysis of Retigabine highlights that the rules of 
evidence, i.e. the way HTA bodies deal with ‘special’ cases, contribute to the 
outcome of pharmaceutical benefit assessment. 
2.  HTA paradigms are different in England and Germany. The previous discussion 
supports this finding as it illustrates how differently HTA bodies approach the 
challenges in instances of chronic diseases. ‘Special’ cases may challenge the 
normal decision-making of HTA agencies, but how these agencies deal with 
such challenges provides valuable insights on the character and flexibility of the 
paradigms. 
 
In relation to the second research finding, the case of Retigabine suggests that 
circumstances may arise in which the dominant HTA paradigms may be challenged, 
challenged in the sense that certain cases of diseases demand a greater flexibility in the 
articulation and application of the paradigm. By looking at such special cases one can 
learn about how HTA decision-making paradigms are articulated in order to address 
case-specific challenges. In the case of Retigabine NICE chose to follow the views of 
clinicians’  when  deciding  on  where  Retigabine  would  fit  in  the  clinical  pathway, 
whereas IQWiG and the FJC decided they could not assess the drug because the wrong 
comparator had been chosen. In the case of the latter, even the views brought forward 
by stakeholders in the assessment hearing process could not change IQWiG’s and the 
FJC’s decision that it was unable to appraise the product. 
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6.6. Conclusion 
 
In terms of the potential variables that were outlined in table 3.2. the empirical 
results  discussed  here  suggest  that  the  most  important  factor  that  determines  the 
outcome of pharmaceutical benefit assessments is independent variable number three 
(the instrument settings of HTA, i.e. the rules of evidence). In itself this might not be a 
surprise as the way data is processed generally has an impact on the outcome. However, 
it does suggest that the methodological dimension of HTA plays a comparatively more 
important role than the political and ethical dimensions of HTA in determining their 
outcome.  
Given  that  one  of  the  goals  of  HTA  is  to  de-politicise  decisions  on 
pharmaceutical coverage, the findings suggest a success when measured against this 
goal. Except in a couple of exceptional cases, which are discussed in chapter 8, this 
study does not imply that political factors such as stakeholder influence matter in a 
significant  way,  except  in  instances  where  the  most  important  principles  of  the 
respective paradigms are already upheld in a manner that satisfies the rules of evidence 
with regards to thresholds and the like. However, while the dominant role of the rules of 
evidence implies that decisions are, by and large, not subject to political considerations, 
for policy-makers it also suggests that any concerns that HTAs give rise to in relation to 
politically and ethically salient issues can only be tackled by ensuring that the rules of 
evidence reflect one’s political and ethical values. This would require re-politicising the 
issue. As long as the rules of evidence that are articulated in normal decision-making 
are not at odds with the wider health care paradigm there might not be a need for this. 
However, in the future policy-makers might be facing the possibility of having to re-
politicise a currently de-politicised area.  
The next chapter discusses themes two, three and four that emerged from the 
empirical analysis undertaken in this thesis. 
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Chapter 7 
Policy Paradigms in Operation II: 
The Interpretation of Evidence 
 
7.0. Introduction 
 
  The empirical evidence analysed as part of this thesis indicates that the decision 
about which forms of evidence are accepted (theme one) within a given HTA policy 
paradigm is compounded, if not determined, by more detailed and complex questions 
pertaining to the available evidence. Seeing as how HTA frequently has a comparative 
element to it, that is HTA bodies compare a new product’s benefits with that of the 
currently  used  alternative,  the  choice  of  an  appropriate  comparator  product  is  an 
important task when carrying out a benefit assessment.  In addition to the choice of 
comparator,  the  assessment  of  the  clinical  effects  in  sub-populations  of  the  overall 
patient population for which a pharmaceutical product is licensed forms a substantial 
part of any benefit assessment in order to determine the relative effectiveness of the 
product in different patient populations. The consultation documents and stakeholder 
interviews  strongly  suggest  that  HTA  bodies  address  these  important  questions  in 
different ways (theme two and three). The fact that these evidence questions form the 
centre of HTAs signals that different ‘rules of evidence’ are applied when determining 
the outcome of pharmaceutical benefit assessments. As we shall see in this chapter, the 
difference between the ‘rules of evidence’ reflects contrasting HTA policy paradigms in 
which different values and decision-making criteria are prioritised over others.  
  This chapter discusses themes two, three and four (table 6.1.) that emerged from 
the data. Theme two evolves around the role that the choice of comparator plays in 
determining the outcome of pharmaceutical benefit assessment. The discussion of this 
theme will highlight that the choice of comparator can impact significantly on whether 
the  available  evidence  is  deemed  appropriate  in  the  sense  that  evidence  might  be 
discarded if it is based on the ‘wrong’ comparator. This has huge implications for how 
the strength and weaknesses of the evidence is assessed which in turn contributes to the 
ability of decision-makers to appraise the product in a positive or negative way. The 
criteria for choosing the comparator product are a reflection of the ‘rules of evidence’. 
Thus, the significance of this issue underscores the research finding that the ‘rules of 
evidence’ are the most important factor in determining the outcome of pharmaceutical  
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benefit assessments. The cases of Fingolimod and Retigabine are employed to illustrate 
how theme two emerged from the data that was collected. 
In the second part of this chapter I analyse theme three of the empirical results, 
i.e. the role played by divisions of sub-groups of patient populations. This will highlight 
that NICE, the FJC and IQWiG follow different rules and criteria in deciding which 
sub-population  analyses  are  relevant  and  meaningful.  However,  in  contrast  to  the 
previous section on the choice of comparator, this section gives rise to the finding that 
contrasting policy paradigms, or rules of evidence, do not necessarily lead to contrasting 
outcomes. This will be shown with reference to the case of Telaprevir. Finally, the last 
section  of  this  chapter  is  dedicated  to  a  discussion  of  how  HTA  thresholds  and 
algorithms are operationalised (theme four) in England and in Germany and how this 
contributes to the outcome of pharmaceutical benefit assessments. 
 
7.1. Theme Two: Choice of Comparator 
 
Majone refers to data as the “[…] raw materials necessary for the investigation 
of a problem […]” (Majone, 1989, p. 46). In pharmaceutical benefit assessments these 
raw materials can be described as the elements that make up a RCT, i.e. the product 
under investigation, the comparator product of the control arm of the study and the 
patient cohort. In order to assess whether these three elements represent the appropriate 
data to determine a product’s clinical effectiveness the marketing authorisation of a 
product  provides  a  useful  starting  point  for  decision-makers.  Notwithstanding  the 
possibility that clinical practice may lead to a situation in which some pharmaceutical 
products may be used outside their licensed indication, the marketing authorisation for a 
product provides the legal remit in which a product can and should be used. While the 
marketing authorisation does not in itself represent a form of data, it impacts on which 
data  is  deemed  to  be  appropriate  for  the  purposes  of  a  pharmaceutical  benefit 
assessment. For example, the indication(s) for which a product is licensed will give rise 
to the current therapy alternatives, i.e. the comparator products currently in use, and the 
patients for whom the product is indicated will give rise to the patient cohort and its 
subgroups.  
Considering  that  market  authorisation  by  the  European  Medicines  Agency 
(EMA) is identical and valid throughout European Member States, one might be led to 
assume that the data on comparator products and subgroups of patient populations give  
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rise  to  similar  benefit  assessment  outcomes  in  countries  with  HTA  procedures. 
However, this is not the case. The empirical research conducted as part of this thesis 
shows that the ultimate outcome of a pharmaceutical benefit assessment will, amongst 
other factors, be determined by the strictness to which the marketing authorisation is 
adhered to when making a decision about the comparator product and patient subgroup 
divisions. A discussion of the cases of Fingolimod, Retigabine and Telaprevir highlights 
the  challenges  that  arise  around  the  issue  of  choosing  the  appropriate  data,  i.e.  the 
‘right’  comparator  product  and  patient  subgroups,  and  how  different  approaches  in 
dealing with those challenges can lead to contrasting appraisals of the same data.  
 
7.2. Theme Two: The Case of Fingolimod 
 
Fingolimod is a treatment that is licensed for multiple sclerosis (MS). MS “[…] 
is  a  disease  of  the  nerves  in  which  inflammation  destroys  the  protective  sheath 
surrounding the nerve cells” (EMA, 2011). It is a chronic disease that comes in different 
forms  and  levels  of  severity.  One  of  the  most  common  forms  is  that  of  relapsing-
remitting MS in which patients go through periods of remissions with no symptoms and 
periods of relapses in which they suffer from attacks and MS symptoms. Table 7.1. 
provides an overview of NICE’s and the FJC’s decisions and reasoning in the case of 
Fingolimod.  
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TABLE 7.1. – Case Study: Fingolimod (NICE, 2012d; G-BA, 2012g; IQWiG, 2012e) 
Indicated for: Highly active relapsing-remitting multiple sclerosis (MS) 
 
  NICE  FJC 
Dependent variable: 
Outcome of benefit 
assessment 
‘Conditional’ recommendation 
 
Recommended as an option for the treatment of highly active 
relapsing-remitting multiple sclerosis (MS) in adults, only if: 
they have an unchanged or increased relapse rate or ongoing 
severe  relapses  compared  with  the  previous  year  despite 
treatment with beta interferon AND the manufacturer provides 
Fingolimod  with  the  discount  agreed  as  part  of  the  patient 
access scheme (PAS) 
Different  benefit  appraisal  for  3  different  patient 
populations: 
1.  Patients with highly active relapsing-remitting 
MS  who  are  heavily  pre-treated:  Additional 
benefit not substantiated 
2.  Patients with highly active relapsing-remitting 
MS  who  are  not  heavily  pre-treated: 
Additional benefit not substantiated 
3.  Patients  with  rapidly  evolving  severe 
relapsing-remitting  MS:  Clue  of  a  marginal 
benefit  
Reasoning/discussion
s/topics raised/public 
context 
-  Accepted 2 RCTs (FREEDOMs and TRANSFORMS) 
-  Initially did not recommend it 
-  Appraisal  committee  made  an  exceptional  case: 
valuable new therapy, oral formulation is an innovation 
-  ICER £25,000-£35,000/QALY 
-  Manufacturer  acknowledged  that  trial  populations  did 
not meet criteria described in marketing authorisation 
-  ERG  very  critical  of  the  presented  evidence,  i.e. 
populations in the clinical trials were broader than those 
defined  in  the  marketing  authorisation.  However, 
accepted  that  manufacturer’s  post-hoc  subgroup 
analyses  provided  a  reasonable  approximation  to  the 
populations in the marketing authorisation 
-  Limited the timeline for which the appraisal 
decision is valid, meaning it will be reassessed 
once more data is available 
-  Accepted  only  1  RCT  (TRANSFORMS), 
FREEDOMS  not  acceptable  because  it  was 
placebo-controlled  and  did  not  allow  for  a 
comparison to a relevant comparator 
-  Division of population according to marketing 
authorisation means higher uncertainty 
-  Manufacturer  highlighted  the  significance  of 
the  oral  formulation  of  Fingolimod  as  an 
added benefit  
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Similarities in 
assessment & 
appraisal 
-  Acknowledged  that  the  mismatch  between  the  patient 
populations  in  the  clinical  trials  and  the  marketing 
authorisation presented uncertainties in the data 
-  Acknowledged that the mismatch between the 
patient  populations  in  the  clinical  trials  and 
the  marketing  authorisation  presented 
uncertainties in the data 
Differences in 
assessment & 
appraisal 
-  NICE  was  not  able  to  make  a  recommendation  for 
patients  with  rapidly  evolving  severe  relapsing-
remitting  MS  because  analysis  that  compared 
Fingolimod  with  the  appropriate  comparator  was  not 
submitted by the manufacturer  
-  Oral formulation accepted as a benefit of value 
 
-  Patient experts placed emphasis on loss of independence 
and implications for employment under MS. They also 
placed emphasis on the benefit of Fingolimod as an oral 
medicine as opposed to one that has to be injected. 
-  Clinical  specialists  said  it  would  provide  the  most 
benefit  for  patients  with  rapidly  evolving  severe 
relapsing-remitting MS because they currently have few 
treatment options 
-  FJC was able to assign a positive (marginal) 
benefit  to  the  patient  group  with  rapidly 
evolving severe relapsing-remitting MS 
 
-  Oral  formulation  not  considered  because  it 
cannot  be  expressed  as  a  patient  relevant 
endpoint.   
  203 
7.2.1. Discussion 
 
Whilst the challenges presented by the RCT data in the case of Fingolimod were 
described  in  similar  ways  by  NICE,  IQWiG  and  the  FJC,  the  way  in  which  these 
challenges were approached by the institutions as well as the ultimate decisions they 
arrived at are dissimilar to each other. The challenges related primarily to a lack of 
congruence between the patient population included in the trials and that covered by the 
EMA license. This in turn gave rise to discussions about the appropriate comparator 
product for assessing Fingolimod’s clinical effectiveness at NICE as well as IQWIG 
and the FJC. Whilst NICE and the FJC ultimately decided to recommend Fingolimod 
for use, the recommendation differed in that it was for two different patient subgroups. 
Whereas NICE recommended Fingolimod, 
 
[…] as an option for the treatment of highly active relapsing-remitting multiple 
sclerosis in adults, only if:  
they have an unchanged or increased relapse rate or ongoing severe relapses 
compared  with  the  previous  year  despite  treatment  with  beta  interferon  […] 
(NICE, 2012d, p. 3), 
 
 
the FJC did not come to the conclusion that there was an added benefit for this patient 
population,  but  instead  assigned  a  hint  of  a  marginal  added  benefit  to  the  patient 
subgroup  of  rapidly  evolving  severe  relapsing-remitting  MS  to  Fingolimod  (G-BA, 
2012g). By contrast, NICE concluded that: 
 
[…] a specific recommendation for the use of fingolimod  in  this  population 
could not be made because the manufacturer had not submitted an analysis of 
fingolimod compared with natalizumab in this population (NICE, 2012d, p. 34). 
 
 
In the case of Fingolimod the two appraisal institutions felt that, based on the available 
evidence,  they  could  only  make  a  decision  that  is  limited  to  one  of  the  patient 
populations covered by the market authorisation. However, the patient population for 
which NICE and the FJC issued a positive decision is not identical, thereby giving rise 
to questions about what determined the ultimate decision. It strongly suggests that the 
way HTA institutions approach challenges of uncertainty and trial design affects the 
final outcome of a pharmaceutical benefit assessment.  
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  In  the  case  of  Fingolimod,  NICE,  IQWiG  and  the  FJC  highlighted  that  the 
patient  populations  in  the  trials  were  more  broadly  defined  than  in  the  marketing 
authorisation  (NICE,  2012d;  G-B,  2012g;  IQWiG,  2012e).  This  means  that  more 
patients with a wider variety of baseline characteristics and previous treatments were 
included  in  the  RCTs  than  covered  by  the  market  authorisation.  This  made  the 
extrapolation of statistically significant results difficult. At NICE “the Committee noted 
that only part of the population covered by the marketing authorisation for fingolimod 
was considered in the manufacturer’s submission” (NICE, 2012d, p. 23) and “it also 
heard that the TRANSFORMS and FREEDOMS trials were not powered to assess the 
efficacy of fingolimod in the subgroups defined by the marketing authorisation” (NICE, 
2012d, p. 25). In a similar vein the FJC concluded that the extrapolation of data results 
for subgroups that fulfill the marketing authorisation criteria is not possible in this case 
(G-BA, 2012g). The lack of congruence between the patient subgroups as outlined in 
the  marketing  authorisation  and  those  patients  included  in  the  clinical  trials  thus 
presented NICE and IQWiG with similar challenges when it comes to assessing the 
appropriateness of the data, the raw material, that was presented as part of the benefit 
assessment process. The way NICE and IQWiG as well as the FJC dealt with these 
challenges  gives  important  insights  into  the  HTA  decision-making  paradigms  in 
Germany and England.  
  Whilst recognising the limitations in the data presented by the manufacturer the 
ultimate  decision  of  NICE  suggests  that  it  was  satisfied  with  the  quality  of  the 
additional evidence derived from mixed treatment comparison and indirect evidence 
that was presented in the process. Even though NICE saw limitations with regards to the 
comparator  chosen  for  “[…]  the  part  of  the  population  covered  by  the  marketing 
authorisation  […],  that  is,  people  with  highly  active  relapsing-remitting  multiple 
sclerosis” (NICE, 2012d, p. 15), it felt that it could make a decision about the clinical 
effectiveness  of  Fingolimod  for  this  patient  population.  NICE  criticised  that  the 
manufacturer only chose one beta interferon (Avonex) as a comparator product, but 
ultimately “the Committee concluded that the available evidence shows that people who 
are treated with fingolimod have lower relapse rates than people treated with Avonex or 
placebo”  (NICE,  2012d,  p.  36).  However,  for  people  with  rapidly  evolving  severe 
relapsing-remitting MS NICE did not make a recommendation due to the fact that, as 
previously  mentioned,  “[…]  the  manufacturer  had  not  submitted  an  analysis  of 
fingolimod compared with natalizumab [the appropriate comparator] in this population”  
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(NICE,  2012d,  p.  34).  Despite  the  challenges  presented  by  the  lack  of  congruence 
between the patient populations included in the clinical trials and that covered by the 
marketing authorisation NICE decided to recommend Fingolimod for one of the patient 
populations on the basis of all available evidence, including oral and written evidence 
that it heard from patients and clinical experts about the advantages of Fingolimod and 
its oral formulation. In the end, 
 
the Committee made an exceptional case and recommended fingolimod for the 
treatment of highly active relapsing-remitting multiple sclerosis in adults […]. 
The Committee accepted that fingolimod is a valuable new therapy and that its 
oral formulation represents innovation in the treatment of multiple sclerosis. The 
Committee recognised that including all of the benefits of fingolimod suggested 
by  the  manufacturer  and  patient  experts  in  the  manufacturer’s  model  could 
decrease the ICER to a level that would be considered a cost-effective use of 
NHS resources (NICE, 2012d, p. 32). 
 
 
  The fact that the Committee made an “exceptional case” (NICE, 2012d, p. 32) 
suggests that the decision was not easy and that there were factors that spoke against the 
recommendation of Fingolimod. In fact, NICE’s draft recommendation in the Appraisal 
Consultation  Document (ACD) was  negative due to  the uncertainties in  the clinical 
evidence and the resulting unfavourable cost effectiveness estimates (NICE, 2011b). 
The  reversal  of  NICE’s  initial  recommendation  as  well  as  its  decision  to  grant 
Fingolimod  the  status  of  an  innovative  pharmaceutical  product  due  to  its  oral 
formulation are special features of this case. It is important to acknowledge that NICE – 
on  balance  of  all  available  evidence  –  made  a  positive  recommendation  despite 
uncertainties that arose  from the divergence between the marketing authorisation of 
Fingolimod  and  the  design  of  the  clinical  trials.  Coming  back  to  the  ‘hierarchy  of 
evidence’ that was explained in chapter 6, NICE followed the hierarchy in the sense that 
it extrapolated the information it saw fit from the available RCT data and then looked to 
other forms of evidence to fill the information gaps and build a stronger evidence base. 
  In  contrast  to  NICE,  IQWiG  and  the  FJC  did  not  accept  the  results  of  the 
indirect comparisons with the appropriate comparator (glatiramer acetate) or any other 
evidence for that matter. The indirect comparisons presented by the manufacturer were 
not accepted by IQWiG because the studies did not include the relevant patient cohort, 
i.e. patients previously treated with a beta interferon (IQWiG, 2012e). This gave rise to 
contrasting  views  between  IQWiG  and  the  pharmaceutical  manufacturer  on  what  
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constitutes  the  ‘best  available  evidence’  that  has  to  be  presented  when  the  highest 
ranked evidence is not  available.  The manufacturer saw the indirect  comparisons it 
presented  as  the  best  available  evidence  (G-BA,  2012g,  p.  61),  whereas  IQWiG 
concluded that this evidence did not answer the decision problem and could therefore 
not be accepted. According to IQWiG, 
 
[…] every  evidence  –  that  is  the best  available as  well as the best  possible 
evidence for a decision problem – must […] be suitable for answering a given 
decision  problem.  If  this  is  not  the  case  then  even  the  […]  best  available 
evidence for a decision problem is irrelevant. This is the case for the indirect 
comparisons  presented  by  the  pharmaceutical  manufacturer  […].  These 
considerations  would  also  apply  […]  to  direct  comparative  studies  (IQWiG, 
2012e, p. 51)
30. 
 
 
Even  though  the  FJC  Ordinance  stipulates  that  the  “best  available  evidence 
level” must be accepted in the absence of the highest level of evidence (G-BA, 2013), 
IQWiG seems to draw a further distinction between the best available and the best 
possible evidence. Thus, in this case IQWiG’s and the FJC’s decisions were a result of a 
strict adherence to the marketing authorisation, which was seen as binding. However, as 
will be further illustrated by the case of Telaprevir in a later section of this chapter, the 
use  of  the  marketing  authorisation  to  determine  the  exact  patient  populations  and 
current therapy alternatives in a given indication for the purposes of pharmaceutical 
assessments  is  not  without  its  challenges.  The  challenges  lie with  issues  of  clinical 
practice  and  practicability  as  well  as  the  divergent  goals  of  the  licensing  and  the 
appraisal processes. In connection to this, an interviewee of a decision-making body in 
Germany pointed out: 
 
A […] topic [...] is the role of the marketing authorisation which is at times a big 
problem […] because we are clearly […] bound by the marketing authorisation 
in our SGB V [Social Code Book V] and this is difficult for the manufacturers 
and for us […] (Interviewee No. 23, 2013, p. 1). 
 
 
 
 
 
 
 
                                                        
30 Translation provided by the author of this thesis.  
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7.2.2. Research Findings   
 
The  case  of  Fingolimod  illustrates  the  impact  that  the  application  of  the 
marketing authorisation has on the appraisal process in that it gives rise to the patient 
population, its subgroups as well as the comparator products in clinical practice. The 
case also illustrates how additional evidence of a lesser hierarchical ranking than RCTs 
may or may not be used by decision-makers to answer a given decision problem. The 
ability  (by  law)  and  the  willingness  of  decision-making  institutions  to  employ 
alternative sources of evidence in the absence of direct comparisons can have a large 
effect on the ultimate outcome of a decision. It is for this reason that Fingolimod is 
recommended  for  a  large  part  of  the  patient  population  covered  by  the  marketing 
authorisation in England (albeit with conditions around previous treatment and relapse 
rates) while in Germany it is only categorised as offering a small added benefit for a 
small part of the patient population. This shows that, when it comes to the role played 
by the marketing authorisation and the issues it raises, divergent ‘rules of evidence’ 
(Majone,  1989)  can  have  a  very  real  impact  on  what  determines  the  outcome  of 
pharmaceutical benefit assessments.  
In  the  case  of  Fingolimod,  the  reasoning  of  the  decision-making  bodies  in 
Germany and England shows that the approaches to dealing with weaknesses in the 
evidence  base  and  decisions  about  the  ‘right’  comparator  are  very  different.  The 
process-tracing exercise in this case gave rise to the following findings: 
1.  It does not just matter what forms of evidence are permissible (theme one) under 
a given HTA paradigms. How the evidence is interpreted in relation to questions 
such  as  the  appropriate  comparator  product  impacts  on  the  outcome  of  the 
benefit  assessments.  This  is  because the decision that the evidence does  not 
include the ‘right’ comparator effectively rules out making an appraisal decision 
on the basis thereof.  
2.  The question of the appropriateness of the comparator and the sub-divisions of 
patient populations are connected to what is considered ‘relevant’ in a specific 
HTA system. This underlines Cartwright’s and Hardie’s (2012) assertion that 
evidence  has  to  be  relevant  to  a  specific  context.  Under  the  English  HTA 
paradigm  the question  of relevance is  operationalised by asking  whether the 
clinical  trial  data  reflects  UK  clinical  practice,  whereas  under  the  German  
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paradigm  it  is  operationalised  by  asking  whether  it  reflects  the  marketing 
authorisation of the given pharmaceutical product. 
3.  Decision-making criteria are established as part of a paradigm during normal 
decision-making processes. In these processes HTA bodies find a way of dealing 
with situations in which the ‘wrong’ comparator was chosen. Here, the case of 
Fingolimod suggests that NICE is willing to consider evidence other than RCTs 
such  as  indirect  comparisons  and  expert  submissions  in  order  to  make  a 
decision. The study data does not include any evidence that the FJC is willing to 
consider evidence from sources other than RCTs. 
4.  Rules of evidence matter. The fact that NICE, the FJC and IQWiG asked similar 
questions about the evidence base and dedicated a substantial amount of time 
within the decision-making processes to these questions demonstrates a similar 
importance  of  questions  regarding  the  ‘rules  of  evidence’  in  both  HTA 
paradigms.  This  also  shows  how  paradigms  are  further  articulated  and 
substantiated during ‘normal’ decision-making processes.  
5.  Different rules of evidence support the theoretical premise that contrasting HTA 
policy  paradigms  are  at  play.  The  fact  that  the  aforementioned  HTA  bodies 
ultimately  found  different  answers  to  the  pressing  questions,  i.e.  with  NICE 
accepting indirect comparisons and IQWiG and the FJC not doing so, indicates 
that different rules of evidence are applied in pharmaceutical benefit assessment 
processes in Germany and England.  
 
7.3. Theme Two: The Case of Retigabine 
 
  Another example that highlights the importance of the choice of comparator in 
determining  the  final  outcome  in  pharmaceutical  benefit  assessment  is  the  case  of 
Retigabine  (see table 6.6.). Even though the EMA has  restricted its  use to  last-line 
therapy in patients where other treatment options have failed due to the incidence of an 
adverse reaction that causes abnormal colouring of the skin (EMA, 2013), Retigabine 
exemplifies how different HTA paradigms affect the way in which similar challenges in 
the available evidence are dealt  with by HTA institutions. In Retigabine’s case this 
ultimately led to a positive recommendation by NICE (2011a) whereas the FJC (G-BA, 
2012f) did not consider itself in a position to make a decision on the additional benefit 
of this product.  
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7.3.1. Discussion 
   
The main challenge in the case of Retigabine was the judgement around its place 
in the treatment pathway and the most appropriate comparator. While clinical specialists 
in Germany and in England agreed that the most likely place of Retigabine in clinical 
practice would be as a second-line therapy in patients where other treatment options 
have failed  or  have  been exhausted, the  FJC and  IQWiG referred to  the marketing 
authorisation of the medicine under which it was also licensed as a first-line treatment 
(G-BA, 2012f; IQWiG, 2012d). Retigabine’s license as a first-line treatment was the 
reason  why  the  FJC  chose  Lamortigine,  also  indicated  as  a  first-line  treatment  in 
epilepsy, as the most appropriate comparator. This choice caused much controversy 
during the HTA process on Retigabine in Germany. This is because there are a number 
of medicines licensed as a first-line treatment for epilepsy and stakeholders criticised 
that the FJC chose Lamortigine out of all of these treatments (G-BA, 2012f). Effectively 
the FJC’s decision led to a situation in which it could not make a decision about the 
additional  benefit  of  Retigabine  because  none  of  the  available  trials  and  evidence 
compared Retigabine with Lamortigine. The FJC argued that in the absence of a clear 
ranking in clinical guidelines of the order in which the various treatment alternatives 
should be used it was under a statutory obligation to choose the most efficient, i.e. the 
cheapest, available alternative which was Lamortigine (G-BA, 2012f).  
  In contrast to the FJC, NICE accepted what clinical experts said about the likely 
place of Retigabine in the clinical treatment pathway. In light of the fact that epilepsy 
treatment is very individualised because every patient reacts to treatment differently, 
NICE  accepted  a  range  of  alternatives  as  appropriate  comparators  and  decided  to 
recommend  Retigabine  once  these  alternatives  have  failed  to  induce  a  beneficial 
outcome  (NICE,  2011a).  One  of  the  main  reasons  for  NICE’s  decision  was  the 
acknowledgement that an additional treatment option would be good for patients who 
have exhausted all other treatment options (NICE, 2011a). In Germany the existing 
HTA  paradigm  prevented  the  FJC  decision-makers  from  taking  a  similarly  flexible 
approach to the challenges of assessing Retigabine. One stakeholder summarised the 
FJC’s approach during the early benefit assessment in the following way: 
 
[…] it [the FJC’s approach] is very formal […] it sticks to law and order very 
strictly and there is little room for practical solutions […] especially in the case  
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of Retigabine one sees that NICE has a different viewpoint, they said ok, after 
those  [other  treatments]  you  are  allowed  to  treat  with  Retigabine,  there  is  a 
benefit here and we will reimburse it then. We tried to argue the same thing but 
the answer was, yes, but unfortunately this is not possible in our Social Code 
Book-driven system […] (Interviewee No. 15, 2013, p. 2). 
 
The last sentence of the above quote gives a deep insight into the strictness by 
which the HTA paradigm is adhered to in Germany and how this restricts a certain level 
of flexibility in some cases. The phrase “[…] this is not possible in our Social Code 
Book-driven system […]” (Interviewee No. 15, 2013, p. 2) can be taken as a code for 
‘this is not possible under the current HTA decision-making paradigm’. This paradigm 
clearly  states  that  the  marketing  authorisation  provides  the  guidance  for  making 
decisions  about  a  medicine’s  place  in  the  treatment  pathway  and  its  relevant 
comparators.  It  also  clearly  stipulates  that  in  the  case  of  more  than  one  suitable 
comparator the most efficient one has to be chosen (BMJV, 2013).  
The FJC’s inability to make a decision on the added benefit of Retigabine due to 
the lack of available evidence on what it considered the appropriate decision problem is 
a reflection of the ideas that form the basis of the HTA paradigm.  It represents  an 
example of how similar challenges are dealt with very differently depending on the 
paradigmatic decision-making criteria that apply. In the case of Retigabine this had a 
large impact in that the availability of the product is different in Germany and England. 
Following the FJC’s negative decision, the pharmaceutical manufacturer in Germany 
decided to withdraw Retigabine from the German market. This means that patients who 
want to receive it and clinicians who want to prescribe it have to apply to individual 
sickness funds in order to have it imported from another European country (Interviewee 
No. 15, 2013). This illustrates how paradigms, interpretive frameworks within a given 
policy area, can have a very real political and social impact.  
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7.3.2. Research Findings 
 
The  English  HTA  paradigms  offers  comparatively  more  room  for  the 
consideration of evidence other than RCTs which is why, in the case of Retigabine, 
NICE  was  able  to  consider  what  clinicians  had  to  say  about  the  administration  of 
Retigabine in routine clinical practice.  
Faced with the same challenges when presented with the evidence, Fingolimod 
and  Retigabine  represent  case  scenarios  in  which  the  HTA  bodies  dealt  with  the 
challenges  in  a  diametrically  opposing  manner,  which  ultimately  led  to  different 
outcomes in the respective benefit assessment decisions. The contrast in the approaches 
taken in the appraisal of Retigabine is especially striking; whereas the FJC (G-BA, 
2012f) and IQWiG (2012d) accepted none of the comparators that were included in the 
available evidence, NICE (2011a) accepted the comparators and included a range of 
comparators  that  had  not  even  been  a  part  of  the  direct  evidence  presented  by  the 
manufacturer.  
Despite  questions  about  the  place  of  Retigabine  in  routine  clinical  practice, 
NICE  was  able  to  recommend  Retigabine  because  it  followed  what  clinicians  were 
saying  about  the  use  of  Retigabine  as  an  option  when  other  treatments  had  failed. 
IQWiG and the FJC on the other hand did not get past Retigabine’s license as a first-
line therapy. NICE’s decision was possible because its paradigm allows for clinicians’ 
viewpoints to be counted as evidence. Even though the German HTA paradigm includes 
the stipulation that the next best level of evidence has to be used in the absence of the 
highest level of evidence (see chapter 6), this stipulation does not appear to extend to 
recognising clinicians’ views as acceptable evidence. The example of Fingolimod and 
Retigabine thus underlines the importance of examining how decision-making criteria 
such as hierarchies of evidence are operationalised when put into normal practice. 
In  summary,  the  discussion  on  the  role  of  the  choice  of  comparator  in 
determining  the  outcome  of  pharmaceutical  benefit  assessment  gives  rise  to  the 
following research findings: 
1.  The  ‘rules  of  evidence’,  as  expressed  through  different  paradigmatic  prisms, 
matter. The discussion of the cases of Fingolimod and Retigabine highlights that 
the outcome of pharmaceutical benefit assessments is not solely determined by 
the evidence input the HTA body accepts, but also by the means (the rules of 
evidence) by which this input is analysed.  
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2.  The discussion on Retigabine and Fingolimod showed how variables combine in 
pharmaceutical benefit assessment to produce certain outcomes. In the above 
cases the application of different rules of evidence ultimately led to different 
results despite a similar assessment of the weaknesses in the evidence base. This 
suggests  that  it  is  not  the  evidence  base  that  determines  the  outcome  of 
pharmaceutical  benefit  assessment,  but  the  decision-making  criteria  that  are 
applied to it. By applying different criteria the evidence gains relevance within a 
given HTA paradigm. 
 
In the next section I elaborate on the third theme that was raised in the majority 
of  the  cases.  Along  with  the  choice  of  comparator  product  and  the  paradigmatic 
decision about which evidence to accept the question of the appropriate sub-division of 
the  patient  population  also  plays  a  role  in  determining  the  final  outcome  in 
pharmaceutical benefit assessments.  
 
7.4. Theme Three: The Sub-Divisions of Patient Populations 
 
An important element in designing and carrying out RCTs is the definition of 
subgroups  of  patients  that  may  experience  a  different  treatment  effect  under  the 
medicine  that  is  being  tried.  The  subgroups  will  usually  undergo  what  is  called  a 
subgroup  analysis,  that  is:  “A  technique  consisting  of  analysing  the  data  from  a 
subgroup separately from those from the overall population studied” (HTA Glossary, 
2014a). Subgroup analyses potentially offer decision-makers a closer look at the effects 
of the treatment which might, for example, lead to restricting the use of the product in 
question to the patient groups that are most likely to benefit from its use. However, 
subgroup analyses are not without challenges as dividing the patient population into 
groups that are smaller than the entire cohort will also affect the statistical significance 
results that are likely to be obtained in these groups. Despite these challenges that have 
to be given due consideration, subgroup analyses form an important part of the work 
HTA institutions perform in assessing and appraising a product’s treatment effects. The 
extent  to  which  HTA  institutions  engage  in  subgroup  analyses  offers  an  interesting 
insight into the paradigmatic differences of how data is used and analysed in different 
contexts. The case of Telaprevir serves as an example of the important role that the sub- 
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divisions of patient populations play and how this might impact on the decisions made 
in relation to assessing the benefit of a new medicine. 
 
7.5. Theme Three: The Case of Telaprevir 
 
  Telaprevir is:  
[…]  indicated  for  the  treatment  of  genotype  1  chronic  hepatitis  C  in  adult 
patients with compensated liver disease (including cirrhosis):  
  Who are treatment naïve;  
  Who have previously been treated with interferon alfa […] alone or in 
combination with ribavirin, including relapsers, partial responders and 
null responders (EMA, 2011a). 
 
Table 7.2. provides an overview of the most important points that can be traced by 
examining  the  benefit  assessment  process  at  NICE,  IQWiG  and  the  FJC. 
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TABLE 7.2. - Case Study: Telaprevir (NICE, 2012e; G-BA, 2012a; IQWiG, 2012c) 
Indicated for: The treatment of genotype 1 chronic hepatitis 
 
  NICE  FJC 
Dependent variable: Outcome of 
benefit assessment 
Recommended  Additional benefit, but not quantifiable 
Reasoning/discussion/topics 
raised/public context 
-  ICERs low at £13,553/QALY for treatment-naïve 
patients and £8,688/QALY for treatment-
experienced patients 
-  Significant features of the treatment: by increasing 
sustained virological response (SVR) rates 
Telaprevir increases the chances of stopping the 
progression of the diseases to more disabling stages 
of liver disease 
-  Offers treatment opportunities for patients with a 
type of hepatitis C virus that is most resistant to 
current treatment alternatives 
-  Public health benefit highlighted: lower 
transmission rates if more patients achieve SVR 
-  More clinically effective than the current 
alternatives 
-  Innovation highlighted 
-  Questions around the sub-divisions of the patient 
population by IQWiG  the FJC did not follow 
IQWiG’s sub-division into 5 different sub-groups 
-  Questions and controversy around whether the 
clinical endpoint SVR was patient relevant 
-  IQWiG interpreted SVR as a surrogate parameter 
for liver carcinoma, not as an endpoint in its own 
right 
-  The FJC accepted SVR as a patient relevant 
endpoint 
-  Clinical experts highlighted public health 
consideration of lower transmission rates 
-  Discussion about operationalisation of benefit 
categories 
-  Stakeholders argued Telaprevir should receive the 
highest benefit category because SVR is 
equivalent to a cure 
Similarities in assessment & 
appraisal  
-  Effective treatment: yes 
-  Stakeholders highlighted effectiveness and 
innovation of treatment 
 
-  Effective treatment: yes 
-  Stakeholder highlighted effectiveness and 
innovation of treatment 
 
Differences in assessment & 
appraisal 
-  No doubt about appropriateness of clinical endpoint 
SVR 
-  Consideration of public health impact: yes 
-  Accepted that SVR was equivalent to a cure 
-  Much doubt and discussion about appropriateness 
of clinical endpoint SVR 
-  Consideration of public health impact: No 
-  Did not accept that SVR is equivalent to a cure  
  215 
7.5.1. Discussion 
 
While  both  NICE  and  the  FJC  came  to  an  overall  positive  appraisal  of 
Telaprevir, the reasons for this as well as the discussions that preceded the ultimate 
decision differed substantially from one another. The differences in the way in which 
subgroup  effects  were  discussed  and  analysed  within  the  German  and  the  English 
context are especially noteworthy as they offer an empirical example of how different 
subgroup  divisions  and  analyses  have  a  potentially  large  impact  on  the  ultimate 
outcome in pharmaceutical coverage decisions. 
  In its ultimate decision the FJC concluded that there was an added benefit of 
Telaprevir for treatment naïve and previously treated patients (G-BA, 2012a). However, 
the FJC also concluded that the extent of the added effect was not quantifiable because 
HIV and hepatitis B (HBV) co-infected patients and patients with liver cirrhosis were 
potentially included in the groups for whom an added benefit was accepted (G-BA, 
2012a). According to the FJC there was no sufficient data for these subgroups of co-
infected  patients  (as  they  were  excluded  from  the  clinical  trials)  and  patients  with 
cirrhosis which is why no statements of certainty could be made about the primary 
endpoint of sustained virological response (SVR) (G-BA, 2012a, p. 4). According to the 
FJC the “scientific data base” (G-BA, 2012a, p. 4) does not permit a quantification of 
the extent of the added benefit. Thus, the FJC’s caveated decision on Telaprevir was 
guided by an uncertainty around the treatment effects within certain patient subgroups 
and whether this skewed the effects in the entire patient population. 
  It is important to note that in the above conclusion in the case of Telaprevir the 
FJC did not follow the divisions of the patient population that had been suggested by 
IQWiG in its assessment of Telaprevir. IQWiG divided the patient population into five 
sub-populations that, according to IQWiG, more accurately reflected the patients for 
which Telaprevir is indicated as per its license. According to IQWiG, the appropriate 
sub-populations and the resulting conclusion about their added benefit were: 
 
  Treatment-naïve patients without cirrhosis (proof of added benefit): 
  Treatment-naïve patients with cirrhosis (no proof of added benefit because of 
lack of useable data); 
  Non-responders with or without cirrhosis (hints of an added benefit); 
  Relapse-patients with cirrhosis (data uncertain);  
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  And  relapse-patients  without  cirrhosis  (no  proof  of  added  benefit)  (IQWiG, 
2012c, pp. 3-11).  
 
In addition to these subgroup analyses, IQWiG conducted a subgroup analysis on the 
impact of the virological load of patients at baseline for the sub-population of therapy-
naïve patients without cirrhosis. This led to IQWiG concluding that the added benefit of 
Telaprevir for treatment-naïve patients without cirrhosis was only proven for patients 
with a high virological load at baseline (IQWiG, 2012c). IQWiG’s reasoning for these 
sub-divisions, while arguably correct on the possible sub-populations that arise out of 
the  license  for  Telaprevir,  was  met  with  considerable  criticism  by  stakeholders  in 
Germany. 
  The  criticism  brought  up  most  frequently  during  the  the  FJC’s  hearing 
procedures on Telaprevir was that the subgroup divisions by IQWiG led to an under-
appreciation  of  the  positive  treatment  effects  of  Telaprevir  (G-BA,  2012a,  p.  36). 
Underlying this criticism is the previous mentioned challenge of subgroup analyses, 
especially if they are conducted post-hoc, of showing statistically significant results in a 
much smaller patient population than the full cohort. Moreover, stakeholders raised the 
issue of the practicability of IQWiG’s subgroup divisions: 
 
Practicability plays a big role […]. Telaprevir is  a very  good example, […] 
IQWiG opened up seven subgroups in total, which were in part even further 
divided […] this was too complex for the FJC, I think, and one decided […] in 
order  to  have  a  comprehensible  decision  for  the  clinician  […]  to  limit  the 
subgroups to two […] [because] there is no sense to differentiate between the 
virological  load  this  high  or  this  high,  or  is  it  a  cirrhotic  patient  or  a  non-
cirrhotic patient which is […] not very clearly differentiable in practice. […] 
many clinicians said, in theory this is true from the formality of the license, but 
in  practice  this  can  hardly  be  demarcated  whether  a  patient  already  has  a 
cirrhosis or not […] Hepatitis C develops over 30 years and the state of the liver 
deteriorates gradually and when exactly a cirrhosis is reached […] that is not 
easily demarcated. […] the other point was that IQWiG found a difference in the 
data according to virological load […] the FJC said despite seeing this from the 
data,  in  practice  the  virological  load  always  varies  […]  [it  is]  a  chance 
measurement on the basis of which we would be denying a patient treatment 
[…] and one did […] not want that (Interviewee No. 5, 2013, p. 3)
31. 
 
 
Contrary to IQWiG the FJC decided that it would consider only two patient 
groups, namely the treatment-naïve group and the treatment-experienced group (G-BA, 
                                                        
31 Translation provided by the author of this thesis.  
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2012a). The other subgroups that IQWiG highlighted could be grouped within those 
two groups according to the FJC. While the FJC did not follow IQWiG’s complex sub-
divisions, it also did not feel able to judge with certainty exactly how big the extent of 
the added benefit of Telaprevir is because the two patient groups for which Telaprevir is 
licensed  includes  groups  for  whom  sufficient  clinical  trial  data  was  not  available, 
thereby rendering the true effect of Telaprevir non-quantifiable (G-BA, 2012a). This 
suggests that, even though IQWiG’s sub-division was not followed, the FJC and IQWiG 
operate within a decision-making paradigm in which the license for a pharmaceutical 
product carries significant weight and will determine which subgroups are deemed to be 
appropriate for the analysis of treatment effects.  
The appraisal documentations on early benefits assessments and the interviews 
conducted  as  part  of  this  research  suggest  that,  along  with  concerns  about  the 
appropriate  comparators  for  a  novel  pharmaceutical,  the  issue  around  whether  the 
pharmaceutical  manufacturers’  evidence  reflects  treatment  effects  for  all  possible 
patient groups for which there is approval status is one that preoccupies much of the 
work the FJC and IQWiG do. This in itself is not unlike the preoccupations of other 
HTA institutions because, after all, the market authorisation dictates the legal realm in 
which a product is allowed to be used and the ‘right’ comparator product gives a benefit 
assessment its meaning, i.e. is the use of the new product better, worse or the same than 
the  current  treatment  pathway.  However,  the  fact  that  IQWiG  and  the  FJC  are 
comparatively strict when it comes to one of their rules of evidence, i.e. that RCT data 
has to be available for every possible indication of a new product, has been criticised by 
stakeholders  for  its  rigidity.  The  fact  that  IQWiG  and  the  FJC  require  convincing 
evidence for each possible patient subgroup as indicated by the license is reflected in 
their undertaking to assign an individual, and frequently different, comparator to each of 
these subgroups that arise from a medicine’s approval status. A representative of the 
pharmaceutical industry criticises the rigorous divisions of the patient populations into 
subgroups in the following way:  
 
One tries to divide the patient population into […] subgroups with the result that 
one cannot serve all of these subgroups on the basis of one’s studies […] post-
hoc sub-populations definitions are also not clean methodologically because the 
study was not powered for it which means one runs the risk that if you, for 
example, divide your entire population into four sub-populations […] one might 
get a significant result for one of them and not for the other three […] in the end 
[…]  one  creates  statistical  artefacts  and  there  is  a  risk  that  one  also  creates  
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constellations  that  are  not  real  anymore  and  have  nothing  to  do  with  the 
[clinical] provision […] in Germany […] (Interviewee No. 6, 2013, pp. 4-5). 
 
 
While subgroup analyses are a part of most benefit assessments they are not 
without challenges. In addition to methodological challenges there are context-specific 
challenges that arise from the way HTA institutions operationalise subgroup analyses. 
Two such context-specific challenges are reflected in the above discussion of IQWiG’s 
and the FJC’s approach to subgroup analyses. One is connected to the way a HTA 
institutions deals with the situation when the evidence presented as subgroup analyses 
does not yield statistically significant results or when the studies in question do not 
permit a certain subgroup analysis that is required by the HTA body. Instead of looking 
to other evidence, IQWiG’s and the FJC’s ‘default’ position on such cases seems to be 
to label the added benefit of a product as ‘non-quantifiable’ due to lack of scientific 
evidence.  
The categorisation of ‘non-quantifiable’ added benefit gives rise to the second, 
and  arguably  even  more  pressing,  issue,  namely  the  issue  of  how  a  certain 
operationalisation of subgroup divisions will impact on service provision in health care. 
As  the  FJC  assigns  an  individual  benefit  category  to  each  indication  for  which  a 
pharmaceutical  product  is  licensed,  we  observe  decisions  in  which  a  product  is 
classified with different benefit categories for each possible patient subgroup. While the 
HTA decision-making framework in Germany requires this, it is clear that this might 
make it difficult for practitioners, payers and patients alike to assess the true value of a 
new  medicine.  The  benefit  category  ‘non-quantifiable’  further  complicates  these 
situations as it provides little direction for stakeholders on what benefit to expect from a 
medicine in comparison to current treatments.  
With reference to the question posed in the previous chapter on what constitutes 
evidence, i.e. what do decision-makers do when the evidence does not yield the answers 
they seek, it appears that the approach in Germany is to go back to the drawing board in 
such cases. This means that if the evidence presented is not satisfactory IQWiG will 
state that this is the case and it will state which data analyses would be needed to give 
rise to the appropriate evidence. Even though the legal framework in Germany dictates 
that  when  evidence  from  the  highest  ranking  is  not  available,  IQWiG  and  the  FJC 
should consider evidence from the next level of the ranking (G-BA, 2013), there seems 
to be an assumption that if the pressing questions cannot be answered by RCT data then  
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the evidence from the next level of the ranking will also not yield satisfactory answers. 
This leads to a situation that one stakeholder described as the following:  
 
[…]  a  premise  of  evidence-based  medicine  is  ‘do  not  dismiss  available 
evidence’. Here [in Germany] even evidence from the licensing studies and from 
other sources that are not in direct relation with the appropriate comparator […] 
are just ignored. […] Purpose of an early benefit assessment so that all those 
involved gain a certain benefit from it […] are pragmatic solutions […] and not 
to  throw  available  evidence  overboard  from  one  day  to  another  due  to  a 
paradigm shift […] (Interviewee No. 6, 2013, pp. 3-4). 
 
 
  The  empirical  evidence  suggests  that  NICE  also  considered  the  question  of 
treatment  effects  in  the  various  possible  subgroups  in  the  case  of  Telaprevir.  A 
representative  of  a  professional  association  involved  in  the  appraisal  process  on 
Telaprevir stated that “[…] a particular issue was in certain subgroups of people with 
Hepatitis C, can they have access, what are the risks?” (Interviewee No 3, 2012, p. 1). 
NICE noted that there were no statistical tests of some of the data in certain subgroups, 
but when reading its technology appraisal guidance 252 (NICE, 2012e) one gets a sense 
that this lack of statistical testing was not believed to undermine the overall positive 
results that the RCTs and the evidence by clinicians and patient experts yielded. The 
following  excerpt  from  NICE’s  guidance  illustrates  how  the  Appraisal  Committee 
considered the issue of treatment effects across subgroups: 
 
The  Committee  discussed  the  clinical  effectiveness  of  telaprevir  plus 
peginterferon alfa and ribavirin compared with peginterferin alfa and ribavirin 
alone  in  previously  untreated  patients.  It  noted  that  the  telaprevir-containing 
regiment statistically significantly increased the sustained virological response 
rates for ‘standard’ treatment (48 weeks) and response-guided regimens. The 
Committee observed that telaprevir did not appear to be less effective in patients 
with cirrhosis than on patients with lower degrees of fibrosis, although it had not 
been  presented  with  any  statistical  tests  of  these  data  […].  The  Committee 
discussed the clinical data for telaprevir in patients who had previously been 
treated.  It  noted  that  telaprevir  statistically  significantly  increased  sustained 
virological response rates […] and that the higher rates […] were also seen in 
the  patient  subgroups  (patients  whose  condition  had  relapsed,  partially 
responded  or  not  previously  responded).  […]  It  observed  that  there  was  no 
difference  in  the  proportion  of  patients  with  cirrhosis  who  had  a  sustained 
virological  response  to  telaprevir  compared  with  the  overall  trial  population 
(NICE, 2012e, pp. 22-23). 
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Whereas NICE was satisfied that the higher SVR rates were seen in the patient 
subgroups of previously treated patients, IQWiG came to a different assessment in that 
only an indication of an added benefit for non-responders with or without cirrhosis 
could be derived from the data (IQWiG, 2012c, p. 4). However, for relapsed patients 
without cirrhosis IQWiG concluded “there were no data on the current approval status 
in this populations available for the present benefit assessment” (IQWiG, 2012c, p. 6). 
  The above example shows that subgroup analyses play a role in the appraisal 
and  assessment  processes  in  Germany  and  in  England.  However,  it  indicates  a 
contrasting approach when it comes to operationalising these subgroup analyses when 
determining the final outcome. While IQWiG and the FJC require data to be translated 
into statistical test results for every indication of a medicine’s approval status, NICE 
appears to be willing to assume a positive treatment effect even when statistical tests 
have not been specifically presented. Presumably this willingness is only present in 
cases where the overall clinical and cost effectiveness evidence is strong and there are 
few safety concerns around the pharmaceutical product. Quoting an interviewee who 
was involved in NICE’s assessment process on Telaprevir:  
 
[…] I think this was a bit of a non-brainer for NICE because the effectiveness of 
the drug was so much more so the only way that they could fall over was if they 
killed people […] or if they priced it so ridiculously that the cost per QALY was 
outside  NICE’s  range  […]  I  think  the  evidence  base  was  […]  strong 
(Interviewee No. 1, 2012, pp. 1-2). 
 
 
The difference in operationalising subgroup analyses is a noteworthy one as it 
provides an insight into the ‘rules of evidence’ that guide decision-making in Germany 
and in England. It seems that the availability of statistically significant test results for 
every patient group that arises out of a pharmaceutical product’s approval status is a 
precondition  for  IQWiG  to  assign  the  highest  benefit  category  to  the  product, 
notwithstanding the possibility that the FJC may overrule IQWiG’s approach in cases 
such  as  Telaprevir’s.  In  contrast,  NICE  is  more  open  to  the  idea  of  assuming 
effectiveness across different subgroups unless the clinical evidence clearly indicates 
otherwise or there are serious safety or cost effectiveness concerns. If the evidence is 
convincing  and  of  good  quality  overall,  NICE  appears  willing  to  consider  other 
evidence alongside the evidence from clinical trials in order to make its judgements,  
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something which played a big role in Telaprevir’s case as will be explained in later parts 
of this thesis.  
This aforementioned willingness to consider other forms of evidence may, in 
part, be due to the fact that according the NICE’s Guide to Social Value Judgements 
(NICE, 2008a), NICE (2008a) has to specifically justify the in- or exclusion of a patient 
group in a recommendation in order to avoid discrimination of patients. In analogy to 
the  principle  that  underlies  jurisprudence  in  democratic  states,  i.e.  ‘innocent  until 
proven guilty’, the empirical research of this thesis suggests that NICE seems to adhere 
to  a  general  principle  of  “effective  unless  proven  ineffective”,  whereas  IQWiG’s 
approach indicates a presumption of “ineffective until proven effective”, the possibility 
that the FJC might overrule some of IQWiG’s rigor in assessing treatment effects in 
patient subgroups notwithstanding. Having said this, it is important to bear in mind that 
this analogy only pertains to the way the above institutions operationalise subgroup 
analyses and not clinical or cost effectiveness more generally. 
 
7.5.2. Research Findings 
 
Despite  a  very  different  assessment  of  the  strengths  and  weaknesses  of  the 
evidence in the case of Telaprevir and despite the application of different decision-
making  criteria,  the  outcome  of  the  benefit  assessment  was  similar  in  England  and 
Germany. This illustrates that the same outcomes can be arrived at by different means 
and through different reasoning processes.  
The overall appraisal of Telaprevir was positive despite very different takes on 
the appropriateness of the data and the criteria applied to it. What remains constant and 
similar to the cases presented earlier in this chapter is that the interpretation of the 
evidence,  i.e.  the  criteria,  standards  and  algorithms  applied  to  it  are  different  in 
Germany  and  England.  However,  that  is  not  to  say  that  these  diverging  criteria 
necessarily result in diverging outcomes. The case of Telaprevir illustrates that similar 
outcomes  can  be  arrived  at  by  different  means,  i.e.  despite  different  inputs  and 
interpretations. As well as offering interesting insights on what determines the outcome 
of pharmaceutical benefit assessment, the discussion on Telaprevir also underscores the 
merits of process-tracing exercises when analysing complex processes. Without tracing 
the questions that were addressed by NICE, IQWiG and the FJC in this case, one might 
have been tempted to  infer a similarity of  argumentation from  the similarity in  the  
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dependent  variable, which would not  have represented an  accurate  account  of what 
determined the outcome in this case.  
In  summary,  the  discussion  on  Telaprevir  leads  to  the  following  research 
findings: 
1.  The case of Telaprevir exemplifies that contrasting HTA policy paradigms do 
not  necessarily  lead  to  different  outcomes  in  the  dependent  variable.  This 
finding is significant because it arises from a case scenario where logic would 
have led one to believe that the outcome would be different (i.e. different input + 
different criteria = different outcome, instead we saw different input + different 
criteria = similar outcome). This shows that one cannot assume that a similar 
outcome  in  the  dependent  variable  is  the  result  of  undisputed  and  strong 
evidence. Even cases in which the outcome in the dependent variable is similar, 
different rules of evidence are applied that help explain this outcome. 
2.  Similarly to the previous sections on Fingolimod and Retigabine, the discussion 
of Telaprevir highlighted the crucial role of the decision-making criteria, the 
rules of evidence, in determining the outcome of the benefit assessment. 
3.  NICE’s paradigms appears to be more secure than the German HTA paradigm. 
The contrast between NICE’s decision-making ease and the FJC’s and IQWiG’s 
decision-making struggles in this case are striking. Whilst NICE dealt with the 
issues of the case with comparative ease, IQWiG and the FJC struggled with the 
articulation and application of their paradigm in the case of Telaprevir. Both the 
limited interpretation of patient relevance as well as the strict application of the 
market authorisation by the FJC would have led to outcomes that would have 
been considered unacceptable and unreasonable by stakeholders. However, this 
finding should not be taken at face value as it is based on one case only and 
needs to be supplemented by evidence from other cases that were examined in 
this thesis. 
4.  The  case  of  Telaprevir  provides  an  important  theoretical  insight  on  how 
contrasting policy paradigms do not, as a matter of course, lead to divergent 
outcomes in the dependent variable. 
 
In the final section of this chapter I discuss the fourth theme that emerges from 
the empirical evidence, namely the question of the operationalisation of thresholds and 
algorithms under HTA paradigms.  
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7.6. Theme Four: Operationalisation of Thresholds and Algorithms under HTA 
Paradigms 
 
  In addition to the themes discussed in the previous sections, another subject that 
played a role in HTA decision-making processes was that of the operationalisation of 
the HTA decision-making paradigm by way of thresholds and algorithms. In addition to 
the  definition  of  the  decision-making  criteria  such  as  cost  effectiveness  or  patient 
relevance, these criteria might be operationalised by placing numerical and statistical 
values to them above or below which they are satisfied. For example, NICE’s guide to 
technology appraisals outlines a threshold range of an ICER of £20,000-£30,000/QALY 
as one that will usually be deemed a cost effective use of NHS resources (NICE, 2008).  
The question of thresholds and algorithms is connected to this thesis’ research 
question because, when they exist, they potentially provide a straightforward answer to 
what determines the outcome of pharmaceutical benefit assessments. That is, in the 
presence  of  decision-making  algorithms  in  the  form  of  numerical  and  statistical 
thresholds that have to be met, stakeholders are aware of what a new product needs to 
achieve  with  regards  to  clinical  or  cost  effectiveness.  Expressing  the  value  of  a 
medicine in a numerical fashion provides an idea of what will be considered beneficial 
in an HTA process. However, despite the apparent advantages of HTA algorithms in the 
form  of  cost  effectiveness  thresholds,  statistical  expressions  of  value  also  carry  the 
danger of under- or over-valuing certain aspects of a new treatment that cannot easily be 
expressed  in  numbers.  In  Germany  and  England  we  observe  two  cases  in  which 
decision-making algorithms are present, albeit in different formats. As will be shown in 
the  following  paragraphs  these  algorithms  influence  the  outcome  of  pharmaceutical 
benefit assessments in both countries.  
  Previous  sections  outlined  that  there  are  exceptional  situations  in  which  the 
recommendation  of  a  medicine  above  NICE’s  cost  effectiveness  range  between 
£20,000-£30,000/QALY might be acceptable, but as a general rule, the threshold range 
applies.  In  terms  of  NICE’s  cost  effectiveness  paradigm  this  means  that  a  clear 
decision-making algorithm exists. A comparable algorithm for the benefit categories is, 
thus far, lacking in Germany.  
In an appendix to its first early benefit assessment in January 2011, IQWiG laid 
out its methods for the operationalisation of the extent of added benefit (IQWiG, 2011). 
According to IQWiG this was necessary because even though the rules of procedure for  
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early  benefit  assessment  provided  some  guidance  by  way  of  definition  of  the  most 
important criteria for the different benefit categories, the effect variables still had to be 
set up in an hierarchical manner according to their importance and decisions had to be 
made about the desirable effect sizes the variables had to meet in order to be considered 
proof of a certain category (IQWiG, 2011). The appendix to IQWiG’s first early benefit 
assessment,  also  referred  to  as  the  ‘Ticagrelor  appendix’  (named  after  the 
pharmaceutical product that was assessed), outlines the statistical thresholds in relation 
to confidence intervals and relative risk ratios that a product needs to meet or overcome 
in order to be assigned to a certain benefit category (IQWiG, 2011, pp. 86-92). Since 
January 2011, this appendix has served as the basis for IQWiG’s operationalisation of 
the extent of added benefit. 
  The  Ticagrelor  appendix  and  the  operationalisation  of  added  benefit  has 
received much criticism by stakeholders in the processes of early benefit assessments. 
The criticisms centre on the lack of scientific validation of the method that IQWiG uses 
and  the  lack  of  transparency  in  relation  to  whether  the  FJC  follows  this 
operationalisation or not. In all of the cases that were examined as part of this thesis, the 
FJC underlines that it  did  not  adopt  IQWiG’s  method for the operationalisation for 
added benefit. The phrasing for this iteration is near-to identical in all cases and reads, 
by  way  of  example,  in  the  following  way:  “The  method  proposed  by  IQWiG  in 
appendix A of the benefit assessment dossier on Ticagrelor […] was not relied on in the 
benefit  assessment  of  Apixaban”
32 (G-BA,  2012b,  p.  3).  However,  despite  this,  the 
instances  in  which  the  FJC does  not  follow  IQWiG  in  its  assessment  of the  added 
benefit are comparatively rare. In the cases that were analysed as part of this thesis these 
instances  include  Boceprevir  and  Telaprevir  in  which  the  FJC  came  to  a  different 
conclusion on the question whether the main clinical endpoint of sustained virological 
response (SVR) rate was  patient  relevant  or not.  Other than that, the FJC followed 
IQWiG’s benefit categorisations, thus putting a question mark on its statements that 
IQWiG’s methods are not followed by the FJC.  
  The most common criticism by stakeholders during the hearing process at the 
FJC centers around the lack of clarity and transparency on how the added is benefit is 
operationalised by the FJC (e.g. G-BA, 2012c; 2012g). Furthermore stakeholders have 
criticised IQWiG’s methods for the operationalisation of added benefit as scientifically 
                                                        
32 Translation provided by the author of this thesis.  
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unfounded and lacking a scientifically substantiated definition (G-BA, 2012c, p. 121). A 
representative of the pharmaceutical industry phrased the issue in the following way: 
“My impression is […] that no algorithm exists. It’s decisions made on individual cases 
which does not necessarily make the situation easier because we cannot draw lessons 
from it” (Interview No. 6, 2013, p. 5). This perception of the FJC’s operationalisation of 
added benefit is underlined by a representative of the HTA decision-making body in 
Germany: 
 
[…]  I  can’t  say  that  […]  the  FJC  has  developed  a  matrix  for  making  its 
decisions. That’s just not the case until now […] I also don’t know whether our 
system is earmarked for this, for structuring something in such a mathematical 
way that it becomes predictable […] it won’t become that way (Interviewee No. 
16, 2013, p. 2). 
 
Even though the FJC reiterates in most benefit appraisal documents that it has 
not adopted IQWiG’s method of the operationalisation of added benefit, the fact that the 
FJC  follows  IQWiG’s  categorisations  more  often  than  not  is  a  good  indicator  that 
IQWiG’s Ticagrelor appendix serves as the an algorithm-like matrix within the German 
HTA paradigm. An interviewee supports this view in the following way:  
 
[…] the FJC follows [IQWiG] most of the time, the FJC says that it does not use 
our methods but it follows our assessments most of the time. So either they are 
using our methods after all, then they [the methods] cannot be that bad or the 
FJC is conducting an independent study to show validity, then the methods can 
also not be that bad (Interviewee No. 23, 2013, p. 4). 
 
 
  To summarise, the HTA decision-making algorithms in Germany and England 
differ in both substance and explicitness. They differ in substance in that the English 
algorithm is based on cost effectiveness ratios whereas the German algorithm is based 
on  statistical  thresholds  that  patient  relevant  endpoints  have  to  meet  in  order  for  a 
medicine to be assigned to a certain benefit category. They differ in explicitness in that 
the English paradigm is explicit with regards to necessary thresholds and algorithms by 
including them in  the  relevant  methods  guidelines. Germany’s HTA is  less explicit 
about its paradigm which gives rise to some confusion and controversy during the early 
benefit assessment processes. While IQWiG has developed an algorithm in the form of 
the  Ticagrelor  appendix,  which  will  be  incorporated  in  a  new  version  of  IQWiG’s 
methods guidelines in 2014 (Interviewee No. 23, 2013), the FJC is more reluctant to  
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subscribe to a decision-making algorithm. The empirical evidence does not give rise to 
conclusive reasons for this and possible reasons that I could offer here would run the 
risk of being speculative in character. Suffice it to say that, regardless of the FJC’s 
apparent reluctance to adopt an algorithm, the empirical evidence suggests that it adopts 
IQWiG’s methods implicitly when it follows IQWiG’s benefit categorisations of new 
medicines.  
 
7.6.1. Research Findings 
 
  When putting the question of thresholds and algorithms into the context of the 
previously discussed themes in the empirical data, we can infer that the presence or 
absence and the operationalisation of algorithms play an important role in determining 
the final outcome of pharmaceutical benefit assessments. This is because once the HTA 
decision-makers have decided which  evidence to  use, which comparator to  use and 
which  patient  populations  to  analyse,  the  results  pertaining  to  these  parameters  are 
measured  against  the  qualitative  and  quantitative  standards  that  the  respective 
algorithms prescribe. Whether or not these standards are met and whether, in case they 
are not met, exceptions can be made influences the outcome of a benefit assessment. 
For example, in the previously discussed examples of Cabazitaxel and Eribulin (see 
tables  6.3.  and  6.4.)  the  results  on  cost  effectiveness  and  clinical  effectiveness  met 
neither the standards of NICE’s cost effectiveness paradigm nor the standards of the 
FJC’s patient relevant paradigm. The operationalisation of the HTA paradigms in terms 
of  thresholds  and  algorithms  can  thus  be  described  as  providing  the  tool  for  an 
assessment  and  appraisal,  whereas  the  previously  mentioned  themes  make  up  the 
substance  that  the  tool  gets  applied  to.  The  above  analyses  highlight  that  both  the 
substance  and  the  tools  matter  when  it  comes  to  determining  the  outcome  of 
pharmaceutical benefit assessments.  
  In conclusion, the brief discussion on the operationalisation of HTA paradigms 
contributes to the following research findings: 
1.  The discussion reaffirms that the rules of evidence matter. The discussion on the 
operationalisation of thresholds and algorithms demonstrates that they especially 
matter when they pertain to what Hall (1989) refers to as the instrument settings 
of  a  policy.  In  the  case  of  HTA  policy  these  instrument  settings  are  the 
algorithms that are applied to the scientific data in order to interpret it. Different  
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instruments  settings  lead  to  different  interpretations  of  the  evidence,  thus 
supporting  the  finding  that  the  ‘rules  of  evidence’  are  the  most  important 
variable in determining the outcome of pharmaceutical benefit assessments in 
systems that employ formalised HTA procedures. 
2.  The  discussion  also  supports  one  of  the  preliminary  conclusions  drawn  in 
chapter  5,  which  put  forward  the  possibility  that  the  operationalisation  and 
conceptualisation  of  thresholds  play  a  significant  role  in  determining  the 
outcome of pharmaceutical benefit assessments as notable differences emerged 
from the analysis of the methodological guidelines. The empirical evidence in 
this  chapter  further  supports  the  conclusion  that  the  operationalisation  of 
thresholds  and  algoirthms  under  different  paradigms  matters  to  the  final 
outcome. 
 
7.7. Conclusion 
 
This  chapter  discussed  the  decision-making  considerations  in  the  cases  of 
Fingolimod, Retigabine and Telaprevir. It showed that in addition to the question of 
what constitutes evidence in the first place (theme one) the way in which this evidence 
is  addressed,  or  interpreted,  plays  an  important  role  in  determining  the  outcome  of 
pharmaceutical benefit assessments. The appropriateness of the choice of comparator 
(theme two) and the appropriateness of the sub-division of patient populations (theme 
three) are important components in the process of making the evidence relevant to the 
given HTA context. The prominence with which they which they were discussed by 
NICE, the FJC and IQWiG in the aforementioned cases suggests a similar importance 
of these variables in both the English and the German context. However, the substantive 
differences with which they were approached suggest that different rules of evidence 
exist. However, a difference in rules of evidence and a difference in assessment of what 
is considered appropriate evidence should not be equated with an inevitable difference 
in  the  assessment  outcome.  As  the  case  of  Telaprevir  shows  the  combination  of 
different  factors  and  reasoning  can  ultimately  lead  to  the  same  outcome,  thus 
suggesting, at least for HTAs, that there is more than one causal path leading to the 
particular score in the dependent variable. 
Even though theme four was discussed comparatively briefly in this chapter, its 
significance in determining the outcome of pharamaceutical benefit assessments should  
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not be underestimated. No matter what other questions certain pieces of evidence give 
rise to and how these questions are resolved, in every case the ultimate hurdle that needs 
to be passed in HTAs is that of thresholds. Whether thresholds are set formally with the 
help  of  ICERs  or  more  generally  with  the  help  of  benefit  categories,  they  are  an 
expression of the limit of the price a society is willing to pay for a pharmaceutical 
product and this limit depends on how clinical benefits are conceptualised and measured 
(see discussion in chapter 5). 
Since thresholds set the limits, or boundaries, of what is considered acceptable 
they are one of the most important elements of any HTA paradigm. They function in 
much  of  the  same  way  that  paradigms  function.  To  recall,  paradigms  function  as 
intellectual constructs that determine what is or is not possible (chapter 2); thresholds 
have a similar boundary-defining role in determining the limits for benefit assessments. 
It is therefore not surprising that one of the conclusions I draw in this thesis is that the 
dominant HTA paradigms in England and Germany can be described according to the 
component that relates to their thresholds, i.e. cost effectiveness in England and patient 
relevance in Germany. Thresholds and algorithms are a crucial factor to understanding 
what determines pharmaceutical benefit assessments. 
In the next chapter I outline the sixth and final theme that was raised in the 
empirical  evidence.  This  theme  relates  to  auxiliary  variables  that  might  play  a 
contributory role in determining the outcome of pharmaceutical benefit assessments. 
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Chapter 8 
 
Policy Paradigms in Operation III: 
Politics and the Articulation of Paradigms 
 
8.0. Introduction 
 
  In this final chapter of the empirical analysis I discuss an additional theme (table 
6.1,  theme  six)  that  may  contribute  to  the  outcome  of  pharmaceutical  benefit 
assessments  in  England  and  Germany.  In  contrast  to  the  themes  discussed  in  the 
previous two chapters, the issues presented here did not arise in every embedded case 
study that was examined. This situation warranted a separate chapter for the discussion 
of these topics.  
  The theme discussed here is summarised in table 6.1. under the theme heading 
‘question of political power and influence’
33. Similarly to the previous themes, this 
theme  have  rise  to  different  concerns  and  foci  in  England  and  in  Germany.  These 
concerns represent the sub-themes that emerged from theme six and are referred to as 
auxiliary variables in this chapter. The variables are labeled ‘auxiliary’ because they do 
not appear to contribute to the final outcome of the pharmaceutical benefit assessment 
as a matter of course, that is in they do not matter in each and every case. Whereas the 
previous themes around evidence questions, the appropriate comparator and subgroups 
of patient populations were crucial elements in every benefit assessment, the variables 
of  public  pressure,  stakeholder  bargaining  power  and  controversies  around  key 
paradigmatic  issues  only  featured  in  a  couple  of  cases.  In  the  interest  of 
comprehensiveness  and  of highlighting areas  for future research the aforementioned 
topics are discussed in this chapter, but the discussion highlights that the role they play 
in contributing to the outcome of pharmaceutical benefit assessments requires further 
exploration that is beyond the scope of this thesis.  
  The  chapter  proceeds  by  providing  an  overview  of  the  different  auxiliary 
variables that arise from the empirical evidence in England and Germany. The auxiliary 
variable  that  arises  from  the  evidence  in  England  is  that  of  ‘public  pressure’.  The 
                                                        
33 The term ‘political’ is used in its broadest sense. That is to say that political power and 
influence is not restricted to politicians and policy-makers, but includes all political actors (e.g. 
lobbying groups, charity organisations, pharmaceutical industry, doctors etc.) who have a stake 
in the outcome of HTAs.  
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evidence  suggests  that  this  variable  potentially  contributes  to  the  outcome  of 
pharmaceutical  benefit  assessments  in  England  when  stakeholder  groups  make  a 
decision to get involved because they believe that the clinical effectiveness data on a 
product warrants stakeholder opposition to a decision made by NICE. For Germany, the 
auxiliary variables include the bargaining power of certain stakeholders vis a vis others 
as well as the conceptualisation of the paradigmatic idea of ‘patient relevance’. The 
section on Germany highlights that, while it is likely that the second of these variables 
contributes to the outcome of the dependent variable, the role of the first one is slightly 
more caveated, due to reasons of potential bias and unavailability of data that will be 
outlined.  
 
8.1. Theme Six: Auxiliary Variables Emerging from the Empirical Evidence 
 
The  previous  chapters  provided  a  discussion  and  analysis  of  the  five  main 
themes that the empirical evidence gave rise to. These themes included questions about 
what constitutes evidence in the first place, what the appropriate comparator and patient 
sub-populations are, how thresholds are operationalised and how the decision-making 
paradigms address situations in which RCT evidence poses challenges.  
The  analysis  showed  that  while  the  five  themes  affect  the  outcome  of 
pharmaceutical benefit assessments in Germany and in England, the way in which the 
themes are addressed varies according the policy paradigms that are applied. Whereas 
the significance of the ‘rules of evidence’ was unequivocal in Germany and England, 
the empirical evidence suggests that additional factors, or auxiliary variables, are at play 
in both countries. In England the additional factor that played a role is the question of 
how public pressure and criticisms might contribute to the outcome of certain cases. In 
Germany,  the  additional  factors  are  the  relative  bargaining  power  of  the  federal 
association  of  statutory  sickness  funds  vis  a  vis  other  stakeholders  and  the 
conceptualisation and operationalisation of the idea of patient relevance. Due to the 
political character of these variables they can be subsumed under questions of political 
power and influence, thus suggesting a connection to the political dimensions of HTA 
that were outlined in chapter 1. 
In the interest of comprehensiveness, the aforementioned topics are discussed in 
the following sections. However, because they represent outliers in the data that was 
collected – that is to say they were mentioned in some, but not all of the embedded case  
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studies – the analysis of the topics will be comparatively brief. I hope that including 
them in this thesis opens future avenues for exploring the role that public pressure and 
bargaining  power  play  in  determining  the  outcome  of  pharmaceutical  benefit 
assessments.  
 
8.2. Theme Six: Public Pressure as an Auxiliary Variable in England 
 
  The  nature  of  HTA  processes,  especially  when  they  have  an  impact  on  the 
availability of new pharmaceutical products within a given health care system, is such 
that HTA bodies frequently face criticism in the public arena, which may come in the 
form  of  media  campaigns,  protests  headed  by  patient  representatives  or  clinicians, 
and/or involvement of policy-makers such as politicians. This trend continues despite 
the  hope  that  HTA  processes  might  contribute  to  de-politicising  the  challenging 
decisions of pharmaceutical coverage. In NICE’s case, the empirical evidence suggests 
that the issue of public pressure may have played a role in two, namely Abiraterone and 
Fingolimod,  out  of  the  ten  cases  of  pharmaceutical  benefit  assessments  that  were 
studied. However, the relative effect of public pressure in the cases of Abiraterone and 
Fingolimod is difficult to measure as it is not a variable whose significance is easily 
admitted by stakeholders. Nevertheless, an overview of how the public became involved 
in the two cases suggests that it may have been an auxiliary variable that contributed to 
the outcome in these cases. 
  In the case of Fingolimod (see table 7.1.) the public pressure on NICE arose in 
the form of two letters by Members of Parliament (MPs). One letter made reference the 
problem of the ‘postcode lottery’ and the comparatively poor performance of the UK in 
terms of access to new treatments for multiple sclerosis. The MP in question wrote:  
 
I  am  […]  very  concerned  that  a  final  NICE  decision  not  to  approve  this 
medication would leave some people with  MS unable to  access  an effective 
treatment option, thus exacerbating both the ‘postcode lottery’ of MS treatment 
that already exists in this country and the relatively poor approach taken by the 
UK  to  MS  care  when  compared  with  other  European  countries  (McKinnel, 
2011). 
 
 
The  fact  that  the  postcode  lottery  and  its  associated  issues  of  inequality  and 
discrimination  are  referred  to  in  the  above  quote  is  interesting  as  it  reflects  an  
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appreciation of the values  contained in  the wider English  health care  paradigm.  As 
outlined in chapter 5 equality, non-discrimination and an end to the postcode lottery are 
amongst the core values that NICE’s paradigm is built on. The above quote suggests 
that stakeholders in England are aware of this and that this awareness might extend to a 
belief that NICE might re-think its position if one appeals to its core values of equality 
and non-discrimination. 
The MPs expressed their concerns as part of the consultation process at NICE. 
As the consultation process is open to the public, this in itself would not be noteworthy. 
However,  when  compared  with  the  other  nine  cases  of  pharmaceutical  benefit 
assessments, Fingolimod is the only case in which MPs got involved in the consultation 
process. Unfortunately, while this is a noteworthy and interesting observation, it does 
not permit any meaningful inferences about the impact this had on the outcome of the 
decision in this case, especially because it was not accompanied by a significant public 
campaign  in  the  media  or  otherwise.  Ultimately,  and  according  to  the  guidance 
produced  by  NICE  (2012d),  the  fact  that  the  pharmaceutical  manufacturer  of 
Fingolimod handed in a patient access scheme for the product seems to have contributed 
more significantly to NICE’s ability to recommend Fingolimod than the fact that two 
MPs got involved. However, by the same token, the influence of the MPs’ involvement 
as  an  auxiliary  variable  cannot  be  entirely  ruled  out  on  the  basis  of  the  empirical 
evidence. 
The  empirical  data  in  the  case  of  Abiraterone  (table  8.1.)  seems  to  provide 
stronger evidence than the data pertaining to Fingolimod to suggest that public pressure 
may  have  influenced  the  final  decision  by  NICE.  Abiraterone  (NICE,  2012f)  is  a 
pharmaceutical product that is licensed for castration-resistant metastatic prostate cancer 
previously treated with specific courses of chemotherapy. Abiraterone’s mode of action 
is  novel  in  that  it is not  a  chemotherapy, but  an anti-hormonal  treatment,  which is 
associated with less side effects than chemotherapies (NICE, 2012f). 
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TABLE 8.1. – Case Study: Abiraterone (NICE, 2012f; G-BA, 2012h; IQWiG, 2011c) 
Indicated for: Castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen 
 
 
 
NICE (2012)  FJC (2012) 
Dependent variable: Outcome 
of benefit assessment 
Recommended (Positive outcome)  Differing benefit assessment for 2 distinct patient 
populations (Positive outcome overall): 
- For ‘best-supportive’ care population: Indication 
for a significant added benefit  
- For Docetaxel re-therapy population: Added 
benefit not substantiated 
Reasoning/discussions/topic 
raised/public context 
- Initially not recommended, only recommended after presentation of 
new evidence 
- Patient Access Scheme (PAS) 
- End-of-life criteria met (initially not met because eligible patient 
population was considered too large) 
- Considered a ‘step change’ 
- Benefit of oral treatment not captured in QALY 
- Significant public campaign following the initial decision of NICE not 
to recommend it 
- Evidence issues: Patient population by manufacturer did not match the 
marketing license 
-  Only  accepted  one  out  of  four  randomised 
controlled  trials  (RCTs)  because  only  one 
matched  patient  population  and  comparator  as 
specified by FJC 
-  FJC  determined  additional  patient  relevant 
endpoints 
- Substantial critique by stakeholders of second 
subgroup  division  as  ‘docetaxel-retherapy’  as  a 
treatment option is not deemed to be underlined 
by sufficient evidence 
Differences/similarities   Positive recommendation, but only on second attempt 
- Accepted four RCTs 
- Specification of clinical outcomes accepted as presented by 
manufacturer 
 
- Subgroup divisions accepted 
- Saw problems with lack of congruence between RCT population and 
licensing population 
 
- Questions around clinical practice 
- Accepted ‘oral treatment’ characteristic as a point for consideration 
 Positive recommendation, highest benefit 
category but only for one patient subgroup 
- Accepted one RCT 
- Additional patient relevant endpoints required in 
addition to outcomes laid out by manufacturer 
- Additional/different subgroup divisions made 
- Saw problems with lack of congruence between 
RCT population and licensing population 
- Questions around clinical practice 
- Did not accept ‘oral treatment’ characteristic as 
a point for consideration  
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Table 8.1. shows that NICE and the FJC made an overall positive decision for 
Abiraterone. However, in NICE’s case this decision was only arrived at after reversing 
the draft recommendation, which did not recommend Abiraterone on the grounds of 
being  cost  ineffective.  The  FJC  categorised  the  additional  benefit  of  Abiraterone 
differently  for  the  two  relevant  patient  populations.  It  assigned  the  category  of 
‘significant  added  benefit’  to  the  patient  population  who  are  no  longer  eligible  for 
another course of chemotherapy and the category of ‘added benefit not substantiated’ 
for those who are still eligible for another course of chemotherapy (G-BA, 2012h). 
Besides  Ipilimumab,  Abiraterone  represents  the  only  case  included  in  this  thesis  in 
which  the  FJC  assigned  the  category  of  ‘significant  added  benefit’,  which  is  why, 
overall,  the  FJC’s  decision  can  be  described  as  positive  in  this  case.  Against  the 
backdrop of the discussion on what constitutes evidence that was presented in chapter 6, 
it is worth highlighting that NICE (2012f) accepted four RCTs as the evidence base in 
the case of Abiraterone, whereas the FJC only accepted one trial that, according to the 
FJC, matched the licensed population and appropriate comparator, thereby highlighting 
once again the importance of theme one and two (G-BA, 2012h). 
  In its Appraisal Consultation Document (ACD), a document that is published if 
the proposed recommendation is negative in order to allow for a consultation process, 
NICE did not recommend Abiraterone (NICE, 2012g). This was because the ICERs 
presented by the manufacturer – and that were already high at £63,200 per QALY - 
would  likely  increase  if  the  utility  values  of  different  health  states  were  modeled 
differently in the health economic model (NICE, 2012g). The initial recommendation by 
NICE  was  met with  large protests in  the form of an extensive media campaign by 
patient groups. The campaign criticised NICE’s draft recommendation on a number of 
issues that, broadly speaking, sought to appeal to the values base of the work that NICE 
does. Most importantly, it criticised that NICE was not convinced that Abiraterone met 
NICE’s end-of-life criteria because the eligible patient population was not considered to 
be small.  
As part of the public campaign that followed NICE’s publication of the ACD, 
statements in the media included, but were not limited, the following assertions about 
the draft recommendation: 
 
Cancer Research UK said the draft decision by the National Institute for Health 
and Clinical Excellence […] made “no sense” and that Nice had used the wrong  
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criteria  to  judge  the  drug.  […]  Owen  Sharp,  chief  executive  of  the  Prostate 
Cancer Charity, said: “[…] This draft is a bitter blow to thousands of men and 
their families and must be overturned” (Boseley, 2012). 
 
Abiraterone is the latest prostate cancer drug to face an NHS ban despite being 
proven to extent life for men with advanced disease […]. It is a fresh blow for 
doctors and patient who hoped a new era of drugs could lessen the deadly toll of 
prostate  cancer,  which  has  been  described  in  the  past  as  a  low-profile 
‘Cinderella’ disease (Hope, 2012) 
 
These examples highlight the protests that NICE faced around its draft recommendation 
on. Eventually, NICE reversed its original position and recommended Abiraterone as a 
treatment option. This was possible because it accepted that Abiraterone fulfilled the 
end-of-life criteria, which it had not originally, and because it was presented with new 
health  economic  analyses  (NICE,  2012f).  Explaining  the  reversal  of  the  original 
recommendation, Sir Andrew Dillon, chief executive of NICE, was quoted in a major 
media outlet as saying:  
 
During the consultation on the draft guidance […], the manufacturer of the drug, 
submitted further information for the committee to consider. This included a 
revised patient accesses scheme which involves providing the drug to the NHS 
at a discounted price, further information on which patients would benefit the 
most  and  clarification  on  how  many  patients  could  receive  the  drug.  These 
factors  enabled  the  committee  to  revise  its  preliminary  recommendation  and 
now recommend the drug for use on the NHS (Edgar, 2012).  
 
 
  While the above statement by Sir Andrew does not include a reference to the 
public campaign that proceeded NICE’s preliminary recommendations, a representative 
of a patient charity that was involved in the public campaign on Abiraterone suggested 
that the campaign generally, and the charity’s involvement in it specifically, may have 
contributed to NICE’s reversal of its position: 
 
We  did  do  some  work  publicly,  and  also  behind  the  scenes,  urging  the 
manufacturer to reduce their price in order for Abiraterone to be made available 
[…] I think that’s important and leading on from there […] is the […] public 
campaigning […] so even though I think the committee are quite rigid […] in 
terms of sticking to their guns […] if they don’t see the evidence and they don’t 
see something as being cost effective then they will mostly still continue to say 
‘no’ but I think what we did do was to communicate to our supporters and also 
to the media the case around Abiraterone and why it should be made available 
[…] we did make a difference there […] there was the public and there was the 
behind the scenes […] in terms of an argument and in terms of influencing […]  
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counteracting what NICE was saying in their draft decision and reasons why we 
didn’t think it was correct […] it made them think again […] (Interviewee No. 
19, 2013, p. 2) 
 
The  above  quote  reaffirms  the  strength  of  the  media  campaign  around 
Abiraterone, and the possible contribution it may have had to the final outcome, but it 
also raises an additional point, which suggests that Abiraterone might be an exceptional 
case. That is the point about the evidence and cost effectiveness. In Abiraterone’s case 
the  clinical  evidence  was  very  strong  and  the  stakeholders  agreed  that  is  was.  By 
contrast,  in  Cabazitaxel’s  case,  which  is  licensed  for  almost  the  identical  patient 
population as Abiraterone is and which was appraised in the same year as Abiraterone, 
the clinical evidence was less convincing and the Appraisal Committee did not reverse 
its decision to not recommend it. Even the charity that was involved in the consultation 
process in both cases admitted that there were flaws in the evidence for Cabazitaxel:  
 
[…] we were of the view that in terms of patient data and in terms of safety and 
quality of life issues we didn’t feel as if the manufacturer had provided enough 
evidence  or  the  trial  hadn’t  shone  a  light  on  those  concerns  […]  we  were 
disappointed  that  NICE  didn’t  recommend  Cabazitaxel  but  we  had  our  own 
concerns […] we weren’t too upset in terms of Cabazitaxel. Abiraterone was 
something completely different […] it was clinically effective, also had benefits 
in  terms  of quality of life and it was  life-extending […] also Cabazitaxel  is 
administered intravenously whereas Abirateron is in pill-form, so overall it was 
[…] very much an effective drug (Interviewee No. 19, 2013, p. 1). 
 
 
The  comparison  with  Cabazitaxel,  a  product  licensed  for  the  same  patient 
population as that of Abiraterone and at the same time, suggests that the success of a 
public campaign depends on the strength of the evidence of the clinical benefits of a 
new product. The empirical evidence presented above makes it difficult to envision a 
situation in which public pressure might lead to a reversal of NICE’s decision despite 
weaknesses in the evidence. The possibility cannot be ruled out, but the above data 
suggests  that  convincing  evidence,  and  the  appropriate  economic  modeling  thereof, 
remains the key that opens the possibility for NICE reversing a decision.  
It is also important to note that Abiraterone may in itself be an unique case with 
exceptional features in that it is a) not a chemotherapy despite the alternative treatments 
for the licensed population consisting mostly of chemotherapies and b) a product that 
can  be  administered  orally  and  was  thus  seen  as  providing  additional  benefits  by  
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patients  and  clinicians  alike.  In  addition  to  the  strong  evidence  on  its  clinical 
effectiveness, these special features of Abiraterone seemed to have contributed to its 
positive appraisal in the end.  
The  unique  characteristics  of  Abiraterone  and  the  strong  clinical  evidence 
arising from the clinical trials also appear to have contributed to stakeholders such as 
the main charity for prostate cancer to embark on a big public campaign. This claim 
arises from the previously presented observation that the charity decided to become 
active in the case of Abiraterone, but not in the case of Cabazitaxel. This suggests that, 
at least in the case of this charity, the commencement of a public campaign is weighed 
against its likely success. Since the evidence on Cabazitaxel was weak and the evidence 
on Abiraterone was strong it makes sense that the latter product became the centre of an 
extensive media campaign.  
Overall, the consultation documents, stakeholder interviews and media excerpts 
on Abiraterone suggest that NICE’s reversal of its decision was a result of reframing the 
clinical effectiveness evidence and adjusting the cost effectiveness calculations. Upon 
being  asked  about  what kind  of issues  determined whether NICE would  change  an 
originally negative recommendation, a former executive director at NICE confirmed the 
previous interpretation: 
 
[…] the biggest issue was interpretation of effectiveness and cost effectiveness 
[…] there would be a debate about what efficacy, effectiveness data should be 
used […]. The other big problem is that there may not be quality of life data in 
the trials, so there would be an application of quality of life from some other 
studies and applied them to the trial […]. Another big issue was the time horizon 
[…] it was normally very very – subjective is the wrong word – but depending 
on your viewpoint, what was the best evidence? (Interviewee No. 11, 2013, p. 
4). 
 
Together with the previous statements drawn from stakeholder interviews, the 
above quote  actually  reaffirms  the significance of the ‘rules  of evidence’, i.e. what 
constitutes evidence and how it should be interpreted, even when NICE is faced with 
public pressure or  when its  decisions  are being challenged. This  is  what  the above 
quoted interviewee referred to as “[…] depending on your viewpoint, what was the best 
evidence” (Interviewee No. 11, 2013, p. 4). In the end, a strong public campaign might 
contribute  to  a  reassessment  of  the  original  interpretation  of  the  evidence,  but  the 
evidence itself is at the core of how NICE justifies its ultimate decision. The presented  
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empirical analysis suggests that the public campaign on Abiraterone highlighted the 
need for approaching the evidence from a different angle, but that it was an auxiliary 
rather  than  a  stand-alone  factor  that  contributed  to  the  final  outcome  of  NICE’s 
appraisal of Abiraterone. 
 
8.2.1. Research Findings 
 
  The cases of Fingolimod and Abiraterone suggest that public pressure can act as 
auxiliary variable that contributes to the outcome of pharmaceutical benefit assessments 
in England. However, based on the sample of cases that was analysed in this thesis, this 
appears to be the exception rather than the rule. In order to better understand the role of 
public pressure, a separate research project that examines the cases in which there was a 
significant  public  campaign  and  whether  this  led  to  a  reversal  of  NICE’s 
recommendation  is  called  for.  While  this  is  beyond  the  scope  of  this  thesis,  the 
empirical evidence does suggest that public pressure can play a contributing factor in 
determining the outcome of pharmaceutical benefit assessments in England.  
  The above discussion highlights that the empirical evidence gives rise to the 
auxiliary variable of ‘public pressure’ in the context of the English HTA paradigm. It 
should be labeled as auxiliary for two reasons. Firstly, the cases that give rise to a 
significant public campaign seem to be the exception rather than the rule. The case of 
Abiraterone suggests that whether a public campaign is initiated depends on the relative 
strength of the available clinical and cost effectiveness evidence, but more case studies 
would be required to confirm this interpretation.  The second reason for why public 
pressure  should  be  labeled  auxiliary  is  based  on  the  observation  that  even  in  the 
instances in which a public campaign is initiated and NICE’s decision is challenged, the 
reasoning process used by NICE and the involved stakeholders comes back to question 
of the ‘right’ evidence and the appropriate interpretation thereof. The public campaign 
might contribute to raising the awareness around a product, but ultimately NICE and the 
involved stakeholders frame their arguments around evidence questions. This in turn 
reaffirms the significance of the ‘rules of evidence’ of what determines the outcome of 
pharmaceutical benefit assessments.  
  In  conclusion,  the  discussion  on  the  role  of  public  pressure  as  an  auxiliary 
variable in the English context gives rise to the following research findings:  
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1.  The auxiliary variable in the English HTA paradigm is public pressure. It is 
auxiliary in the sense that it does not arise in every case and when it does, the 
ultimate  decision-making  reasoning  by  NICE  still  centres  on  evidence-based 
questions. 
2.  The way in which the public campaign and protests were framed in the case of 
Fingolimod  and  Abiraterone  confirms  the  existence  of  a  shared  value-based 
HTA paradigm. In both cases public statements included references to values 
such  as  equality,  non-discrimination,  and  a  general  concern  for  the  fate  of 
patients, all of which are at the heart of the wider paradigm under which the 
NHS operates. This confirms a) that policy paradigms exist in HTA systems and 
that they reflect wider ideas and values and b) a consonance between the HTA 
paradigm as it is laid out in theory and how it is operationalised in practice in 
England. 
3.  The  fact  that  arguments  and  re-interpretations  are  framed  with  reference  to 
evidence questions by stakeholders such as patient groups and decision-makers, 
even when re-assessing a decision amidst public pressure, reaffirms the central 
role  that  the  ‘rules  of  evidence’  play  in  determining  the  outcome  of 
pharmaceutical benefit assessments. 
 
For Germany the empirical evidence does not suggest that public pressure plays 
a role as an auxiliary variable. Instead the questions of bargaining strength amongst 
stakeholders  and  the  operationalisation  of  patient  relevance  arise  within  the  theme 
pertaining to political power and influence. These questions are discussed in the next 
section. 
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8.3. Theme Six: Bargaining Powers and the Idea of Patient Relevance as Auxiliary 
Variables in Germany 
 
  Individual  pharmaceutical  benefit  assessments  receive  comparatively  little 
attention in the public arena in Germany. There was no significant public campaign in 
any of the cases that were analysed as part of this thesis. Public pressure as an auxiliary 
variable in Germany does not seem to play the role it does in England. Instead, the 
empirical evidence indicates that the relative bargaining power amongst stakeholders, as 
well as the operationalisation of patient relevance, might contribute to the outcome of 
pharmaceutical benefit assessments.  In relation to the latter, stakeholders perceive  a 
dissonance between the theory and the practice of the concept of patient relevance. In 
terms of the former, stakeholders are suggesting that the strong position of the federal 
association  of  statutory  sickness  funds  in  the  early  benefit  assessment  process  may 
impact on the ultimate outcome of the assessments in the sense that the association can 
shape the decision problems of the assessments in a way that benefits their interests. A 
brief overview of how these two issues are constructed in the empirical evidence is 
given in the following sections. 
  As  outlined  in  chapter  4,  the  institutional  structure  of  the  early  benefit 
assessment process in Germany is such that the federal association of statutory sickness 
funds, that is the umbrella organisation for all sickness funds and the representation of 
payers’ interests, is involved at every stage of the assessment process. As a member of 
the FJC the federal association of statutory sickness funds is involved in the decision on 
what  the  appropriate  comparator  should  be.  Upon  receiving  a  recommendation  by 
IQWiG,  it  is  then  involved  in  making  a  decision  on  the  added  benefit  of  a  given 
pharmaceutical  product.  Finally,  the  association’s  representatives  negotiate  the 
reimbursement price based on the early benefit assessment and other considerations in 
the  price  negotiations  with  the  pharmaceutical  manufacturers.  In  the  empirical  data 
gathered as part of this thesis, the role of the association of statutory sickness funds has 
been characterised as “dominant”. The concern over the strong position of the federal 
association  of  statutory  sickness  funds  was  especially  raised  by  pharmaceutical 
representatives: 
 
[…] the question of the appropriate comparator is crucial in the whole process 
and  its  connected  to  another  problem,  namely  that  the  same  people  always 
decide  on  the  crucial  procedural  steps  […]  the  FJC  dominates  through  the  
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federal  association  of  statutory  sickness  funds  […].  [It]  decides  on  the 
appropriate comparator, then on the added benefit and in the end it negotiates 
with the manufacturer (Interviewee No. 14, 2013, p. 3)
34. 
 
 
  According  to  the  pharmaceutical  represe ntatives  who  were  interviewed  in 
Germany the strong position of the federal association of statutory sickness funds 
impacts on the outcome of pharmaceutical benefit assessments because the choice of the 
appropriate comparator essentially determines how the assessment will proceed and 
what the likely outcome will be. As discussed in the case of Retigabine, IQWiG (2012d) 
and the FJC (2012f) were not of the view that the appropriate comparator was chosen 
for the early benefit assessment. This decision rendered the manufacturer’s submission 
and the analysis of the clinical effectiveness evidence useless to such an extent that the 
presented evidence was not even considered by IQWiG and the FJC because it was 
based  on  the  ‘wrong’  comparator.  The  choice  for  comparator,  to  which  the  federal 
association of statutory sickness funds can contribute within the FJC, had a real impact 
in this case.  
  Connected to the perception that the strong position of the federal association of 
statutory sickness funds plays a big role in the German HTA system is another concern 
that  was  raised  frequently  during  the  interview  process  with  pharmaceutical 
manufacturers,  namely  the  concern  that  the  association  has  a  stronger  bargaining 
position in the price negotiations by virtue of the fact that it is involved in every step of 
the assessment process and that it is an experienced negotiator due to the number of 
negotiations it is involved in. One representative of the pharmaceutical industry alerted 
to this issue as follows: 
 
[…]  we  have  a  classic  monopolisation  due  to  the  fact  that  it  [the  federal 
association  of  statutory  sickness  funds]  always  negotiates,  it  has  extreme 
learning curve effects […] it has a market dominance […], it can develop tactics 
[…] it is an ideal world for the federal association of statutory sickness funds. 
For the manufacturers the situation is: some have more experience because they 
have done 2 or 3 negotiations […] others have one product, small biotechnical 
manufacturers […] they have one product every 3 years and they are completely 
disadvantaged […]. […] the federal association of statutory sickness funds will 
have 120 negotiations in 3 years (Interviewee No. 6, 2013, pp. 9-10)
35. 
   
                                                        
34 Translation provided by the author of this thesis. 
35 Translation provided by the author of this thesis.  
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While the above concern moves beyond the question of what determines the outcome of 
pharmaceutical benefit assessments as it relates to the stage that comes after the benefit 
assessment, it is still noteworthy because it highlights the antagonistic way in which the 
federal  association  of  statutory  sickness  funds  is  viewed  by  the  pharmaceutical 
stakeholders in Germany.  
The  frequency  with  which  this  issue  was  raised  in  the  interviews  justifies 
mentioning it as a possible auxiliary variable, but it is not without caveats. The main 
caveat is that the dominance of the federal association of statutory sickness funds was 
mainly raised  as  an issue  by pharmaceutical  manufacturers.  It  might  therefore  be  a 
reflection of a phenomenon that one might usually expect in a corporatist system that 
relies heavily on bargaining structures and the power distributions these gives rise to. 
More research would have to be undertaken to determine exactly how the institutional 
distribution  of  bargaining  power  affects  the  outcome  of  pharmaceutical  benefit 
assessments in Germany, but such research is beyond the scope of this thesis.  
The  second  caveat  is  the  fact  that  the  criticism  raised  by  pharmaceutical 
representatives in Germany fails to take account of the fact that, at the two crucial 
stages of the assessment process, i.e. the determination of the appropriate comparator 
and the appraisal of the added benefit, the federal association of statutory sickness funds 
is not the sole decision-maker in the process. That is to say, that it represents only one 
member group in the FJC, the other member groups are the physician and the hospital 
associations. While the federal association undoubtedly is a big player in making the 
decision on the choice of comparator and in deciding on the added benefit of a product, 
it is not the only player.  
In terms of the values of accountability and transparency, the criticisms voiced 
by pharmaceutical manufacturers in relation to the question whether a member of the 
FJC should be involved in the price negotiations, appear legitimate. However, it is more 
difficult to understand why the federal association of statutory sickness funds should be 
conceived of as the sole culprit of pursuing one’s own interests in the process. The fact 
that stakeholders raise such concerns about the dominant role of the federal association 
of statutory sickness funds demonstrates that there are underlying concerns amongst the 
stakeholder community about the institutional basis of the HTA paradigm in Germany. 
The questions of whether or not these concerns are justified and how the dominance of 
the payers’ association in the benefit assessment process impacts on the outcome of 
assessment processes requires further in-depth research that is beyond the scope of this  
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thesis. If future research can confirm that the dominance of the federal association of 
statutory sickness funds indeed contributes to benefit assessment outcomes, this would 
be  a  significant  finding  in  relation  to  the  role  played  by  institutional  variables  in 
Germany. 
In addition to the perceived dominance of the federal association of statutory 
sickness funds in the early benefit assessment process, the empirical data suggests a 
dissonance between how the theoretical premise of ‘patient relevance’, the key idea 
within the German HTA policy paradigm, is perceived by stakeholders and how it is 
operationalised by decision-makers in practice. This dissonance arises from the debates 
around the definition and operationalisation of the concept of patient relevance in case-
specific contexts and how a stringent and formal approach to defining the concept helps 
explain the outcome of pharmaceutical benefit assessments in certain cases. 
As  outlined  in  chapter  5,  the  added  benefit  of  a  pharmaceutical  product  is 
measured by its patient relevant therapeutic effect, which is expressed by way of patient 
relevant  clinical  endpoints.  The  main  endpoints  that  the  FJC  and  IQWiG  consider 
patient relevant are mortality, morbidity and quality of life in terms of side effects. In 
each case of an early benefit assessment IQWiG and the FJC decide which clinical 
endpoints, in addition to the ones just mentioned, will be considered patient relevant. In 
addition to the centrality of mortality, morbidity and quality of life the two HTA bodies 
operationalise the concept of patient relevance by focusing on what the patient feels and 
whether this can be measured. According to a representative of the FJC this explains 
why, for example, laboratory parameters that are included in a given clinical trial will 
not automatically be considered patient relevant: 
 
[…] laboratory parameters alone are not usually considered patient relevant. […] 
we had big discussions about this in the case of hepatitis and the virus load […] 
do  I  have  hepatitis  if  I  can  detect  it  [in  the  blood]  or  not?  […]  what  is 
symptomatic,  what  the  patient  feels,  quality  of  life  etc.  […]  that  is  patient 
relevant (Interviewee No. 16, 2013, p. 3). 
 
The above quote helps explains why, in the case of Telaprevir and Boceprevir, 
IQWiG  only  accepted  the  main  clinical  endpoint  of  sustained  virological  response 
(SVR)  as  a  surrogate  endpoint  for  the  patient  relevant  endpoint  of  hepatocellular 
carcinoma,  but  not  as  a  patient  relevant  endpoint  in  itself.  In  IQWiG’s  view,  the 
clearance  of  the  hepatitis  C  virus  from  the  blood  does  not  allow  for  an  accurate  
  244 
measurement  of  how  the  patient  feels  or  whether  he/she  will  develop  follow-on 
complications from the hepatitis C infection in the future, which is why SVR in itself 
could not be considered patient relevant (IQWiG, 2012c). Similarly, IQWiG and the 
FJC do not usually accept the endpoint ‘progression-free survival’ as a patient relevant 
endpoint  in  the  assessment  of  oncological  products  because  it  does  not  accurately 
express what a patient feels: 
 
[…] what the patients do not feel […] is not patient relevant. […] things that 
patients do not feel but that only become apparent through diagnostic imagining, 
through laboratory diagnostics […] we would say […] progression-free survival 
in the case of oncological therapies in which the progression is only determined 
through diagnostic imaging […] is not a patient relevant endpoint per se […] 
(Interviewee No. 23, 2013, p. 5). 
 
 
  The  above  examples  illustrate  how  patient  relevance  is  conceptualised  and 
operationalised  by  IQWiG  and  the  FJC.  However,  this  conceptualisation  and 
operationalisation  is  criticised  by  the  stakeholders  as  being  too  narrow  in  what  is 
considered patient relevant. For example, the form of administration, i.e. intravenous or 
oral, of a pharmaceutical product is not considered patient relevant by IQWiG and the 
FJC because it cannot be measured as a clinical endpoint. This meant that in the case of 
Abiraterone and Fingolimod the form of administration was considered as an additional 
benefit of the treatment by NICE (2012d) while IQWiG (2012e) and the FJC (G-BA, 
2012g) did not consider that this aspect gave rise to additional benefits. While the term 
‘patient relevance’ led pharmaceutical manufacturers and other stakeholders to argue 
that the form of administration could be considered relevant to the patients (G-BA, 
2012g),  IQWiG  and  the  FJC  did  not  see  its  effect  in  any  clinical  endpoints  and 
concluded that the effects of the form of administration on the actual state of health of 
the patients could not be measured. 
  Connected to the criticism that IQWiG’s and the FJC’s conceptualisation, and 
especially  their  operationalisation,  of  patient  relevance  is  the  criticism  that  the 
involvement  of  patients  in  the  early  benefit  assessment  is  comparatively  under-
developed. Stakeholders in Germany question the legitimacy of the use of the concept 
of patient relevance if patient representatives are not asked about their view of what is 
patient relevant in specific cases. This seems to reflect an institutional situation in which 
patient  groups  do  not  make  a  wide  use  of  the  involvement  mechanisms  that  are  
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available to them and in which an insitutionalised patient representation  in the FJC 
speaks  for  all  patients  rather  than  for  specific  patients  with  certain  diseases.  The 
following excerpts of the stakeholder interviews exemplify how the above issues are 
being framed in the discussion of what determines pharmaceutical benefit outcomes in 
Germany: 
 
[…]  typically  the  industry  fights  with  the  FJC  or  IQWiG  about  the  patient 
relevance. We say one thing, they say another, but de facto only patients can 
answer the question whether something is relevant for him (Interviewee No. 14, 
2013, p. 4) 
 
[…] we do not notice the patient representation […], that may be a result of the 
degree  of  organisation  considering  the  patient  groups  often  have  voluntary 
members who cannot get involved so much due to time constraints. […] if you 
would give the patients a stronger voice in the FJC or on the topic of patient 
relevance, but I think one would have to formalise this. One cannot say we will 
wait until the patients get involved and then we will consider it somehow […]. 
Instead […] the impetus has to come from the institutional side to say, we want 
to  consider  patients  more  and  that  is  why  we  are  creating  the  structure  that 
makes this possible (Interviewee No. 12, 2013, p. 8). 
 
 
  The brief overview of how the issue of patient relevance and the associated issue 
of  patient  involvement  are  framed  in  the  German  HTA  context  is  relevant  as  an 
auxiliary variable to answering this thesis’ research question because it suggests that the 
different  ways  in  which  the  key  concept  of  patient  relevance  is  interpreted  by  the 
different stakeholders plays a role in what clinical endpoints are considered by the FJC 
as part of a benefit assessment. The inclusion or exclusion of clinical endpoints has a 
direct impact on how strong or weak the evidence base is, which in turn impacts on the 
outcome of a pharmaceutical benefit assessment. Empirically this means that IQWiG’s 
and the FJC’s operationalisation of patient relevance contributes to the final outcome of 
pharmaceutical  benefit  assessment.  This  is  directly  connected  to  how  concepts  and 
values are defined within the rules  of evidence that were discussed in  the previous 
chapters. As such the significance of patient relevance is an extension of the previously 
discussed  rules  of  evidence.  However,  what  is  striking  about  concept  of  patient 
relevance is the heated debate amongst stakeholders about what is and what should be 
considered patient relevant, which gives rise to a within-paradigm dissonance that is 
described below.  
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   The conceptualisation and operationalisation of patient relevance in the German 
system gives rise to a dissonance between the perceived theory and practice of the HTA 
paradigm. This observation is of great relevance to the theoretical premise of this thesis 
in  that  there  seems  to  be  confusion  amongst  stakeholders  around  the  meaning  and 
implications  of  the  idea  of  patient  relevance,  which  indicates  a  within-paradigm 
contestation of this term. This contestation gives rise to questions about the institutional 
basis  of  the  Germany  benefit  assessment  system  and  the  comparative  lack  of 
involvement of patients.  
Three  scenarios  are  imaginable  when  it  comes  to  resolving  the  apparent 
dissonance within the German HTA paradigm. The first one is a further specification as 
to  how  the  FJC  and  IQWiG  conceptualise  and  operationalise  patient  relevance,  the 
second one is a pragmatic approach in which the two organisations gradually widen the 
operationalisation of the term and the third one is an institutional solution in which 
patients are given more of a voice on how patient relevance should be understood. An 
assessment of the likelihood of each of the scenarios is beyond the scope of this thesis. 
For the purpose of this thesis, the key finding that arises from the above discussion is 
that, in contrast to the English paradigm, the empirical evidence suggests that key ideas 
of the German HTA paradigm are contested in practice, which a) leads to a dissonance 
between paradigm theory and practice and b) might lead to a revision of key concepts in 
the  German  HTA  paradigm  to  account  for  the  current  definitional  and  operational 
challenges in the future.  
 
8.3.1. Research Findings 
 
  The empirical evidence, and especially the interviews with stakeholders from the 
pharmaceutical industry in Germany, gives rise to the strength of bargaining powers of 
certain stakeholders vis a vis others as a contributor to the outcome of pharmaceutical 
benefit assessments. For the purposes of comprehensiveness this theme was included in 
the empirical section of this thesis. However, due to the fact that it was predominantly 
raised  as  an  possible  explanatory  variable  by  pharmaceutical  stakeholders,  the  true 
impact of the relative bargaining power of certain stakeholders vis a vis others in the 
bargaining  process  cannot  be  conclusively  assessed  within  the  scope  of  this  thesis. 
Future research is needed to assess the impact of this issue and such research would 
need to include an analysis of documents such as minutes of FJC meetings in which the  
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appropriate comparator is discussed and minutes of negotiations between the sickness 
insurance  funds  and  the  pharmaceutical  manufacturers.  This  data  is  currently  not 
available in the public domain, which further exacerbates the problem of assessing the 
role that the bargaining power of certain stakeholders plays in determining the outcome 
of pharmaceutical benefit assessments in Germany. 
  Despite  the  aforementioned  caveats  in  relation  to  ‘bargaining  power’  as  an 
auxiliary variable, the fact that it was raised by stakeholders in the interview process 
and in FJC hearings contributed to the research findings that are presented in this thesis. 
As  previously  discussed,  one  of  this  thesis’  research  findings  is  that  HTA  policy 
paradigms  are  different  in  different  countries  and  that  this  difference  reflects 
institutional and ideational differences of the wider health care paradigm. Regardless of 
the fact that the issue of ‘bargaining power’ arose predominantly in interviews with 
pharmaceutical  stakeholders,  the  fact  that  it  arose  at  all  reflects  the  institutional 
paradigmatic construct of the German system as a corporatist system. Corporatist health 
care systems are based on bargaining structures, powers and struggles and it is not 
surprising  that  at  least  one  stakeholder  group  views  the  institutional  structure  as  a 
contributing factor in pharmaceutical benefit assessments. Vice versa, the fact that this 
issue does not arise in the English context reflects a system in which struggles over 
bargaining power are less pronounced. Thus, the fact that the auxiliary variables that 
arise from the empirical evidence differ in Germany and England further supports the 
conclusion that HTA policy paradigms are different and that they reflect that wider 
health care paradigms. 
  The  controversy  around  patient  relevance  acts  as  an  auxiliary  variable  in 
Germany. This is mainly because, as was highlighted in the previous chapters, ‘patient 
relevance’ is a recurring sub-theme in the majority of the themes that arise from the 
empirical data. The above empirical examples in relation to the cases of Fingolimod, 
Abiraterone, Telaprevir and Boceprevir reaffirm the central role of the idea of patient 
relevance  as  an  overriding  value  within  the  German  HTA  paradigm.  However,  in 
addition to this reaffirmation, the discussion presented in this section in relation to how 
the conceptualisation and operationalisation of patient relevance is contested gives rise 
to a further noteworthy research finding.  In relation to the value, or idea of patient 
relevance,  there  is  a  dissonance  between  the  theory  and  the  practice  of  the  HTA 
paradigm  that  manifests  itself  by  different  stakeholders  conceptualising  patient 
relevance differently, with some arguing that the concept should be understood more  
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literally to include patients’ views more widely. However, the illustrative quotes by 
representatives from IQWiG and the FJC suggest that currently the principle of patient 
relevance should neither be equated with patient preferences nor with aspects of patient 
involvement.  The  principle  should  solely  be  viewed  within  the  context  of  clinical 
benefits. 
The  exact  effect  of  the  described  dissonance  on  the  ultimate  outcome  of 
pharmaceutical  benefit  assessments  is  difficult  to  evaluate.  However,  the  empirical 
evidence presented in this thesis suggests that the operationalisation of the concept of 
patient relevance has a big impact on which evidence is included in an assessment, that 
is to say that clinical trials are only included if the clinical endpoints are considered 
patient relevant. This in turn has a big impact on the outcome of the pharmaceutical 
benefit assessment as this is based on the available evidence.  
More importantly though, the dissonance between theory and practice within the 
German  HTA  paradigm  has  significant  theoretical  implications.  It  suggests  a 
disagreement  within  the  stakeholder  community  on  how  the  concept  of  patient 
relevance should be articulated and operationalised in normal decision-making. Except 
for general criteria such as mortality, morbidity and quality of life policy-makers in 
Germany did not specify how the concept of patient relevance could, or should, be 
operationalised. This led to an articulation of the paradigm in a way that does not take 
account of patient preferences and patient involvement. This in turn is criticised by 
stakeholders who question whether the operationalisation of patient relevance is in line 
with the wider paradigm. Thus, while the patient relevance paradigm can be described 
as dominant in the German context, multiple understandings of patient relevance appear 
to exist. This demonstrates that an idea such as patient relevance can mean different 
things  to  different  stakeholders.  It  implies  that paradigms  can  face  within-paradigm 
contestation  that  might  ultimately  lead  to  changing  or  further  developing  certain 
principles. This can be expected for the principle of patient relevance in Germany.  
In summary, the discussion of the auxiliary variables of ‘bargaining power’ and 
the  conceptualisation  of  patient  relevance  in  the  German  context  gives  rise  to  the 
following research findings: 
1.  The  empirical  evidence  pertaining  to  pharmaceutical  benefit  assessment 
processes in Germany gives rise to two potential auxiliary variables: the relative 
bargaining  power  of  certain  stakeholders  vis  a  vis  others  and  the 
conceptualisation of patient relevance. While the validity of the first variable is  
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difficult to assess because of a potential bias arising from the fact that only 
pharmaceutical representatives raised it and because of a lack of available data 
to validate the claim, the contributory role played by second variable is less 
caveated  because  it  arises,  in  different  formats,  throughout  the  empirical 
evidence that was analysed.   
2.  The contrast between auxiliary variables in England and in Germany suggests 
that  the  HTA  policy  paradigms  are  different  in  both  countries  and  that  this 
difference determines which auxiliary variables might contribute to the outcome 
of pharmaceutical benefit assessments. The difference also reflects  the wider 
health care paradigms in both countries in that the auxiliary variables outlined in 
the case of German are logical extensions of a corporatist health care system, 
whereas  the  role  of  public  pressure  in  England  suggests  that  accountability 
towards the patients and the public dominates the sphere of auxiliary variables. 
3.  Finally, the importance of the definition and operationalisation of the idea of 
patient  relevance  in  the  German  HTA  paradigm  has  significant  theoretical 
implications with regards to the theory and practice of policy paradigms. The 
German case highlights that within-paradigm dissonances and contestations can 
exist, meaning that paradigms  are fluid rather than rigid  constructs that may 
develop  and  change during normal  decision-making processes, depending on 
how severe the dissonances between theory and practice are. This underlines 
Kuhn’s (1962) point that a paradigm can only be understood by examining its 
application  in  normal  science  or,  for  the  purpose  of  this  thesis,  in  normal 
decision-making processes. 
 
In  the  next  and  final  chapter  I  draw  together  the  conclusions  and  research 
findings that the previous empirical analysis gave rise to and outline areas for further 
research into what determines the outcomes of pharmaceutical benefit assessments in 
countries that employ formalised HTA procedures.  
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Chapter 9 
 
Conclusion 
 
9.0. Introduction 
 
The  preceding  chapters  demonstrated  that  HTA  paradigms  in  England  and 
Germany are different (table 9.1.)
36. In fact, except for the underlying rationale for 
conducting HTAs, the importance of thresholds (albeit in different formats) and a value 
core, table 9.1. suggests more differences than similarities when it comes to institutional 
and ideational features that characterise HTA paradigms. Based on the identification of 
the HTA paradigms one might therefore conclude that these differences play a role in 
determining the outcome of pharmace utical benefit  assessments.  However, the six 
themes (table 6.1.) that emerged from the empirical analysis indicate more similarities 
in what matters with regards to the operationalisation of the paradigms than might have 
been expected, therefore underlining the theoretical premise that the mere identification 
of a paradigm is insufficient when it comes to understanding its effect. In practice, that 
is when paradigms are established and applied in normal decision -making, only three 
categories of factors (table 9.2.) appear to matter. These are the rules of evidence that 
paradigms give rise to, the core and periphery of values  and procedural characteristics 
such as patient involvement and public pressure.   This implies that paradigms are 
nuanced in the way they operate. By e xamining how they are applied in practice, we 
learn about their crucial features and what distinguishes them from those in other 
national contexts. 
There is a striking similarity in the  kind of issues that arose in the consultation 
and  decision-making  processes  in  the  ten  embedded  cases.  The  broad  themes  that 
emerged were identical. Five out of six themes centred on questions of the quality, 
appropriateness and interpretation of evidence. However, the way the HTA agencies 
dealt with these themes and addressed the issues was different, thus suggesting that 
different rules of evidence arise in the process  of articulating HTA paradigms. The 
                                                        
36 Table 9.1. depicts the main features of the HTA paradigms in Germany and England as they 
were identified in chapters 4 and 5. They are presented in relation to the potential independent 
variables outlined in table 3.2. (chapter 3) in order to give an indication of the variables that 
would  affect  the  outcome  of  pharmaceutical  benefit  assessments  according  to  the  HTA 
paradigm.  
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empirical analysis demonstrates that the outcome of pharmaceutical benefit assessments 
in health care systems that employ formalised HTA procedures is determined by how a 
similar  set  of  themes  around  the  evidence  base  on  a  pharmaceutical  product  gets 
transformed, interpreted and framed in the context of a given HTA paradigm. 
In this final chapter I present and discuss the research findings that gave rise to 
the  aforementioned  conclusion.  There  are  eight  findings  that  emerged  from  the 
empirical  analysis.  The  findings  were  interpreted  with  reference  to  the  theoretical 
framework presented in chapter 2, the HTA paradigms outlined in chapters 4 and 5 and 
the dimensions of HTAs that were introduced in chapter 1. Following the discussion of 
the research findings,  I provide an overview of the implications of the research, its 
limitations and possible areas for future study. 
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TABLE 9.1. – HTA Paradigms England and Germany (See chapters 4 and 5 for detailed discussion) 
Features of the HTA 
paradigm 
England  Germany 
Decision-making in health care 
(=Institutional feature (IV2)) 
Centralised,  national  decision-making  on  the  coverage  of 
new pharmaceuticals.  
Localised  decion-making  on  implementation  of  national 
guidelines and health care service provision. 
Corporatist decision-making structures based on bargaining 
between providers and payers (statutory sickness insurance 
funds) 
Challenges to the health care 
system, i.e. resource 
considerations (=Institutional 
feature (IV2)) 
Acknowledgement of finite health care resources in NHS 
Constitution 
Lack of acknowledgement of finite health care resources in 
Social Code Book V 
Cost containment policies 
(=Institutional feature (IV2)) 
Long  history  of  cost  containment  and  priority  setting  in 
health  care.  Expressed  in  terms  of  ‘value  for  money’  in 
NHS Constitution. 
Priority  setting  not  an  established  feature.  Controversies 
around whether priority setting is occurring.  
Nikolaus-case gave rise to a right to health care treatment 
even if evidence of effectiveness is lacking. 
Values & principles 
(=Ideational features (IV1)) 
Reference to wider social values such as equality and non-
discrimination in NHS Constitution.  
Reference  to  health-specific  values  such  as  right  to 
treatment and solidarity. 
Purpose of HTA (=Institutional 
features (IV2)) 
To  recommend  the  in-  or  exclusion  of  a  pharmaceutical 
product based on its clinical and cost effectiveness. 
To inform price setting negotiations between the sickness 
insurance funds and the pharmaceutical manufacturers. 
Procedural values of HTA 
(=Institutional features (IV2)) 
Importance of accountability and transparency recognised. 
Stakeholders  involved  in  each  of  the  numerous  steps  of 
HTA, i.e. in assessment and appraisal stages. 
Importance of transparency recognised. 
Procedural steps of HTA limited. Stakeholder involvement 
limited to hearings in assessment stage, no involvement in 
appraisal stage. 
Rationale of HTA (IV 2 & 3)  There can and should be a limit on what a health care state 
(Moran, 1999) should be willing to pay. 
There can and should be a limit on what a health care state 
(Moran, 1999) should be willing to pay. 
HTA criteria and principles 
(=Institutional and ideational 
features (IV 3)) 
Clinical and cost effectiveness. Thresholds in the form of 
ICERs.  
Thresholds  conceptualised  as  thresholds  for  ‘value  for 
money’ 
Clinical  effectiveness  conceptualised  as  the  therapeutic 
patient  relevant  effect.  Six  categories  of  added  benefit. 
IQWiG  employs  own  method  for  operationalisation  of 
thresholds between benefit categories. 
Thresholds conceptualised as thresholds for ‘right’ price. 
Core and periphery of values 
(IV 1 & IV 3) 
Yes, cost effectiveness as the most important value. Other 
values such innovation and social values can be considered. 
Yes,  patient  relevance.  Benefit  categories  express  other 
values such as innovation.  
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TABLE 9.2. – Paradigms in Normal HTA Decision-Making in England and Germany (see chapters 6-8 for detailed discussion) 
 
Operationalisation  and  articulation  of  the 
paradigm based on case study analyses of 
what factors that determine the outcome of 
pharmaceutical benefit assessments. 
England  Germany 
HTA criteria and principles (=IV 3)  The majority of factors that are considered are 
related  to  questions  of  evidence,  the  quality 
and  the  interpretation  thereof.  Rules  of 
evidence are applied, i.e. use of thresholds in 
the form of ICERs.  
Rules  of  evidence  are  the  expression  of  the 
HTA paradigm. 
The majority of factors that are considered are 
related to questions of evidence, the quality of 
evidence and the interpretation thereof. Rules 
of evidence are applied, i.e. the need for the 
comparator  product  to  reflect  the  licensed 
indication  and  the  non-consideration  of 
laboratory  parameters  as  patient  relevant 
endpoints. 
Rules  of  evidence  are  the  expression  of  the 
HTA paradigm. 
Core and periphery values (=IV 1 & IV 3)   Cost effectiveness (=core) has to be ensured.  
End-of-life criteria (=periphery) are applied in 
order  to  ensure  cost  effectiveness  in  some 
cases.  
Once cost effectiveness is given, other factors 
such  as  innovation  (=periphery)  can  be 
considered. 
Patient  relevance  (=core)  has  to  be  ensured. 
Controversies  around  conceptualisation  and 
operationalisation  of  the  term.  Other 
principles  do  not  play  a  large  role.  This 
suggests no significant values at the periphery 
of decision-making. 
Procedural values (=IV 2)  Public  pressure  and  stakeholder  involvement 
may affect the outcome in exceptional cases. 
Distribution  of  bargaining  powers  between 
stakeholders  may  affect  the  outcome  in 
exceptional cases.  
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9.1. Research Findings 
 
  The six themes (table 6.1.) that were identified in the empirical data can be 
subsumed under three features of the HTA paradigms (table 9.2.). During the process of 
normal decision-making, the factors that matter the most in determining the outcome of 
benefit assessments are the criteria of HTA in the form of rules of evidence, the core 
and periphery of values and, in exceptional cases, procedural values with regards to 
stakeholder involvement. All of these factors emerged as relevant in relation to themes 
that centred on questions of evidence. This indicates that the factors that play a role in 
normal decision-making are more limited than the principles that are contained in the 
overall  paradigm.  In  HTA  decision-making  processes  principles  that  require 
specification such as the question of how to operationalise thresholds play an important 
role, whereas other features of the HTA paradigm such as equality or solidarity appear 
to be adhered to implicitly but not referred to explicitly.  
What follows is an overview of the eight research findings that emerged from 
this study, which will qualify the above statements in more detail.  
  
9.1.1. Research Finding One: ‘Rules of Evidence’ Matter 
 
The empirical evidence suggests that the most important variable in determining 
the outcome of pharmaceutical benefit assessments is what Majone (1989) refers to as 
the ‘rules of evidence’. What constitutes evidence as part of a pharmaceutical benefit 
assessment, how it is defined and the criteria by which it is interpreted play a key role in 
determining the outcome of assessments. This finding is supported by the fact that five 
out  of  six  themes  that  emerged  from  the  empirical  data  centred  on  questions  of 
evidence. The kind of issues that were discussed was similar in England and Germany. 
However, the way in which the issues were addressed differed. This difference can be 
explained  by  different  rules  of  evidence  that  are  applied  in  the  process  of  normal 
decision-making. 
The three empirical chapters discussed the six themes that emerged from the 
data.  Chapter  6  outlined  how  evidence  is  conceptualised  in  different  HTA  policy 
paradigm contexts and how this impacts on the final outcome of pharmaceutical benefit 
assessments. Chapter 7 dealt with operational questions such as the definition of patient 
subgroups and comparator products for the purpose of assessments. Chapter 8 extended  
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the discussion by presenting auxiliary variables that might play a role in individual 
cases  of  pharmaceutical  benefit  assessments.  Each  of  the  chapters’  conclusions 
highlighted the importance of the so-called rules of evidence for the final decision in a 
given case.  
The importance of the rules of evidence is exemplified by how a given HTA 
policy  paradigm  responds  to  ‘special’  cases  in  which  long-term  effects  of  a  given 
medicine cannot be captured accurately by the average length of randomised controlled 
trials (RCTs). Decisions on whether or not to use certain pieces of evidence ultimately 
have  an  effect  on  the  final  decision  of  pharmaceutical  benefit  assessments  as  the 
exclusion of certain pieces of evidence precludes the consideration of their data when 
making decisions.  This  is  illustrated by  the cases  of Retigabine and Fingolimod,  in 
which NICE and the FJC came to different decisions because the FJC did not consider 
all,  or  in  Retigabine’s  case  any,  of  the  evidence  submitted  by  the  pharmaceutical 
manufacturer. 
In  relation  to  the  theoretical  framework  the  above  remarks  suggest  that 
‘instrument settings’ (Hall, 1993) have the most effect on the outcome of HTAs. This 
implies that the methodological choices made by policy-makers and decision-makers 
are key to understanding the outcome and effect of HTA processes. 
 
9.1.2. Research Finding Two: HTA Paradigms Take Different Forms 
 
While the ‘rules of evidence’ matter in both Germany and England, the format 
they take differs. This demonstrates how HTA paradigms take different formats even 
when  they  are  applied  to  broadly  similar  themes  such  as  evidential  questions.  The 
difference can be explained by reference to the values and goals that are embedded in 
the wider policy paradigms of HTA and health care. For example, the use of ICERs by 
NICE reflects a health care paradigm in which ‘value for money’ has a long-standing 
tradition, whereas the FJC’s use of benefit categories is a logical extension of a health 
care  system  that  is  based  on  bargaining  between  payers  and  providers.  The  FJC’s 
benefit categories may appear unspecific, but they are a means of aiding the decision-
making  process  without  undermining  the  institutional  bargaining  structure  that  is 
inherent to the German health care system. In other words, the use of benefit categories 
ensures that the institutional features of the Germany paradigm remain intact.   
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Chapters  6, 7 and 8 provided a detailed discussion  of the differences  in  the 
conceptualisation and operationalisation of the rules of evidence under a given HTA 
paradigm. The differences include how clinical  effectiveness is conceptualised, how 
uncertainties in the evidence are dealt with and what pieces of evidence are considered 
in the absence of good-quality evidence. The discussion contained in these chapters 
gives rise to the conclusion that England’s HTA paradigm is one of cost effectiveness, 
whereas Germany’s is one of patient relevance. These are the dominant paradigms in 
England and Germany. This finding supports the branch of literature that highlights that 
different paradigms can exist in the same policy field (see chapter 2). However, the 
identification of national auxiliary paradigms would require more research than was 
feasible  within  the  context  of  this  thesis.  Suffice  it  to  say  in  this  regard  that  the 
consultation documents in Germany suggest that the pharmaceutical industry may be 
advocating a paradigm in which cost savings are considered more than is currently the 
case. 
 
9.1.3. Research Finding Three: A Similarity in Outcome Should not be Interpreted 
as a Similarity in Reasoning, or: Contrasting HTA Paradigms do not Necessarily 
Lead to Contrasting Outcomes 
 
 
  The case of Telaprevir, and to a lesser extent the cases of Cabazitaxel, Eribulin 
and  Ipilimumab,  illustrates  that  different  reasons,  and  different  reasoning,  in  the 
decision-making  processes  does  not  preclude  the  possibility  that  the  assessment 
outcomes in different countries may be similar. This suggests that there is more than 
one causal path to a positive, or negative, outcome in HTAs. It also underlines the 
importance  of  not  sampling  cases  on  the  dependent  variable,  an  approach  that  is 
tempting when examining HTAs as different cases are perceived as the most interesting 
cases. However, this thesis shows that researchers can learn valuable lessons from cases 
in  which  HTA  outcomes  are  similar.  The  crucial  lesson  is  that  different  rules  of 
evidence  do  not,  as  a  matter  of  course,  lead  to  different  outcomes.  Moreover,  the 
comparative outcomes of a HTA cannot be understood without an examination of the 
argumentative processes that led to it. In other words, one cannot make inferences about 
the  independent  variables  based  on  the  similarity  or  dissimilarity  in  the  dependent 
variable.  The  empirical  analysis  presented  in  chapters  6-8  underscores  that  
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pharmaceutical benefit assessments are the result of complex applications of paradigms 
rather than of one or two factors being present or absent in a specific case. 
 
9.1.4. Research Finding Four: Core and Periphery Values Exist 
 
Chapter 5 gave rise to the question whether there are principles and values in a 
paradigm that are weighted more in comparison to others, thus a core and periphery of 
values, or a minimum threshold of criteria, that have to be met. The empirical analysis 
supports the theory that core and periphery values exist. This becomes apparent when 
examining the thresholds or hurdles that evidence in a given HTA process needs to meet 
in order to receive a positive appraisal. The terms ‘core’ and ‘periphery’ of values are 
used here for want of better words to describe the observation that certain principles 
appear  to  be  given  more  weight  than  others  under  the  English  and  German  HTA 
paradigms. 
In England the principle that forms the core of decision-making is that of cost 
effectiveness. In Germany the most important principle is that of patient relevance. The 
empirical  evidence  suggests  that  it  is  more  difficult  for  pharmaceutical  products  to 
receive a positive appraisal if the above values are not addressed in manner that satisfies 
the decision-making criteria. In fact, all of the positive appraisals included in this thesis 
were explained with reference to cost effectiveness or patient relevance respectively.  
Whilst a core of values exists in England and Germany with regards to one 
principle that appears to carry more weight than others, a difference is apparent when it 
comes to periphery values. Whereas England’s decision-making paradigm does in fact 
appear to allow for the consideration of principles such as innovation and social values 
as  periphery  decision-making  values  once  cost  effectiveness  is  met,  the  empirical 
evidence in Germany does not suggest that other principles are considered once the 
criterion  patient  relevance  is  satisfied.  This  appears  to  be  connected  to  the 
conceptualisation  of  the  benefit  categories  as  incorporating  the  most  important 
outcomes that the treatment with a new medicine can have, thus implying no need for 
additional, or periphery, values to be considered outside the core benefit categories.  
Finally,  both  the  theory  and  the  practice  of  the  English  paradigm  include 
contingencies for when the usual cost effectiveness threshold is not met. Values such as 
innovation  and,  most  frequently,  end-of-life  considerations  are  invoked  if  cost 
effectiveness is not met. This allows for flexibility in operationalising the paradigm in a  
  258 
way that alters the threshold criteria by reference to other values in cases that warrant it. 
In contrast, the empirical evidence in Germany suggests that invoking principles other 
than patient relevance is a difficult to impossible endeavour. From a theoretical point of 
view  this  is  an  interesting  finding  as  it  reveals  that,  at  least  in  the  case  of  HTAs, 
paradigms are further articulated in normal decision-making when uncertainties arise or 
when  thresholds  are  not  met.  This  is  in  line  with  Kuhn’s  (1962)  thoughts  on  the 
importance of ‘normal science’ as a process in which tools, criteria and concepts of a 
paradigm are refined. As a result, NICE has developed its rules of evidence to allow for 
the consideration of other values to supplement cost effectiveness considerations, whilst 
the  FJC  and  IQWiG  are  sticking  to  the  concept  of  patient  relevance  as  the  main 
paradigmatic principle.  
However, the point on the flexibility, or lack thereof, of paradigms should not be 
overemphasised as it may be a result of the fact that NICE has existed longer and has 
therefore had more opportunities to further articulate its paradigm. In time, the FJC and 
IQWiG may (have to) do the same. Alternatively, if it does not, it would make for an 
interesting study on how certain institutional, cultural or societal prohibit it from further 
articulating its HTA paradigm in a way that addresses potential shortcomings of given 
pieces of evidence. 
 
9.1.5.  Research  Finding  Five:  Thresholds  as  the  Expression  of  Paradigms  in 
Normal Decision-Making 
 
  The importance of thresholds for HTA paradigms cannot be overemphasised. 
Against  the  background  of  the  underlying  rationale  for  HTAs,  i.e.  HTAs  are  about 
finding out whether the use of a product promises enough clinical benefit to justify a 
certain price or the inclusion in a health care benefit basket, thresholds are the means by 
which the limits of clinical benefit or cost effectiveness are given meaning. That is not 
to say that thresholds are uncontroversial, indeed Appleby et al. (2009) point out that 
the method, or lack thereof, by which they are set is frequently criticised. However, the 
point here is not to justify whether certain threshold levels are appropriate or not but to 
highlight their importance as an expression of the dominant HTA paradigms. In each 
and every case that was analysed in this thesis, the products had to meet the thresholds 
of cost effectiveness and patient relevance respectively. The HTA paradigms that were 
identified derive their labels from those thresholds as they were the ultimate hurdles the  
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evidence had to surpass. This finding calls for further research that includes a larger 
number of cases in order to examine whether it can be generalised, i.e. whether HTA 
paradigms always take the form of the thresholds they contain.  
 
9.1.6. Research Finding Six: Paradigmatic Coherence Matters 
 
While both the cost effectiveness paradigm and the patient relevance paradigms 
arise from the ideational and institutional characteristics of their respective health care 
systems, in Germany there appears to be a dissonance between the theory and practice 
of how the paradigm operates. As outlined in chapter 5, the criterion that health care 
decisions are to be based on the ‘generally accepted state of medical knowledge’ is 
contained in Social Code Book V (BMJV, 2013). For the purpose of HTA, this criterion 
is operationalised by using the principle of patient relevance. However, the way it is 
operationalised  is  frequently  perceived  as  a  mismatch  between  theory  and  practice. 
Stakeholders criticise the way patient relevance is operationalised as giving inadequate 
recognition of the ‘generally accepted state of medical knowledge’. For example in the 
case  of  Telaprevir  the  main  clinical  endpoint  was  only  accepted  as  a  surrogate 
parameter rather than an endpoint in its own right (chapter 6 and 7) even though clinical 
experts underlined that it is generally accepted by the international medical community 
as an endpoint in its own right (G-BA, 2012a). The perceived mismatch between theory 
and practice in the Germany paradigm gives rise to controversies and insecurities that 
are yet to be resolved. 
The  way  thresholds  and  HTA  criteria  are  operationalised  impacts  on  the 
outcome of pharmaceutical benefit assessment. However, the finding described in the 
previous paragraph has theoretical implications as it demonstrates that paradigms are 
not static constructs. Instead they require refinement and articulation that may or may 
not give rise to alterations to rules of evidence. Moreover, it highlights the importance 
of paradigms being coherent within themselves, an importance that has previously been 
raised by Hall (1993, p. 290). 
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9.1.7. Research Finding Seven: Ideational and Institutional Variables Matter 
 
As the overview in table 9.2. shows the themes that emerged in the empirical 
analysis can be characterised as reflecting both ideational and institutional variables. 
Ideational variables matter to the outcome of benefit assessments in that the rules of 
evidence reflect a value judgement about considering certain principles and not others. 
For example, the use of ICERs in England reflects a value judgement that ‘value for 
money’ has to be safeguarded whilst the use of benefit categories in Germany reflects a 
value  judgement  about  comparing  clinical  benefits  of  medicines  within  diseases 
categories and not across them. Essentially, these choices reflect views on how one sees 
the world and on what the world around you, i.e. in its institutional constructs, allows 
you to consider. 
The  empirical  evidence  does  not  suggest  a  dominant  role  of  institutional 
variables in the pharmaceutical benefit assessment process. However, this demands a 
word of caution as the role of institutional variables may be more implicit in nature. For 
example,  the  above  mentioned  choice  for  ICERs  and  patient  relevance  respectively 
reflects institutional goals of HTAs in England in Germany. Since the purpose of HTAs 
in England is to inform the decision on the in- or exclusion of a pharmaceutical product 
in  the  health  care  benefit  basket,  the  use  of  QALYs  and  ICERs  to  compare  cost 
effectiveness across disease categories gives a clear answer on what is considered a cost 
effective use of NHS resources. By contrast, the impact of the categorisation of clinical 
benefits in Germany is less clear. The FJC does not attach price recommendations to a 
benefit  category,  which  means  that  it  is  still  up  to  the  sickness  funds  and  the 
pharmaceutical  manufacturers  to  negotiate  an  adequate  price.  In  this  way  the 
methodological choices in England and Germany also reflect the institutional features of 
the respective paradigms. 
Finally, the empirical discussion in chapter 8 gives rise to the question whether 
institutional variables such as public pressure and stakeholder involvement are more 
likely to matter in exceptional cases. In ‘normal’, or comparatively uncontroversial, 
cases the impact of public pressure and stakeholder involvement on the outcome of 
pharmaceutical benefit assessments is low. It appears to matter more in highly salient 
cases  such  as  the  case  of  Abiraterone  in  England.  This  observation  gives  rise  to 
numerous  complexities  that  need  to  be  considered  in  future  research.  These 
complexities include the question whether the resources of the advocacy groups in the  
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case  of  Abiraterone  were  more  abundant  than  in  the  other  cases.  However,  it  is 
noteworthy that the same advocacy groups embarked on an extensive media campaign 
in the case of Abiraterone, but not in the case of Cabazitaxel. In the context of this 
thesis,  the  role  of  public  pressure,  stakeholder  involvement  and  the  distribution  of 
bargaining powers as an independent variable cannot be conclusively assessed as it only 
emerged as an auxiliary variable in a few cases. 
 
9.1.8.  Research  Finding  Eight:  Paradigms  can  Explain  Empirical  Phenomena 
other than Policy Change 
 
  The use of paradigms to guide the interpretation of the empirical findings proved 
helpful in explaining the outcomes of pharmaceutical benefit assessments. The broad 
categorisation  of  variables  into  ideational  and  institutional  features  based  on  Hall’s 
(1993)  conceptualisation  of  policy  paradigms  helped  maintain  the  construct  for  the 
analysis throughout  the thesis.  However, the effect  of paradigms  only really  gained 
meaning in relation to this thesis’ research question through an examination of normal 
decision-making processes as advocated by Kuhn (1962). 
  The empirical analysis of ‘normal’ decision-making processes in the form of 
pharmaceutical benefit assessments showed that paradigms function in a more nuanced 
and less static manner than is portrayed in the extant literature. Paradigms, and the rules 
of evidence therein, are articulated and redefined in HTA processes, especially when 
uncertainties  that  emerge  from  the  evidence  need  to  be  addressed.  In  practice,  the 
paradigmatic  factors  that  determine  the  final  outcome  of  pharmaceutical  benefit 
assessments  are  less  numerous  than  the  mere  identification  of  a  paradigm  would 
suggest. In practice, what matters are the rules of evidence, the core values and, to a 
lesser extent, the public pressure that is exerted. This conclusion was only possible by 
tracing the argumentative and reasoning processes in the ten embedded case studies.  
The aforementioned assertions have implications for the branch of public policy 
literature  that  examines  the  role  of  paradigms.  They  suggest  that  a  more  in-depth 
understanding of paradigms can be gained by engaging in a three-step analytical process 
focused on identification, operationalisation and impact. That is to say that in addition 
to identifying a paradigm, its operationalisation has to be examined before evaluating its 
impact. Currently, most authors in the field focus on the identification and the impact 
without providing  an  account  of  what  it is  about  a paradigm  that matters  in  actual  
  262 
decision-making.  What  I  suggest  makes  the  use  of  paradigms  to  explain  empirical 
puzzles both more lengthy and more complex. However, in the case of this thesis, the 
approach  gave  rise  to  a  specific  and  nuanced  set  of  paradigmatic  variables  that 
determine the outcome of pharmaceutical benefit assessments. This provides a good 
basis for exploring whether a similar delineation of paradigm characteristics is possible 
in other policy areas. 
 
9.2. Generalisability and Limitations of the Research Findings 
   
  As with most qualitative studies, the generalisability of the research findings to 
other  cases  of  pharmaceutical  benefit  assessments  has  to  be  viewed  with  caution 
because  generalisability  increases  with  a  larger  number  of  cases.  The  aim  of  this 
research was not the establishment of definite cause-and-effect relationships that would 
be generalisable to a wider set of cases, but the detailed analysis of the decision-making 
processes  of  benefit  assessments  to  understand  what  determines  the  final  outcome. 
Given that ‘evidence’ is at the core of HTA processes it is probable that the analysis of 
more cases of pharmaceutical benefit assessments would lead to similar findings as the 
ones  presented  here.  However,  further  research  is  needed  to  determine  whether  the 
conclusion that the outcome of benefit assessments is determined by how a similar set 
of questions is addressed by different rules of evidence under given paradigms is valid 
for other cases. As outlined in research finding eight, such research would not only need 
to identify a given paradigm, but also examine how it is operationalised in order to 
understand its effect. 
  Despite the cautious remarks on generalisability, this thesis contains at least one 
significant finding, which is likely to be generalisable to other cases of HTAs. This is 
the finding (see 9.1.3.) that the score of the dependent variable does not necessarily 
allow for an account of the reasons that contributed to the outcome. As the case of 
Telaprevir demonstrated, the outcome in the dependent variable can be similar even if 
different  rules  of  evidence  are  applied  in  the  process.  This  has  methodological 
implications in terms of generalisability. Inferences based on the dependent variable 
should be avoided in the field of pharmaceutical benefit assessments if one wishes to 
understand what shapes the outcomes.  
  There are three main limitations of the research findings. The first is theoretical 
in kind in that the question arises whether paradigms matter as much in decision-making  
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areas that are not strongly evidence-based. That is to say, are evidence-based policies 
more likely to be shaped by paradigms than other, perhaps more political and strategic, 
decision-making areas such as foreign or military policy? More research is required to 
address whether this is indeed a limitation of the research findings. 
  The second limitation relates to the finding that political factors are not a major 
contributor in determining the outcome of benefit assessments. The finding may be a 
result of under-representation or social desirability bias in the data. That is to say that 
decision-makers are unlikely to admit that a decision was made due to political concerns 
as  this  would  undermine  their  organisation’s  standing  as  an  independent,  quasi-
scientific decision-making body. This is connected to a third limitation, that is the lack 
of data to provide conclusive answers to some of the questions raised. For example, in 
Germany  the  proceedings  of  the  committees  that  prepare  the  benefit  assessment 
decisions  for  the  FJC  are  made  public  only  in  summary  form,  meaning  that  the 
arguments  brought  forward  in  this  process  are  not  easily  traceable.  Therefore,  the 
research findings might be limited due to social desirability bias and data restrictions. 
However, such limitations are not unique to this research. Overall, the research findings 
still provide a valuable contribution to the question of what determines the outcomes of 
pharmaceutical benefit assessments and how paradigms shape them. They also give rise 
to questions that future research should address, some of which have been alluded to in 
this section and more of which are outlined in the following section. 
    
9.3. Future Areas of Research 
 
  In addition to the topics outlined in the previous section, there are three key 
topics  that  demand  further  research.  The  first  is  the  question  that  so-called  ‘issue 
characteristics’ (Lowi, 1964) of medicines and the diseases they are indicated for play. 
Are value judgements and considerations different when the medicine being assessed is 
one for cancer versus one for, for example, blood pressure? This question demands 
further  exploration  because  cancer  treatments  receive  much  public  and  financial 
attention.  Much  of  the  current  research  funds  are  dedicated  to  cancer  research  and 
debates around treatment, especially end of life treatment, for cancer patients are very 
emotional  in  the  media.  The  majority  of  medicines  undergoing  HTAs  are  cancer 
treatments. This might be a compounding factor determining the outcome of benefit 
assessments on cancer treatments. The question emerges whether the research findings  
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contained  in  this  thesis  are  generalisable  to  cases  other  than  cancer  treatments.  As 
outlined in chapter 3, the sample of cases that was analysed was evenly spread in terms 
of the diseases for which the new interventions were indicated. Nevertheless, the fact 
that a large number of medicines that undergo benefit assessments are cancer drugs 
warrants  an  analysis  on  whether  decision-making  is  somehow  different  in  cases  of 
different disease indications. 
In this study that above question emerged in relation to the benefit assessments 
of  the  cancer  interventions.  The  two  cases  (Cabazitaxel  and  Eribulin)  that  did  not 
receive a positive appraisal from either NICE or the FJC were cancer treatments, more 
specifically chemotherapy treatments. Meanwhile, the two cancer treatments that did 
receive  a  positive  appraisal  were  Abiraterone,  which  is  a  hormonal  therapy,  and 
Ipilimumab, which works by activating the immune system to fight cancer cells. Both 
of these treatments are very different from chemotherapies, which are associated with 
substantial side effects. The role that these issue characteristics play in the likelihood of 
whether a new medicine is recommended demands further exploration. 
  The  second  topic  that  demands  further  research  arises  from  the  auxiliary 
variables discussed in chapter 8. The role of these auxiliary variables would justify a 
research study in its own right and would most likely include issues of stakeholder and 
lobbying influence. However, at least in Germany’s case, access to appropriate data 
would  be  challenging  because  the  FJC’s  decision-making  minutes  are  not  publicly 
accessible  and  the  price  negotiations  between  sickness  funds  and  pharmaceutical 
manufacturers are confidential. Nevertheless, it is a study waiting to be done. It is also a 
study that could employ theoretical frameworks such as Sabatier’s advocacy coalition 
frameworks in order to examine whether the dominant HTA paradigms are more or less 
aligned with the belief systems of a given advocacy coalition. 
  The  third  area  that  demands  further  research  is  connected  to  the  theoretical 
contribution that this thesis makes. The thesis demonstrates that ideational accounts of 
policy processes can help explain the outcome of complex decision-making processes 
and not just the outcome of processes of policy change. The relevance of this finding to 
other policy areas such as environment, defense or education policy is worth exploring 
in  future  research.  If  ideational  accounts  can  explain  decision-making  processes  in 
addition to change in different policy areas, this gives rise to a wide range of subject 
areas that could be explored from a new angle. This would demand a move away from  
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the preoccupation with the outcomes of dependent variables to an analysis of the causal 
mechanisms determine the outcomes of decisions. 
 
9.4. Policy Implications 
 
  The main finding of this study concludes that questions around evidence, and 
how they are addressed by applying different rules of evidence, determines the outcome 
of  pharmaceutical  benefit  assessments.  In  the  proceeding  paragraphs  I  distinguish 
between the policy implications this has for different stakeholders. The implications are 
different  for  different  stakeholders  in  the  kind  of  opportunities  and  challenges  they 
present. While the policy implications for policy-makers are complex, they are positive 
and full of potential for the pharmaceutical industry and challenging for patient and 
public organisations. 
  The implications for policy-makers relate to the wider political goals and hopes 
that have been attached to the introduction of HTA policies. These goals include a) the 
hope  that  difficult  health  care  priority  setting  decisions  can  be  de-politicised  by 
establishing  independent  scientific  institutions  to  carry  out  evaluations  of  the  best 
available evidence and b) that these evaluations will lead to improved decision-making 
and, potentially, efficiency savings by distinguishing between effective and ineffective 
treatments  (see  chapter  1).  The  empirical  results  suggest  that  the  goal  of  ‘de-
politicising’ decisions in health care has been achieved in both England and Germany in 
the sense that the outcome of pharmaceutical benefit assessments is determined by the 
rules of evidence that are applied under a given HTA paradigm. However, there are 
political developments in both countries that suggest that the effect of achieving this 
goal might not be as well perceived by policy-makers as was intended.   
  In 2010 the Conservative-Liberal Democratic Government in England created a 
Cancer Drugs Fund (CDF) of £200 million annually to provide patients access to cancer 
drugs that have not been recommended by NICE and that their clinician thinks they will 
benefit from (NHS England, 2014). Additionally, the Government intended to “[…] 
reform NICE and move to a system of value-based pricing, so that all patients can 
access the drugs and treatments their doctors think they need” (Cabinet Office, 2010, p. 
25). Whilst the future of value-based pricing (VBP) – a pharmaceutical pricing system 
in which the price of a new medicine is to reflect its value – remains uncertain, both the  
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creation of a CDF and the move towards a system of VBP give rise to the question 
whether there is a dissatisfaction with the current HTA paradigm in England. 
Politically the establishment of a CDF undermines NICE’s paradigm in that it 
suggests that NICE’s recommendations are, in  some instances, not  good enough.  A 
policy observer summarises this in the following way:  
 
[…] the fund had the political benefit of defusing the damaging arguments that 
have  arisen  when  officials  have  denied  patients  access  to  expensive  cancer 
treatment […] on cost-benefit grounds (Cook, 2014). 
 
 
Not withstanding political opportunism as a motivating factor in the creation of the 
CDF, the fund represents a budget that is external to the rest of the NHS budget. It also 
represents a political decision to prioritise cancer patients over other patients such as 
patients with rare and/or chronic long-term conditions who might also benefit from a 
stand-alone fund that ensures access to medicines that are not considered cost effective 
by NICE. The latter raises the question of how the CDF is justified in relation to values 
such as equality and non-discrimination.  
This  study  demonstrated  that  the  outcomes  of  pharmaceutical  benefit 
assessments  are  determined  by  methodological  processes  and  choices.  Political 
considerations  and  influence  did  not  feature  prominently  in  the  data.  However,  the 
outlined  developments  in  relation  to  the  CDF  and  VBP  imply  that  there  is  a  trend 
towards  re-politicising  health  priority  setting  because  the  HTA  paradigm  does  not 
address the questions that policy-makers consider politically and ethically salient. This 
has wider policy implications in relation to the question of whether the de-politicisation 
of a policy area is ever truly possible. Authors such as Landwehr (2009) and Holm 
(1998) have argued that it is not possible in the field of HTA. The findings contained in 
this thesis suggest that although a de-politicisation is possible, in reality it may not be 
desirable.  The  described  developments  appear  to  indicate  that  the  effect  of  de-
politicising decisions may not be in line with political commitments that policy-makers 
wish to uphold. The implications of this are wide-ranging in that it questions the very 
reason for conducting HTAs in the first place. If policy-makers are happy to mitigate 
the effects of benefit assessment outcomes on the availability of medicines for certain 
patient  populations  by  introducing  policies  to  circumvent  them,  the  question  arises  
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whether financial and political resources should be spent on conducting HTAs in the 
first place. 
Meanwhile,  a  political  debate  on  the  effects  of  early  benefit  assessments  is 
developing in Germany, especially in relation to the implications of a new medicine 
being categorised in one of the higher benefit categories. As outlined in chapters 4 and 
5,  the  outcomes  of  benefit  assessments  in  Germany  inform  the  price  negotiations 
between the sickness funds and the pharmaceutical manufacturers. The system is based 
on  the  idea  that  the  higher  the  benefit  category,  the  higher  the  price  that  a 
pharmaceutical manufacturer can demand for the product in question. However, the 
political  question  that  has  recently  emerged  is  whether  a  high  benefit  category 
automatically justifies the product being priced very highly, or, whether there can or 
should be limits on what a manufacturer can demand even if a product is considered 
highly innovative.  
The above debate specifically arose around a new pharmaceutical product called 
Sofosbuvir (brand name Sovaldi), indicated for the treatment of chronic Hepatitis-C 
infections. The FJC assigned the second highest benefit category to Sofosbuvir (G-BA, 
2014).  Since  this  decision  in  February  2014,  the  pharmaceutical  manufacturer  of 
Sofosbuvir has been criticised for the high price it is demanding at €60.000 for a 12-
week  treatment  course  (Deutsche  Apotheker  Zeitung,  2014).  Clinicians,  statutory 
sickness funds and politicians are criticising the price as unacceptable. According to 
Jens Spahn, an expert on health policy in the current Government: “Sovaldi is a real 
innovation and a blessing for many patients, but that does not justify an astronomical 
price  by  any  stretch  of  the  imagination”
37 (Deutsche  Apotheker  Zeitung,  2014a). 
Similarly, NICE criticised the pharmaceutical manufacturer of the new breast cancer 
drug Kadcyla for not offering “[…] its new treatment at a price that would enable it to 
be available for routine use in the NHS” (NICE, 2014d). There appears to be a similar 
political  debate about  the price setting for new  pharmaceuticals  in  Germany and in 
England. 
In  light  of  the  research  findings  the  outlined  political  debate  is  significant 
because  it  suggests  that  the  current  HTA  paradigms  do  not  adequately  address  this 
important factor. The pharmaceutical benefit assessment outcomes are determined by 
methodological and scientific questions in relation to the evidence on a product. This 
                                                        
37 Translation provided by the author of this thesis.  
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implies that the issues that are considered are comparatively limited and do not address 
wider concerns such as the ‘right’ price for a product. Even in the German HTA system, 
where the benefit  category is  supposed to  indicate whether  a higher or lower price 
would be justified, the higher categories are not matched by a category of prices, which 
would provide guidance for the negotiating parties.  In connection to pharmaceutical 
price  setting  policies,  the  thesis’  findings  indicate  that  there  is  little  room,  or  little 
willingness  by decision-makers, to  consider pharmaceutical  prices  under the current 
HTA paradigms in England and Germany. This implies that the situation can only be 
rectified by altering the current systems in a way that allows for the incorporation of 
price considerations within the rules of evidence. This is likely to only be possible if the 
political will is strong enough, thus underlining the likelihood of a re-politicisation of 
the area. 
The final two policy implications that I draw attention to relate to the impact that 
dominant  HTA  paradigms  of  cost  effectiveness  and  patient  relevance  have  on 
stakeholders in the area. The existence of diverging HTA paradigms is challenging for 
pharmaceutical manufacturers because the evidence base on a given product has to be 
tailored to specific national paradigms. This can consume resources and time and is 
therefore  frequently  criticised  as  a  negative  outcome  of  the  introduction  of  HTA 
policies.  However,  while  there  is  no  question  that  the  adjustment  to  different  HTA 
system requires time and resources, I argue that it ultimately presents opportunities to 
make evidence better and stronger. That is to say, that while the onus of adjusting the 
evidence  base  to  new  criteria  lies  with  pharmaceutical  manufacturers,  they  can 
contribute to better health care by considering a wider set of criteria and principles in 
clinical  trials  than  is  currently  the  case.  The  findings  of  this  research  imply  that 
pharmaceutical manufacturers are in a good position to meet the demands of different 
HTA  systems  because  they  are  the  providers  of  evidence.  The  outcomes  of 
pharmaceutical  benefit  assessments  in  England  and  Germany  are  determined  by 
evidential questions, thus, while time-consuming, the HTA paradigms do not appear to 
constitute the huge black box of randomness and antagonism that the pharmaceutical 
industry occasionally still portrays them as. 
Whilst  the  implications  of  the  findings  are  potentially  positive  for  the 
pharmaceutical industry, the implications are more challenging for stakeholders such as 
patient and public organisations. The finding that the outcome of pharmaceutical benefit 
assessments is based on complex and detailed interpretations of an evidence base gives  
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rise  to  the  inference  that  patient  and  public  views  will  carry  more  weight  if  they 
contribute to these interpretations. This in turn demands expertise, resources and skills 
from  patient  groups,  the  attainment  of  which  might  not  be  realistic  or  feasible. 
According to one interviewee in England:  
 
[…] many if not most patient organisations […] if they are of a certain size and 
can afford to employ people like me to contribute to something which is quite 
technical and quite specific […] we do […] address NICE in terms of […] what 
evidence  we  provided,  how  we  can  interpret  their  appraisal  […]  patient 
organisations have themselves become experts in NICE processes (Interviewee 
No. 19, 2013, p. 4). 
 
 
There is no guarantee that every patient group will be able to address the issues 
that  a  HTA  body  considers  important  in  the  way  that  is  described  in  the  above 
interview. For example, an interviewee in Germany asserted:  
 
[…] in Germany we […] have the problem that patient organisations are not 
very well organised […] there are a lot that are not in a position to see through 
the complex process, that depends on the financial and human resources that one 
has […] and these people then come together with people who do this for a 
living […] (Interviewee No. 8, 2013, p. 6). 
 
 
The  above  remarks  imply  that  the  kind  of  patient  and  public  participation  and 
consultation  that  ultimately  affects  the  outcome  of  benefit  assessments  is  hard  to 
achieve. While some patient organisations in England have risen to the challenge and 
have  become  experts  themselves,  this  development  is  quite  unique  at  this  point. 
Politically, this calls for an examination of the status quo and of the true involvement 
that patient and public organisations have in the process of HTA. The question arises 
whether current HTA paradigms require alterations to better accommodate the more 
societal and ethical perspectives that patients contribute to the process. 
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9.5. Concluding Remarks 
   
  The  eight  research  findings  give  rise  to  the  conclusion  that  the  outcome  of 
pharmaceutical benefit assessments in health care systems that employ formalised HTA 
procedures is determined by how a similar set of themes around the evidence base on a 
pharmaceutical product gets transformed, interpreted and framed in the context of a 
given HTA paradigm. This conclusion contributes to the empirical knowledge on HTA 
procedures by underlining that evidence gains relevance and meaning within national 
contexts  and  does  not  carry  relevance  in  its  own  right.  Pharmaceutical  companies, 
national  governments,  HTA  decision-making  bodies,  clinicians  and  patient  groups 
interpret  the  available  evidence  from  their  own  unique  perspectives.  However,  the 
dominant perspectives of how to interpret evidence are found in the dominant HTA 
paradigms in countries that employ HTA processes to inform decision-making in health 
care. The dominant HTA paradigms in England and Germany are the cost effectiveness 
and patient relevance paradigms respectively. The identification of these paradigms is 
another empirical contribution of this thesis. 
   In  addition  to  contributing  to  a  better  empirical  understanding  of  what 
determines  the  outcome  of  pharmaceutical  benefit  assessments,  this  thesis’  most 
important contribution is theoretical. By using policy paradigm frameworks and Kuhn’s 
(1962) concept of ‘normal science’ to analyse and interpret the results of this study, I 
demonstrated that theories of paradigms can help explain empirical phenomena other 
than  policy  change.  Moreover,  I  demonstrated  that  the  features  and  functions  of 
paradigms  can  be  understood  better  by  analysing  how  they  are  operationalised  in 
normal practice.  
The themes that emerged from the empirical analysis showed they were limited 
to three sets of variables that were identified as part of the broader HTA paradigms 
(table 9.2.). In practice, what matters in determining the outcome of pharmaceutical 
benefit  assessments  are  firstly,  the  criteria,  or  rules  of  evidence,  in  HTA  decision-
making, secondly, the values core within a HTA paradigm and thirdly, albeit to a lesser 
extent, procedural factors such as the involvement and pressure of stakeholders in the 
assessment  process.  This  suggests  that  paradigms,  when  articulated  and  applied  in 
normal  decision-making  processes,  are  more  manageable,  measurable  and  fluid 
intellectual constructs than the extant literature depicts them to be. It also suggests it is 
possible to describe the important independent variables of paradigms by examining  
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how they are operationalised. Future studies on policy paradigms would benefit from 
the analysis of how paradigms operate in ordinary, i.e. ‘normal’, processes and not just 
in the extraordinary processes of policy change. 
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APPENDIX A 
 
Overview of NICE and Federal Joint Committee Decisions 
 
Product & Indication  NICE  Federal Joint Committee 
Abiraterone (Prostate Cancer)  -  Initially not recommended (ICER too high, End of life 
criteria not met) 
-  Then recommended upon presentation of new evidence 
-  End of life criteria met 
-  Patient Access Scheme 
-  Oral drug benefit not captured in QALY 
-  ICER likely less than £50,000 
-  Divided up the patient population 
into two subpopulations 
-  For ‘best supportive care’ 
population: Indication for a 
significant additional benefit 
-  Docetaxel-re-therapy population: 
Additional benefit not 
substantiated, missing data 
Apixaban (Prevention of 
thromboembolic events after hip 
or knee replacements) 
-  Recommended 
-  More clinically effective and cheaper than at least one 
comparator (enoxaparin) 
-  ICER not clear 
-  For knee-replacement population: 
No additional benefit 
-  For hip replacement population: 
Marginal additional benefit 
Boceprevir (Chronic Hepatitis C 
genotype 1) 
-  Recommended 
-  ICERs all below £20,000/QALY 
-  Clinically more effective than the comparator alone at 
achieving sustained virological response (SVR, taken as 
equivalent to a cure) 
-  For patient-naïve patients: 
additional benefit but not 
quantifiable 
-  For therapy-experienced patients: 
additional benefit but not 
quantifiable 
Cabazitaxel (Prostate Cancer)  -  Not recommended, ICER too high at £87,500 QALY 
-  Uncertainty about robustness of ICER 
-  Effective, life-extending treatment but too much 
additional weight would have to be put on QALYs to 
make it an appropriate use of NHS resources 
-  Best-supportive care population: 
Indication for marginal additional 
benefit 
-  Docetaxel-re-therapy population: 
No additional benefit substantiated, 
proof/data missing 
Eribulin (Advanced Breast  -  Not recommended, ICER of £68,600/QALY likely  -  Marginal additional benefit  
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Cancer)  underestimated 
-  Concerns over toxicity profile 
-  However, first drug in the population to show an overall 
survival benefit in an RCT 
 
Fingolimod (Multiple Sclerosis)  -  Committee made an exceptional case for this drug, 
recommended it (after initially not recommending it and 
facing considerable protest) 
-  Patient Access Scheme 
-  Valuable new therapy, oral formulation is an innovation 
-  £25,000-£35,000/QALY 
-  Marginal benefit only for patients 
with rapidly progressing severe 
MS, not for other patients such as 
patients with highly active 
remitting MS 
 
Ipilimumab (Advanced 
Melanoma) 
-  Recommended 
-  End of  life criteria met 
-  Patient Access Scheme 
-  £42,200/QALY  
-  Innovation because of few advances in advanced 
melanoma; currently the treatment option for these 
patients is enrolment in clinical trials 
-  Significant additional benefit 
 
Retigabin (Epilepsy)  -  Recommended 
-  ICERs highly uncertain but novel mode of action and 
provision of new treatment option where others have 
failed 
-  Additional benefit not 
substantiated, missing data/proof 
Telaprevir (Chronic hepatitis C, 
genotype 1) 
-  Recommended 
-  ICERs low 
-  Public health benefit highlighted 
-  Stigma reduction etc. 
-  Additional benefit, but not 
quantifiable 
Ticagrelor (Acute coronary 
syndromes) 
-  Recommended for all patient populations under 
consideration (4 in total) 
-  All ICERs under £10,000/QALY 
-  Significant additional benefit for 
patients with non-ST-segment 
elevated myocardial infarction 
-  No additional benefit in the other 
three patient populations  
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APPENDIX B 
 
Interview protocol 
 
Open-ended questions for semi-structured interviews in England: 
 
1.  How  would  you  describe  your  involvement  [or  the  involvement  of  the 
institution/group  you represent] in the assessment process of [insert name of 
pharmaceutical product]?  
 
2.  What were the main points you brought forward in the above process? 
 
3.  Do you feel your involvement in the process made a difference? [If yes, follow 
up on how it made a difference]  
 
4.  What determined NICE’s ultimate decision in this process? 
 
5.  How  would  you  describe  the  main  principles  that  guide  decision-making  at 
NICE? 
 
6.  How would you describe the influence of other stakeholders in the assessment 
process?  [Follow-up  question:  What  is  your  relationship  with  these 
stakeholders?] 
 
7.  Do  you  feel  that  NICE  does  a  good  job  at  balancing  the  issues  of  clinical 
benefits and need, costs and innovation? 
 
8.  What role should NICE play when it comes to disinvestment incentives?  
 
9.  How  do  you  view  the  future  of  health  technology  assessment  in  England, 
especially in light of the Government’s plans to introduce a system of value-
based pricing for pharmaceuticals? 
 
 
Open-ended questions for semi-structured interviews in Germany: 
 
1.  How  would  you  describe  your  involvement  [or  the  involvement  of  the 
institution/group  you represent] in the assessment process of [insert name of 
pharmaceutical product]?  
 
2.  What were the main points you brought forward in the above process? 
 
3.  Do you feel your involvement in the process made a difference? [If yes, follow 
up on how it made a difference] 
 
4.  What determined the FJC’s ultimate decision in the process? 
 
5.  How  would  you  describe  the  main  principles  that  guide  decision-making  at 
IQWiG and the FJC?  
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6.  How would you describe the influence of other stakeholders in the assessment 
process?  [Follow-up  questions:  What  is  your  relationship  with  these 
stakeholders? How would you describe the influence of patient organisations in 
the assessment process?] 
 
7.  What role does the requirement for ‘patient relevant’ outcomes play during the 
assessment process? [Follow-up: How would you define patient relevance?] 
 
8.  In your view, what role does the consideration of costs play in determining the 
outcome of pharmaceutical assessment processes? 
 
9.  What role have the early benefit assessments played in the price negotiations 
between sickness funds and pharmaceutical manufacturers? 
 
10. How do you view the future of early benefit assessments of pharmaceuticals in 
Germany? 
 
 
Themes explored with the above questions:  
 
  Perception of guiding decision-making principles (generally and in the specific 
cases) 
  Perception of stakeholders’ own involvement and influence in the process 
  Perception of other stakeholders’ influence 
  Perception of role of specific (paradigmatic) issues such as patient relevance, 
costs, balance between different considerations, methods 
  Wider impact of HTA on pharmaceutical policy and health care system 
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